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SUMMARY 
 
Background – Colorectal cancer (CRC) is the second most common cause of cancer death. 
CD4+ T cells play an important role in anti-tumour immunity by promoting immune processes 
that can mediate tumour inhibition. CD4+ immunity to tumours, however, is not able to prevent 
tumour outgrowth. It is hypothesised that tumour outgrowth can occur due to weak recognition 
of tumour-derived epitopes by tumour-reactive T cell receptors (TCRs) and due to negative reg-
ulation by inhibitory T cell molecules. In this study, CD4+ T cell responses to the oncofoetal 
antigen 5T4 are studied at the molecular level. The function of the co-inhibitory molecule LAG-
3 is described biophysically and monoclonal antibodies which recognise LAG-3 were devel-
oped. 
Results – Three 5T4-reactive CD4+ T cell clones were shown to recognise 5T4-derived pep-
tides restricted to HLA-DR1. Each clone was sensitive to antigen and produced TH1 cytokines 
despite exhibiting weak recognition of cognate antigen. Subsequently, the structural character-
istics of a 5T4-derived peptide epitope was described through x-ray crystallography which 
revealed insights into MHC-II presentation of peptides. Cell expressed LAG-3 was shown to 
interact with MHC-II at the cell surface and was characterised at the protein level using surface 
plasmon resonance (SPR) where LAG-3 bound MHC-II via an intermediate affinity interaction. 
Thirdly, through the immunisation of mice, anti-LAG-3 antibodies were cloned and character-
ised in terms of their specificity and function. 
Conclusions – These studies demonstrate how tumour-specific CD4+ T cells can produce 
immune-stimulatory molecules in vitro yet exhibit weak engagement of cognate antigen. It is 
shown that peptide flanking residues of HLA-DR1 presented epitopes can contribute to peptide 
anchoring as well as form structural features that may influence TCR binding. It is shown that 
LAG-3 binds MHC-II at higher affinity than CD4 with implications in its inhibitory function. 
Finally, specific antibodies that bind LAG-3 have been characterised with potential for thera-
peutic development. 
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1 Chapter 1: Introduction 
1.1 Tumourigenesis and colorectal cancer  
Cancer is a highly heterogeneous disease characterised by aberrant cell growth and evasion of 
the immune system (Hanahan & Weinberg 2011). According to statistics collated by Cancer 
Research UK, in the UK in 2014, combined cancer related deaths were estimated at ~163,000 
with a reported incidence of ~352,000 new cancer cases reported the previous year (Cancer 
Research UK 2016). In 2011 in England & Wales the combined 10-year survival for all cancers 
was ~50 % with marginally higher survival in women compared to men. Different cancer types, 
however, exhibit a wide range in survival; cancer of the testis resulted in a ~98 % 10-year sur-
vival compared to ~1 % in pancreatic cancer. As a result, a better understanding of how tumours 
are shaped by the immune system and how the immune system can be modulated through ther-
apy is required. 
1.1.1 Colorectal cancer epidemiology  
Colorectal cancer (CRC) is the formation of primary cancer of the lower gastrointestinal tract 
from the large bowel to the anus. CRC is the second most common cause of cancer death world-
wide. In the UK in 2014, there was over ~16,000 deaths as a result of CRC with a reported 
incidence of ~41,000 new cases in the previous year (Cancer Research UK 2016). Incidence 
rates are more common in men that in women and increase with age, highlighted by 58 % of all 
cases diagnosed in people aged 70 or over (2011-2013). In 2011 in England & Wales, 10-year 
survival was ~57 % and thus higher than the combined overall 10-year survival rate for all can-
cers. Disease occurrence varies worldwide with higher prevalence in the developed world 
(particularly Europe, North America & Oceania) likely due to environmental and lifestyle fac-
tors including diet; with incidences in developing countries on the rise (Haggar & Boushey 
2009). Such increases have been attributed to changes towards a more ‘Westernised” lifestyle 
in developing areas (Center et al. 2009). Risk factors of disease are a combination of both envi-
ronmental/lifestyle factors – such as consumption of red and processed meat, smoking and 
excessive alcohol intake – as well as disease/genetic factors such as family history, inflamma-
tory bowel disease, diabetes and obesity (Brenner et al. 2014). 
1.1.2 Formation of CRC tumours 
CRC is a heterogenous disease that can develop over long time periods (>10 years) and can arise 
through multiple driving pathways. The majority of CRC pathology manifests as cellular disor-
der of the mucosa resulting in dysplastic adenomas. Uncontrolled proliferation of epithelial cell 
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division at intestinal crypts most commonly results in the formation of adenomatous polyps 
which can progress to malignant adenocarcinomas (Ponz de Leon & Di Gregorio 2001). Such 
dysplasia is driven by the gradual acquirement of mutations within mucosal epithelial cells. 
Commonly acquired mutations occur in the Adenomatous polyposis coli gene (APC-gene), for 
example, which is a tumour suppressor gene pivotal in WNT signaling and thus maintaining 
cellular proliferation (Powell et al. 1992). Tumourigensis, however, can occur through a plethora 
of mutations in cellular maintenance signaling pathways including WNT, MAPK, PI3K, TGF-
β, p53 pathways as well as DNA mismatch-repair mechanisms (Fearon 2011).  Whole genome 
sequencing and large-scale analysis of genomic organization has shown that hypermutated tu-
mours driven by errors in DNA repair, termed microsatellite instable tumours, are molecularly 
distinct from non-hypermutated tumours which are driven by chromosomal instability (The 
Cancer Gene Atlas et al. 2012). 
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1.2 T cells as part of the immune system 
The first line of defence between a multi-cellular organism and the surrounding environment 
are the physical barriers that encapsulate it. In order to survive, however, organisms must inter-
act and exchange material from this environment – whether oxygen through the respiratory 
system or water, food and therefore energy through the digestive system. Moreover, physical 
barriers cannot prevent pathology derived from the cells from within the organism, such as the 
case of cancer. As a result, the organism utilises a complex network of cells and soluble factors, 
known as the immune system, to mediate protection of the host from undesired entities. This 
network can be broadly categorised into two components: innate immunity and adaptive im-
munity.  
1.2.1 Innate immunity 
Innate immunity incorporates the physical barriers against pathogens as well as a number of 
cellular and molecular factors that make up the immediate response against pathogenic entities. 
These innate immune processes can be triggered by common hallmarks of pathogens or injury 
(Janeway & Medzhitov 2002). For example, innate cells such as macrophages, neutrophils and 
dendritic cells, express pattern recognition receptors (PRRs) which can recognise molecular sig-
nals termed pathogen-associated molecular patterns (PAMPs) or damage-associated molecular 
patterns (DAMPs). In response to their activation through PPRs, innate cells can engulf cells 
and cellular debris through phagocytosis and signal to other arms of the immune system by the 
release of soluble molecules – cytokines, chemokines and small molecule inflammatory media-
tors – to trigger a response against the insult or pathogen. Such a response can be broadly 
described as acute inflammation, whereby blood vessels dilate and increase permeability, local 
temperature is increased and cellular and soluble immune mediators are delivered to the area. 
Innate immunity is characterised by its limited ability to adapt to damage or pathogens over 
time. This property is as a result of innate receptors, such as PRRs, being germline encoded.  
1.2.2 Adaptive immunity 
The adaptive immunity arm of the immune system is characterised by its ability to alter over 
time as a result of adapting to encountered pathogens or immunogens throughout the lifetime of 
the organism. This functionality is required by higher organisms due to the vast array of potential 
aggressors exhibiting large variability and faster evolutionary time scales. Moreover, adaptive 
immunity mediates the process of immunological memory and is thus the target of vaccination.  
Adaptation is achieved through the specific recognition of pathogenic material using recep-
tors that, unlike innate receptors, are highly variable. This is achieved via somatic gene 
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processes. The pathogenic material recognised by these receptors are termed antigens and can 
be in the form of proteins, short peptides, carbohydrates, lipids or small molecules. The highly 
variable receptors that recognise antigens are the B-cell receptor (or antibodies in its soluble 
form) or the T cell receptor (TCR). These receptors are expressed on B and T cells, respectively, 
which are generated and developed in the primary lymphoid organs.  
Whilst innate immunity does not adapt over time, innate immune processes are essential for 
the initiation and function of an adaptive immune response. Complement, for example, is re-
cruited to opsonised antibody targets on cellular material and is able to lyse cells through the 
formation of the membrane attack complex (MAC) which perforates cellular membranes (Tegla 
et al. 2011). Crucially, for this thesis, the communication between innate cells performing as 
professional antigen presenting cells (APCs) are essential in triggering the T cell response 
against antigens. 
1.2.3 T cells 
T cells are a lymphocytic cell type that are defined by their maturation in the thymus and their 
expression of the highly variable antigen receptor: the T cell receptor (TCR). This TCR is vari-
able between different T cells and is thus clonotypic. As a result, clonotypic T cells possess 
unique TCR gene sequences and therefore a unique receptor with a unique specificity. Due to 
this highly variable receptor, T cells are able to bind to and respond to pathogens or tumours via 
the specific recognition of a vast array of antigenic markers. 
1.2.4 Generation of the αβT cell repertoire 
T cells are a highly heterogeneous cell population. As a result of the processes described herein, 
a pool of clonotypic T cells, defined by their TCR sequence (T cell clonotype) is generated and 
trained to distinguish pathogenic ‘foreign’ molecular antigens from molecular antigens derived 
from the host (self-antigens). To achieve this function, T cells undergo TCR gene assembly, T 
cell development and thymic selection. The result of which is a vast population of T cell clono-
types termed the T cell repertoire. An overview of the processes involved in generating the T 
cell repertoire described in this section are illustrated in Figure 1.1. 
1.2.4.1 TCR generation 
The generation of T cells bearing diverse TCR sequences occurs via the somatic recombination 
of TCR genes during the development of T cells in the thymus. This process allows the theoret-
ical generation of 1018 unique αβ TCRs from the TCR loci from a genome that encodes  
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(Figure legend overleaf) 
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Figure 1.1 – Overview of TCR generation, T cell development and thymic selection: 
Haematopoietic stem cells (HSC) migrate via blood from bone marrow to thymus and 
differentiate into the common lymphoid progenitor (CLP) before committing to the T cell 
lineage to form double negative (DN) thymocytes. Within the thymic outer cortex, simultaneous 
rearrangement of TCRβ,γ & δ chains occurs and upon which a successful rearrangement of 
TCRβ chain commits thymocytes to the TCRαβ lineage. Arranged TCRβ chain associates with 
the pre-T cell receptor alpha (pTα) chain to form the pre-TCR on surface of thymocytes before 
acquisition of both CD4 and CD8 co-receptors to form pre-TCR+ double positive (DP) 
thymocytes. Consequent rearrangement of the TCRα chain is triggered allowing the formation 
of TCRα chain pairing to form TCRαβ+ DP thymocytes which travel through to the thymic inner 
cortex where they undergo positive selection against self-MHC molecules expressed by the 
thymic cortical epithelial cells. TCRαβ rearrangements which do not signal through the TCR 
due to insufficient binding to self-MHC are subjected to death by neglect due to programmed 
cell death. DP thymocytes which pass positive selection migrate to the thymic medulla where 
they undergo negative selection. Based on negative selection against tissue specific antigens 
(TSAs) presented on APCs within the medulla, candidate thymocytes are deleted by apoptotic 
signalling or licensed for the periphery as naïve CD4+ TH precursors or CD8+ T cell precursors 
– depending on TCR engagement with MHC TSAs and consequent signal strength.  
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approximately 3 x104 genes in order to bind near infinite possible antigenic sequences (Davis & 
Bjorkman 1988).  
During the formation of αβ T cells, thymocytes which commit to the T cell lineage from 
common lymphoid progenitor (CLP) cells, upon entry into the thymus, undergo the process of 
TCR gene assembly, firstly via somatic recombination at the TCRβ locus (Hedrick et al. 1984). 
This process is termed V(D)J recombination. Within the human germline encoded TCRβ loci 
are a number of gene segments: two constant (C), two diversity (D), thirteen joining (J) and 52 
variable (V) segments. Catalysis by the recombination activation genes-1 and -2 (RAG1 & 
RAG2) allow the recombination of one of each of the gene segments to form a candidate TCRβ 
chain sequence (Figure 1.2a) (Schatz & Swanson 2011). The resultant TCRβ chain is conse-
quently transcribed, translated and transported to the cell surface where it associates with the 
pre-TCR α chain (pTα) and associates with CD3 component subunits (Fehling et al. 1995). The 
ability of the pre-TCRαβ/CD3 complex to successfully signal through the formed TCRβ repre-
sents the first positive selection step in TCR generation (von Boehmer 2005). Upon successful 
recombination to a TCRβ chain, TCRγ and TCRδ chain recombination is halted (which occurs 
simultaneously) and the thymocyte is committed to the αβ T cell lineage. 
Following acquisition of both CD4 and CD8 co-receptors, rearrangement of the TCRα locus 
is triggered (Figure 1.2b). Arrangement of the TCRα is similar to the TCRβ locus except it 
differs in the constituent gene segments: one constant (C), 61 joining (J) and between 70 and 80 
variable (V) segments. Crucially, the TCRα locus contains no diversity (D) gene segments, thus, 
TCRα chain diversity is generated through VJ recombination only (Schatz & Swanson 2011).  
Whilst the selection of different combinations of V(D)J gene segments introduces diversity 
to the TCR repertoire, further variation is introduced during recombination through the process 
of junctional diversity. During recombination of both TCRα and TCRβ, double stranded breaks 
catalysed by RAG1/2 recombinases form hairpin loop coding ends of recombining gene seg-
ments. Consequently, the DNA repair enzyme Artemis cleaves these hairpin ends leaving single 
stranded palindromic nucleotide sequences (P nucleotides) (Ma et al. 2002). These single 
stranded extensions are consequently capped by random nucleotide addition by the enzyme ter-
minal deoxynucleotidyl transferase (TdT), paired and ligated to complete the join between gene 
segments (Schatz & Swanson 2011). This process is error-prone and consequently adds non-
germline encoded nucleotide sequences to the junctions between recombined gene segments. In 
arranged TCRα genes there is a single junction – between VJ segments – whereas in arranged 
TCRβ genes there are two junctions – between VD and DJ. As a result, the TCRβ chain exhibits 
a further level of diversity compared to the TCRα (Davis & Bjorkman 1988). 
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a) Organisation of the TCRβ locus containing variable (V), diversity (D), joining (J) and 
constant (C) gene segments (top). The number of gene segment introns within each cluster is 
defined as numbers below segment labels. Consequent somatic recombination between V,D,J 
and C segments results in the formation of an assembled TCR gene sequence (bottom). 
b) Organisation of the TCRα locus containing variable (V), joining (J) and constant (C) gene 
segments (top) and assembled TCRα gene (bottom); labelled as in a). 
c) Contribution of gene segments to the expressed αβ TCR highlighting the additional presence 
of D-gene incorporation into the TCRβ chain; coloured and labelled as in a) and b). 
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1.2.4.2 Shaping the T cell repertoire via positive and negative thymic selection 
Having arranged TCRα and TCRβ genes and expressed the consequent αβ TCR at the cell 
surface of developing thymocytes (Figure 1.2c), generated TCRs are selected to be both func-
tional and tolerant to self through the process of positive and negative selection. Together, these 
processes create an αβT cell repertoire that is restricted to antigens presented on MHC molecules 
(by positive selection) and with constraints on self-reactivity (by negative selection) which 
forms the basis of central T cell tolerance. Firstly, αβ TCRs, which have already undergone β 
selection with the pTα chain (described previously), undergo the process of positive selection 
(Hogquist et al. 1992) . Here, self-antigens bound to MHC molecules are presented by thymic 
cortical epithelial cells to developing αβ TCR bearing thymocytes which, at this stage, express 
both CD4 and CD8 co-receptors – termed double positive (DP) thymocytes. TCRs which are 
able to bind self-peptide-MHC molecules with sufficient affinity to induce T cell triggering re-
ceive consequent survival signals and are able to proceed to further development. T cells bearing 
αβ TCRs without sufficient binding capacity for MHC are deleted through the process of neglect 
over approximately 36 hours (in mice) (Stritesky et al. 2013).  
Secondly, MHC binding-capable T cells migrate to the thymic medulla where they undergo 
negative selection against self-peptide MHC-molecules presented by medulla thymic epithelial 
cells (mTECs) and thymic dendritic cells (Gallegos & Bevan 2004). These cells present an array 
of tissue specific antigens (TSAs) to candidate αβ TCRs which, if very strongly engaged by the 
expressed TCR above a certain threshold, signal for deletion by apoptosis and are thus removed 
from the T cell repertoire (Kappler et al. 1987). αβ TCRs which engage MHC presented TSAs 
weakly are licensed for the periphery. A portion of MHC-II restricted αβ T cells which exhibit  
higher end of affinities to TSAs – but not so high as to be deleted – are differentiated to thymi-
cally-derived regulatory T (tTreg) cells by expression of the FoxP3 transcription factor and 
consequent expression of CD25 (Hsieh et al. 2012) – the functional consequence of which will 
be described to follow. 
Once they have undergone positive and negative selection, thymocytes leave the thymus as 
naïve T cells which survey and sample the periphery for cognate MHC presented antigens. The 
outcome of TCR generation, T cell development and thymic selection is a peripheral T cell rep-
ertoire of approximately 107 to 108 T cell clonotypes (Turner et al. 2006). 
1.2.5 T cell types 
T cells represent an immune cell that exhibits a high degree of functional, molecular and phe-
notypic variability. As a result, T cells can be categorised into a number of different types and 
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subsets based on the type of TCR they possess, the cell surface markers expressed on their sur-
face and ultimately the function they perform as part of the immune system. An overview of the 
T cell types and subsets discussed in this section, with focus on those of the CD4+ lineage, is 
outlined in Figure 1.3. 
T cells are separated into two distinct cell types based on their TCR expression. γδ TCR 
expression defines the γδ T cell which seem to perform ‘innate-like’ function. The full extent of 
γδ T cell function is not fully understood, however, these T cells are able to recognise a large 
array of non-peptide ligands and are thought to be important in generating early responses to 
pathogens (Vantourout & Hayday 2013). αβ TCR expression defines the αβ T cell which make 
up the majority of T cells in the periphery and are the focus of this thesis. Unlike antibodies or 
B cell receptors, αβ TCRs do not directly recognise antigenic markers in situ i.e. directly as part 
of the antigenic protein or, for example, on the surface of an evading pathogen. Instead, most 
‘conventional’ αβ TCRs bind to peptide derivatives of antigenic proteins presented by (APCs) 
on the antigen presentation family of proteins called major histocompatibility complex (MHC). 
‘Conventional’ T cells therefore survey the periphery for antigens presented on MHC molecules 
bearing peptide ligands for which their expressed TCR can bind.  
In contrast, a portion of αβ T cells such as invariant natural killer T cells (iNKT), mucosal-
associated invariant T (MAIT) and germline-encoded mycolyl-reactive (GEM) T cells make up 
the ‘unconventional’ T cell fraction which do not bind MHC presented peptide ligands (Godfrey 
et al. 2015). Nevertheless, upon binding of ligand all T cells can undergo the process of T cell 
triggering, consequent activation and clonal expansion. The functional consequence of such ac-
tivated T cells is diverse – from direct lysis of ligand bearing cells, to the release of immune 
stimulatory cytokines or immune regulatory factors.  
The functional fate of T cell triggering is dependent on the T cell phenotype, driven by a 
number of different surface and transcriptional factors. In conventional αβ T cells, there are two 
major types: CD4+ T cells and CD8+ T cells defined by their expression of respective namesake 
co-receptors. Commitment to either lineage occurs during thymocyte development - based on 
the restriction of the αβ TCR recombined – resulting in two functionally distinct T cell types. 
Commitment to either lineage occurs prior to negative selection and is thought to be driven by 
a number of different models including (a) CD4/CD8 specific signalling instruction, (b) TCR 
signal strength or (c) stochastic binding of CD4 or CD8 during positive selection (Germain 
2002).  
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Figure 1.3 – Overview of αβ T cell lineage subsets: 
Schematic overview of the lineage of various, but not all, αβ T cell subsets. T cell (black) and 
corresponding restriction ligand (grey) is shown. Collated from (Dong & Martinez 2010; 
Godfrey et al. 2015). 
TH = T helper, TFH = T follicular helper, Tr1 = type 1 regulatory T cells, Treg = regulatory T cells, 
tTreg = thymus-derived Treg, pTreg = peripherally-derived Treg, MAIT = Mucosal-associated 
invariant T cells, GEM = germline-encoded mycolyl-reactive, CD1b/c/d = cluster of 
differentiation 1b/c/d, NKT = Natural killer T cells, HLA-E = Human Leukocyte Antigen-E. 
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The primary difference is their restricting ligands: CD8+ T cells express TCRs which bind pep-
tides presented on MHC class I (MHC-I) molecules the result of which is generally to lyse ligand 
bearing presenting cells. CD4+ T cells, on the other hand, express TCRs that bind peptides pre-
sented on MHC class II molecules; the functional consequence of which is far more diverse – 
from enhancing to regulating adaptive and innate immune responses. 
1.2.6 CD4+ T cell subsets 
The range of effector functions performed by CD4+ T cells is mediated by a further differentia-
tion in the periphery of antigen unexperienced (naïve) CD4+ T cells, upon antigen stimulation, 
into various subsets defined by their function. CD4+ T cells can be categorised into two seem-
ingly opposite functional phenotypes: those that undertake ‘helper’ or effector function and 
those that perform ‘regulatory’ or homeostatic function. This subset definition is generally as-
signed due to the expression of signature cytokine molecules and lineage-defining transcription 
factors. 
1.2.6.1 T helper cells 
T helper (TH) cells are generally described functionally as promoting immunity through a num-
ber of different mechanisms, including the release of inflammatory cytokines resulting in 
consequences on the activity of innate and adaptive immune responses. The exact pathways by 
which TH cells enhance immune networks is dependent on the functional differentiation of naïve 
T cells during the processes of T cell priming, described in more detail in section 1.3.4. Here, 
activation of naïve T cells in the presence of T cell ‘polarising’ cytokines within the microenvi-
ronment results in the differentiation to effector CD4+ TH cell subsets. Each subset can therefore 
be defined by the polarisation cytokine which signals their differentiation, the consequent tran-
scription factors which initiate this differentiation of phenotype and the characteristic ‘signature’ 
cytokine profile of the TH cell subset. 
The T helper 1 (TH1) subset, for example, is polarised by IFNγ and IL-12 signalling, differ-
entiated through expression of the lineage-specific transcription factors STAT4 and T-bet and 
characterised by the expression of the inflammatory cytokine IFNγ (Kaiko et al. 2008). The 
function of activated TH1 cells, through release of IFNγ and other cytokines (such as IL-2, IL-
12, TNFα & TNFβ), involves the provocation of cell-mediated immunity, for example, through 
stimulation of antigen presentation by triggering assembly of the immunoproteasome (Griffin 
et al. 1998) and the activation of macrophages (Nathan et al. 1983). A further description of TH1 
function, with a focus on TH1 responses to tumours, will be described to follow. 
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In contrast, the TH2 subset of cells, polarised by IL-4, is characterised by the lineage-specific 
transcription factors STAT6 and GATA-3 and production of cytokines such as IL-4, IL-5, IL-9, 
IL-10 and IL-13 (Mosmann & Coffman 1989). TH2 effector functions include stimulating B cells 
and class switching to IgE antibodies (Shimoda et al. 1996), with consequent influence on mast 
cells and eosinophil activation (Amin 2012; Deo et al. 2010).  
TH17 cells, polarised under a microenvironment of IL-6 and TGFβ and absence of IL-4 and 
IL-12 are driven to differentiate by the RORγT transcription factor and are characterised by the 
expression of the signature IL-17 cytokine (Kaiko et al. 2008). IL-17 expressing TH17 cells have 
implications in neutrophil recruitment to sites of inflammation (Miyamoto et al. 2003). In a 
study of 125 colorectal tumour patients, an elevated TH17 gene expression signature by tumour 
infiltrating lymphocytes correlated with poorer patient prognosis (Tosolini et al. 2011). 
Finally, IL-6 and IL-21 cytokines are able to polarise and differentiate T follicular helper 
(TFH) cells through expression of the Bcl6 transcription factor which, in turn, produce further 
IL-6 and IL-21 (Eto et al. 2011). These cells enhance the formation of germinal centres in sec-
ondary lymphoid organs and thus shape adaptive B cell immunity. A summary of other TH cell 
subsets is presented in Figure 1.3. 
1.2.6.2 T cells with regulatory function 
CD4+ T cells possessing regulatory function are defined by their ability to suppress immunity 
and are essential in maintaining self-tolerance. The most characterised T cell with regulatory 
function is termed the regulatory T (Treg) cell, which are characterised, in humans, by CD25 
surface marker expression and the transcription factor FoxP3 (Sakaguchi 2005). Differentiation 
of Treg cells can occur under TGFβ polarising signalling where differentiation towards a regula-
tory phenotype is induced by FoxP3 expression through SMAD2/SMAD4 signalling molecules 
(Pollizzi & Powell 2014). 
Treg cells, in response to antigen encounter, release cytokines which possess suppressive ca-
pacity such as IL-10, TGF-β and IL-35 (Sakaguchi et al. 2009). Additionally, Treg cells suppress 
effector T cells through cell-contact mechanisms. For example, Treg cells can effect antigen 
presentation through competitive blockade of APCs and consequent prevention of effector T cell 
access (Onishi et al. 2008). Moreover, Treg cells can modulate APC expression of CD80 and 
CD86 co-signalling molecules through trogocytotic ligand ripping by the suppressive molecule 
CTLA-4 (Qureshi et al. 2011). In addition, Treg cells are able to modulate local T cell immunity 
by ‘mopping’ of the T cell growth cytokine IL-2 through their high affinity IL-2 receptor α chain 
(CD25) thus resulting in effector T cell deprivation (Pandiyan et al. 2007). Additionally, through 
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an unknown mechanism, expression of the co-inhibitory molecule LAG-3 by Treg cells is re-
quired for optimal Treg function (Huang et al. 2004). 
As well as ‘classical’ FoxP3+ Treg cells, other T cell subsets with regulatory function have 
been described, however, lack of subset specific cell surface markers have limited their charac-
terisation and functional distinction from other subsets with regulatory function. TH3 cells have 
been shown to be distinct regulatory subset induced from naïve TH cells that are characterised 
by high expression of TGF-β with implications in antibody class switching to IgA (Fukaura et 
al. 1996). It has been postulated, however, that observed TH3 cell function, is an extension of 
peripherally induced Treg cells due to contradicting evidence of FoxP3 expression by the poten-
tial subset (Gol-Ara et al. 2012). 
One distinct T cell subset with regulatory function is the Type 1 regulatory (Tr1) cell subset 
which is characterised by the expression of cell surface CD49b and LAG-3 (Gagliani et al. 
2013). Tr1 cells express high levels of the immunosuppressive cytokines IL-10 and TGF-β but 
also low levels of IFN-γ, IL-2 and IL-5 whilst lacking IL-4 expression (Willimsky & 
Blankenstein 2005). Tr1 cells are able to modulate the presentation of antigens by the direct 
killing of myeloid derived APCs through the release of granzyme B and perforin (Magnani et 
al. 2011). Despite a highly suppressive function, Tr1 cells do not express FoxP3 and thus are 
considered a phenotypically distinct regulatory T cell subset (Vieira et al. 2004).  
1.2.6.3 T cell plasticity 
Despite classification of TH subsets, TH cells exhibit plasticity and can therefore be influenced 
into shifting functionality or phenotypic conversion (Hirahara et al. 2013). IFNγ signalling, for 
example, can interconvert TH2 cells to TH1 cell function by inducing T-bet expression, highlight-
ing a capacity for plasticity in TH cell subsets (Hegazy et al. 2010). Moreover, plasticity between 
TH and Treg subsets also occurs. Whilst the Treg lineage can be determined in thymocyte develop-
ment – characteristic of thymically derived Treg cells (tTreg cells) – regulatory function can also 
be induced peripherally by the interconversion of TH cells to Treg cells. T cells with this induced 
regulatory function are termed peripherally-derived Treg cells (pTreg). Such interconversion can 
occur when naïve TH cells encounter pMHC antigen under sub-immunogenic conditions and 
consequently induce Treg function (Apostolou & von Boehmer 2004). 
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1.3 Antigen specific activation of CD4+ T cells 
Within the periphery, circulating CD4+ T cells sample antigen presenting cells via their TCR 
and, upon binding cognate MHC-II presented antigen, initiate TCR triggering, consequent T cell 
signalling and activation. The ability of CD4+ T cells to mount a response to tumour antigens is 
dependent on the immune microenvironment and the molecular interactions that occur at the 
interface between CD4+ T cells and antigen presenting cells. This interface is termed the immu-
nological synapse, within which, the TCR-pMHC interaction is key to initiating an antigen 
specific functional response. Upon activation, T cells proliferate through clonal expansion, dif-
ferentiate and perform subset specific functions which modulate immunity. 
1.3.1 Structural features of the T cell receptor 
An αβ TCR is a heterodimeric protein comprised of TCRα and TCRβ chains generated by so-
matic recombination as described previously. The structure of an assembled human TCR was 
first described in 1996 (Garcia et al. 1996). The TCR is formed by covalent linkage of the TCRα 
and TCRβ chains via a membrane proximal disulphide bridge (Claverie et al. 1989). Each TCR 
chain forms two Ig-like domains: a membrane proximal constant domain (C) and membrane 
distal variable (V) domain (Figure 1.4a). These domains are encoded by corresponding C- and 
V(D)J-gene segments as described in section 1.2.4 whereby the Vα domain is constructed from 
V- and J-gene segments, whilst Vβ is constructed from V-, D- & J-gene segments (Figure 1.4b). 
Association of the Vα and Vβ domains results in the highly variable membrane distal antigen 
binding site of the αβ TCR (Chothia et al. 1988).  
The surface of the antigen binding site is constructed from six variable loops which mediate 
binding – termed complementarity determining regions (CDR) loops; numbered CDR1α -2α -
3α and CDR1β -2β and -3β (Davis & Bjorkman 1988).  The variability within these loops are 
generated during TCR gene arrangement. In both the Vα and Vβ domain, CDR1α, CD2α, 
CDR1β and CDR2β are encoded within the V-gene segments and thus variability is induced by 
variable (V) domain selection only – known as combinatorial diversity. Thus CDR1 and CDR2 
represent the germline encoded segments of the antigen binding surface. Contrastingly the 
CDR3 loops exhibit higher variability as they are encoded by the junctions between recombined 
V(D)J-segments and are thus non-germline encoded. The Vα CDR3α loop sequence is derived 
from the V-J junction about which junctional diversity occurs as well as combinatorial diversity. 
Furthermore, the Vβ CDR3β loop is encoded by two junctions via incorporation of the D-gene 
segment at the TCRβ locus. As a result, the CDR3β loop is also non-germline encoded and 
exhibits increased variability compared to CDR3α due to junctional diversity introduced at both 
V-D and D-J junctions. 
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Figure 1.4 –The αβ T cell receptor (TCR) and its highly variable antigen receptor: 
a) Cartoon representation of the structure of the extracellular domain of a TCR. TCRα chains 
and TCRβ chains associate and are covalently linked via a disulphide bridge (S – S) at the 
membrane proximal region of the TCR. The heterodimeric TCR contains four Ig-like domains 
classified as Cα, Vα, Cβ and Cβ. At the membrane distal edge, the six complementarity 
determining region (CDR) loops (coloured and labelled accordingly) make up the antigen 
binding site. Images generated from PDB: 4GKZ (Holland et al. 2012). 
b) Contribution of the assembled TCRα and TCRβ genes to the formation of the highly variable 
antigen binding site as a result of somatic recombination. Variable domains Vα and Vβ are 
encoded by TCRα VJ and TCRβ VDJ gene segments, respectively. Constant domains Cα and 
Cβ are encoded by the TCRα C- and TCRβ C-gene segments, respectively. CDR1 and CDR2 
loops of both TCR chains are encoded by respective V-gene segments. CDR3α is encoded by 
the TCRα VJ junction. CDR3β is encoded by the TCRβ V-D-J junction.  
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1.3.2 Presentation of antigens by MHC-II molecules 
Unlike antibodies, TCRs do not bind to native immunogenic molecules in solution or directly 
on pathogenic entities. Instead, αβ TCRs bind antigens presented on MHC molecules to the T 
cell repertoire. Due to positive selection during TCR rearrangement and a preselection bias in 
the germline TCRα and TCRβ genes, the T cell repertoire is shaped to recognise peptide antigens 
presented on MHC molecules and thus TCRs are ‘hardwired’ for binding MHC (Garcia et al. 
2009; Dai et al. 2008). As a result, TCRs are ‘restricted’ to MHC engagement. This system of 
antigen presentation and recognition allows exchange of antigenic material from innate immun-
ity to adaptive immunity. Moreover, presentation of antigens on the surface of cells allows the 
detection of intracellular antigens which are inaccessible to antibodies. 
1.3.2.1 MHC-II molecules and their role in presenting to CD4+ T cells 
As previously eluded to, classical MHC molecules are divided into two classes: MHC class I 
molecules (MHC-I) and MHC class II molecules (MHC-II). In humans, the MHC family of 
proteins are encoded by the human leukocyte activation (HLA) complex of genes which contains 
over 200 individual genes. The studies described in this thesis involve presentation of peptide 
antigens by MHC-II molecules and, thus, will be the focus of this section. 
In humans, MHC-II presenting molecules are encoded by the HLA- DR, -DP and -DQ loci. 
Whilst each MHC-II molecule is structurally related and functionally similar, subtle differences 
between different MHC molecules exist, particularly at the peptide binding region (discussed to 
follow). For example, there are almost 2000 known alleles of the HLA-DRB1 gene which de-
fines the MHC-II molecule HLA-DR1 according to the IPD and IMGT/HLA database 
(Robinson et al. 2015). Ultimately, the variations between MHC-II genes and alleles possessed 
by a single individual allows the presentation of different peptide sequences by different MHC-
II molecules, thus, increasing the number of potential presentable peptide chemistries– termed 
the ligandome (Rammensee 1995). The genes encoded by MHC loci are highly polymorphic 
and thus variable between individuals. Indeed the MHC gene complex is the most polymorphic 
region within the human genome (Potts & Slev 1995). For MHC-II molecules, these genes are 
generally expressed on cells with professional APC function.  
In the periphery, professional APC function is typically performed by multiple immune cell 
types including: B cells, dendritic cells and macrophages (Kambayashi & Laufer 2014). MHC-
II expression, however, can be induced in non ‘professional’ APCs (Kambayashi & Laufer 2014) 
such as mast cells and eosinophils, but also on non-haematopoietic cells such as mucosal epi-
thelial cells (Shiao et al. 2007). Professional APCs, however, expressing MHC-II molecules, 
survey the body via constant uptake of soluble antigens, degraded cellular material – or whole 
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cells through phagocytosis pathways – and present peptide derivatives on MHC-II molecules at 
their surface. Upon activation by innate process such as PPR signalling in dendritic cells and 
macrophages or by B cells in response to antigen specific activation through the B cell receptor, 
professional APCs can enter the lymphatic system where they present antigens to naïve CD4+ T 
cells in secondary lymphoid organs (Itano & Jenkins 2003).  
1.3.2.2 Processing of antigens onto MHC-II molecules 
Presentation of peptide epitopes on MHC-II molecules classically occurs through the processing 
of extracellular antigens through the endocytic pathway. By this pathway, exogenous antigens 
are internalised by professional APCs, processed to peptide derivatives and presented to the T 
cell repertoire on MHC-II molecules (Watts 1997). Antigen uptake can occur through a number 
of different processes and is cell type dependent. Macrophages, for example, can phagocytose 
whole cells through phagosomes resulting in MHC-II antigen presentation within 20 minutes in 
vitro (Harding & Geuze 1992). B cells can specifically internalise antigens by receptor mediated 
endocytosis through the B cell receptor (BCR) (Lanzavecchia 1990).  
Acquired antigens are compartmentalised into low pH endocytic vesicles which degrade 
whole proteins through lysosomal proteolysis by peptidases such as the cathepsin family (Watts 
1997). Endocytic vesicles fuse with precursor invariant chain (Ii)-associated MHC-II molecule 
containing vesicles to form the MHC-II compartment. Consequent cleavage of the Ii chain re-
sults in MHC-II molecules bound with the class II-associated invariant-chain peptide (CLIP) 
which prevents early exchange of peptides into the presenting molecule. Through the action of 
the MHC-II molecules HLA-DM, CLIP removal is catalysed allowing for the exchange of pep-
tides capable of binding MHC-II at a higher affinity (Denzin & Cresswell 1995). Consequently, 
peptide loaded MHC-II molecules are transported to the cell surface via exosomes to the cell 
surface in order to present to the T cell repertoire.  
1.3.2.3 Characteristics of peptide presentation on MHC-II molecules 
MHC-II molecules are approximately 60 kDa heterodimeric glycoproteins consisting of an α 
and β chain each anchored to the plasma membrane via a transmembrane domain (Brown et al. 
1993). Each chain organises as two Ig-like domains resulting in a four domain extracellular 
portion with domains noted α1, α2, β1 & β2 (Figure 1.5a). The membrane proximal α2 and β2  
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Figure 1.5 – Structural features of peptides presented on MHC-II molecules: 
a) Cartoon and stick representation of the structure of an influenza-derived peptide (magenta) 
presented on the MHC-II molecule HLA-DR1. The assembled HLA-DR1 structure, comprised 
of α chain (pale pink) and β chain (pale green) form four Ig-like domains: α1, α2, β1 and β2. 
The peptide is presented at the membrane distal end of the protein. 
b) Top down view of peptide binding into the open ended peptide binding groove of HLA-DR1. 
The peptide lies above a bed of eight anti-parallel β sheets, walled by α chain and β chain helices. 
Coloured as in a). 
c) Top down view of the MHC (surface) binding the 13mer influenza-derived peptide (spheres). 
Peptide core residues (black) are bound into the P1, P4, P6 and P9 binding pockets resulting in 
a two amino acid N-terminal peptide flanking residues (N PFR) and two amino acid C-terminal 
peptide flanking residues (C PFR). 
All images generated from PDB: 1FYT (Garboczi et al. 1996)  
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domains exhibit less variation and are involved in the binding of the CD4 co-receptor (Yin et al. 
2012). At the membrane distal end of the associated MHC-II molecule, however, the α1 and β1 
domains combine to form a peptide binding groove upon which the peptide antigens presented 
to TCRs are loaded. In MHC-II molecules, the peptide binding groove is constructed from both 
α and β chains of the MHC. The resulting binding groove consists of a base of eight anti-parallel 
β sheets that form the ‘floor’ of the peptide binding groove (Brown et al. 1993). The concaved 
nature of the groove is constructed from two helical portions that span the length of the molecule 
in anti-parallel orientation forming the ‘walls’ to the binding groove (Figure 1.5b). The helical 
portion that lines the α domain side of the groove is discontinuous and is comprised of a 310 
helix followed by an α-helix structure, linked by a flexible loop. Contrasting to MHC-I mole-
cules, the sides of the peptide binding groove are in an open conformation which has 
implications in the binding of MHC-II restricted peptides (Holland et al. 2013). 
1.3.2.4 Binding of the core peptide epitope to MHC-II molecules 
Through elution of peptides from MHC molecules, it was revealed that different MHC mole-
cules bound different peptide sequences which were characterised by allele-specific peptide 
motifs (Falk et al. 1991). Elucidation of the first high-resolution structure of an MHC-II mole-
cule (HLA-DR1) highlighted that the polymorphic residues of MHC-II molecules were focused 
on the areas of the α1β1 peptide binding groove (Stern et al. 1994). As a result, each MHC-II 
molecule has a motif of preferential peptide ‘anchoring’ residues which orientate into the MHC 
molecule in the direction of the membrane (Rammensee et al. 1995). Together, these studies 
showed that peptides are bound into a series of peptide binding pockets, lined by polymorphic 
residues, which determine allele-specific peptide motifs. The MHC-II molecule HLA-DR1, for 
example, is described to have four binding pockets, designated: P1, P4, P6 and P9 (Jones et al. 
2006). These concaved pockets make extensive contacts with the peptide and generally facilitate 
the largest binding energy of peptide to MHC-II stability. Due to the formation of four anchoring 
points to the peptide, MHC-II bind peptides deeply into the groove in a flat extended confor-
mation (Stern & Wiley 1994). Due to the open-ended conformation of MHC-II peptide binding 
grooves, MHC-II molecules are able to bind peptides of varying length – typically between 12-
20 amino acids (Holland et al. 2013). MHC-II molecules, however, maintain a nine amino acid 
binding ‘core’ which facilitates the majority of binding between peptide and MHC-II (Figure 
1.5c). For HLA-DR1, the nonamer binding core residues of a peptide are fixed by the P1, P4, 
P6 and P9 pockets which anchor the peptide (Stern & Wiley 1994; Jones et al. 2006).  
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1.3.2.5 Influence of peptide flanking residues on MHC-II peptide presentation 
The ability to facilitate longer peptides is enabled by the extension of peptide residues outwards 
and beyond the peptide groove. This property is unique to MHC-II molecules and is not gener-
ally observed in MHC-I molecules which have a fixed width within the groove – and extension 
of peptide length results in ‘bulging’ out of the centre of the groove and a consequent increase 
in peptide height (Holland et al. 2013). These residues which extend out of the peptide binding 
core, in MHC-II systems, are termed the peptide flanking residues (PFRs). 
The role of PFRs on peptide to MHC-II binding and consequent TCR activation is yet to be 
fully elucidated. Analysis of a murine I-AK restricted hen egg white lysozyme epitope revealed 
that naturally processed antigen, by B-cell lymphoma cell lines, showed an increased relative 
abundance of presented peptides with extended PFRs compared to the core nine amino acid 
binding core (Nelson et al. 1992). Such higher abundance was later attributed to an increased 
pMHC half-life by PFR containing peptides at the surface of APCs in vitro (Nelson et al. 1994). 
Subsequently, this increased pMHC stability was shown to influence T cell activation in a mu-
rine I-Ab presented self-peptide system where the length of both N-terminal and C-terminal 
PFRs impacted the ability to activate a cognate CD4+ T cell clone in vitro (Sant’Angelo et al. 
2002). Here, Sant’Angelo et al. showed, via pMHC stability assays, that increasing PFR length 
at both termini allowed increased MHC-II peptide stability – whilst mutation of these residues 
did not impact clone activation. Together, these observations suggested that, in the system stud-
ied, both N- and C-terminal PFRs primarily promote enhanced T cell activation through 
enhanced peptide presentation. Such findings have been supported by computational modelling 
where increased N- and C-terminal flanks were predicted to enhance peptide to MHC-II binding 
affinity and a predicted optimal length of 18-20 was calculated (O’Brien et al. 2008).  
1.3.3 Structural and biophysical characteristics of MHC-II engagement by TCRs 
Understanding of how TCRs bind to cognate pMHC molecules has been driven by the study of 
soluble TCR and MHC molecules using biophysical and structural techniques (Bridgeman et al. 
2012). Such techniques have been applied to numerous different TCR-pMHC systems: from the 
study of viral antigen-specific TCRs binding cognate peptides, to tumour-specific TCRs binding 
tumour-derived presented antigens (Hennecke & Wiley 2002; Deng et al. 2007). Analysis of 
different TCR-pMHC systems has revealed a number of different patterns and molecular rules 
that generally define TCR engagement of pMHC molecules and, thus, provide a snapshot of the 
rules governing binding by the TCR repertoire as a whole (Rudolph et al. 2006). Data describing 
TCR engagement to MHC-I restricted antigens, however, far outweighs that of MHC-II re-
stricted counterparts. As a result, less is known about how CD4+ T cells engage their ligand. 
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Despite parallels in structural organisation and generation, MHC-II engagement by TCRs 
occurs at a comparatively weak affinity compared the binding of antigen by antibodies 
(Bridgeman et al. 2012). This low affinity is attributed to slow association rates (Kon) followed 
by fast dissociation rates (Koff) (Boniface et al. 1999). The affinity at which TCRs bind cognate 
pMHC antigens is governed by the MHC restriction; whereby TCRs restricted to MHC class I 
molecules bind at higher affinity than MHC class II counterparts (Cole et al. 2007). Moreover, 
the affinity of TCR engagement is also dependent on the chemistry of the presented peptides 
and the TCR’s antigen binding site constructed from the CDR loops (Peled et al. 2008). As a 
result, variation in binding strength is observed by different TCRs binding to different peptide 
epitopes on the same MHC molecule (D. Cole et al. 2007). The origin of the peptide antigen 
also appears to influence the affinity of cognate TCR engagement to pMHC. Viral-derived pep-
tide antigens, for example, have been shown to be bound by TCRs at higher affinity that those 
derived from either self or tumour-derived antigens (Aleksic et al. 2012). For TCRs restricted 
to MHC-II molecules, this exact affinity range is unknown as TCRs have been shown to bind to 
cognate pMHC-II at unmeasurably low affinities. However, such binding can be confirmed via 
experimental multimersation effects (Li et al. 2005; Deng et al. 2007). An estimate of the poten-
tial affinity range between TCRs and pMHC-II molecules is between 5 – 500 µM (KD) 
(Bridgeman et al. 2012).  
The mode of binding between TCRs and pMHC occurs via the antigen binding site located 
on the membrane distal surface of the TCR Vα & Vβ domains which is comprised of the six 
CDR loops, described previously. All TCRs described structurally, except one, bind atop pMHC-
II ligands with a fixed polarity whereby the TCRα chain interacts largely with the MHC β chain 
and the TCRβ chain interacts primarily with the MHC α chain (Rossjohn et al. 2015). This po-
larity is also replicated in MHC-I restricted TCR engagement. As a result of this polarity, MHC-
II engagement is not parallel to the long axis of the peptide. Instead TCRs bind diagonally across 
the peptide at an angle termed the ‘crossing angle’ or ‘docking angle’. The docking angle of 
TCR engagement of MHC-II, according to a meta-analysis of available structure data, is on 
average 76 ° within a range of 44 – 115 ° (Rossjohn et al. 2015). The exception to this standard 
geometry is a HLA-DR4 restricted TCR, expressed from an in vitro induced Treg clone which 
bound its cognate self-peptide HLA-DR4 with a reversed polarity and at a considerable tilt 
(Beringer et al. 2015). The result of this abnormal binding mode was that the Treg derived TCR 
engaged the pHLA-DR4 molecule using the TCRα chain only. 
Analysis of the CDR loop contribution to binding of pMHC has shown that, similarly, TCRs 
exhibit commonality in binding. MHC-II restricted TCRs generally bind the MHC portion using 
the germline encoded CDR1 and CDR2 loops whilst the non-germline encoded CDR3 loops are 
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located centrally to the antigen binding site and bind primarily the peptide (Feng et al. 2007). 
This observation led to the hypothesis that TCRs are hardwired to bind MHC-II molecules first 
via CDR1 and CDR2 ‘codons’ allowing for CDR3 loop ‘scanning’ for peptide specificity 
(Garcia et al. 2009). These rules, however, appear flexible as shown by the binding of a single 
TCR to two peptides bound to the same MHC-II molecule – which exhibited a differential foot-
print of ligand engagement (Mazza et al. 2007). 
TCRs have been shown to exhibit a high degree of cross-reactivity resulting in the ability of 
single TCRs can bind more than a million different peptides (Wooldridge et al. 2012). The nature 
of the CDRs suggests that the surface interface, which make up the antigen binding site of the 
TCR, may exhibit inherent plasticity which enables such cross-reactivity (Garcia & Wilson 
1999). Structural studies of TCRs and pMHC-II molecules in ligated and unligated states, how-
ever, have shown that, in contrast, minimal CDR loop movements can occur to mediate binding 
and that loop flexibility is not required to bind to the same peptide epitope presented on two 
different MHC-II molecules (Holland et al. 2012). 
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Figure 1.6 – Engagement of pMHC-II by a TCR: 
a) Cartoon and stick representation of an influenza-reactive TCR (cartoon; blue:aqua) binding 
to an influenza-derived peptide (sticks; pink) presented on the MHC-II molecule HLA-DR1 
(cartoon; pale pink/pale green). TCR engagement occurs via a generally conserved polarity: Vβ 
over α1 and Vα over β1. 
b) Top down view of CDR loop binding over the pMHC-II surface volume. CDR1α and CDR2α 
primarily bind the β1 domain of MHC-II whilst CDR1β and CDR2β primarily bind the α1 
domain. CDR3α and CDR3β interact primarily with the bound peptide core (black). In this 
influenza model, only the CDR1α binds over the peptide flanking residues (red) at the N-
terminus. CDR loops coloured according to inset labels. 
All images generated from PDB: 1FYT (Jens Hennecke et al. 2000)  
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1.3.3.1 Influence of PFRs on TCR engagement of MHC-II presented peptides 
As well as enhancing pMHC-II stability, described previously, PFRs have also been implicated 
in pMHC-II engagement. Such an interaction was evidenced by structural data describing the 
influenza-reactive HA1.7 TCR in complex with the hemagglutinin derived HA306–318 peptide 
presented by HLA-DR1, where a direct electrostatic interaction between the TCR and the N-
terminal flanking P-1 lysine residue was observed (J Hennecke et al. 2000). Moreover, mutation 
of the P-1 residue of this peptide epitope to an alanine resulted in decreased HA1.7 clone pro-
liferation (Alexander et al. 1993). Together, these data provide evidence of N-terminal PFRs 
influencing TCR engagement and thus T cell functionality. 
Similarly, analysis of the contribution of PFRs to engagement by TCRs has shown that C-
terminal PFRs are able to modulate binding, in particular, through large positively charged res-
idues that elevate the peptide height of the C-terminal PFR (Godkin et al. 2001). Indeed, 
disruption of the C-terminal PFR of an HIV-derived peptide, which protruded out of the MHC 
binding groove, abrogated the ability to activate a cognate TCR clone (Zavala-Ruiz et al. 2004). 
In addition, modification of a residue in the C-terminal flank to introduce large positively 
charged arginine residues both increases TCR affinity and TCR repertoire selection in a HLA-
DR1 restricted influenza model (Cole et al. 2012; Holland et al. 2013). These data provide fur-
ther evidence of TCR engagement with the PFRs and a potential capacity for enhancement of 
TCR binding through introduction of basic residues within the C-terminal PFR. 
1.3.4 T cell activation and priming through T cell signalling processes 
Engagement of TCR molecules with sufficient capacity to bind pMHC molecules can result in 
the activation of T cells through the process of T cell signalling. The affinity of TCR binding to 
pMHC correlates with the degree of T cell activation (Corse et al. 2011). The way in which the 
TCR transduces this ligand discrimination and receptor sensitivity to trigger T cell signalling is 
currently disputed; with evidence for a number of different TCR triggering models such as the 
kinetic segregation model (James & Vale 2012), serial triggering (Valitutti et al. 1995) and con-
formational/mechanistic models, amongst others (van der Merwe & Dushek 2011). 
Nevertheless, the functional consequence of TCR binding cognate MHC is the initiation of a 
signalling cascade about the TCR/CD3 complex which can ultimately lead to T cell activation. 
The process by which antigen inexperienced T cells encounter antigen and are activated for 
the first time is termed T cell priming. T cell activation in naïve T cells cannot occur via stimu-
lation through the TCR alone (Pollizzi & Powell 2014). It is understood that T cell activation 
requires, firstly, the presence of the CD4 co-receptor which localises the phosphokinase Lck to 
the TCR/CD3 complex which, upon TCR triggering, results in a phosphorylation of the CD3ζ 
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chain ITAMs. This signal is cascaded through consequent recruitment of the ZAP70 kinase to 
the TCR/CD3 complex. Consequent signal transduction results in the eventual dephosphoryla-
tion and consequent nuclear translocation of NFAT – a transcription factor with immune target 
genes. This process is defined as the ‘signal 1’ of T cell signalling. The consequence of signal 1 
transduction alone due to TCR triggering, however, leads to induction of T cell anergy through 
the induction of suppressive gene targets (Appleman & Boussiotis 2003).  
Instead, induction of activation requires a second signalling cascade, ‘signal 2’ which is pro-
vided by the co-stimulatory molecule CD28 (Pollizzi & Powell 2014). CD28 localisation to the 
immune synapse is enabled by the expression of its ligands CD80/CD86 on the surface of APCs. 
Upon CD28 recruitment to the immune synapse, signal transduction results in the nuclear trans-
location of the immune master transcription factor NF-κB. Moreover, through phosphorylation 
of RAS by CD28 and the ‘signal 1’ signalling molecule DAG, both signal 1 and 2 are integrated 
to allow the activation of AP-1 – a third transcription factor. As a result of both signal 1 and 2 
transduction and consequent localisation of the three canonical transcription factors, NF-κB, 
AP-1 and NFAT, naïve T cells are licensed for activation. 
As a result of the requirement for signal 2 in the activation of naïve T cells, APCs are able to 
modulate the priming of the T cell response to presented antigens by regulation of the CD28 
ligands CD80/CD86 expression during antigen presentation (Hertz et al. 2001). Indeed, 
CD80/CD86 are only expressed on activated dendritic cells and, as a result, require their activa-
tion through innate signalling processes before licensing naïve T cell priming. 
As mentioned previously, a number of different CD4+ T cell subsets exist. The functional fate 
of naïve T cells, upon priming by APCs, is determined by a third signal: the T cell polarisation 
signal (Kaiko et al. 2008). Upon priming of naïve T cells through both signal 1 and 2, cytokines 
within the microenvironment influence the functional outcome of naïve T cell differentiation. 
This process forms the basis of CD4+ T cell subset generation as described previously in section 
1.2.6. 
Antigen experienced memory T cells, however, have altered requirements of T cell signalling 
to induce activation (London et al. 2000). In such cells, a lower threshold of signalling is re-
quired for activation, although a degree of co-stimulatory signalling is still required for memory 
T cell activation (Boesteanu & Katsikis 2009). 
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1.4 5T4 as a model of αβ T cell immunity to tumours 
Strong evidence of a role of the immune system and CD4+ T cells in suppressing tumours was 
shown by a number of studies of tumour models in mice in the late 20th and early 21st Century. 
In 1994, a role for the inflammatory cytokine IFNγ was implicated in tumour progression using 
the Meth A mouse fibrosarcoma tumour model (Dighe et al. 1994). Here, dominant negative 
IFNγ receptor (IFNγRDN) tumours exhibited enhanced tumour growth in tumour implanted 
BALB/c mice. This enhanced growth, induced by loss of IFNγ signalling function, was shown 
to render IFNγRDN tumours insensitive to LPS-induced tumour rejection.  
In 2001, evidence of a role for adaptive immunity in tumour rejection was revealed by the 
generation of the RAG2-/- knock out mouse (Shankaran et al. 2001). In these studies, RAG2-/- 
mice, which effectively have no functional T or B cell repertoire, exhibited increased tumour 
rates using the methylcholanthrene- (MCA)-induced tumour model providing evidence of lym-
phocyte involvement in limiting tumour growth in wild type RAG2 sufficient mice. Moreover, 
the tumour limiting capacity by the immune system was shown to be dependent once more on 
IFNγ. 
In 2005, a direct role of CD4+ T cells and professional APCs presenting tumour-derived an-
tigens was revealed using a transgenic mouse system and the MOPC315 mouse myeloma 
tumour model (Corthay et al. 2005). Here, mice bearing a monoclonal TCR repertoire specific 
for a tumour-antigen expressed by implanted myeloma tumours (via transgenic TCR expression 
on a SCID mutated background) were resistant to tumour formation; whilst non-transgenic mice 
exhibited higher tumour burden. It was shown that tumour implantation resulted in the recruit-
ment of macrophages to the tumour site, consequent presentation of tumour-derived peptides on 
MHC-II molecules, subsequent activation of tumour-specific CD4+ T cells in the lymph nodes 
and subsequent release of effector cytokines. These studies therefore highlighted a role of mac-
rophages presenting tumour-derived antigens to tumour-specific CD4+ T cells in the observed 
ability to suppress tumour formation. 
1.4.1 The tumour immunoediting hypothesis 
Postulation as to why the immune system is able to recognise tumours through immunosurveil-
lance, yet immunocompetent individuals still develop tumours, led to the formulation of the 
tumour immunoediting hypothesis (Dunn et al. 2002). It was hypothesised that the immune sys-
tem shapes tumours by adding a selection pressure to tumour formation by which a selective 
advantage to the tumour is to survive in an anti-tumour-competent environment. This hypothesis 
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was evidenced by the transplant of tumours developed in either immunocompetent or immuno-
deficient environments. Tumours grown in RAG2-/- mice and transplanted into RAG2+ WT mice 
were suppressed at a higher rate than tumours grown in RAG2+ immunocompetent WT mice 
and transplanted into RAG2+ immunocompetent WT mice (Shankaran et al. 2001). This obser-
vation suggested that tumours grown in immunodeficient mice were more immunogenic than 
tumours grown in the absence of anti-tumour immunity. It was consequently reasoned that tu-
mours grown in an immunocompetent environment were ‘imprinted’ by anti-tumour immunity 
and that those grown in the absence of an immunocompetence were yet to be shaped or ‘edited’ 
into a tumour variant which had evolved to avoid anti-tumour immunity. Thus in the presence 
of immunocompetence, highly immunogenic tumour variants are eliminated whilst those which 
exhibit low immunogenicity have a selective advantage. At this stage, the tumour is said to be 
in a state of equilibrium with the immune system. Outgrowth of such cells eventually occurs 
due to the escape of tumours from anti-tumour immunity. This led to the formulation of three 
stages on cancer immunoediting, known as the three Es of cancer immunoediting: Elimination, 
Equilibrium and Escape. 
1.4.2 TH1 responses to tumours 
As described previously, TH1 cell differentiation is achieved by the stimulation of primed CD4+ 
T cells by professional APCs under IL-12 polarising signal conditions (Kaiko et al. 2008). The 
consequence of TH1 cell polarisation is the release of an inflammatory cytokine profile including 
IFN-γ, TNFα, TNFβ as well as autologous TH1 promoting IL-2 and IL-12. 
Analysis of the genetic profile of immune cell infiltrate into tumours in a large cohort of 
patients revealed that expression of TH1 immunity associated genes such as those that encode 
IFNγ, Granzyme-B and CD3ζ negatively correlated with tumour recurrence and thus suggests 
that TH1 immunity is an overall correlate of better clinical outcome (Galon et al. 2006). Much 
of the anti-tumour function by tumour specific TH1 cells is attributed to IFNγ. As described 
previously, removal of IFNγR function on tumour mouse models suggested a direct role for 
IFNγ on tumours (Dighe et al. 1994). Synergistically, IFNγ and TNFα are able to induce tumour 
cell senescence and thus arrest tumour cell cycle through the release of reactive oxygen species 
and NADPH oxidases (Hubackova et al. 2015). IFNγ induces MHC-I upregulation on tumour 
cells and thus may contribute to the increased tumour burden in IFNγRDN mice through removal 
of cytotoxic T cell elimination of tumour cells (Propper et al. 2003). Moreover, IFNγ has been 
shown to induce MHC-II expression on tumour cells and thus may themselves be able to present 
antigens to CD4+ T cells as a result of IFNγR signalling (Thibodeau et al. 2012). IFNγR signal-
ling also induces the production of CXCL10 which possesses anti-angiogenic properties 
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(Angiolillo et al. 1995) as well as serves as a chemoattractant for various immune cells (Liu et 
al. 2011). 
As well as having a direct effect on tumour cells expressing IFNγR, release of IFNγ has a 
broader effect on anti-tumour immunity. As eluded to previously, IFNγ has been shown to induce 
macrophage activation at tumour sites which, as a result, present tumour-derived antigens to 
CD4+ T cells (Corthay et al. 2005). Moreover, such macrophage activation results in the release 
of anti-tumour factors such as reactive oxygen species (Mantovani et al. 2004). 
1.4.3 Regulatory responses to tumours 
As a result of thymic selection against self-presented antigens, TCR clonotypes with an in-
creased affinity to self-antigens can enter the periphery as thymic-derived Treg (tTreg) cells 
through acquired expression of the FoxP3 transcription factor (Maloy & Powrie 2001). Due to 
the self-derived nature of tumour antigens, with the exception of neo-antigens, the generation 
of tumour-specific tTreg cells as a consequence of central tolerance is a barrier to immunity to 
tumours. Moreover, antigen stimulation of naïve CD4+ T cells in the absence of co-stimulation 
can lead to T cell anergy and T cell priming in the presence of TGFβ can lead to the induction 
of Treg function and the differentiation to peripherally-derived (pTreg) cells (Pollizzi & Powell 
2014). Indeed, human breast tumours have been shown to express TGFβ and thus may directly 
alter naïve T cell polarisation (Relf et al. 1997). In contrast, however, analysis of the infiltrating 
T cell repertoire of FoxP3- cells compared to FoxP3+ Treg in the MCA induced tumour model 
revealed little overlap in the repertoires of effector and regulatory T cell populations suggesting 
that Treg conversion does not significantly contribute to the population of Treg cells residing in 
tumours (Hindley et al. 2011).  
Many studies have focused on the frequency of Treg cells in cancer patients and their potential 
impact on tumour progression. For example, the degree of infiltrate of FoxP3+ Treg cells into 
ovarian tumours has been shown to correlate with poorer disease prognosis (Curiel et al. 2004). 
In a cohort of 42 patients with epithelial malignancies, the frequency of Treg cells, identified as 
CD4+ CD25+ T cells, were shown to be elevated in the peripheral blood compared to that of 
healthy controls (Wolf et al. 2003). In addition, Treg cells, identified as CD4+ CD25+FoxP3+ cells 
have been shown to be increased in both the peripheral blood and mesenteric lymph nodes of 
patients with CRC (Clarke et al. 2006). Removal of such regulatory cells was shown to unmask 
tumour-antigen-specific CD4+ T cell responses in vitro. 
Infiltration of other suppressive T cell subsets such as Tr1 cells have also been implicated in 
generating regulatory responses to tumours. Tr1 cells are thought to be a subset of induced cells 
with regulatory function as a result of chronic antigen stimulation and priming in the presence 
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of IL-10 (Vieira et al. 2004). Tr1 cells have been shown to be enriched at the sites of human 
hepatocellular carcinomas (Pedroza-Gonzalez et al. 2015) as well as in peripheral blood of head 
and neck squamous cell carcinoma patients (Mandapathil et al. 2009). Moreover, enrichment of 
a highly suppressive T cell subset infiltrating in colorectal tumours, characterised by the expres-
sion of the latency associated peptide (LAP) and LAG-3, have also been identified by our group 
in Cardiff and implicated in possessing potent immunosuppressive capacity (M Scurr et al. 
2013). It is possible that these detected cells are also Tr1 or Tr1-like cells. Identification of LAG-
3 and CD49b as surface co-markers for Tr1 cells will likely aid the further characterisation of 
Tr1 cells and their role in tumours by allowing methodologies for their identification from other 
T cells with regulatory function in vivo (Gagliani et al. 2013). 
Nevertheless, these cells with regulatory phenotype are characterised by expression of high 
levels of IL-10 which suppresses dendritic cell and macrophage maturation causing down-reg-
ulation of MHC and co-stimulatory molecules as well as the inhibition of TH1 cytokines by 
CD4+ T cells (Sato et al. 2011). As a result, levels of IL-10 in the serum correlate positively with 
melanoma disease progression suggesting a role of IL-10 producing regulatory T cell subsets in 
allowing tumour progression (Itakura et al. 2011). 
1.4.4 5T4 is a cancer antigen expressed on solid tumours 
5T4, also known as Trophoblast glycoprotein or Wnt-Activated Inhibitory Factor 1 (WAIF1) is 
a tumour associated antigen (TAA) expressed on a number of different tumours including blad-
der, breast, cervix, endometrium, lung, oesophagus, ovary, pancreas, stomach and testicular 
tumours – as shown by immunohistological staining (Southall et al. 1990). Immunohistological 
staining of non-transformed tissue, however, is limited to human placental tissue as well as some 
detected staining in oral sites; particularly in the presence of inflammation (Ali et al. 2001) . As 
a result of this restricted expression, 5T4 has been highlighted as a target antigen for immuno-
logical therapy. Due to its expression in placental tissue and the foetal trophoblast, 5T4 is 
classified as an oncofoetal antigen. 
5T4 is a single pass transmembrane glycoprotein consisting of a 42 kDa protein component 
and average glycosylated molecular weight of 72 kDa (Hole & Stern 1990). 5T4 functions as a 
modulator of WNT signalling by inhibiting canonical β-catenin signalling and promoting non-
canonical WNT pathways (Kagermeier-Schenk et al. 2011). It’s function is likely to be 
dependent on the short intracellular domain as transfection of cytoplasmic domain deficient 5T4 
into epithelial cells was not able to induce enhanced mobility observed by in vitro delivery of 
wild type 5T4 (Carsberg et al. 1996). The high resolution structure of 5T4 revealed the extra-
cellular domain of 5T4 as a twisted solenoid made up of eight leucine rich repeat units (Zhao et 
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al. 2014). Whilst potential ligand hotspots required for WNT signalling function have been de-
scribed, no ligand or signalling partner molecules of 5T4 have identified, thus, the mechanisms 
by which 5T4 modulates WNT signalling are not fully understood. Nevertheless, due to its role 
in WNT signalling, aberrant expression of 5T4 in humans has potential implications in cellular 
migration and therefore metastatic capacity. Indeed, murine fibroblast cells transfected with 5T4 
exhibit increased motility and dispersion as well as altered morphology in vitro (Woods et al. 
2002) 
 Expression of 5T4 is observed at high frequency in human colorectal tumours. In a cohort 
of 72 colorectal cancer patients, 85 % exhibited 5T4+ tumours as shown by immunohistological 
staining (Starzynska et al. 1992). In the same cohort, presence of 5T4 expressing tumours was 
a correlate of poor-prognosis with a five year survival rate of 22 % in patients histologically 
determined as 5T4+ compared to 75 % in 5T4- tumour patients (Starzynska et al. 1994).  
1.4.5 Immune responses to 5T4  
Knowledge of the immune response to 5T4 in either healthy individuals or cancer patients was 
limited pre-2000. Despite this, development of a cancer vaccine with the aim of boosting im-
mune responses to 5T4 antigen was developed (Mulryan et al. 2002). 
In healthy individuals, 5T4-reactive CD8+ T cells have been detected in the peripheral blood 
of a healthy donor (Redchenko et al. 2006). Such responses were observed ex vivo in one of 30 
tested donors from which cultured T cell lines were grown from the single responding donor. 
Consequent analysis of 5T4-derived peptides revealed an epitope restricted to the HLA-C mol-
ecule Cw7 from the donor. Subsequent cultured T cell lines and clones were shown to lyse 5T4 
expressing autologous presenting cells.  
Similarly, ex vivo IFNγ response rates to 5T4 whole protein was detected at a rate of 1/14 
CRC patient blood samples, however, depletion of Treg cells unmasked a response in a further 
5/14 patients (Clarke et al. 2006). In a study of 5T4 responses in pre-operative CRC patients, 
7/19 patients were classified as 5T4 responders by IFNγ ELISpot assays whilst post-surgery 
responses were increased to 14/19 patients (Betts et al. 2012). This increase in responders could 
be attributed to the decrease in Treg suppression post-operation due to fewer 5T4 responders 
requiring Treg removal to unmask 5T4 responses which correlated with increased Treg numbers 
in pre-operative patients compared to post-operative patients and healthy controls. Moreover, in 
vitro cultured IFNγ responses to an overlapping peptide library of 5T4 revealed that 5T4 re-
sponses were detected in 100 % of healthy donors and correlated, along with Treg numbers, with 
disease progression in CRC patients (Scurr et al. 2013). Presence of a detectable 5T4+ T cell 
response pre-operatively, however, did not influence 5-year tumour recurrence rates but did not 
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negatively correlate with tumour recurrence – as exhibited by a different tumour antigen: carci-
noembryonic antigen (CEA) (Scurr et al. 2015)  
Few studies have begun to identify T cell epitopes of 5T4 in order to describe the observed 
response to 5T4 in healthy donors and tumour patients at the antigenic level. Assaying the po-
tential for MHC-I presentation revealed peptide epitopes of 5T4 initially identified in vitro and 
later characterised ex vivo in vaccinated CRC patients (Shingler et al. 2008). As a result, three 
further epitopes of 5T4 have been identified which were restricted to HLA-A1 and -A2 mole-
cules – as shown by ex vivo responses in individual HLA-A1+ and -A2+ colorectal patients. 
Subsequent detection of CD8+ T cells specific to two of these epitopes (restricted to HLA-A2) 
using 5T4-derived MHC-I multimer staining was achieved in in vitro cultured T cell lines from 
multiple (healthy and renal cell carcinoma) donors (Tykodi et al. 2012). Moreover, one of these 
epitopes 5T417–25 was shown to be naturally processed on renal cell carcinoma cells and a cyto-
toxic T cell clone grown against this epitope was able to directly lyse a 5T4 expressing renal 
cell carcinoma cell line. 
A study into the potential recognition of 5T4 by CD4+ T cells highlighted that indeed CD4+ 
T cells were detectable in in vitro cultured T cell lines from healthy donors (Elkord et al. 2008). 
Such responses, however, were enhanced upon removal of CD25+ cells suggesting once more 
that Treg cells may play a role in dampening immune responses to 5T4. Nevertheless, a CD4+ T 
cell epitope of 5T4 (5T4222–236) restricted to HLA-DR4 was identified. IFNγ producing CD4+ T 
cells were detectable in T cell lines cultured from 4 out of 9 HLA-DR4+ healthy donors. Conse-
quently, 5T4 responses were shown to deteriorate with tumour stage. 
From studies in mice, it has been hypothesised that for a successful anti-5T4 and consequent 
anti-tumour T cell response, central tolerance must be broken. mRNA transcripts for 5T4 have 
been detected in the thymus suggesting that, at least in mice, 5T4 is likely presented as a TSA 
by thymic antigen presenting cells during negative selection (Castro et al. 2012). Indeed, knock 
out of 5T4 in mice was shown to enable enhanced antibody and IFNγ mediated CD8+ T cell 
responses as a result of 5T4 vaccination compared to 5T4 replete wild type C57BL/6 mice. 
Moreover, modulation of Treg cells via antibody depletion enhances CD8+ T cell responses after 
vaccination in wild type 5T4 replete mice to levels observed in 5T4 knock out mice. It has there-
fore been hypothesised that removal of 5T4 expression from the thymus enables a T cell 
repertoire more receptive to 5T4 recognition and effector function. Clearance of implanted 5T4+ 
B16 tumours in such mice, however, was not halted in 5T4-/- mice unless immunity was boosted 
via 5T4 vaccination, thus, suggesting a role for induced tolerance to 5T4 in the periphery. These 
data highlight how the induction of tolerance to tumour vaccine targets, such as 5T4, is a chal-
lenge of cancer vaccination efficacy (Zhou et al. 2006). 
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1.4.6 Potential therapeutic enhancement of immunity to 5T4 
Immunity to 5T4 antigens in both humans and mice appears to be masked by regulatory T cell 
mechanisms. Consequently, a highly attenuated, non-replicating modified vaccinia virus Ankara 
(MVA) vaccine encoding 5T4 (MVA-5T4/Trovax®) has been developed in efforts to enhance 
immunity in cancer patients. This vaccine showed promise in pre-clinical models where tumour 
burden is reduced in the 5T4+ CT26 murine tumour model and where a prolonged immunity to 
tumour was maintained six months post treatment (Mulryan et al. 2002). This prolonged im-
munity in vaccinated mice was consequently shown to be dependent on CD4+ T cell and 
antibody mediated immunity (Harrop, Ryan, et al. 2006). 
Vaccination of 22 metastatic colorectal patients with MVA-5T4/Trovax® in a phase I/II trial 
showed that the vaccine is generally well tolerated and is able to boost 5T4-specific neutralizing 
antibodies (Harrop, Connolly, et al. 2006). Furthermore, combination treatment of MVA-
5T4/Trovax® in conjunction with 5-fluorouracil, folinic acid, and oxaliplatin chemotherapeutic 
agents in a phase II trial of seventeen metastatic colorectal cancer patients resulted in enhance-
ment of IFNγ mediated T cell immunity in cultured T cell lines from vaccinated patients (Harrop 
et al. 2007). In both these trials, presence of anti-5T4 immunological responses retrospectively 
correlated with survival and over half of patients exhibited stable disease or clinical response as 
classified by radiological computed tomography (CT) of tumour burden. 
Despite some promising detection of enhanced immunity in colorectal patients treated with 
MVA-5T4/Trovax® these CRC patients do not clear their tumours (Harrop, Connolly, et al. 
2006; Harrop et al. 2007). As a result, further knowledge of natural and induced immune re-
sponses to 5T4 is required in order to design better vaccines which would promote a more robust 
cell mediated responses including both CD8+ T cell immunity enabled through CD4+ TH1 type 
immunity.  
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1.5 LAG-3 as a modulator of immunity 
Lymphocyte activation gene-3 (LAG-3), also known as cluster of differentiation 223 (CD223), 
is an immune checkpoint receptor which has implications in the modulation of immunity. Due 
to its perceived role in suppressing immune responses – particularly T cell responses – LAG-3 
has recently been branded as a promising therapeutic target molecule for modulation of immun-
ity in cancer (Sierro et al. 2011). Despite this interest, the function of LAG-3, particularly at the 
molecular level, is not fully understood. 
1.5.1 The LAG3 gene and protein sequence 
The LAG3 gene was first isolated and characterised in 1990 from cDNA of an activated IL-2 
dependent NK cell line termed F5 (Triebel et al. 1990). It was defined as possessing eight exons 
spanning ~7 kbp at the DNA level which was transcribed as a ~2 kbp mRNA transcript. This 
mRNA transcript was not detectable in resting T cell blasts but was detected in T cell blasts 
activated with PHA, hence its lymphocyte activation gene etymology. Analysis of the sequenced 
gene revealed a domain organisation containing four extracellular Ig-like domains, a single 
transmembrane domain sequence and a short cytoplasmic tail (Figure 1.7a). The four extracel-
lular domains were designated D1 to D4, in the membrane distal to proximal direction, and were 
characteristic of a V-type Ig-like (D1) followed by three C2-type Ig-like domains (D2 – D4). 
Within the V-type D1 domain, a novel sequence feature in the V-type Ig-like predicted arrange-
ment was observed: an addition 30 amino acid insertion between the predicted C and C’ β-
strands (Figure 1.7b). 
1.5.1.1 Similarities to the CD4 co-receptor 
Although the protein sequence homology between LAG-3 and CD4 is barely above background 
levels (~20 % protein sequence identity) upon examination of the LAG3 gene, a number of fac-
tors highlighted LAG-3 as a structural homologue of the CD4 co-receptor. Firstly, the LAG3 
gene was located to chromosome 12 (12p13) and is thus located adjacent to CD4 (Triebel et al. 
1990; Isobe et al. 1986). Secondly, both CD4 and LAG3 exhibit similar intron/exon gene organ-
isation (Triebel et al. 1990). Furthermore, it was observed that CD4 also consists of four Ig-like 
domains within its extracellular portion. These four domains exhibit structural homology be-
tween D1 and D3 as well as between D2 and D4 – a property exhibited by both LAG-3 and CD4 
– suggesting that both molecules evolved through duplication of a two domain precursor.  
The biggest similarity between LAG-3 and CD4 was shown by evidence of the functional 
binding of MHC-II molecules by LAG-3 – of which CD4 is also a ligand. A comprehensive  
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Figure 1.7 – Overview of the sequence inferred LAG-3 domain arrangement: 
a) Domain arrangement as inferred from the LAG-3 protein sequence. Sequence analysis 
suggests LAG-3 possesses four extracellular Ig-like domains (D1-D4), a single transmembrane 
domain (TM) and a short cytoplasmic tail (CT). D1 domain contains a V-type Ig-like domain 
(V) whilst D2 to D4 contains C2-type Ig-like domains (Triebel et al. 1990). 
b) 2D schematic representation of LAG-3 D1 domain Ig-like sequence inferred domain 
organisation as demonstrated in (Triebel et al. 1990). The V-type domain contains an additional 
30 amino acid (aa) ‘extra loop’ sequence between C and C`β-strands not characteristic of V-type 
Ig-like domains. NH2 = N-terminus, COOH = C-terminus. 
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overview of the current evidence of a LAG-3-MHC-II interaction is described to follow in Chap-
ter 4. 
1.5.2 Expression of LAG-3 by immune cells 
LAG-3 is expressed on a number of different cell types confined to immune cells. LAG-3 is 
expressed on activated but not resting CD4+ and CD8+ T cells (Huard et al. 1994). Expression 
of LAG-3 by human PBMCs stimulated in vitro by PHA stimulation results in detectable LAG-
3 expression after two days, maximal at day eight and trends towards baseline by day twelve. 
LAG-3 expression kinetics by (CD4+ & CD8+ co-purified) T cells in mice in vitro via CD3/CD28 
bead activation are slightly altered: LAG-3 is detectable 24 hours after stimulation, maximal at 
48 hours and returns to baseline after 96 hours (Sega et al. 2014). LAG-3 expression at the 
transcription level is detected in mouse TCRγδ+ intraepithelial lymphocytes (Shires et al. 2001), 
as well as at the protein level on TCRγδ+ splenocytes of C57BL/6 mice (C. J. Workman et al. 
2002). Similarly, LAG-3 expression is detected on 2B4+ mouse splenocyte derived NK cells. 
Indeed, expression of LAG-3 on both TCRγδ+ and NK cells was significantly higher compared 
to both CD4+ and CD8+ T cells. 
LAG-3 is expressed on human LAG-3+ CD49b+ Tr1 cells extracted directly from peripheral 
blood without the requirement of in vitro stimulation (Gagliani et al. 2013). Similarly, LAG-3 
expression is detectable on a subset of CD4+CD25+FoxP3+ T cells in peripheral blood, however, 
this subset of cells are functionally active and may represent LAG-3 upregulation as a conse-
quence of Treg activation (Camisaschi et al. 2010). LAG-3 expressing Tr1 cells, in vivo, can be 
generated by the treatment of mice with MHC-II coated nanoparticles and thus may present a 
methodological way of generating LAG-3+ cells in vitro (Clemente-Casares et al. 2016). 
LAG-3 is also expressed on activated (CD19+) B cells during in vitro stimulation of PBMC 
cultures (Kisielow et al. 2005). The kinetics of LAG-3 expression by B cells is concurrent with 
that of LAG-3 expression on T cells, albeit at lower levels. LAG-3 expression on activated B 
cells was only observed in the presence of co-culture with activated T cells and was shown to 
be endogenously produced.  LAG-3, therefore, may be a surface marker of B cell activation 
mediated by T cells.  
Finally, LAG-3 is expressed at high levels by CD11clow B220+ PDCA-1+ plasmacytoid den-
dritic cells (pDCs) in mice (Workman et al. 2009). Interestingly, expression of LAG-3 by these 
immune cells is detected both as a membrane bound protein (after activation with CpG) and as 
a secreted form of LAG-3, termed soluble LAG-3 (sLAG-3). Consequently, sLAG-3 is detect-
able in mouse and human serum of which pDCs are thought to be the main producers with 
contribution by CD4+ T cells (Workman et al. 2009; Triebel et al. 2006; Annunziato et al. 1996). 
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pDC expression of LAG-3 has been shown to have both a cell intrinsic role in mediating pDC 
homeostasis as well as having an influence on T cell expansion. 
1.5.3 Inhibition of T cell activation through LAG-3 
Given the evidence of binding between LAG-3 and MHC-II, much of the functional studies into 
LAG-3 have focused on the role of LAG-3 in CD4+ T cells. First insights into a role for LAG-3 
in the suppression of T cell responses was revealed by the influence of LAG-3 function upon 
antigen specific activation of human CD4+ T cell clones (Huard et al. 1994). Incubation of an 
anti-LAG-3 antibody in T cell activation assays resulted in the increased production of IFNγ. 
This process was shown to be antigen specific as anti-LAG-3 antibody blockade had no effect 
on mitomycin or IL-2 stimulation of CD4+ T cell clones. Similar experiments using LAG-3 fu-
sion proteins highlighted that LAG-3 binding to MHC-II expressing T cells resulted in inhibition 
of T cell activation and thus suggests LAG-3 may function to limit T cell to T cell mediated 
presentation and activation in humans (Huard et al. 1996). Having observed that LAG-3 function 
causes the downregulation of T cell activation in an antigen-specific manner, it was hypothesised 
that LAG-3 may interrupt TCR/CD3 signalling (Hannier et al. 1998). Crosslinking of LAG-3 
proteins on the surface of MHC-II expressing cells resulted in the downregulation of TCR and 
CD3 expression as shown by flow cytometry and consequent inhibition of Ca2+ influx leading 
to the reasoning that LAG-3 associated with the TCR/CD3 complex.   
After review of the experiments described in humans, it was hypothesised that the main 
mechanism of LAG-3 suppression of CD4+ T cell activation may be through the competitive 
binding for MHC-II with the CD4 co-receptor (Huard et al. 1995). Following on from these 
studies in humans, however, LAG-3 functionality was shown to be dependent on the cytoplas-
mic domain of LAG-3 which consequently suggested that blockade of CD4 engagement by 
LAG-3 may not be the only mechanism of LAG-3 mediated T cell inhibition (Workman et al. 
2002). Transduction of wild type LAG-3 into a T cell hybridoma clone (3A9) abrogated peptide 
specific clone activation, however, this effect was only exhibited in a CD4 replete variant of the 
3A9 clone and not a CD4 deplete variant. These data suggested that the negative regulatory 
function of LAG-3 was dependent on CD4 expression. Similar experiments were performed by 
transduction of a truncated LAG-3 construct deficient in the cytoplasmic tail of LAG-3 which 
resulted in the loss of T cell regulation in response to antigen. Furthermore, mutation of the 
unique cytoplasmic KIEELE motif abrogated function. Similar functionality was later shown in 
vivo by restoring LAG-3 expression in LAG-3-/- knock out mice (Workman & Vignali 2003). 
Here, using the OT-II transgenic mouse model, LAG-3 restoration resulted in reduced antigen 
specific release of IL-2 and IFNγ cytokines. The mechanisms by which LAG-3 mediates an 
- 38 - 
 
inhibitory signal into the T cell is currently unknown. Recruitment of an accessory protein to 
the intracellular domain via a unique EP repeat motif in the LAG-3 has been documented 
(Iouzalen et al. 2001). This protein, termed LAG-3-associated protein is a 45 kDa protein with 
no obvious homologues.  
Biochemical analysis of the protein constituents of LAG-3 on expressing cells revealed the 
presence of oligomeric association of truncated LAG-3 products at the cell surface (Li et al. 
2004). A 54 kDa fragment which corresponded to the extracellular portion of LAG-3 was shown 
to associate with full length LAG-3 at the cell surface. A comprehensive overview of the evi-
dence of LAG-3 oligermisation is described in Chapter 4. The formation of soluble truncation 
products, however, raises implications in the function of LAG-3 mediated suppression of T cell 
activation. Through the use of CD4-LAG-3 fusion constructs, the cleavage of LAG-3 to form 
sLAG-3 was shown to be dependent on the membrane proximal D4 domain of LAG-3 (Li et al. 
2004). Moreover, this cleavage was shown to be performed by the metalloproteases ADAM10 
and ADAM17 which act as a regulatory mechanism to LAG-3 function by cleavage and conse-
quent release of LAG-3 from the T cell surface (Li et al. 2007). Indeed, formation of LAG-3 
cleavage-resistant mutants rendered cells unable to proliferate and produce cytokines. 
LAG-3 function through an interaction with MHC-II can be rationalised for CD4+ T cell 
inhibition, however, LAG-3, as described previously, is expressed on a number of different im-
mune cell types including CD8+ T cells (Huard et al. 1994). A role of LAG-3 in inhibiting T cell 
activation in CD8+ T cells is less obvious. Nevertheless, transduction of LAG-3 into primary 
CD8+ T cells in vitro reduced the release of IFNγ in response to cognate antigen stimulation 
which was also shown to be dependent on the cytoplasmic tail of LAG-3 (Tian et al. 2015). 
Initial studies have identified a second potential ligand for LAG-3: the adhesion molecule 
LSECtin/CLEC4G which is expressed on endothelial cells (Xu et al. 2014). Such binding may 
explain how CD8+ T cells are modulated by LAG-3 expression. 
1.5.4 Effect of LAG-3 engagement on dendritic cells 
As well as mediating a cell intrinsic effect on T cells, LAG-3 also exhibits a cell extrinsic mod-
ulatory effect on interacting APCs. LAG-3 engagement of a soluble form of LAG-3, the LAG-
3:Fc fusion protein, exhibits an immunostimulatory effect on human monocyte-derived den-
dritic cells (Andreae et al. 2002). LAG-3:Fc was shown, firstly, to bind to mature but not 
immature MHC-II expressing dendritic cells – an observation attributed to the requirement of 
MHC-II molecules to clustered in organised lipid rafts. Nevertheless, LAG-3:Fc was able to 
induce morphological changes and phenotypic maturation of dendritic cells resulting in the up-
regulation of CD80/CD86, CD40 and CD83 in a similar capacity to the innate stimulatory 
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molecule LPS. The consequent outcome was that LAG-3:Fc matured dendritic cells captured 
less antigen and instead shifted function towards presentation to T cells as shown by increased 
proliferation of CD4+  T cells in a mixed lymphocyte reaction co-cultured in the presence of 
LAG-3:Fc matured dendritic cells. These data suggested that LAG-3 – at least in the form of a 
soluble fusion protein – is able to stimulate dendritic cells and consequently CD4+ T cell im-
munity in a similar capacity to that of LPS. 
In a wider study, the effects of LAG-3:Fc binding to whole PBMC populations was studied 
and it was shown that LAG-3:Fc could only bind to 10 % of all MHC-II positive cells (Brignone 
et al. 2007). These cells were attributed to myeloid-derived dendritic cells, once again, and a 
small number of monocytes. Binding to these cells, however, resulted in the production of IFNα 
and CCL4 (MIP-1β) and consequent activation of CD8+ effector memory T cells through the 
promotion of TH1 immunity. This activation of CD8+ T cells as a consequence of LAG-3:Fc 
treatment of PBMCs was show to be cell contact dependent. 
In apparent contrast to the previous described studies, LAG-3 expressed on the surface of 
Treg cells was shown to instead inhibit dendritic cell activation through an interaction with MHC-
II expressing cells. This effect was shown in mice whereby Treg-dendritic cell interactions were 
required to inhibit dendritic cell activation in a T cell antigen specific manner (Liang et al. 2008). 
Upon engagement of MHC-II expressing dendritic cells in the presence of cognate peptide, 
LAG-3 expressing OT-II transgenic Treg cells were able to inhibit maturation of dendritic cells 
as indicated by decreased expression of CD86. Such an effect was not observed in either OT-II 
Treg cells deplete of LAG-3, conventional OT-II T cells or in the absence of peptide. Truncation 
of the cytoplasmic tail of LAG-3 had no effect on the ability to inhibit dendritic cell maturation 
and required cell-cell contact. These data suggest that dendritic cell inhibition was as a result of 
a direct mechanism mediated by LAG-3 interacting with MHC-II expressing cells and not by 
signalling through the T cell. 
These studies therefore present contrasting roles of an extrinsic function of LAG-3 on den-
dritic cell function. Importantly, these studies vary in the formulation of LAG-3 by which these 
experiments are constructed. Observed activation of dendritic cells occurs via LAG-3 in a solu-
ble form whereas inhibition of dendritic cells was demonstrated in a membrane bound setting 
with the addition of peptide specificity. One model which may explain this observed difference 
is that soluble release of LAG-3, through cleavage, can promote distal antigen non-specific pro-
motion of dendritic cell maturation whilst allowing antigen specific downregulation of dendritic 
cells presenting exhausted/regulatory antigens – mediated by surface bound LAG-3. Alterna-
tively, discordance may be observed due to differences in mouse and human immunology or 
artefactual effects of LAG-3 dimerisation by the LAG-3:Fc molecule. 
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1.6 LAG-3 and cancer: a potential therapeutic target 
1.6.1 Immune checkpoint inhibitor therapies 
Immune checkpoint therapies are a class of therapeutics which aim to enhance immunity to 
tumours by modulation of regulatory signals and pathways (Sharma & Allison 2015). Through 
central and peripheral tolerance mechanisms, described previously, immunity is poised between 
reactivity to non-self whilst preventing reactivity to self (Houghton & Guevara-Patiño 2004). 
This balance in self / non-self discrimination is tuned by the activating and regulatory networks 
that govern immunity. Modulation of regulatory signals within this network which tip the bal-
ance towards reactivity to self may facilitate enhanced immune activity. As a result, the aim of 
checkpoint inhibitor therapies are to enhance immunity to self and thus increase the selection 
pressure on tumours (Sharma & Allison 2015). Such modulation, however, comes at a cost as 
tuning the immune system towards self renders individuals at risk to the symptoms of autoim-
munity. 
Ipilimumab, for example, targets CTLA-4, a co-inhibitory molecule which is expressed at 
low levels on naïve effector T cells but is upregulated upon T cell activation and maintained in 
intracellular stores of memory cells (Jago et al. 2004). CTLA-4 expressed at the cell surface 
competes with CD28 for binding of CD80/CD86, thus preventing signal 2 of T cell activation 
and instead promoting T cell inhibition (Boesteanu & Katsikis 2009). Consequently, ipilimumab 
binds and blocks CTLA-4 function allowing the continuation of CD28 based signal 2 activation. 
Moreover, CTLA-4 is expressed on Treg cells and is required for maximal function (Read et al. 
2000). Ipilimumab is designed such that binding to CTLA-4 can mediate immune cell depletion 
of ipilimumab opsonised cells, a concept discussed in Chapter 5, and has therefore been shown 
ex vivo to promote cytotoxicity of Treg cells in melanoma patients (Romano et al. 2015). 
Currently, two immune checkpoint therapies have approval for use in England and Wales by 
the National Institute for Health and Care Excellence (NICE) for the treatment of unresectable 
or metastatic melanoma. These two therapeutic agents, ipilimumab (Yervoy®) and nivolumab 
(Opdivo®) are monoclonal antibodies that target the immune checkpoint molecules CTLA-4 
and PD-1, respectively (Hodi et al. 2010; Topalian et al. 2014). Both agents have shown clinical 
efficacy in the treatment of metastatic melanoma in phase III clinical trials both as individual 
and combined therapies where treatment of a combined therapy group exhibited a progression 
free survival of 11.5 months compared to ipilimumab alone (2.9 months) and nivolumab alone 
(6.9 months) (Larkin et al. 2015). Despite clinical success in patients with melanoma, clinical 
benefit of current checkpoint inhibitors have shown underwhelming response rates in colorectal 
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cancer (Singh et al. 2015). However, trials are currently underway to assess nivolumab and 
ipilimumab combined therapy in metastatic CRC (ClinicalTrials.gov Identifier: NCT02060188) 
1.6.2 Implications of LAG-3 expression in human tumour progression 
Exhibiting parallels with CTLA-4, LAG-3 function is required for optimal Treg suppressive func-
tionality (Huang et al. 2004). As a result of T cells with regulatory function being involved in 
suppressing anti-tumour immunity, it has been hypothesised that LAG-3 contributes to immune 
escape by tumours (Goldberg & Drake 2011).  
Indeed, in a study of 45 patients with Hodgkin lymphoma (HL), LAG-3 expression was de-
tected on lymphocytes infiltrating into areas of malignant Hodgkin Reed-Sternberg (HRS) cells 
via immunohistochemistry (Gandhi et al. 2006) Moreover, LAG-3+ T cells were detected at 
higher frequencies in the peripheral blood of HL patients who were yet to undergo chemotherapy 
compared to patients in remission and healthy controls – suggesting that LAG-3 expression may 
correlate with disease state severity. 
In the described studies of HL patients, LAG-3 expression was not confined to co-expression 
of FoxP3 and thus suggested LAG-3 expression was distinct from classical FoxP3+ Treg cells 
(Gandhi et al. 2006). In contrast, enrichment of LAG-3+ T cells into both melanoma and colo-
rectal tumour sites were restricted mainly to LAG-3+ FoxP3+ CD4+ CD25+ T cells where this 
subset of cells were increased in peripheral blood, tumour bearing lymph nodes and tumour sites 
(Camisaschi et al. 2010). This subset of cells exhibited an effector memory phenotype whilst 
producing the immunosuppressive cytokines IL-10 and TGFβ. Functional analysis of LAG-3hi 
and LAG-3low T cells from PBMC of healthy donors revealed that LAG-3hi cells exhibited sup-
pressive capacity to inhibit T cell proliferation which required cell-cell contact. As a result, these 
data show that this subset of LAG-3+ FoxP3+ CD4+ CD25+ T cells are residing in tumours as 
well as peripheral blood and have a direct suppressive capacity on other T cells. 
Similar observations have been made in non-small-cell lung cancer patients (Wei et al. 2015). 
In a study of 53 patients, increased numbers of FoxP3+ CD4+ CD25+ T cells were detected and 
found to express high levels of several inhibitory molecules such as LAG-3 but also CTLA-4 
and PD-1. The phenotypic consequence of this was, once again, associated with IL-10 and TGFβ 
release. Also in non-small-cell lung cancer patients, infiltrated CD8+ T cells were found to ex-
press the same inhibitory molecules but also Tim-3 and BTLA (Thommen et al. 2015). A role 
for reduced anti-viral clearance in viral induced hepatocellular carcinoma (HCC) by LAG-3 has 
also been observed (Li et al. 2013). Expression of LAG-3 on Hepatitis B virus (HBV)-specific 
CD8+ T cells within the tumour sites of HCC patients revealed upregulation compared to 
matched peripheral blood and, once again, impaired function. 
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Together, these data highlight how T cells with inhibitory and regulatory phenotype in a tu-
mour context express multiple inhibitory molecules and thus use multiple seemingly redundant 
pathways to mediate T cell suppression. This regulatory phenotype is possessed by a variation 
of LAG-3 expressing T cell subsets. As a result, successful targeting of such cells may require 
the combinational targeting of multiple suppressive pathways concurrently. 
1.6.3 Implications of LAG-3 expression in human colorectal cancer 
Expression patterns of LAG-3 exhibited by T cells in tumours, in general, are replicated in col-
orectal cancer, however, preferential detection of T cells with regulatory function that display 
Tr1 or Tr1-like function has been observed. 
Analysis of CD4+ T cells extracted from matched tumour, healthy colon and peripheral blood 
of CRC patients revealed the presence of a population of FoxP3- cells that were characterised 
by the surface expression of LAP, CD39, CTLA-4 along with LAG-3 which were specific to 
tumour alone (Scurr et al. 2013). These cells, isolated from CRC tumours, exhibited a Tr1-like 
phenotype characterised by high expression of IL-10. Consequent isolation of CD4+ LAP+ cells 
via fluorescence-activated cell sorting (FACS) enabled the assaying of the suppressive capacity 
of this population. Using in vitro suppression assays, CD4+ LAP+ cells exhibit an approximate 
50-fold suppressive capacity compared to FoxP3+ Treg cells. 
Definition of Tr1 cells as expressing LAG-3 and CD49b concurrently has since allowed the 
study of Tr1 cell infiltrate into CRC tumours (Gagliani et al. 2013). Analysis of T cell infiltrate 
in 108 matched CRC tumour and peritumoural samples revealed the enrichment of a diverse 
range of T cells infiltrated into tumours (Chen & Chen 2014). In these patients, high frequency 
of FoxP3+ Treg cells were detected but also high frequency of LAG-3+ cells including those that 
co-expressed CD49b (Tr1 cells) as well as a subset of LAG-3+ CD49b- cells. 
1.6.4 LAG-3 blockade and depletion in animal disease models 
There is currently no published data on the efficacy of LAG-3 blockade or depletion in humans. 
However, there are ongoing clinical trials assessing the safety and efficacy of anti-LAG-3 anti-
bodies in cancer patients. An overview of current anti-LAG-3 antibodies are presented in 
Chapter 5. Nevertheless, rationale for the development of therapeutics modulating LAG-3 func-
tion has been displayed in animal models of disease. 
Evidence for LAG-3 as a therapeutic intervention target in cancers has been demonstrated in 
both the Sa1N fibrosarcoma and MC38 colon adenocarcinoma murine tumour model whereby 
blockade of PD-1 and LAG-3, through a combined intervention regime administered after de-
tection of palpable tumours, resulted in tumour clearance in mice (Woo et al. 2012). In the MC38 
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CRC tumour model, all tumour bearing mice in the untreated control group developed tumours 
(0 of 10 mice tumour free after day 50). In anti-PD-1 treated mice, 4 out of 10 mice remained 
tumour free after 50 days. Interestingly, anti-LAG-3 treated mice exhibited decreased tumour 
rate, however, all mice still developed tumours (0 of 10 mice tumour free after day 50). Combi-
nation treatment of anti-LAG-3 and anti-PD-1 resulted in reduced tumour burden compared to 
both control, LAG-3 mono-treament and PD-1 mono-treatment (8 of 10 mice tumour free after 
day 50). Analysis of treated mice revealed that dual blockade of PD-1 and LAG-3 induced in-
creased numbers of CD8+ IFNγ expressing T cells in the tumour draining inguinal (DLN) and 
non-draining brachial and axillary lymph nodes (NDLN). 
Interestingly, a second study analysing the therapeutic modulation of LAG-3 expressing cells 
in autoimmunity demonstrates a seemingly opposite rationale for anti-LAG-3 therapy (Poirier 
et al. 2011). In this study, it was hypothesised that depletion of LAG-3 expressing cells – there-
fore depleting activated cells – would deplete disease-mediating T cells in a T cell driven 
autoimmune disorder. This was despite the effects LAG-3 depletion may have on the targeting 
of LAG-3 expressing T cells with regulatory function – which have anti-autoimmune potential 
(Okazaki et al. 2011).  
Nevertheless, non-human primates were challenged with tuberculin-purified protein deriva-
tive (PPD), a model of delayed-type hypersensitivity, after administration of an anti-LAG-3 
antibody designed to deplete LAG-3 expressing cells (Poirier et al. 2011). Treatment of animals 
with anti-LAG-3 before challenge indeed resulted in reduced disease severity compared to PPD 
administration without anti-LAG-3 therapy. This protection prevented symptoms completely in 
animals challenged two days after treatment with anti-LAG-3 but also exhibited reduction in 
symptoms during re-challenge six weeks after anti-LAG-3 intervention. This time period sug-
gests that treatment was able to have a persisting effect over the period of weeks. 
Together, these two studies show that current development of LAG-3 therapeutics, in phase 
I/II clinical trials, have contrasting hypothesised outcomes. An implication of these two pre-
clinical studies is that targeting of LAG-3 as a mechanism for shifting self / non-self discrimi-
nation in favour of enhanced tumour immunity requires better understanding of LAG-3 biology.  
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1.7 Aims of Thesis 
The overall aim of this thesis is to study the efficiency of the CD4+ T cell immune response to 
tumours through molecular studies of the TCR-pMHC-II interaction in the context of colorectal 
cancer and its impediment by the co-inhibitor molecule LAG-3. My overall hypothesis is that 
effector anti-cancer CD4+ T cell responses are suboptimal due to multiple causes that include 
key cell intrinsic mechanisms including (i) weak recognition of tumour antigens through TCR-
pMHC interactions, and (ii) negative regulation by the cell surface CD4 homologue molecule 
LAG-3. 
To explore this hypothesis further, I had three overall key objectives:  
- To measure TCR binding of tumour-antigen derived pMHC at the cellular/molecular 
level to explore whether anti-cancer TCRs were engaged weakly 
- To study and measure LAG3-pMHC binding at the cellular, biophysical and structural 
level  
- To develop anti-LAG-3 monoclonal antibodies for the study and targeting of LAG-3. 
This would be achieved firstly through the study of CD4+ T cell responses to the oncofoetal 
antigen 5T4 by molecular analyses of the presentation of 5T4-derived peptide epitopes and con-
sequent recognition by 5T4-reactive CD4+ T cell clones derived from healthy donors. The 
outcomes of these molecular studies are described in Chapter 3. Secondly, the efficiency of 
CD4+ T cell immunity to tumours would be analysed through understanding of the function of 
the co-inhibitory molecule LAG-3 which has been implicated in the functional efficiency of 
CD4+ T cells infiltrated into colorectal and other tumours. It was hypothesised that LAG-3 may 
bind to MHC-II molecules using a higher affinity interaction than that of CD4 engagement and, 
thus, has potential to impede T cell activation within a tumour context. The outcomes of these 
functional analyses are detailed in Chapter 4. Finally, the generation of anti-LAG-3 antibodies 
would be performed through the generation and functional characterisation of monoclonal anti-
bodies against human LAG-3 protein generated through the immunisation of mice. The 
generation of anti-LAG-3 antibodies should aid future studies of LAG-3 structure-function and 
may possess future therapeutic potential in the depletion and/or blockade of LAG-3 expressing 
cells in the tumour context. The progress of this translational project is detailed in Chapter 5. 
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2 Chapter 2: Materials and Methods 
NB. A full list of reagents used is available in Appendix 1. 
2.1 Generation and characterisation of 5T4-reactive T cell clones 
2.1.1 List of materials 
2.1.1.1 Antibodies 
αLAG-3-FITC: Fluorescein isothiocyanate (FITC)-conjugated anti-human LAG-3 clone 17B4 
– Enzo Life Sciences 
αCD4-APCy: Allophycocyanin (APCy)-conjugated anti-human CD4 clone – Miltenyi Biotec 
αCD14-PB: Pacific Blue™ anti-human CD16 Antibody clone 3G8 - BioLegend 
αTCR-FITC: FITC-conjugated anti-human αβ TCR clone IP26 – BioLegend 
αPE: Unconjugated anti-phycoerythrin (PE) clone PE001 - BioLegend 
2.1.1.2 Buffers 
Phosphate Buffered Saline Dulbecco ‘A’ (PBS) – Oxoid:8 g/L Sodium chloride, 0.2 g/L 
Potassium chloride, 1.15 g/L Disodium hydrogen phosphate & 0.2 g/L Potassium 
dihydrogen phosphate, pH 7.3 
PBS-T: PBS, 0.05 % Tween 20 
Dextramer buffer: 0.05 M Tris-HCl, 15 mM Sodium azide, 1 % BSA, pH 7.2  
Mammalian Cell Freezing Buffer: 90 % FCS & 10 % DMSO 
2.1.1.3 Culture media 
R0: RPMI 1640 media, 2mM L-Glutamine, 100 IU/mL Penicillin & 100 µg/mL Streptomycin. 
R5: RPMI 1640 media, 5 % FCS, 2mM L-Glutamine, 100 IU/mL Penicillin & 100 µg/mL 
Streptomycin. 
R10: RPMI 1640 media, 10 % FCS, 2mM L-Glutamine, 100 IU/mL Penicillin & 100 µg/mL 
Streptomycin. 
CD4+ T cell media (TCM): RPMI 1640 media, 10 % FCS, 2mM L-Glutamine, 100 IU/mL 
Penicillin & 100 µg/mL Streptomycin, 0.02M HEPES, 1mM Non-essential amino acids, 
1mM Sodium pyruvate, 200IU/mL human recombinant IL-2 (Proleukin®) 
2.1.1.4 Peptides 
5T4p2: AGDGRLRLARLALVLLGWVS 
5T4p12: FARRPPLAELAALNLSGSRL 
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5T4p38: LLVLYLNRKGIKKWMHNIRD 
All peptides synthesised at 90 % purity solubilised in DMSO by Peptide Protein Research 
Ltd. (Hampshire, UK). 
2.1.2 Culture of cells 
T2 (174 x CEM.T2) (ATCC® CRL-1992™) cells (henceforth T2) and T2 cells stably expressing 
surface expressed HLA-DR1 through lentiviral gene delivery (henceforth T2-DR1) were ob-
tained from and produced by Alexander Greenshields Watson (Cardiff University). Autologous 
BLCL cells were generated by Dr Chris Holland (previously Cardiff University). Autologous 
BLCL, T2 and T2-DR1 cells were cultured at 37 ˚C, 5 % CO2 in R10 media. All APCs were 
cultured in suspension by renewing culture media three times per week, maintaining cells at a 
density of 3 x 105 and 1 x 106 cells/mL. 
5T4-reactive T cell clones were maintained by culturing at 3 x106 cells/mL in 24-well plates, 
replacing half the culture volume three times per week with fresh CD4+ TCM without homoge-
nous dispersion of the cells in the well. Every 2-4 weeks, T cell clones were expanded in 
conjunction with Dr Garry Dolton (Cardiff University) using irradiated (3100 Gy) allogeneic 
PBMC feeder cells from three separate healthy donors and 1 µg/mL phytohemagglutinin (PHA) 
performed. 
2.1.3 Generation of 5T4-reactive T cell clones 
Three CD4+ T cell clones specific for three distinct 20mer amino acid peptides (5T4p2, 5T4p12 
& 5T4p38) derived from the full length 5T4 protein were produced by Dr. Garry Dolton (Cardiff 
University) using the T cell library cloning methodology as outlined previously (Theaker et al. 
2016). In brief, PBMCs were isolated from a HLA-DR1+ donor using density gradient centrifu-
gation by extraction of the buffy coat layer formed from Lymphoprep™ (Axis-Shield) 
centrifugation. CD4+ T cells were enriched from PBMCs by magnetic separation using anti-
CD4+ microbeads (Miltenyi Biotec) and consequently plated at approximately 1x104 cells per 
well of a 96-well U-bottom plate. Plated cells were expanded using human T-Activator 
CD3/CD28 Dynabeads® (Life Technologies) at a cell to bead ratio of 1:2 in CD4+ TCM. After 
14 days culture, individual wells of the expanded cell library were screened for reactivity to the 
pool of three 5T4 derived peptides (1x10-5 M) in the presence of T2-DR1 cells as antigen pre-
senting cells. Reactivity to peptide was determined by the release of IFNγ using enzyme linked 
immunospot assay (ELISpot) according to manufacturer’s instructions (Mabtech). Library wells 
positive for IFNγ expression in the presence of 5T4 peptides by ELISpot were pooled and ex-
panded by culturing pooled cells with 1x10-5 M individual peptide for 4 hours. Activated cells 
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were consequently enriched by IFNγ capture isolation (Miltenyi Biotec). The subsequent en-
riched line was tested for individual reactivity to 5T4 peptides in the presence of T2-DR1 cells 
as APCs via IFNγ ELISpot as described previously. The enriched 5T4-reactive T cell line was 
cloned by single cell serial dilution cloning and resulting clones validated for reactivity to the 
individual 5T4-derived peptides as described to follow.  
2.1.4 Peptide sensitivity cytokine/chemokine release ELISA 
T cell peptide stimulation assays were performed by co-culturing individual 5T4-reactive T cell 
clones with T2-DR1 as antigen presenting cells (APCs) with or without the presence of cognate 
5T4 derived peptides. One day prior to the assay, T cell clones were rested in R5 media over-
night. The following day, T cell clones were counted via haemocytometer, washed with 10 mL 
PBS and resuspended in R5 media at 4.44 x105 cells/mL. Similarly, T2-DR1 cells were counted, 
washed with 10 mL PBS and resuspended in R5 media at 8.88 x105 cells/mL.  
T cells were peptide specifically stimulated by combining 45 µL of T2-DR1 with 45 uL of T 
cells resulting in 4 x104 and 2 x104 APCs and T cells per well, respectively. Serial dilutions of 
cognate peptide were prepared in R0 media at a concentration range of 10-3 to 10-9 M. 10 µL of 
peptide at each concentration was added to the T cell-APC culture to form a final volume of 100 
µL, thus resulting in a final peptide concentration range of 10-4 to 10-10 M. In addition, negative 
control wells were incubated with no peptide and positive control wells incubated with 10µg 
polyhydroxyalkanoates (PHA; Alere). All conditions were performed in at least duplicate. Cells 
were cultured overnight at 37 ˚C, 5 % CO2.  
The following day, cells were spun at 1500 rpm for 5 min and supernatants harvested for 
analysis of their release of human IFNγ, TNFα and MIP-1β due to exposure of T cell clone’s 
cognate peptide. ELISA assays were performed using sandwich ELISA kits according to man-
ufacturer’s protocol (R&D Systems). In brief, half-area 96 well plates were coated overnight at 
room temperature with relevant capture antibody and later blocked with 1 % BSA. Supernatants 
and serial diluted protein standards were incubated on coated plates for 1 hour 15 min at room 
temperature before incubation with detect antibody (1 hour 15 min, room temperature), followed 
by streptavidin-horseradish peroxidase (HRP; 20 min, room temperature). Between each incu-
bation step, wells were washed three times with 150 µL PBS-T. Lastly, ELISA plates were 
developed using HRP substrate colour reagents and stop solution (R&D Systems) and absorb-
ance at 450 nm measured on a microplate absorbance reader (Bio-rad). 
- 48 - 
 
2.1.5 IFNγ release ELISpot assays 
T cell activation assays were performed by co-culturing peptide-pulsed T2, T2-DR1 or autolo-
gous BLCL cells as APCs and consequent level of T cell activation determined by IFNγ release 
Enzyme-Linked ImmunoSpot (ELISpot) kit assays (Mabtech). One day prior to the assay, T cell 
clones were rested in R5 media overnight. 
Firstly, 96-well ELISpot plates (Millipore) were incubated with 70 % ethanol for 30 seconds, 
washed three times with PBS and coated with anti-human IFNγ capture antibody overnight at 4 
˚C. Prior to use, unbound capture antibody was removed from wells and washed three times 
with PBS and consequently blocked with 150 µL of R5 media. 
In order to prepare APCs, cells were first counted via haemocytometer, washed with 15 mL 
PBS, resuspended in R5 and plated into wells of a separate 96-well plate at 1.8x105 cells per 
well at a volume of 180 µL per well. Peptide was prepared by 10 times serial dilution of 5T4 
derived peptides from 10-3 to 10-7 M concentration in R0 media. 20 µL of prepared peptide at 
various concentrations was added to the APC culture to form a final volume of 200 µL, thus 
resulting in a final peptide concentration range of 10-4 to 10-8 M. APCs were cultured at 37 ˚C, 5 
% CO2 for 2-3 hours after which cells were washed twice with 150 µL of PBS to remove un-
bound peptide. After washing, anti-DR blocking wells were incubated with 10 µg/mL L243 
clone antibody for 1 hr at 37 ˚C. Cells were next washed and resuspended in R5 media at a 
concentration of 1x106 cells/mL and plated (50 µL; 5x104 cells per well) onto the blocked 
ELISpot plate. 5T4-reactive T cell clones were counted and serial diluted such that 300 T cell 
clones (50 µL) were added to each well of their cognate peptide-pulsed APCs. Positive control 
wells were incubated with co-cultured T cells and peptide-pulsed APCs were incubated over-
night at 37 ˚C, 5 % CO2. 
The following day, cultured cells were removed from ELISpot plates and washed four times 
with PBS, incubated with IFNγ detection antibody (1 hour, 37 ˚C), washed four times with PBS 
and incubated with streptavidin-alkaline phosphatase conjugate (Strep-ALP) for 1 hour at room 
temperature in the absence of light. ELISpot plates were subjected to a final wash four times 
with PBS before being developed using a colorimetric alkaline phosphatase substrate reagent 
kit (Bio-rad). Once spots had developed, the colorimetric reaction was stopped by washing the 
wells of the plate with tap water. The developed plate was left to dry before being imaged and 
analysed using an immunospot analyser (Cellular Technology Limited).  
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2.1.6 MHC-II Multimer staining of 5T4-reactive T cell clones 
MHC-II multimers, were assembled within 24 hours before the day of use by combining 2 µL 
of Phycoerythrin (PE)-labelled dextramer backbone (Immudex) with 0.5 µg of refolded and 
biotinylated peptide-HLA-DR1 monomers per stain. Biotinylated peptide-HLA-DR1 molecules 
were produced as described in section 2.2. 
T cell clones were counted via haemocytometer allowing the transfer of 1x105 cells per stain 
to FACS tubes for analysis. T cells were washed with 4 mL of sterile PBS, cells pelleted by 
centrifugation at 1800 rpm for 5 minutes, resuspended via vortex and treated with 50 nM da-
satanib for 30 minutes at 37 ˚C. MHC-II multimers were made up to a working volume of 10 
µL per stain in dextramer buffer, centrifuged at 16.1k g for 1 minute and added directly to cog-
nate T cell clones without washing after dasatinib treatment. T cell clones were incubated on ice 
for 30 minutes before washing with PBS. Stained cells were boosted using an anti-PE secondary 
antibody for 20 minutes before washing with PBS (Tungatt et al. 2015). Cells were then stained 
for viability using LIVE/DEAD® Fixable Violet Dead Cell Stain (Invitrogen) for 5 minutes at 
room temperature and then stained for surface markers (αCD4-APC, αLAG-3-FITC, αTCR-
FITC) for 20 min on ice where appropriate. Stained cells were analysed on a FACS Canto II 
(BDBiosciences) correcting for compensation using Anti-Mouse Ig CompBeads (BDBiosci-
ences) bound to corresponding conjugated antibodies used in the experiment. Viability stain was 
compensated using (αCD14-PB) bound compensation beads. 
2.1.7 Biophysical analysis of TCR-MHC interactions 
In brief, the tcra and tcrb gene sequences which encode the T cell receptor (TCR) of three 5T4-
reactive T cell clones (D821, D104 & C112) were sequenced from cDNA by Dr. Meriem Attaf 
(Cardiff University). Constructs from sequencing data were designed in silico to include modi-
fications to the TCRα and TCRβ extracellular domain sequences by addition of a non-native 
disulphide bridge between the refolded TCRα and TCRβ constant domains as previously pub-
lished (Boulter et al. 2003). TCR-α and TCR-β chains of the three 5T4-reactive T cell clones 
(D821, D104 & C112) were cloned into the pGMT7 expression plasmid using restriction endo-
nuclease cloning as outlined in section 2.4.4. TCRα and TCRβ chain inclusion bodies were 
processed from cell lysates and refolded by gradual denaturant dilution of combined TCRα and 
TCRβ chains through denaturant dialysis as previously published (Boulter et al. 2003). 
SPR binding analysis was performed using a BIAcore T200 SPR instrument as described 
previously (Cole et al. 2012). In brief, BIAcore CM5 sensor chips (GE Healthcare Life Sciences) 
were immobilised with prepared biotinylated pMHC molecules by amine coupling of streptav-
idin to chip surfaces as described in section 2.5.4. Prepared biotinylated pMHC molecules were 
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immobilised to streptavidin coated CM5 sensor chips by injection of pMHC molecules to im-
mobilise ~500 RU of ligand. pMHC-TCR binding was assayed using a dilution series kinetic 
equilibrium approach using immobilised pMHC molecules coated to sensor chips as experi-
mental ligand and soluble TCR as experimental analyte. 
2.1.8 Cryopreservation of generated cell lines 
Generated cell lines and clones were cryopreserved by freezing multiple aliquots of pre-conflu-
ent cells at a viability of more than 90 %. Cells to be frozen were harvested by centrifugation 
for 5 min at 1500 rpm and resuspended in mammalian cell freezing buffer. Cells were aliquoted 
into cryovials and cooled at a rate of -1°C/min to a final temperature of -80 °C using a Mr. 
Frosty™ Freezing Container (Thermo Scientific) after which cells were transferred to vapour 
phase liquid nitrogen storage until required. 
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2.2 Generation of MHC-II molecules 
2.2.1 List of materials 
2.2.1.1 Oligonucleotide reagents 
pGMT7-DRα – Cloned by Dr Christopher Holland (Previously of Cardiff University) 
pGMT7-DRα-bt – Cloned by Dr Christopher Holland  
pGMT7-DR1β – Cloned by Dr Christopher Holland 
2.2.1.2 Buffers 
Bacterial Cell Lysis Buffer: 10 mM Tris, 10 mM MgCl2, 150 mM NaCl, 10 % glycerol; pH 8.1 
Inclusion Body Wash Buffer: 50 mM Tris, 0.5 % Triton X-100, 100 mM NaCl, 2 mM EDTA; 
pH 8.1 
Inclusion Body Resuspension Buffer: 50 mM Tris, 100 mM NaCl, 2 mM EDTA; pH 8.1 
Urea Buffer A: 8 M Urea, 20mM Tris pH 8.1 and 0.5mM EDTA; pH 8.1 
Urea Buffer B: 8 M Urea, 1 M NaCl, 20mM Tris pH 8.1 and 0.5mM EDTA; pH 8.1 
MHC-II refold buffer: 25 % glycerol, 20mM TRIS, 1 mM EDTA, 20 mM NaCl, 1.48 g/L (13 
mM) cysteamine hydrochloride & 0.83 g/L (3.7 mM) cystamine hydrochloride. 
CAPS elution buffer: 50 mM 3-(Cyclohexylamino)-1-propanesulfonic acid (CAPS); pH 11.5 
Neutralisation buffer: 300 mM Sodium phosphate; pH 6 
Biomix A – Avidity: 0.5M Bicine Buffer; pH8.3  
Biomix B – Avidity: 100mM ATP, 100mM MgO(Ac)2 & 500μM Biotin  
d-Biotin Buffer – Avidity: 500 μM d-biotin  
Sample loading buffer (4 X): 1 M Tris, 0.008 % Bromophenol blue, 10 % SDS, 40 % glycerol; 
pH 6.8 
Reducing sample loading (4 X): 4M Dithiothreitol (DTT), 1 M Tris, 0.008 % Bromophenol 
blue, 10 % SDS, 40 % glycerol; pH 6.8 
2.2.1.3 Culture media 
TYP media: 16g/L Tryptone, 16g/L Yeast Extract, 5g/L Potassium Phosphate Dibasic & 5 g/L 
Sodium chloride.  
2.2.1.4 Peptides 
5T4p2: AGDGRLRLARLALVLLGWVS 
5T4p12: FARRPPLAELAALNLSGSRL 
5T4p38: LLVLYLNRKGIKKWMHNIRD 
HA-PKY: PKYVKQNTLKLAT 
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All peptides synthesised at 90 % purity solubilised in DMSO at 20 mg/mL by Peptide
 Protein Research Ltd. (Hampshire, UK). 
2.2.2 Construction of HLA-DR1 bacterial expression plasmids 
The expression plasmids for the production of HLA-DR1 molecules were designed and cloned 
previously into the pGMT7 expression plasmid based on published methodoliges by Dr Chris-
topher Holland (Previously of Cardiff University) (Frayser et al. 1999). HLA-DRα constructs 
consisted of the extracellular domain of HLA-DRA*0101 (Uniprot: P01903, residues [26-207]). 
HLA-DR1β consisted of the extracellular domain of HLA-DRB1 (Uniprot: P04229, residues 
[30-219]). For the production of biotinylated HLA-DR1 molecules, a third construct, denoted 
HLA-DRα-biotin tag (-bt) was cloned previous to include a C-terminal biotinylation signal se-
quence (GLNDIFEAQKIEWHE; AviTag™) ligated to the HLA-DRA*0101 sequence 
described, via a flexible linker (GSGG). 
2.2.3 Production of HLA-DR1 inclusion bodies 
2.2.3.1 Culturing of recombinant E. coli cells 
pGMT7-DR1β and pGMT7-DRα or pGMT7-DRα-bt plasmids were transformed into Ro-
setta™(DE3) competent BL21 strain-derived Escherichia coli cells (Novagen) as described in 
section 2.4.4.3. Three individual colonies were picked from transformed plates, transferred to 
30 mL of TYP media supplemented with 50 µg/mL carbenicillin and cultured at 37 °C and 
shaken at 220 rpm to an optical density at 600 nm (OD600) of between 0.4 and 0.6. Starter 
cultures were consequently transferred to 1 L TYP media supplemented with 50 µg/mL carben-
icillin and cultured at 37 °C, 220 rpm. Expression of recombinant protein was induced by 
addition of 0.5 mM Isopropyl β-D-thio-galactoside, (IPTG; Fisher Scientific) when cultures had 
reached an OD600 of between 0.4. and 0.6 after which cultures were continued for 3 to 4 hours. 
Bacterial cells were harvested by centrifugation at 4000 rpm for 20 mins, cell pellets were re-
suspended by vortex and homogenisation in bacterial cell lysis buffer and frozen at -20 °C. 
Samples before and after IPTG induction were analysed via SDS-PAGE for confirmation of 
protein expression. 
2.2.3.2 Processing of HLA-DR1 inclusion bodies 
Frozen cells were thawed at room temperature and subjected to sonication, on ice, using a 
Sonopulse HD 2070 with MS73 probe (Bandelin) at 60 % output power for 20 minutes using a 
one second on, one second off oscillation cycle. High yield cell cultures were subject to a second 
iteration of freeze, thaw and sonication as described to ensure complete cell lysis. Lysed cells 
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were treated with 160 µg/mL deoxyribonuclease (DNAse) for 2 hours, shaken at 220 rpm at 37 
°C. Lysed cell suspension was pelleted by high-speed centrifugation at 10,000 rpm for 20 mins 
and washed in 100 mL of inclusion body wash buffer by resuspension of the cell pellet by ho-
mogenisation. Lysed cell pellets were washed at least twice by successive centrifugation and 
resuspension in inclusion body wash buffer, as described, until pellets appeared clear of gelati-
nous material. Washed pellets were consequently resuspended by homogenisation in inclusion 
body resuspension buffer, pelleted by high-speed centrifugation at 10,000 rpm for 20 mins and 
resuspended in urea buffer A by homogenisation. Solubilised inclusion bodies were subjected 
to a final centrifugation at 10,000 rpm for 20 mins to remove impurities insoluble in urea buffer 
A by harvesting the supernatant fraction after centrifugation. 
2.2.3.3 Purification of HLA-DR1 inclusion bodies 
Unpure HLA-DR1 inclusion body preparations solubilised in urea buffer A were 0.45 µm fil-
tered using vacuum filtration and purified by ion exchanged chromatography using 5 mL Hi-
Trap Q Sepharose High Performace anion exchange columns (GE Healthcare Life Science) on 
an ÄKTA FPLC or ÄKTApure fast protein liquid chromatography (FPLC) system. Unpure pro-
tein was bound to ion exchange columns and eluted by ionic competition using a variable elution 
gradient of NaCl containing urea buffer B. Eluted protein was collected as 1 mL fractions and 
analysed for protein purity using SDS-PAGE. Fractions containing high purity HLA-DR chains 
were analysed for contamination by DNA using a NanoDrop ND100 (ThermoScientific) by an-
alysing protein concentration (Absorbance at 280 nm) and nucleotide concentration 
(Absorbance at 260 nm). Fractions containing an A260/A280 ratio greater than 1 were discarded 
due to considerable contamination with DNA. Purified HLA-DR chains were stored at -20 °C 
until use. 
2.2.4 Refolding of HLA-DR1 molecules from inclusion bodies 
Refolding of heterodimeric HLA-DR1 molecules was achieved by instant denaturant dilution 
of HLA-DRα and HLA-DR1β chains in the presence of excess HLA-DR1 restricted peptide as 
previously published (Frayser et al. 1999). 5 mg/L of HLA-DRα or HLA-DRα-bt inclusion bod-
ies and 5 mg/L of HLA-DR1β inclusion bodies were added to cold MHC-II refold buffer 
supplemented with 0.5 mg/L peptide. Refold mixture was stirred vigorously for 1 hour before 
being left to incubate for 72 – 96 hours at 4 °C. Refold mixture was then 0.45 µm filtered using 
vacuum filtration and concentrated to a volume of approximately 20 mL using a 10 kDa molec-
ular weight cut-off (MWCO) Vivaflow® crossflow concentration cassette (Sartorius). 
Concentrated refold was then washed with 500 mL of PBS and further concentrated to a volume 
of approximately 2 mL using 10 kDa MWCO centrifugal filter units (Merck Millapore). 
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2.2.5 Purification of functional heterodimeric HLA-DR1 molecules 
Concentrated refolds were purified using antibody affinity purification columns containing 
an immobilised α-HLA-DR antibody (L243 clone). α-HLA-DR affinity columns were produced 
using Pierce™ Protein A IgG Plus Orientation Kit (ThermoFisher Scientific) according to man-
ufacturer’s protocols by crosslinking 8 mg of L243 antibody (produced by Sian Llewelyn-Lacey, 
Cardiff University) per 1 mL of immobilised protein-A beads. Refolded protein was applied to 
affinity columns equilibrated in PBS by flowing protein sample through columns at least four 
times. Non-specific proteins were washed from the column using PBS before eluting L243 spe-
cific proteins using CAPS elution buffer. Eluted protein samples were pH neutralised using an 
equal volume of neutralisation buffer. Affinity purified HLA-DR1 protein samples were con-
centrated to a volume of 1 mL using 10 kDa MWCO spin filtration columns according to 
manufacturer’s protocols (Millipore) and further purified by size exclusion chromatography 
(SEC) using Superdex 200HR gel SEC columns on an an ÄKTA FPLC or ÄKTApure FPLC 
system (all GE Healthcare Life Sciences). SEC columns were equilibrated with appropriate 
buffer such that HLA-DR1 molecules were filtrated into the appropriate buffer for downstream 
applications. Protein concentration was analysed using NanoDrop ND100 (ThermoScientific) 
measuring absorbance at 280 nm and calculated using extinction coefficients generated using 
the ExPASy ProtParam tool (SIB Swiss Institute of Bioinformatics). 
2.2.6 Biotinylation of HLA-DR1 molecules 
Between affinity and SEC purification steps as outlined in section 2.2.5, HLA-DR1 molecules 
refolded with HLA-DRα-bt inclusion bodies were biotinylated using a BirA biotinylation kit 
(Avidity). Affinity purified HLA-DR1-bt molecules were washed by dilution with 15 mL of 
crystallisation buffer and concentrated to 700 µL using a 10 kDa MWCO spin filtration column. 
HLA-DR1-bt samples were then supplemented with 100 µL Biomix A, 100 µL Biomix B, 100 
µL d-Biotin 500 µM and 2 µL BirA enzyme (Avidity). Biotinylation reaction was incubated 
overnight at room temperature after which, excess biotin was washed by dilution with 15 mL of 
crystallisation buffer and concentrated to 1 mL for purification via SEC as outlined in section 
2.2.5. 
Biotinylated HLA-DR1-bt molecules were assayed for efficient biotinylation by streptavidin 
shift assay. 5 µg of biotinylated HLA-DR1-bt was incubated with 5 µg of streptavidin and ana-
lysed by SDS-PAGE for the formation of complexed HLA-DR1-streptavidin under non-
reducing conditions. 
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2.2.7 Polyacrylamide gel electrophoresis 
Produced protein sample was analysed for quality via sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE). Approximately 5 µg of protein to be analysed was combined 
with sample loading buffer. Samples run in reducing conditions were combined with reducing 
sample loading buffer (containing 1 M DTT) and boiled at 95 °C for 5 min prior to SDS-PAGE 
analysis. Prepared samples were run on Bolt™ 4-12 % Bis-Tris Plus Gels using NuPAGE® 
MES SDS Running Buffer in a Bolt™ Mini Gel Tank (all ThermoFisher Scientific). Gels were 
run at 200 V for 25 min using a Bio-Rad Powerpac 200 power supply (Bio-rad Laboratories).  
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2.3 Structural analysis of MHC-II molecules by X-ray Crystallography 
2.3.1 List of materials 
2.3.1.1 Buffers 
Crystal   buffer: 10 mM Tris, 10 mM NaCl, pH8.1 
2.3.2 Preparation of protein samples 
Purified pMHC-II molecules produced as outlined in section 2.2 were filtrated into Crystal 
buffer during SEC purification and concentrated to approximately 1 - 5 mg/mL using spin fil-
tration columns for crystallisation screening. 
2.3.2.1 Vapour diffusion condition screening 
pMHC-II samples were screened for crystal formation using sitting drop vapour diffusion 
screening plates set up using an Art-Robbins Gryphon robot (Art Robbins Instruments, LLC.). 
Crystallisation screens were performed using a customised protein crystallisation screen opti-
mised for the formation of pMHC, TCR and pMHC-TCR complexed crystals termed 
TCR/pMHC Optimized Protein crystallization Screen (TOPS) (Bulek et al. 2012). Crystal for-
mation was also screened using two commercial screens; PACT premier™ MD1-29 (Molecular 
Dimensions) and JBScreen PEG/Salt HTS CS-205L (Jena Bioscience GmbH). Crystallisation 
screens were set up in ARI INTELLI-PLATE 96-2 Low Volume Reservoir plates (Art Robbins 
Instruments, LLC.) by dispensing 60 µL and 200 nL of mother-liquor screen solution into plate 
reservoirs and sitting drop wells, respectively. 200 nL of pMHC prepared sample was next dis-
pensed into sitting drop wells to form a final drop volume of 400 nL. Dispensed plates were 
sealed immediately using ClearVue™ Sealing Sheets (Molecular Dimensions) and imaged us-
ing a Formulatrix Rock Imager 2 (Formulatrix, Inc.) directly after applying plate seal. Plates 
were incubated at 18 °C, imaged and screened for crystal formation after day 1, 3 and 7 followed 
by irregular intervals thereafter. 
2.3.2.2 Crystal microseed condition screening 
pMHC-II molecules were also screened for crystal formation using hanging drop vapour diffu-
sion with the inclusion of homologous or heterologous pMHC-II crystal microseeds. Crystal 
microseed stocks were prepared from successfully formed crystals of the same pMHC or similar 
pMHC using a MicroSeed Beads™ kit according to manufacturer’s instructions (Hampton Re-
search). Formed crystals were first crushed using a macro crystal crusher in sitting drop well 
screening plates. Crushed crystals were then diluted in the sitting drop well with 60 µL of 
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mother-liquor solution from screening plate reservoir and transferred to a seed bead tube. Seed 
bead tubes were vortexed vigorously for 30 sec, kept on ice and used within 1-2 hours and frozen 
at -80 °C after use. Microseed experiments were set up by hand using the hanging drop vapour 
diffusion method on EasyXtal X-Seal crystal supports and EasyXtal 15-well DG plates 
(Qaigen). Plate reservoirs were first filled with 500 µL of crystal screen buffer before hanging 
drops of 1 µL crystal screen buffer, 1.5 µL of target protein and 0.5 µL of microseed stock were 
prepared on crystal supports. Hanging drops were repeated using neat microseed stock and two 
serial dilutions of 1:10 and 1:100 within the cell well. Microseed stocks were diluted using the 
crystal seed stock solution from which they were grown. Plates were sealed by tightly screwing 
supports to wells, incubated at 18 °C and screened for crystal formation after day 1, 3 and 7 
followed by irregular intervals thereafter using a Leica S4E light microscope (Leica Microsys-
tems). 
2.3.3 Crystal harvesting and data collection 
Crystals were cryoprotected by addition of 0.5 µL of 20 % ethylene glycol diluted in appropriate 
crystal screen buffer. Cryo-protected crystals were picked from wells using 20 µm or 40 µm 
mounted loops (Molecular Dimensions). Picked crystals were immediately flash frozen in liquid 
nitrogen, transferred to Diamond Light Source (DLS) storage pucks and maintained in liquid 
nitrogen until completion of data collection. X-ray diffraction data was collected at Diamond 
Light Source (Didcot, United Kingdom) via a Beamline Allocation Grant (BAG) under the Prin-
cipal Investigator applicant Dr Pierre Rizkallah (Cardiff University). Crystals suspended in a 
stream of liquid nitrogen were diffracted using a fixed wavelength of x-rays. 1000 diffraction 
images were collected by rotation of crystals through 200 ° at 0.2 sec exposures resulting in 0.2 
° of rotation per exposure. Reflected x-rays were detected using a Pilatus 2M detector. 
2.3.4 Determination and analysis of crystal structures 
Obtained diffraction images were processed using the DLS automated data processing pipeline. 
Phases were solved using molecular replacement in PHASER using solved pMHC-II as a model 
(McCoy 2006). Generated molecular models were analysed and refined through molecular ma-
nipulation in COOT (Emsley & Cowtan 2004) and computationally refined through iterative 
TLS refinement using REFMAC5 (Murshudov et al. 2011) until convergence of Rwork and Rfree. 
Computational analyses were performed using the stated software available through the CCP4 
computational suite (Winn et al. 2011). Refined models were subjected to a final round of REF-
MAC5 refinement and visualised using PyMOL Molecular Graphics System (Schrödinger, 
LLC.). Contact tables were generated using NCONT (CCP4) using a custom python script to 
annotate contact type (available from: https://github.com/brucemaclachlan/annotcontacts). 
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2.4 Generation of a stably expressing LAG-3+ cell line 
2.4.1 List of materials 
2.4.1.1 Oligonucleotide reagents 
LAG-3.pUC57 – Custom synthesis by Genewiz 
P2A.rCD2.pELNsxv – Prof. James Riley, University of Pennsylvania 
pMD2.G – Addgene plasmid #12259 
pMDLg/pRRE – Addgene plasmid #12251 
pRSV-Rev – Addgene Plasmid #12253 
pELNsxv-for primer (GCTAGCTCTAGAGCCGCCACCATG) – Custom synthesis by 
Eurofins Genomics 
pELNsxv-rev primer (GAGAAGTTGGTGGCACCGGAGCCGC) – Custom synthesis by 
Eurofins Genomics 
2.4.1.2 Antibodies 
rCD2-PE: Phycocyanin conjugated anti-rat CD2 Mouse IgG2a, κ antibody clone OX-34  – 
Biolegend  
LAG-3-PE: Phycocyanin conjugated anti-human LAG-3 Goat polyclonal IgG antibody clone 
– R&D Systems 
2.4.1.3 Buffers 
Flow cytometry (FC) buffer: PBS & 2 % FCS 
TE Buffer: 10 mM Tris, 1mM EDTA & pH 8.0 with HCl 
HEPES buffered water: 2.5 mM HEPES, pH 7.3 with HCl 
Calcium chloride (CaCl2) solution: 2.5 M CaCl2·2H2O 
HEPES buffered saline: 280 mM NaCl, 50 mM HEPES, 1.5 mM Na2HPO4 & pH 7.0 with 
NaOH 
2.4.1.4 Culture media 
R10 media: RPMI 1640 media, 10 % FCS, 2mM L-Glutamine, 100 IU/mL Penicillin & 100 
µg/mL Streptomycin. 
D10 media: Dulbecco's Modified Eagle Medium (DMEM), 10 % FCS, 2mM L-Glutamine, 100 
IU/mL Penicillin & 100 µg/mL Streptomycin. 
TYP-Agar media: 16g/L Tryptone, 16g/L Yeast Extract, 5g/L Potassium Phosphate Dibasic, 5 
g/L Sodium chloride & 15 g/L Agar Bacteriological.  
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TYP media: 16g/L Tryptone, 16g/L Yeast Extract, 5g/L Potassium Phosphate Dibasic & 5 g/L 
Sodium chloride.  
2.4.2 Cell lines and culture 
The J.RT3-T3.5 Jurkat cell line (ATCC® TIB-153™) was obtained from Dr. John Bridgeman 
(Cardiff University) as a frozen stock in 90 % FCS 10 % DMSO. The Human Embryonic Kidney 
293T (HEK 293T) cell line (ATCC® CRL-3216™) was obtained from Dr. Bruno Laugel (Car-
diff University) as a frozen stock in 90 % FCS 10 % DMSO. Cells were initiated from frozen 
culture by rapidly thawing cells at 37 °C before washing in 10 mL of pre-warmed R10 media. 
Washed cells were centrifuged at 1500 rpm for 5 minutes and subsequent cell pellet resuspended 
in 5 mL of fresh pre-warmed R10 media. Cells were transferred to a T25 tissue culture flask. 
J.RT3-T3.5 Jurkat cells (henceforth Jurkat) and cell lines derived thereof were subsequently 
cultured at 37 ˚C, 5 % CO2 in R10 media. Jurkat cells were cultured in suspension by renewing 
culture media three times per week, maintaining cells at a density of 1 x 105 and 1 x 106 cells/mL. 
HEK 293T cells were cultured at 37 ˚ C, 5 % CO2 in D10 media as an adherent monolayer culture 
by passaging at 80-90 % confluency. 
2.4.3 Construction of a LAG-3 lentiviral delivery vector 
An expression construct consisting of the full length sequence of human LAG-3 (Uniprot: 
P18627) flanked by a 5’ XbaI restriction site (TCTAGA), Kozak sequence (GCCGCCACC) and 
start codon (ATG) and a 3’ XhoI restriction site (CTCGAG) was codon optimised for human 
expression systems and chemically synthesised contained within the pUC57 vector (Genewiz).  
2.4.4 Cloning of the LAG-3 lentiviral delivery vector 
The synthesised full length LAG-3 construct (described in 2.1.3) was cloned into the pELNsxv 
third generation lentiviral transfer vector (kindly provided by Prof. James Riley, University of 
Pennsylvania) containing a self-cleaving P2A linked rat CD2 (rCD2) expression cassette within 
the multiple cloning site (P2A.rCD2.pELNsxv). The final constructed plasmid was designed 
such that full length human LAG-3 a P2A linker and rCD2 are expressed under the control of a 
single promoter in one continuous open reading frame. 
2.4.4.1 Vector and insert digestion and purification 
All restriction digests were performed according to manufacturer’s protocols and in supplied 
FastDigest buffer. 1 µg of the synthesised LAG-3 construct (described in 2.4.3) supplied within 
a commercial pUC57 vector was double digested in a 20 µL XbaI and XhoI restriction endonu-
clease reaction for 30 minutes at 37 °C. Likewise, the P2A.rCD2.pELNsxv vector was double 
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digested in a 20 µL XbaI and XhoI restriction endonuclease reaction for 30 minutes at 37 °C. 
The resulting digestion products were analysed by 1 % agarose gel electrophoresis for digestion 
efficiency using an ultraviolet transilluminator. Digestion products of expected electrophoretic 
mobility for the digested insert and digested vector, as indicated by a molecular weight marker 
(Bioline), were excised from the agarose gel and purified using the QIAquick Gel Extraction 
Kit (Qiagen). 
2.4.4.2 Insert ligation and transformation 
Purified XbaI/XhoI digested LAG-3 insert and XbaI/XhoI digested P2A.rCD2.pELNsxv vector 
samples were analysed for absorbance at 260 nm using a nano spectrophotometer allowing 
measurement of DNA concentration. Ligation of insert into the carbenicillin resistant 
P2A.rCD2.pELNsxv vector was achieved by incubating 50 ng of vector with 18.5 µg of insert 
(a 1:2 molar ratio of vector:insert) with T4 DNA ligase and DNA ligase buffer (Life Technolo-
gies) overnight at room temperature. Ligation reactions were screened for successful construct 
formation by transforming 1 µL of the ligation mixture into XL10 Gold Ultracompetent Esche-
richia. Coli (E. coli) cells (Agilent Technologies) as described below. 
2.4.4.3 Transformation of competent Escherichia. Coli (E. coli) 
E. coli bacterial cells were transformed by thawing 25 µL of competent cells for 5 minutes on 
ice. Thawed cells were incubated with 1 µL of ligation reaction for 5 minutes, mixing frequently 
via agitation before incubating at 42 °C for 2 minutes. Cells were subsequently returned to ice 
for 5 minutes before being positively selected on TYP-agar media culture dishes containing 50 
mg/L carbenicillin. Transformation plates were incubated over night at 37 °C and subsequently 
analysed for the growth of distinct bacterial colony formation. 
2.4.4.4 Screening for successful construct formation 
Plasmid DNA from bacterial colonies selected on carbenicillin TYP-agar plates were first pre-
pared using a plasmid DNA mini-prep kit according to manufacturer’s protocols (Zymo 
Research). Prepared plasmid DNA was analysed via restriction screening by digesting candidate 
DNA in a 20 µL XbaI and XhoI restriction endonuclease reaction for 30 minutes at 37 °C as 
described previously. Consequent digestion products were analysed by 1 % agarose gel electro-
phoresis for a digestion product of the molecular size of the desired LAG-3 insert. Positive 
colonies by restriction screening were subsequently analysed by DNA sequencing performed by 
Central Biotechnology Services (CBS; Cardiff University) using the pELNsxv-for and pELNsxv-
rev primers described in section 2.4.1.1. DNA sequencing results were compared to the known 
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sequence of the desired construct by the multiple sequence alignment program Clustal Omega 
(EMBL European Bioinformatics Institute).  
2.4.4.5 Production of the LAG-3.P2A.rCD2.pELNsxv transfer vector 
A sequencing positive clone confirmed to carry the LAG-3.P2A.rCD2.pELNsxv lentiviral trans-
fer vector was consequently inoculated in 400 mL of TYP media supplemented with 50 mg/L 
carbenicillin overnight at 37 °C, shaking at 220 rpm. Subsequent plasmid DNA was prepared 
from the culture using a PureLink® HiPure Plasmid Filter Maxiprep Kit according to manufac-
turer’s protocols (Life Technologies). 
2.4.5 Generation of a LAG-3 encoding lentivirus 
LAG-3 encoding lentiviral particles were generated by calcium chloride transfection of the 
LAG-3.P2A.rCD2.pELNsxv transfer vector and the pMD2.G, pMDLg/pRRE, pRSV-Rev pack-
aging vectors into HEK 293T cells (Dull et al. 1998). HEK293T cells were prepared at 80 % 
confluency by replenishing culture media with fresh D10 media 4 hours prior to transfection.  
DNA particulates were generated by firstly combining 1.1 mL of TE buffer pH 8.0, 15 µg 
pMD2.G, 15 µg pMDLg/pRRE, 15 µg pRSV-Rev and 583 µL of HEPES buffered water, in the 
order described, before briefly vortexing. Secondly, 18.75 µg of the LAG-
3.P2A.rCD2.pELNsxv transfer vector and 190 µL CaCl2 solution were added in the order de-
scribed before briefly vortexing. Thirdly, whilst vortexing, 1.9 mL of HEPES buffered saline 
was added dropwise to the transfection mixture before incubating at room temperature for 18 
min to allow DNA precipitates to form. The transfection mixture was then added dropwise into 
the culture media of HEK293T cells under gentle agitation and avoiding direct pipetting on the 
cell monolayer. Treated HEK293T cells were incubated overnight for 16 hours at 37 ˚C and 5 
% CO2 after which the transfection mixture was replaced with fresh D10 media. Packaged len-
tiviral particles were harvested after 24 hours and 48 hours of culture at 37 ˚C and 5 % CO2, 
0.45 µm filtered and concentrated by ultracentrifugation at 150,146 x g for 2 hours at 4°C. Con-
centrated virus was resuspended in 300 µL of R10 media and stored at -80 °C via flash freezing 
on dry ice. 
2.4.6 Lentiviral transduction of Jurkat cells 
Jurkat cells were transduced with the generated LAG-3.P2A.rCD2 lentivirus by incubating 2 x 
105 cells seeded in a 48 well plate with increasing volumes of lentiviral preparation (50 µL, 100 
µL and 150 µL) overnight at 37 ˚C and 5 % CO2. Following overnight incubation, lentiviral 
containing media was diluted out using 1 mL fresh R10 media and cells were cultured for 10 
days until cells reached maximum growth capacity. 
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2.4.7 Flow cytometric analysis of LAG-3 transduction efficiency 
2.4.7.1 Fluorescence antibody staining of Jurkat cells 
Transduced Jurkat cells were prepared for antibody staining by splitting the suspension culture 
by a ratio of 1:2 using fresh R10 media one day prior to analysis. Cells to be analysed were 
transferred to a 96 well plate and washed twice by successive centrifugation for 5 min at 1500 
rpm and resuspension in 150 µL FC buffer. Washed cells were stained for rCD2 expression and 
LAG-3 expression in separate single stain experiments using rCD2-PE (1:1500 dilution) and 
LAG-3-PE (1:15 dilution) antibodies respectively for 30 min at 4 ˚C. Stained cells were washed 
twice in FC buffer as described previously, resuspending in 200 µL FC buffer for analysis. 
2.4.7.2 Flow cytometric analysis of fluorescent antibody stained cells 
Fluorescent antibody stained Jurkat cells transduced with the generated LAG-3.P2A.rCD2 len-
tivirus were analysed for rCD2 and LAG-3 expression a BD FACSCanto II flow cytometer. 
Consequent data was analysed using the FlowJo (Tree Star Inc.) software package. 
2.4.8 Limit dilution cloning of transfected Jurkat lines 
A single cell derived LAG-3+ T cell line was cloned by limit dilution of the Jurkat cell line 
transduced with 150 µL of LAG-3.P2A.rCD2 lentiviral preparation. The parent Jurkat cell line 
was counted three times using a haemocytometer and serially diluted in fresh R10 media such 
that 0.5 cells were seeded into all wells of a 96 well plate. Cloning plates were incubated at 37 
˚C and 5 % CO2 and monitored regularly for cell growth and media consumption. Consequent 
wells containing multiplied cells were expanded into 48 well plates after 21 days of culture and 
into T25 tissue culture flasks after a further four days using fresh R10 media. Individual daughter 
clones were screened for LAG-3 expression using the protocol outlined in section 2.4.7. 
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2.5 Molecular and biophysical analysis of LAG-3-MHC-II binding 
2.5.1 List of materials 
2.5.1.1 Antibodies 
αLAG-3-FITC: Fluorescein isothiocyanate (FITC)-conjugated anti-human LAG-3 clone 17B4 
– Enzo Life Sciences 
αCD4-APCy: Allophycocyanin (APCy)-conjugated anti-human CD4 clone – Miltenyi Biotec 
αCD14-PB: Pacific Blue™ anti-human CD16 Antibody clone 3G8 - BioLegend 
αTCR-FITC: FITC-conjugated anti-human αβ TCR clone IP26 – BioLegend 
αPE: Unconjugated anti-phycoerythrin (PE) clone PE001 – BioLegend 
α-LAG-3: Unconjugated anti-LAG-3 clone 17B4 – Kindly provided by Professor Frédéric 
Triebel (Prima BioMed, Sydney, Australia) 
2.5.1.2 Buffers 
TBSB buffer: 20 mM Sodium citrate, 86 mM Sodium chloride, 100 mM L-arginine, 0.02 % 
Tween-20, pH 7.4 with citric acid 
2.5.2 Characterisation of cell lines 
Multimer staining was performed on JRT LAG-3+ C8 and JRT WT cells produced and cultured 
as described in section 2.4 and MOLT-3 cells provided by Angharad Lloyd (Cardiff University). 
MOLT-3 cells were cultured in suspension by renewing culture media two or three times per 
week, maintaining cells at a density of 1 x 105 and 2 x 106 cells/mL. TCR, LAG-3 and CD4 
expression by each of the three described cell lines was characterised using the standard anti-
body staining for flow cytometry protocol as outlined in section 2.4.7 using antibodies outlined 
in section 2.5.1.1. Antibody staining was performed as single stains and analysed of a FACS 
Canto II flow cytometer (BD Bioscience). 
2.5.3 Multimer staining of LAG-3+ cells 
PE-conjugated MHC-II dextramers were assembled using HLA-DR1 HA306-318 (PKY) mono-
mers into multimers as described in section 2.1.6. Negative control multimers were assembled 
from HLA-A2 hTERT540–548 (ILA) monomers kindly provided by Michael Crowther (Cardiff 
University). Cells were stained as described previously for cognate T cell clone staining and 
according to a protocol published previous (Tungatt et al. 2015) with the following additional 
steps. Cells were counted and 1x105 cells per stain transferred to FACS tubes for analysis. Cells 
were washed with 4 mL of PBS and treated with 50 nM dasatinib for 30 min at 37 ˚C. Cells 
were first blocked with unconjugated anti-LAG-3 (17B4 clone) or irrelevant antibody (anti-
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CD4-APCy) or PBS for unblocked samples. After blockade for 1 hr on ice, cell samples were 
washed with PBS and incubated with MHC-II multimers for 30 min on ice. After incubation 
with multimers, stained cells were washed with PBS, boosted using an anti-PE secondary anti-
body for 20 min and stained for live/dead cells as described previously. Stained cells were 
analysed on a FACS Canto II flow cytometer (BD Bioscience) as described previously. HLA-
DR1 HA306-318 (PKY) multimer staining of the cognate T cell clone DCD10, provided by Andrea 
Schauenburg (Cardiff University), performed as described in section 2.1.6.  
2.5.4 Analysis of LAG-3-MHC-II binding via surface plasmon resonance (SPR) 
2.5.4.1 Preparation of protein samples 
LAG-3:Fc protein was obtained through a collaboration with Professor Frédéric Triebel (Prima 
BioMed, Sydney, Australia) in the form of a GMP-grade sample expressed in glycosylation-
sufficient Chinese hamster ovary (CHO) cells at 30 mg/mL as described previously (Huard et 
al. 1995). LAG-3:Fc sample was gel filtrated into fresh TBSB buffer the day of SPR experi-
ments. Biotinylated MHC-II molecules were prepared as described previously (section 2.2). 
Spodoptera frugiperda (sf9) insect cell produced HLA-DR1 CLIP was kindly provided by An-
drea Schauenburg. HLA-A2 hTERT540–548 (ILA) monomers were kindly provided by Michael 
Crowther (Cardiff University) as a negative control. 
2.5.4.2 Immobilisation of streptavidin 
Analysis of LAG-3-MHC-II interactions were performed on a BIAcore T200 surface plasmon 
resonance (SPR) instrument (GE Healthcare Life Sciences). Firstly, sensor chips were activated 
by injection of 10mM N-(3-dimethylaminopropyl)-N3-ethylcarbodiimide (EDC) and 400mM 
N-hydroxysuccinimide (NHS) which was combined directly before use. Secondly, approxi-
mately 5000 response units (RU) of streptavidin was covalently linked to the activated sensor 
chip by injection of 200 µg/mL streptavidin solution in 10 mM acetate pH 4.5 (Sigma-Aldrich). 
Finally, the chip surface was deactivated by injection of 1 M ethanolamine (GE Healthcare Life 
Sciences). 
2.5.4.3 Immobilisation of pMHC molecules 
Prepared biotinylated pMHC molecules were immobilised to streptavidin coated CM5 sensor 
chips by injection of pMHC molecules at a flow rate of 10 µL/min in order to obtain an even 
distribution of pMHC molecules across each flow cell. pMHC molecules were injected until a 
desired ligand concentration was loaded onto sensor chips as indicated by increase in RU as a 
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result of ligand injection. Remaining free streptavidin sites were blocked using injection of free 
biotin.  
2.5.4.4 Measurement of LAG-3:Fc-MHC-II binding by SPR 
LAG-3-MHC-II binding was measured using immobilised pMHC coated sensor chips as exper-
imental ligand and soluble LAG-3:Fc as experimental analyte. All experiments were performed 
at 25 °C. LAG-3:Fc molecules were serial diluted by half resulting in a dilution series of ten 
concentrations (typically 10 mg/mL to 10 µg/mL). Each dilution of LAG-3:Fc was sequentially 
injected at 30 µL/min for 30 sec over all four flow cells of the pMHC immobilised sensor chip 
followed by a dissociation period of 300 sec at 30 µL/min. Association and dissociation of ana-
lyte was recorded in real-time and RU curves were analysed in BIAevaluation v4.1 software 
(GE Healthcare Life Sciences). Response unit changes were analysed as background subtracted 
sensograms by subtraction of background bulk effect response unit changes observed in nega-
tive control flow cells from experimental MHC-II immobilised response unit changes. Kinetic 
analyses of LAG-3:Fc binding were performed in BIAevaluation v4.1 using the simultaneous 
ka/kd fitting function. Equilibrium analyses were performed using nonlinear regression least 
squares ordinary fit of the Michaelis-Menton kinetic equation in GraphPad Prism v5 (GraphPad 
Software, Inc). Applied analyses are detailed in Chapter 4. All sensograms presented were plot-
ted using GraphPad Prism v5.  
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2.6 Analysis of LAG-3:Fc and MHC-II via negative stain electron 
microscopy 
2.6.1 Sample preparation 
LAG-3:Fc was provided by a collaboration with Professor Frederic Triebel (Prima Biomed, 
Sydney, Australia) after encouragement (Brains Brewery, Cardiff, UK). LAG-3:Fc was formu-
lated as described previously (Huard et al. 1995) and provided at a concentration of 30 mg/mL 
in TBSB buffer. For negative stain microscopy, LAG-3:Fc was serially diluted to a concentration 
of 20 µg/ml in TBSB buffer. 
pMHC-II was produced as described in section 2.2 by the refolding of HLA-DR1 with the 
5T4p12 peptide (DR1-5T4p12). DR1-5T4p12 was serially diluted to a concentration of 20 µg/mL 
in TBSB buffer and combined at a 1:1 molar ratio with LAG-3:Fc prepared as described (hence-
forth LAG-3:Fc-DR1). 
2.6.2 Preparation of grids 
Negative stain electron microscopy grids were prepared according to an optimised protocol for 
the imaging of macromolecular complexes of low symmetry (Rames et al. 2014). Carbon film 
coated 400 mesh copper grids (Agar Scientific) were glow discharged using a SC7620 Mini 
Sputter Coater/Glow Discharge System (Quorum Technologies Ltd) for 30 seconds. 4 µL of 
prepared LAG-3:Fc or LAG-3:Fc-DR1 complex samples were pipetted onto grids suspended 
over ice at a 45 ° tilt angle for 60 seconds. Excess protein solution was removed via blotting 
using Whatman® No. 1 filter paper (GE Healthcare Life Sciences). Grids were then washed 
three times in 40 µL droplets of deionised water, removing excess water with filter paper be-
tween washes. Washed grids were next incubated in three droplets of 0.2 µm filtered 2 % uranyl 
acetate (Sigma-Aldrich) for 3 seconds, 10 seconds and 60 seconds, consecutively, removing 
excess stain with filter paper between incubations. Stained grids were left to dry for 30 minutes 
at room temperature before being stored until imaging. 
2.6.3 Data collection 
Negative stained grids were imaged at Research Complex at Harwell (Didcot, United Kingdom) 
with access through a visitor access grant. Data was collected on a JEM-2100 LaB6 transmission 
electron microscope (JOEL USA, inc) equipped with a Gatan US1000-1 2048 x 2048 charged-
couple device (CCD) digital imaging camera. Micrographs were collected at 50,000 X magni-
fication at an acceleration voltage of 200 kV, sampling rate of 2.1 Å/pixel and spherical 
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aberration Cs of 1.0mm. Grids were exposed to a maximum electron dosage of 25 e-/Å2. Micro-
graphs were collected with a 0.5 second exposure time at defocus levels of between 0.1 and 1.5 
µm. 
2.6.4 Image processing 
LAG-3:Fc or LAG-3:Fc-DR1 complex negative stain micrographs were analysed using the 
EMAN2.1 scientific image processing suite (Tang et al. 2007). Processing steps were performed 
through command-line based execution of EMAN2.1 programs in combination with the graph-
ical user interface (GUI) project workflow program e2projectmanager.py. 
2.6.4.1 Micrograph selection 
Recorded micrographs were curated for quality by viewing images using e2evalimage.py and 
removing micrographs with poor contrast. Micrographs which contained excessive astigmatism 
and drift, as indicated by non-spherical or incomplete Thon rings, respectively, in generated 2D 
power spectrums, were also removed from consequent analyses. 
2.6.4.2 Particle picking 
Particles from raw collected micrographs were picked using e2boxer.py interactive boxing pro-
gram. Single particles were picked manually with a box size of 196x196 pixels for LAG-3:Fc 
and 224x224 pixels for LAG-3:Fc-DR1. Picked particles were outputted with edge normalisa-
tion as particle stacks in .hdf format. 
2.6.4.3 Particle pre-processing 
Particle images were first contrast transfer function (CTF) corrected using e2ctf.py by automated 
estimation of defocus values in conjunction with observed defocus at micrograph collection. 
CTF parameters were refined by calculation of particle structure factors and an estimated am-
plitude contrast of 60 %. Particle images were corrected for CTF by the generation of phase 
flipped images. 
Particle images were further pre-processed through filtering of high and low frequency noise, 
mask application and image normalisation using e2proc2d.py. High resolution noise was re-
moved from particles using a Gaussian low pass filter with a cut-off wavelength of 10 Å. 
Similarly, low frequency noise was removed with a cut-off Gaussian high pass filter wavelength 
of 200 Å for LAG-3:Fc and 300 Å for LAG-3:Fc-DR1. Furthermore, a circular mask of radius 
0.9 X the particle box size with a linear drop off of 4 pixels was applied. Finally, particle images 
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were normalised to bring mean pixel intensity across particles to a zerofloat, thus, normalising 
particle images across all image stacks. 
2.6.5 2D class averaging 
Pre-processed particle images were processed into representative 2D class averages via the ref-
erence free classification approach by e2refine2d.py. For LAG-3:Fc and LAG-3:Fc-DR1, the 
top 1000 particle images with best signal to noise ratio were classified into 24 classes through 
15 iterations of refinement.  
2.6.6 Initial model building 
Initial models were built from class averages featuring unique particle views using e2ini-
tialmodel.py. Multiple initial models of LAG-3:Fc and LAG-3:Fc-DR1 were generated from 
between 5 – 15 of the highest quality class averages, with each initial model refined by at least 
6 iterations of refinement. Generated initial models were curated by visualisation and analysis 
of quality score defined by the program. 
2.6.7 3D refinement 
Particle datasets and generated initial models were used to refine 3D single particle reconstruc-
tions of LAG-3:Fc and LAG-3:Fc-DR1 using e2refine_easy.py. Models were generated and 
refined via multiple rounds; first starting with particle images with the best signal to noise ratio 
and a low resolution target of 35 Å. Each refinement was performed with no symmetry restraint 
(C1 symmetry), through at least 8 refinement iterations using the highest precision parameter 
available (speed parameter value of 1). Generated refined models were visualised and used as a 
starting model for further refinement rounds with additional particle images and higher resolu-
tion targets. This iterative process was repeated until convergence of resolution and model 
quality. Model resolutions are calculated according to the ‘gold standard’ resolution criteria 
(Scheres & Chen 2012). 
2.6.8 Visualisation of models  
Single particle reconstructions of LAG-3:Fc were visualised using UCSF Chimera v1.1 
(Pettersen et al. 2004). Surface volumes were rendered using a 0.5 σ cut-off value. 
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2.7 Generation of anti-LAG-3 antibodies 
2.7.1 List of materials 
2.7.1.1 Antibodies 
αMouse-HRP: Horse Radish Peroxidase AffiniPure Goat Anti-Mouse IgG, F(ab')₂ Fragment 
Specific No. 315-035-047 – Jackson Immuno Research Laboratories Ltd. 
αMouse-FITC: FITC Goat Anti-Mouse Ig Clone Polyclonal (RUO) No. 554001 – BD 
Biosciences 
αLAG-3-FITC: Anti-human LAG-3 clone 17B4 – Enzo Life Sciences 
2.7.1.2 Buffers 
PBS-T: PBS, 0.05 % Tween 20 
FC buffer: PBS, 2 % FCS 
Red Blood Cell Lysis Buffer: 155 mM Ammonium chloride (NH4Cl), 10 mM Potassium 
bicarbonate (KHCO3), 0.1mM Ethylenediaminetetraacetic acid (EDTA), pH 7.2 with 
HCl 
2.7.2 Cell lines and culture 
Generated mouse B cell hybridoma cell lines were cultured at 37 ˚C, 5 % CO2 in R10 media by 
maintaining cells as a suspension culture at density of between 5 x104 and 5 x105 cells/mL. 
Mouse B cell hybridomas cell lines were cryoprotected and initiated from frozen culture when 
required as described in section 2.4.2 and 2.1.8 respectively. Wild type Jurkat (WT-JRT) and 
LAG-3+ Jurkat (LAG-3-JRT) cells were cultured as described in section 2.4.2. 
2.7.3 Immunisation of mice 
The generation, initial cloning and ELISA screening of mouse anti-human LAG-3 B cell hy-
bridomas through the in vivo immunisation of mice was kindly performed by and in 
collaboration with Professor B. Paul Morgan (Cardiff University). 
2.7.3.1 Preparation of antigen 
Antigen was prepared by diluting 20 µg of human LAG-3:Fc fusion protein (AdipoGen) in 300 
µL of phosphate buffered saline (PBS) and combined with 300 µL of either Freund’s Complete 
Adjuvant (CFA) or in Freund’s incomplete adjuvant (IFA) (Sigma-Aldrich). The antigen and 
adjuvant were mixed via vigorous vortex to form an emulsion. 
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2.7.3.2 Immunisation schedule 
Four C57BL/6 mice were first immunised via subcutaneous injection with 20 µg of human 
LAG-3:Fc emulsified in CFA, as described. Mice were then consequently boosted with 20 µg 
of LAG-3:Fc emulsified in IFA, as described, at four weeks post-challenge followed by addi-
tional boosts at week five and week six post-challenge. Mouse sera was isolated from each 
mouse via tail bleed and screened for LAG-3:Fc specific antibody production by direct enzyme-
linked immunosorbent assay (ELISA) as described to follow. The mouse with highest sera re-
activity via ELISA was administered a final boost of 20 µg LAG-3:Fc, intravenously without 
adjuvant, two days before sacrifice and splenectomy.  
2.7.4 Generation of a mouse B cell hybridoma line 
Mouse splenocytes were isolated by forcing the harvested mouse spleen through a cell strainer 
using the plunger of a syringe and rinsed through with R10 media in order to form a cell sus-
pension. Harvested splenocytes were centrifuged at 800 g, resuspended in 10 mL of red blood 
cell lysis buffer and incubated for 10 minutes at room temperature. Splenocytes were centrifuged 
at 800 g, resuspended in R10 media and cultured at 37 ˚C, 5 % CO2 until fusion. Cultured sple-
nocytes were fused to the BALB/c derived Sp2/0-Ag14 (ATCC® CRL-1581™) mouse 
myeloma cell line via polyethylene glycol cell fusion. 
2.7.5 Single cell cloning of anti-LAG-3 hybridomas 
The parent B cell hybridoma line was serially diluted across 96 well plates by successive dilu-
tions by a dilution factor of two. Cloning plates were incubated at 37 ˚ C, 5 % CO2 and monitored 
regularly for cell growth and media consumption. Culture wells exhibiting growth, with prefer-
ence for wells seeded at the highest dilution factor, were selected for further cloning and 
reactivity screening via ELISA and flow cytometry, as described to follow. This process was 
repeated as a second and third iteration of cloning. For the fourth and final iteration of cloning, 
B cell hybridomas were counted and serially diluted such 0.33 cells were plated into wells of a 
96-well plate. Cell growth was monitored and final clones which had formed distinct single 
colonies of divided cells were selected for reactivity screening via ELISA and flow cytometry 
to ensure clonality. Consequent wells containing multiplied cells were expanded into 48 well 
plates after 21 days of culture and into T25 tissue culture flasks after a further four days using 
fresh R10 media. 
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2.7.6 LAG-3:Fc reactivity screening by ELISA 
Specificity of antibody contained within B cell hybridoma supernatants or mouse sera for LAG-
3:Fc was tested using a direct ELISA approach. Half-area 96 well plates were coated with 50 
µL of 1 µg/mL human LAG-3:Fc protein in PBS for 1 hour at 37 ˚C. Plates were then blocked 
with 100 µL of 1 % BSA in PBS for 1 hour at 37 ˚C followed by washing three times with PBS-
T. 50 µL of neat B cell hybridoma supernatants or serial diluted mouse sera were added to coated 
plates for 1 hour at 37 ˚C before washing three times with PBS-T. Plates were then incubated 
with an anti-Mouse-HRP secondary antibody (Jackson Immuno Research Laboratories Ltd.) di-
luted 1:2000 in PBS. Plates were washed three times with PBS-T and developed using HRP 
substrate colour reagents and stop solution (R&D Systems) and absorbance at 450 nm measured 
on a microplate absorbance reader (Bio-rad). 
2.7.7 LAG-3 reactivity screening by flow cytometry 
Specificity of antibody contained within B cell hybridoma supernatants or immunised mouse 
serum for LAG-3 was tested by flow cytometry analysis of stained wild type Jurkat (WT-JRT) 
and LAG-3+ Jurkat (LAG-3-JRT) developed in section 2.4. WT-JRT and LAG-3-JRT cells were 
counted and 2 x105 cells plated into wells of a 96 well plate. Cells were washed twice with FC 
buffer by addition of 150 µL of FC buffer and pelleting of cells by centrifugation at 1500 rpm 
for 5 minutes. Cells were resuspended in 40 µL mouse serum (diluted 1:3), B cell hybridoma 
supernatant (neat), FC buffer (negative control) or commercial FITC-conjugated anti-LAG-3 
(positive control; 17B4 clone; 1:200 dilution; Enzo Lifescience) on ice for 30 min. Cells were 
washed twice with FC buffer, as described previously, and then resuspended, where appropriate, 
in 30 µL anti-Mouse-FITC conjugate (1:50 dilution, BD Biosciences) on ice for 30 min in the 
absence of light. Stained cells were washed twice with FC buffer and resuspended in 200 µL for 
analysis on a FACSCanto II flow cytometer (BD Biosciences). Obtained data was analysed in 
Flow Jo v10 (FlowJo, LLC).  
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2.8 Production and characterisation of anti-LAG-3 antibodies 
2.8.1 List of materials 
2.8.1.1 Culture media 
R10-Ig- media: RPMI 1640 media, 10 % Ig- FCS, 2mM L-Glutamine, 100 IU/mL Penicillin & 
100 µg/mL Streptomycin. 
2.8.1.2 Buffers 
NaOH wash buffer: 0.5 M Sodium hydroxide 
Glycine elution buffer: 0.1 M Glycine, pH 2.5 with Hydrogen chloride 
Neutralisation buffer: 1 M Tris, pH 10.5 with Sodium hydroxide 
Endotoxin low Phosphate Buffered Saline Dulbecco ‘A’ (PBS) – Invitrogen: 8 g/L Sodium 
chloride, 0.2 g/L Potassium chloride, 1.15 g/L Disodium hydrogen phosphate & 0.2 g/L 
Potassium dihydrogen phosphate, pH 7.3 
PBS-T: PBS, 0.05 % Tween 20 
Western blot lysis buffer: 150 mM Sodium chloride, 50 mM Tris, 2 % v/v Triton X-100 
FC buffer: PBS, 2 % FCS 
Sodium acetate pH 4.5 buffer: 10 mM sodium acetate pH 4.5 with Acetic acid 
TBSB buffer - 20 mM Sodium citrate, 86 mM Sodium chloride, 100 mM L-arginine, 0.02 % 
Tween-20, pH 7.4 with citric acid 
Glycine pH 1.5 buffer: 10 mM Glycine, pH 1.5 with HCl 
2.8.1.3 Antibodies 
anti-Mouse-HRP conjugate:  F(ab')2-Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP 
conjugate No. A24524 – ThermoFisher Scientific 
αMouse-FITC: FITC Goat Anti-Mouse Ig Clone Polyclonal  (RUO) No. 554001 – BD 
Biosciences 
IgG2a isotype control: unconjugated mouse IgG2a, κ isotype control – BioLegend  
IgG2b isotype control: unconjugated mouse IgG2b, κ isotype control – BioLegend 
Anti-LAG-3 (17B4): Unconjugated anti-LAG-3 clone 17B4 – Kindly provided by Professor 
Frédéric Triebel (Prima BioMed, Sydney, Australia) 
Anti-LAG-3 (13E2): Unconjugated anti-LAG-3 clone 13E2 – Kindly provided by Professor 
Frédéric Triebel (Prima BioMed, Sydney, Australia) 
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2.8.2 Production of purified anti-LAG-3 antibodies 
2.8.2.1 Culturing of cells 
Large scale culturing and purification of anti-LAG-3 antibodies was performed by and in col-
laboration with Dr Emma Jones (Cardiff University). Cloned hybridomas were cultured in R10-
Ig-  media using INTEGRA CELLine flasks (INTEGRA Biosciences AG) according to manu-
facturer’s protocols. 
2.8.2.2 Purification of antibodies 
Antibody samples were purified from culture supernatants using a Protein L affinity column in 
conjunction with an ÄKTA Prime FPLC system (GE Healthcare Life Sciences). Prior to purifi-
cation, FPLC system was cleaned with NaOH wash buffer. Culture supernatants were loaded 
onto affinity columns equilibrated with PBS. Bound antibody was eluted by a single step equi-
libration of affinity columns with Glycine elution buffer. Eluted samples were collected in 2 ml 
fractions into tubes pre-filled with 50 µL Neutralisation buffer. Fractions containing protein, as 
indicated by A280 spectra, were concentrated and dialysed into endotoxin low PBS using 10 kDa 
MWCO centrifugal filter units (Merck Millapore). Purified antibody samples were analysed for 
protein concentration and stored in aliquots at 2 mg/mL. 
2.8.3 Western blot characterisation of antibodies 
The ability of generated anti-LAG-3 antibodies to detect whole protein by Western blot assay 
was performed against cell lysates of LAG-3-Jurkat cells and WT Jurkat cells, generated and 
cultured as described previously. To produce lysates, 5 x106 cells were harvested from culture 
by centrifugation at 1500 rpm, washed with 10 mL of PBS and resuspended in 1 ml of cold 
Western blot lysis buffer. Cells were vortexed for 1 minute before centrifugation at 16,100 g for 
5 min at 4 °C. The resulting supernatant was harvested and assayed for protein concentration 
using a NanoDrop ND100 (ThermoScientific). LAG-3-Jurkat and WT-Jurkat cell lysates were 
normalised to an equal protein concentration by dilution in Western blot lysis buffer. 
LAG-3-Jurkat and WT-Jurkat cell lysates were separated by SDS-PAGE, as described previ-
ously, by loading equal volume of each cell lysate. Separated proteins were transferred to 0.45 
µm polyvinylidene fluoride (PVDF) membranes using a Bolt® Mini blot transfer module (Ther-
moFisher Scientific). Invitrolon™ PVDF/Filter Paper Sandwich membranes (ThermoFisher 
Scientific) were pre-wet with 100 % isopropanol (Fisher Chemicals) for 30 sec before thorough 
washing in deionised water. PVDF membranes, filter papers and sponges were soaked in Bolt® 
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Transfer Buffer and assembled into transfer module according to manufacturer’s instructions 
(ThermoFisher Scientific). Membrane transfer was performed at 20 V for 60 minutes. 
Obtained blots were washed 3 times for 5 min under agitation in PBS-T and blocked for 1 hr 
in 5 % whole skimmed milk-PBS-T (Premier Foods Group Ltd). Blocked membranes were 
washed as above, cut and incubated separately with 5 ml of different anti-LAG-3 mAbs over-
night at 4 °C. Primary anti-LAG-3 antibodies were prepared from purified antibody samples 
diluted to 2 µg/mL in 5 % whole skimmed milk-PBS-T. After primary incubation, membranes 
were washed and incubated with 5 mL of goat anti-Mouse IgG-HRP conjugated secondary an-
tibody (ThermoFisher Scientific) diluted 1:5,000 in 5 % whole skimmed milk-PBS-T for 1 hr at 
room temperature. Probed membranes were washed and developed using Pierce™ ECL Plus 
Western Blotting Substrate (ThermoFisher Scientific) and blots imaged using a myECL™ Im-
ager in chemiluminescent imaging mode (ThermoFisher Scientific). Optimal exposure time was 
determined by the myECL™ Imager software. 
2.8.4 Flow cytometric characterisation of antibodies 
The ability of generated anti-LAG-3 antibodies to bind surface expressed LAG-3 was assessed 
by staining LAG-3-Jurkat cells and analysed via flow cytometry. LAG-3-JRT cells were counted 
and plated at 1 x105 cells into wells of a 96 well plate. Cells were washed twice with FC buffer 
by addition of 150 µL of FC buffer and pelleting of cells by centrifugation at 1500 rpm for 5 
minutes. Antibodies were prepared at multiple concentrations by serial dilution of purified anti-
body samples of known concentration, determined as described previously, in PBS. Cells were 
resuspended in 50 µL of anti-LAG-3 on ice for 30 min. Cells were washed twice with FC buffer, 
as described previously, and then resuspended in 50 µL anti-Mouse-FITC conjugate at 2 µg/mL  
(BD Biosciences) on ice for 30 min in the absence of light. Stained cells were washed twice 
with FC buffer, resuspended in 200 µL FC buffer and transferred to tubes for analysis on a 
FACSCanto II flow cytometer (BD Biosciences). Obtained data was analysed using Flow Jo 
v10 (FlowJo, LLC) and GraphPad Prism 5 (GraphPad Software, Inc). 
2.8.5 Antibody-antigen kinetic analysis by SPR 
Characterisation of anti-LAG-3 antibody to LAG-3 antigen interactions were performed on a 
BIAcore T200 surface plasmon resonance (SPR) instrument (GE Healthcare Life Sciences) us-
ing a single injection kinetics approach. LAG-3:Fc was immobilised directly to CM5 sensor 
chip by EDC/NHS amine activation coupling as described in section 2.5.4.2. Approximately 
1,500 response units of LAG-3:Fc was immobilised to flow cells 2 and 4 by injection of 50 
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µg/mL LAG-3:Fc diluted in sodium acetate pH 4.5 buffer. Purified anti-LAG-3 antibody sam-
ples were prepared by gel filtration into TBSB buffer and concentrated to 0.2 mg/mL. Kinetic 
measurements were made by injection of analyte antibodies at 30 µL/min for 200 seconds and 
consequent dissociation period of 1200 sec. Chip regeneration was performed by a 30 sec injec-
tion of glycine pH 1.5 buffer. Obtained association-dissociation sensograms were analysed for 
conformity to kinetic rate models using BIAevaluation v4.1 software (GE Healthcare Life Sci-
ences) and plotted in GraphPad Prism 5 (GraphPad Software, Inc). 
2.8.6 Antibody competition analysis by SPR 
Analysis of competition for binding of anti-LAG-3 antibodies was performed on a BIAcore 
3000 SPR instrument (GE Healthcare Life Sciences) using a sequential injection approach. 
LAG-3:Fc coated CM5 sensor chips and anti-LAG-3 antibodies were prepared as described in 
section 2.8.5. Experiments were performed at a flow rate of 30 µL/min. Ligand binding site 
saturation was first achieved by injection of an anti-LAG-3 antibody for 200 sec and consequent 
dissociation period of 300 sec before 80 sec injection of a second anti-LAG-3 antibody. Analysis 
of competition was performed by comparison of association profile of anti-LAG-3 antibodies 
with and without previous saturation by potential competitor anti-LAG-3 antibody. Chips were 
regenerated and data analysed as described previously. 
2.8.7 Molecular blockade of LAG-3-MHC-II binding 
Blockade of LAG-3:Fc-MHC-II interaction was performed using SPR as described in section 
2.5.4 using MHC-II as immobilised ligand and LAG-3:Fc as analyte with the following altera-
tions. Prior to SPR analysis 2 µM LAG-3:Fc analyte was incubated with 13.2 µM  irrelevant 
(IgG2a isotype control) 17B4, 13E2 or 6F7 purified antibody samples. Combined LAG-3:Fc-
antibody samples were co-injected over immobilised MHC-II and binding analysed as in section 
2.5.4. Consequently, titrating concentrations of 6F7 (0.6 – 13.2 µM) were incubated with 2 µM 
LAG-3:Fc and co-injected as described. The ability for generated anti-LAG-3 antibodies to 
block MHC-II multimer binding to JRT LAG-3+ C8 cells was assayed as described in section 
2.5.3.  
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3 Chapter 3: Molecular and cellular basis of CD4+ T cell re-
sponses to 5T4 
3.1 Abstract  
Recognition of the oncofoetal tumour antigen 5T4 by CD4+ T cells has been detected in both 
healthy donors and patients with colorectal cancer. Moreover, responses to 5T4 peptide antigens 
deteriorates with tumour stage due to increased regulation of adaptive immunity towards tu-
mours. Consequently, characterisation of the CD4+ T cell response to 5T4 antigens at the clonal 
and epitope level should aid understanding in the sub-optimal response to the self-derived 5T4 
antigen. To this end, using T cell activation assays, three 5T4-reactive clones were shown to be 
sensitive to 5T4 peptide epitopes by producing TH1 cytokines in response to antigen. However, 
using pMHC-II multimer staining and surface plasmon resonance, TCR engagement by cognate 
antigen was shown to be minimal to undetectable despite known antigen recognition in cell-
based assays e.g. IFNγ-release. In order to gain insights into the structural characteristics of 
5T4-peptide presentation to the TCR repertoire, the structure of a 5T4-derived peptide presented 
on HLA-DR1 was solved to 1.95 Å. This structure revealed a flat presented peptide binding core 
offering minimal high enthalpy contact points with the TCR. Structural order at the peptide 
flanking residues, including a C-terminal hairpin loop, however, showed projection of the pep-
tide away from the peptide binding groove and thus available for TCR contact. These features, 
as well as a near-optimal HLA-DR1 binding motif, may contribute to 5T4-peptide immunogen-
icity. These studies therefore describe the immunogenicity of tumour-derived peptide antigens 
and reveal novel structural phenomena of MHC-II peptide presentation. 
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3.2 Introduction 
CD4+ T cells can detect the occurrence of cancerous cells via the recognition of presented pep-
tides from tumour-derived proteins. These tumour associated antigens (TAAs) can be processed 
by antigen presenting cells (APCs) into peptide fragments which are presented at the cell surface 
via major histocompatibility complex class II (MHC-II) molecules. Peptide bound MHC-II 
complexes (pMHC-II) are in turn recognised by CD4+ T cells via their antigen specific T cell 
receptor (TCR). The ability to sufficiently present TAA-derived peptides on MHC-II molecules, 
and consequently form this interaction between pMHC-II and cognate TCR, governs CD4+ T 
cell activation and the consequent immune response against TAAs expressed by cancer cells.  
One such TAA recognised by CD4+ T cells is the oncofoetal antigen 5T4 (Trophoblast gly-
coprotein/Wnt-Activated Inhibitory Factor 1/WAIF1) which is expressed on most solid cancers 
whilst rarely expressed on healthy adult tissue (Elkord et al. 2008). Indeed, in a cohort of 72 
colorectal patients, 85 % of patients were 5T4 tumour positive (Starzynska et al. 1992). These 
properties have highlighted 5T4 as a potential marker for immunotherapies which aim to target 
5T4+ tumours directly or through the enhancement of immune responses to TAA expressing 
cancer cells (Stern et al. 2014). Specifically, a modified vaccinia Ankara viral vaccine (MVA-
5T4) termed Trovax® is currently under development and has undergone a phase I/II clinical 
trial in colorectal cancer patients (Harrop et al. 2006). In both pre-clinical models and small 
phase II studies, individuals vaccinated with MVA-5T4 generate a consistent antibody response 
against 5T4 (Harrop et al. 2013). 
3.2.1 T cell clones as a model for studying the CD4+ T cell response to 5T4 
Study of human T cell responses to antigens at the molecular, cellular, structural and biophysical 
level has been enabled by the generation of human T cell clones, their consequent maintenance 
in culture and their analysis at the protein level. Generation of T cell clones, and thus the TCR 
that defines their clonotype, provide a snapshot of the T cell repertoire against a chosen antigen, 
such as tumour antigens like 5T4. Characterisation of the function and phenotype of such clones 
might give an indication as to the immunology of the active response to a specific peptide anti-
gen (Matsuzaki et al. 2015). The generation of T cell clones allows the study of clonal TCR 
heterodimer molecules. (Deng et al. 2007). Acquisition of tumour reactive T cell clones there-
fore provide a model for the study of tumour recognition through the TCR and the peptide 
ligands, presented by MHC molecules. Characterisation of T cell clones against tumour anti-
gens, such as 5T4, therefore help validate the recognition of peptide epitopes and their potential 
immunogenicity. 
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3.2.2 Analysing T cell recognition through structural and biophysical techniques 
Recognition of tumour-derived peptide antigens is dependent on TCR engagement to ligands 
presented on MHC molecules with sufficient affinity to initiate triggering of T cell activation. 
The degree of T cell activation is driven in part by the affinity at which its TCR binds cognate 
pMHC-II (Corse et al. 2011). Thus, quantification of the affinity of TCR engagement by a tu-
mour reactive TCR is a direct measurement of the possible potency in the response to tumour 
via the recognition of 5T4-derived peptide antigen. Detection and measurement of this binding 
affinity has been performed mostly by surface plasmon resonance (SPR), in particular, using the 
BIAcore series of instruments (Bridgeman et al. 2012). 
SPR instruments allow the label-less real-time measurement of the kinetics of protein-protein 
interactions. This is achieved through the detection of binding between an immobilised ligand 
attached to a glass surface chip layered with gold and an analyte in solution which is flowed 
over the surface chip via a microfluidics flow cell. Measurement of binding is facilitated by the 
change in refractive index of light at the angle of total internal reflection upon the surface of the 
glass chip as a consequence of the change in mass at the chip surface upon binding. As a result, 
real time binding of proteins is detected and represented as sensograms which plot response 
units (RU) – the measured SPR signal – as a function of time. From sensograms, the kinetics of 
an interaction can be elucidated and, thus, the affinity of the interaction calculated. 
SPR experiments have been used extensively in the characterisation of TCR to pMHC inter-
action affinity where pMHC tagged with biotin are immobilised to SPR sensor chips via the 
high-affinity interaction between biotin and streptavidin. This coupling technique allows the 
MHC molecule to be immobilised in neutral buffer conditions as well as fixing the orientation 
of immobilised MHC. Consequently, TCR binding to pMHC is measured by flowing TCR over 
the chip surface. These standards in T cell biophysics allow the comparison of affinities obtained 
by SPR data in order to describe differences in binding affinity by TCRs specific to a variety of 
antigens (Bridgeman et al. 2012).  
 Such biophysical studies have shown that TCRs expressed by tumour-reactive T cell clones 
recognise their cognate tumour derived antigens using a sub-optimal weak interaction (KD > 100 
µM) in both the context of MHC-I and MHC-II presented antigens compared to that of presented 
pathogenic non-self-antigens (typical KD = 25 µM - 40 µM) (D. Cole et al. 2007) Moreover, 
tumour reactive TCRs have been described structurally despite exhibiting an affinity for cognate 
pMHC-II below the detectable sensitivity of SPR instruments (Deng et al. 2007).  
Understanding TCR engagement by SPR affinity measurements in conjunction with struc-
tural techniques has therefore enabled an understanding of the molecular characteristics of 
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epitopes recognised by TCRs at high affinity compared to low affinity. Acquisition of such data 
has therefore begun to describe pMHC surface volumes that elucidate a high affinity T cell 
response and residues within epitopes which contribute to such a response. Molecular under-
standing of MHC-II presented epitopes however is limited compared to MHC-I counterparts. In 
particular, the full extent of the contribution by peptide flanking residues of MHC-II epitopes to 
TCR binding is under-described (Holland et al. 2013). These peptide flanking region residues, 
which extend out of the core MHC-II binding region, have been shown to have mixed influence 
on TCR recognition of pMHC-II molecules (Sant’Angelo et al. 2002; Zavala-Ruiz et al. 2004) 
Thus, a comprehensive understanding of TCR engagement of MHC-II presented ligands is yet 
to be achieved. 
Knowledge of what makes an immunogenic TCR epitope has led to the structure led design 
of altered peptide ligands (APLs) with the aim of improving TCR engagement to weak affinity 
pMHC ligands. Such modifications can be designed to enhance peptide binding to MHC-II in 
order to increase immunogenicity (Chen et al. 2013). Alternatively, modification of residues 
with the aim of enhancing pMHC-II engagement by TCRs have also been designed. Such mod-
ifications have been to exchange large positively charged residues into the flanking regions of 
MHC-II presented epitopes in order to optimise TCR binding and thus alter the TCR repertoire 
(Cole et al. 2012). Indeed, modification of peptide epitopes presented on MHC-I molecules have 
been incorporated into tumour vaccinations and shown to increase immunogenicity to tumour 
in the context of melanoma antigens (Parkhurst et al. 1996). Such alterations to MHC-II re-
stricted epitopes not yet been successfully designed to enable enhancement of tumour-derived 
peptide epitope immunogenicity (Chen et al. 2013). 
Together, SPR with x-ray crystallography techniques can be used to therefore describe the 
efficiency of the TCR/pMHC axis to present and recognise tumour antigens, such as 5T4, and 
therefore describe the effectiveness of the T cell immune response against cancer. Furthermore, 
structural and biophysical understanding of 5T4-derived peptide epitopes could be used to infer 
structure led design of enhanced antigens through the incorporation of APL sequences into tu-
mour vaccines such as MVA-5T4. 
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3.2.3 Aims 
CD4+ T cell responses to 5T4-derived peptide antigens presented on MHC-II molecules are de-
tectable in healthy donor PBMCs as well as in patients with colorectal cancer. These responses, 
however, negatively correlated with progression of disease from stage I to stage III tumours 
(Martin Scurr et al. 2013). Analysis of the non-diseased human CD4+ response to 5T4 within the 
periphery therefore provides a good model of the effectiveness of the TH cell response to 5T4 
antigen. Such effectiveness is governed by the ability of MHC-II molecules to present 5T4-
derived peptide epitopes and for such epitopes to be detected by 5T4-reactive TCRs.  
As a result, the overall aim of this chapter was to analyse at the molecular, biophysical and 
structural level, the efficiency of the TCR/MHC-II recognition/presentation axis of 5T4 derived 
peptide antigens. Due to the commonality of the HLA-DRB1*0101 allele, as well as the avail-
ability of cellular and protein reagents, these studies focus around peptides presented on HLA-
DR1. The overall aim of this chapter is divided into the following sub-aims: 
(i) To review the current available data to determine candidate immunogenic 5T4-derived 
peptide antigens 
(ii) To assess the MHC restriction of 5T4-reactive CD4+ T cell clones 
(iii) To characterise the functional sensitivity of 5T4-reactive CD4+ T cell clones to peptide 
antigen 
(iv) To assess the ability of 5T4-reactive T cell clones to bind their cognate pMHC-II 
(v) To gain structural insights into the molecular presentation of 5T4-peptide antigens on 
MHC-II molecules. 
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3.3 Selection of 5T4 epitopes and generation of 5T4-reactive clones 
Prior to this project, current data on peptide epitopes of 5T4 presented on MHC-II molecules 
was reviewed. 5T4-derived peptide epitopes that were known to elicit a CD4+ T cell response 
were consequently chosen for screening and selection of CD4+ T cell clones specific to 5T4 
peptide antigens.   
3.3.1 Immunogenic epitopes of 5T4 
Previous studies within our group in Cardiff have highlighted immunogenicity to 5T4 exhibited 
within the periphery of both a cohort of healthy donors and colorectal cancer patients (detailed 
in the thesis of Dr. Matthieu Besneux 2015). Such studies characterised a number of peptide 
epitopes presented on MHC-II alleles to CD4+ T cells cultured in vitro. Mapping of CD4+ T cell 
epitopes within 5T4 was achieved by culture of CD4+ enriched T cell lines to individual peptides 
and consequent determination of 5T4-peptide-specific responses within cultured lines to peptide 
via IFNγ ELISpot indicated T cell activation. Here, sixteen candidate peptides, which had pre-
viously been identified as immunogenic using pooled peptide screening, were tested for 
responding cells in a number of individuals of diverse HLA type. These studies highlighted 5T4 
epitopes for which there was a presence of tumour-peptide specific T cell populations that ex-
hibited activation in response to stimulation in both healthy donors and colorectal cancer donors 
(Figure 3.1; all data and figures adapted from Besneux M., Thesis 2015).  
In general, responses to the candidate 5T4 peptides were higher in healthy individuals com-
pared to patients as signified by an elevated average percentage of positive responders across 
all peptides (Figure 3.1a&b). Despite exhibiting strong frequent responses in healthy donors, 
responses to immunogenic peptides in healthy donors were decreased amongst the patient co-
hort. In individuals that did respond to each peptide, however, the magnitude of the response 
was greater compared to healthy controls (Figure 3.1c&d). For example, 5T4 p12 response rates 
in patients was less than 20 % (~80 % in healthy controls), however, the mean IFNγ response 
(measured by ELISpot) in those responders was increased more than three-fold to ~250 mean 
spot forming cells (sfcs)/105 cultured cells (75 mean sfcs/105 cells in healthy donors). Our group 
has shown this loss of 5T4 recognition correlates with colorectal tumour progression and is 
thought to be the result of immune regulation through expansion of CD4+ regulatory T cell sub-
sets in advanced disease (Scurr et al. 2013). 
In healthy donors, peptide specific CD4+ T cells were observed in 50 % or more of tested 
individuals against five peptides: 5T4p2, p12, p20, p26 & p38; listed in Table 3.1. As well as 
showing a consistent response across donors, these five peptides exhibited a strong response to 
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peptide as quantified by the mean IFNγ sfcs/105 cells in ELISpot assays. As a result of the de-
scribed data, it was reasoned that study of the 5T4 CD4+ T cell response to these peptides in 
healthy donors would provide an understanding of how surveillance of tumour antigens such as 
5T4 is mediated in individuals without disease and is therefore a model of potential reactive 
response against 5T4 antigen.  
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Figure 3.1 – Available data describing immunogenic 5T4 peptide epitopes: 
a) Analysis of the percentage response rate of candidate 5T4 peptides (y-axis) to elicit IFNγ 
indicated activation of CD4+ T cell lines cultured in vitro from healthy donors via stimulation 
with queried peptide. 5T4 responses in healthy donors were robust in which responses to five 
peptides (bold) were observed in more than half of donors. Responders were classified as donors 
exhibiting ≥25 sfcs/105 cells above background and a two-fold increase above background. Inset 
n values represent number of donors tested for each peptide.  
b) Analysis of the percentage response rate of candidate 5T4 peptides, as described in a), to 
elicit CD4+ T cell activation of lines cultured from colorectal cancer (CRC) patients. CRC 
patients showed an overall decrease in percentage responders. 
c) 2D-plot of percentage response rate, as described in a), as a function of the magnitude of 
observed response (mean IFNγ sfcs/105 cells) in healthy donors. Five peptides (black dots) 
exhibited both high response rates and a strong magnitude of response. 
d) 2D-plot of percentage response rate and magnitude as described in c) in CRC patients. 
Response rates were lowered in CRC patients, however, those responders exhibited an increased 
magnitude of response compared to healthy donors.  
NB. All responses analysed using data obtained from Besneux, M. Thesis, 2015. 
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3.3.2 Clone generation strategy 
Having reviewed five potential 5T4 epitopes which generated prevalent CD4+ T cell responses 
in the periphery of a cohort of healthy donors, each of the five peptides (Table 3.1) were used to 
generate CD4+ T cell clones using a T-cell library parallel generation approach by Dr Garry 
Dolton (Cardiff University) (Theaker et al. 2016). T cell clones were generated from a pool of 
CD4+ enriched PBMCs from an HLA-DR1+ healthy donor (HD216) (Appendix 2).  
Cultured T cells from a CD4+ enriched library were expanded in vitro and successfully 
screened for peptide reactivity against the combined pool of five 5T4 candidate peptides and 
later individual peptides. IFNγ release in response to peptide was chosen as the principal selec-
tion criteria due to the cytokine’s role in defining TH1 cell activation and it’s key role in 
mediating T cell immunity to tumours (Dighe et al. 1994). This selection was achieved by IFNγ 
release detected by ELISpot assay in response to 5T4-peptide-pulsed HLA-DR1+ lymphoblas-
toid cell line (LCL) presenting cells, termed T2-DR1 cells (Czerkinsky et al. 1983). Thus, 
presentation of peptide by HLA-DR1 only expressing transduced T2-DR1 cells favoured the 
selection of T cell clones restricted to HLA-DR1 (HLA-DRB1*0101).   
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Table 3.1 – Immunogenic 5T4-derived peptides selected for the generation of CD4+ T cell 
clones 
aa = amino acids, LRR = Leucine Rich Repeat 
 
  
 Origin Length (aa) Sequence Domain origin 
5T4 p2 5T411-30 20 AGDGRLRLARLALVLLGWVS Signal peptide 
5T4 p12 5T4111-130 20 FARRPPLAELAALNLSGSRL Extracellular LRR 1-2 
5T4 p20 5T4191-210 20 QNRSFEGMVVAALLAGRALQ Extracellular LRR 4-5 
5T4 P26 5T4251-270 20 YVSFRNLTHLESLHLEDNAL Extracellular LRR 6-7 
5T4 p38 5T4371-390 20 LLVLYLNRKGIKKWMHNIRD Transmembrane/Intracellular 
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3.4 5T4-reactive CD4+ T cell clones derived from healthy peripheral blood 
Three 5T4-reactive T cell clones were generated: (i) GD.D821 which was cloned in response to 
5T4p2, (ii) GD.D104 cloned in response to 5T4p12 and (iii) GD.C112 which was cloned in 
response to 5T4p38. 
To examine their molecular phenotype, each clone was first analysed for its TCR clonotype 
and cell surface expression of TCR, co-receptor and the co-inhibitory molecule LAG-3. In order 
to characterise the function of these clones in vitro, each clone was examined for activation in 
response to cognate peptide presented on an allele of restriction, assayed for the production of 
functional cytokines/chemokines in response to cognate peptide and analysed for the compara-
tive sensitivity of each clone. 
3.4.1 Clonotyping 
To clarify the clonality of each generated T cell clone and provide sequence definition of the 
TCRs expressed by each clone, the transcribed TCR sequences from each clone was sequenced 
through TCR clonotyping performed by Dr Meriem Attaf (Cardiff University). These data con-
firmed each T cell clone to indeed be clonal and derived from a unique recombination event as 
shown by three independent clonotypes (Table 3.2). Overall, the acquisition of these sequences 
characterise three unique 5T4-reactive clones with differential antigen binding receptors of 
which the translated protein sequence is known. 
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Table 3.2 – Unique clonotype of three 5T4-reactive T cell clones 
TRAV = T cell receptor alpha variable, TRAJ = T cell receptor alpha joining, CDR = Comple-
mentarity determining region, TRBV = T cell receptor beta variable, TRBJ = T cell receptor 
beta joining & TRBD = T cell receptor beta diversity. 
  
  TCRα  TCRβ 
Clone Antigen TRAV TRAJ CDR3  TRBV TRBJ TRBD CDR3 
GD.D821 5T4 p2 19 23 CALSEGLIYNQGGKLIF  7-2 1-5 2 CASSLESGLANQPQHF 
GD.D104 5T4 p12 12-1 45 CVVNRYSGGGADGLTF  2 2-7 2 CASRGGSSYEQYF 
GD.C112 5T4 p38 23/DV6 57 CAAEDQGGSEKLVF  5-1 2-4 2 CASSLVDGDIQYF 
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3.4.2 Unstimulated 5T4-reactive T cell clones are competent to antigen stimulation 
In order to assess whether each T cell clone was antigen receptor and co-receptor replete, and 
thus liable to antigen stimulation, each clone was co-stained with CD4 and pan-TCR antibodies 
and analysed by flow cytometry. Each clone exhibited detectable surface co-expression of TCR 
and CD4 co-receptor (Figure 3.2a). GD.D821 and GD.D104 clones exhibited almost no heter-
ogeneity in antigen receptor and co-receptor expression status as signified by 99 and 98 % of 
live T cell clones CD4+TCR+ dual-positive, respectively. Whilst the cultured GD.C112 clono-
typic cells were also broadly CD4+ TCR+, dual-positive cells were limited to 88 % of live T cell 
clones highlighting an overall heterogeneity in TCR expression amongst the clonotypic popula-
tion. Such heterogeneity was caused by an observed downregulation in TCR expression 
compared to GD.D821 and GD.D104 clones as signified by a population (11 % of live T cells) 
of CD4+ TCR- cells. Such downregulation of TCR is typical in CD4+ T cells as a result of recent 
T cell activation (Gallegos et al. 2016). 
Having established that each of the T cell clones express antigen receptor and co-receptor, 
each clone was next checked for constitutive expression of the co-inhibitory molecule LAG-3 
which, as discussed further in Chapter 4, can cause inhibition of T cell activation (Liang et al. 
2008). LAG-3 expression by CD4+ cells, across all clones, was minimal with less than 1 % of 
live CD4+ T cells expressing the co-inhibitory molecule (Figure 3.2b). As a result, in unstimu-
lated culture conditions, the generated 5T4-reactive T cell clones appear competent to receive 
antigen stimulation as indicated by the cell surface expression of markers tested. 
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Figure 3.2 – Surface expression characterisation of 5T4-reactive T cell clones: 
a) Flow cytometric analysis of CD4 and TCR expression of the three 5T4-reactive T cell clones. 
Each clone exhibited expression of both antigen receptor and co-receptor as indicated by > 88 
% of cells CD4+ TCR+. Quadrant gates set according to FMO/unstained negative control 
populations. 2D plots representative of two independent experiments. 
b) Flow cytometric analysis of CD4 and LAG-3 expression of the three 5T4-reactive T cell 
clones. Each clone exhibited minimal staining of LAG-3 surface expression as indicated by < 1 
% of CD4+ cells expressing detectable LAG-3. Quadrant gates set according to FMO/unstained 
negative control populations. 2D plots representative of two independent experiments. 
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3.4.3 Determination of restriction of 5T4-reactive T cell clones to HLA-DR 
Whilst the selection criteria for the generation of these clones included an ability to respond and 
activate in the presence of HLA-DR1 replete presenting cells, such assays did not rule out the 
possibility of self-presentation between T cell to T cell on HLA molecules of other alleles ex-
pressed on the surface of the T cell clones themselves. As a result, each T cell clone was analysed 
for the ability to release IFNγ as a surrogate marker for T cell activation by ELISpot in response 
to peptide pulsed APCs performed at low T cell numbers (300 T cells per well) and an excess of 
presenting cells (50,000 per well). 
Each of the three generated 5T4-reactive T cell clones showed peptide specific release of 
IFNγ in response to overnight incubation with autologous corresponding peptide-pulsed B lym-
phoblastoid cell line (B-LCL) presenting cells as shown by IFNγ ELISpot assay (Figure 3.3a). 
Each clone exhibited maximal IFNγ release compared to PHA control in response to autologous 
B-LCL presenters pulsed with 10-5 M of corresponding peptide as shown by equivalent number 
of IFNγ spot forming cells (sfcs) equating to approximately 100 % of maximal (PHA) response.  
In order to indicate restriction to HLA-DR molecules, blockade of HLA-DR molecules with 
a pan anti-DR antibody, after peptide pulsing and before co-incubation with T cells, abrogated 
the IFNγ release by each corresponding cognate T cell clone. Blockade of -DR molecules was 
most effective on 5T4p2 presentation to GD.D821 in which activation was reduced to back-
ground levels of IFNγ release (~100 % blockade). Likewise, blockade of DR molecules on 
5T4p38 presentation to GD.C112 abrogated IFNγ release by ~60 %. Blockade of 5T4p12 
presentation to GD.D104 had a less marked effect (~30 % blockade) on peptide-specific activa-
tion and consequent IFNγ release thus suggesting that (i) the GD.D104 clone may not be 
restricted by HLA-DR, (ii) the GD.D104 may exhibit increased sensitivity to 5T4p12 compared 
to the GD.D821 and GD.C112 clones or (iii) the 5T4p12 peptide has an increased affinity for 
the restricted HLA molecule compared to 5T4p2 or 5T4p38. 
In order to test whether each clone exhibited dose-dependent response to cognate peptide 
presented on pulsed APCs, T cell clones were stimulated with 10 times reduced concentration 
of peptide (10-6 M) and, once again, analysed for the effect of pan anti-DR blockade on T cell 
clone activation (Figure 3.3b). At 10-6 M GD.D821 and GD.C112 exhibited ablation or reduc-
tion of activation, respectively, whilst GD.D104 remained maximally stimulated despite 
reduction in peptide concentration.  
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Figure 3.3 – Validation of HLA-DR restriction of 5T4-reactive CD4+ T cell clones: 
a) IFNγ ELISpot assays on the three 5T4-reactive T cell clones showing peptide specific 
activation of T cell clones in response to overnight co-incubation with 10-5 M cognate peptide-
pulsed autologous B-LCL presenter cells. Peptide-specific IFNγ release (peptide) is observed 
compared to no-peptide controls (media) and is abrogated by the blocking of DR molecules on 
peptide pulsed B-LCL presenter cells (+ α-DR Ab) prior to co-incubation with corresponding T 
cell clone. Phytohaemagglutinin (PHA) positive control wells indicate maximal IFNγ T cell 
clone response. Inset numbers represent raw spot forming cells (sfcs) counts. Presented ELISpot 
wells representative of experiments performed in duplicate on 300 T cells per well. 
b) Mean background subtracted quantification of IFNγ sfcs for assays as shown in a) performed 
at 10-5 and 10-6 M concentration of peptide. Peptide-specific response (+) was observed 
compared to no-peptide control (-) as well as abrogation of IFNγ release by α-DR blocking (+) 
compared PBS control (-). Plotted mean values are background subtracted by equivalent no-
peptide control and calculated from experiments in duplicate (error bars = SEM). 
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To further narrow the HLA restriction of the three generated 5T4-reactive T cell clones as 
being indeed restricted to 5T4-derived peptides presented on the HLA-DR1 molecule, each of 
the three clones were analysed for IFNγ release indicated activation by peptide-pulsed present-
ers which express HLA-DR1 as the only MHC-II molecule at the cell surface (T2-DR1 cells) in 
comparison to HLA-DR1 null cells (T2-WT).  
As with autologous presenters, each T cell clone exhibited corresponding peptide specific 
activation of T cells as indicated by an increase in IFNγ sfcs compared to no-peptide media only 
control (Figure 3.4a). Such activation was observed in HLA-DR1 expressing cells (T2-DR1) 
only and not observed in HLA-DR1 deficient cells (T2-WT) providing direct evidence of HLA-
DR1 restriction; including the GD.D104 clone, which, in B-LCL assays was minimally effected 
by anti-DR blockade. Moreover, inclusion of anti-DR blocking once more abrogated the degree 
of IFNγ indicated activation of each T cell clone in the presence of HLA-DR1 replete presenting 
cells. Sensitivity of each clone followed a similar trend compared to autologous B cell presented 
experiments described previously. All clones exhibited less activation using T2-DR1 presenters 
compared to B-LCLs except GD.D104. Similarly, only the GD.D104 clone was sensitive to 10-
6 M peptide, suggesting this clone is the most sensitive to antigen (Figure 3.4b). 
These data therefore show direct requirement for HLA-DR1 in the peptide specific activation 
of the generated CD4+ 5T4-reactive T cell clones. In addition, these data once more highlight 
the difference in efficiency of the T cell activation-peptide presentation axis between each of the 
three 5T4-reactive T cell clones and their HLA-DR1 presented 5T4-derived peptides. 
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Figure 3.4 – Validation of HLA-DR1 restriction of 5T4-reactive CD4+ T cell clones: 
a) IFNγ ELISpot assays on the three 5T4-reactive T cell clones showing peptide specific 
activation of T cell clones in response to overnight co-incubation with 10-5 M cognate peptide-
pulsed DR1-transfected (T2-DR1) and DR1-null (T2-WT) presenters. Peptide-specific IFNγ 
release (peptide) was observed with T2-DR1 presenters compared to no-peptide controls 
(media) and was abrogated by the blocking of DR molecules on peptide pulsed T2-DR1 
presenter cells (+ α-DR Ab) prior to co-incubation with corresponding T cell clone. Equivalent 
responses are not observed with DR1-null (T2-WT) presenters. PHA wells indicate maximal 
IFNγ T cell clone response. Inset numbers represent raw spot forming cells (sfcs). Presented 
ELISpot wells are representative of experiments performed in duplicate. 
b) Mean background subtracted quantification of number of IFNγ sfc for assays as shown in a) 
performed at 10-5 and 10-6 M concentration of peptide. Peptide-specific responses (+) were 
observed compared to no-peptide control (-) with DR1-expressing (DR1 +) compared to DR1-
null (DR1 -) presenters. Abrogation of IFNγ release by α-DR blocking (+) compared to PBS 
control (-) was also observed with DR1-transfected presenters. Plotted mean values are 
background subtracted by equivalent no-peptide control and calculated from experiments in 
duplicate (error bars = SEM). 
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3.4.4 Functional cytokine release in response to HLA-DR1 presented 5T4 epitopes 
Having observed differences in sensitivity amongst the 5T4-reactive T cell clones, it was rea-
soned that each clone may produce different functional markers of activation. As a result, each 
clone was subjected to T cell activation assays in response to titrating concentration of cognate 
peptide presented by HLA-DR1 only expressing cells and functional cytokine/chemokine re-
lease measured by ELISA (Figure 3.5).  
3.4.4.1 MIP-1β 
Each clone, in response to titrating concentration of corresponding 5T4-derived peptides pre-
sented on T2-DR1 cells, produced titrating amounts of the early activation marker MIP-1β 
(Figure 3.5a). Each clone exhibited sensitivity to peptide within a similar sensitivity range and 
resulted in a similar maximal chemokine release. GD.D104 remained the most sensitive clone 
to cognate peptide as indicated by an EC50 of 10-7.0 M peptide. GD.D821 was the second most 
sensitive; EC50 of 10-6.3 M. Maximal MIP-1β response for GD.C112, and consequent calculation 
of an accurate EC50 sensitivity value, proved difficult to achieve due to lack of solubility at 
concentrations of peptide above 10-5 M. Despite this, using MIP-1β as a marker for T cell acti-
vation, all three T cell clones were indeed responsive to peptide presented in the context of HLA-
DR1.  
3.4.4.2 IFNγ 
 Analysis of the TH1 type 1 inflammatory cytokine, IFNγ, expression by each clone highlighted 
that the GD.D821 and GD.C112 clones are poorer IFNγ producers in response to titrating pep-
tide (Figure 3.5b). Whilst induction of IFNγ was possible in these two clones, considerable IFNγ 
release was not detected until high concentrations of peptide (GD.D821: 10-4 M and GD.D104: 
10-5 M). The maximal release of IFNγ by these two clones was not determined due to the re-
quirement of such high concentrations of peptide. It is worth noting, however, that maximal 
IFNγ release by GD.C112 may be hampered by the solubility of the 5T4p38 peptide at concen-
trations above 10-5 M. 
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Figure 3.5 – 5T4-reactive T cell sensitivity and functional cytokine/chemokine release: 
a) Background (no peptide) subtracted MIP-1β release in response to overnight co-culture of 
GD.D821, GD.D104 and GD.C112 clones with HLA-DR1 only (T2-DR1) presenting cells and 
titrated concentrations of cognate peptide. Dashed lines (grey) show non-linear log(agonist) vs 
response curve fitting from which EC50 value (inset, in Molar; n.d. = not determined) is 
calculated. Error bars = SEM, experiments performed in triplicate and representative of two 
independent experiments.  
b) Background subtracted IFNγ release in response to HLA-DR1 presented cognate peptide as 
described in a). 
c) Background subtracted IFNγ release in response to HLA-DR1 presented cognate peptide as 
described in a). 
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On the other hand, release of IFNγ by GD.D104 was robust and detectable down to lower 
concentrations of peptide (10-6 M). In addition, maximal release observed at 10-4 M or 10-5 M 
peptide was greatest amongst the three clones. As a result, the GD.D104 is a sensitive IFNγ 
producing 5T4-reactive T cell clone to cognate peptide characterised by a low EC50 of 10-5.5 M 
peptide. These data highlight that IFNγ remains a good marker for T cell activation of the 
GD.D104 clone, however, stimulation of GD.D821 and GD.C112 requires much higher concen-
tration of peptide to induce IFNγ release.  
3.4.4.3 TNF-α 
Each clone was next tested for the release of TNF-α in response to peptide. Like MIP-1β, pro-
duction of TNF-α release was much more consistent throughout the three clones (Figure 3.5c). 
Indeed GD.D821 and GD.C112 clones, which were poor IFNγ producers in response to peptide, 
exhibited robust release of TNF-α in response to lower titrated concentrations of peptide (10-4 
M or 10-5 M). Similarly, GD.D104 also produced TNF-α in response to lower peptide concen-
trations suggesting that this clone is a strong dual producer of both these TH1 cytokines. 
GD.D821 exhibited increased TNF-α sensitivity to peptide compared to GD.D104 with an EC50 
of 10-5.3 M peptide. Despite an undeterminable EC50 value for the TNF-α sensitivity of GD.C112, 
production of TNF-α at the highest testable concentration of peptide (10-5 M) resulted in the 
highest TNF-α release quantified out of all three clones. 
3.4.4.4 Summary of cytokine/chemokine profile 
Each of the three 5T4-reactive T cell clones produce three markers of T cell activation and con-
sequent function; MIP-1β, IFNγ and TNF-α, in response to cognate peptide and HLA-DR1 only 
expressing cells. The release of each cytokine/chemokine, however, occurred to varying degrees 
of sensitivity (summarised in Table 3.3). Expression of IFNγ and TNF-α strongly indicate that 
these 5T4-reactive T cell clones derived from the TH1 subset of CD4+ T cells within the periph-
eral blood of a healthy donor. 
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Table 3.3 – Summary of 5T4-reactive T cell clone cytokine/chemokine sensitivity to peptide 
Scored sensitivity to release stated cytokine/chemokine in response to decreasing concentration 
of peptide. Sensitivity graded from least sensitive (+) to most sensitive (+++). Calculated 
logEC50 values are recorded in parentheses. logEC50 values for GD.C112 could not be 
determined (n.d.) due to lack of solubility at concentrations higher than 10-6 M. IFNγ release 
logEC50 was also not determined due to failure to reach maximal IFNγ release by 10+4 M peptide.  
 
Clone Restriction Antigen MIP-1β IFNγ TNF-α 
GD.D821 HLA-DR1 5T4 p2 +++ (-6.3) + (n.d.) +++ (-6.1) 
GD.D104 HLA-DR1 5T4 p12 +++ (-7.0) +++ (-5.5) ++ (-5.3) 
GD.C112 HLA-DR1 5T4 p38 +++ (n.d.) ++ (n.d.) +++ (n.d.) 
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3.5 Minimal detectable recognition by 5T4-reactive T cell clones 
Differential sensitivities to antigen by the 5T4-reactive T cell clones may be contributed to (a) 
each 5T4-derived peptide exhibiting a different binding affinity for HLA-DR1, and hence pep-
tide-HLA stability, and thus modulating the effective cognate pHLA-DR1 ligand concentration, 
(b) TCR engagement by each of the T cell clones occurring at differing affinities (c) a combina-
tion of both or (d) other factors out with TCR-pMHC engagement. As a result, cellular and 
biophysical analysis of cognate pHLA-DR1 engagement by each T cell clone were attempted 
using recombinantly produced 5T4-derived pHLA-DR1 molecules and 5T4-reactive T cell 
clone expressed TCRs to assay the effectiveness of presentation/recognition of antigen. 
3.5.1 Prediction of 5T4-derived peptide binding affinity to HLA-DR1 
To give an indication as to the potential affinity of each 5T4-derived peptide for HLA-DR1, 
each peptide was analysed for predicted binding affinity to HLA-DR1 using the peptide to HLA 
neural network prediction server NetMHCII 2.2 (Nielsen & Lund 2009). As such, each peptide 
sequence was predicted to capably bind HLA-DR1 (Table 3.4). 5T4p2 and 5T4p12 were classi-
fied as predicted strong binders for HLA-DR1 (IC50 < 50 nM) whilst 5T4p38 was classified as 
a weak binder (IC50 = 50 - 500 nM). This analysis, therefore, gives an indication as to the 
quality of each 5T4-derived peptide to be presented to each corresponding cognate clone. Ex-
amination of the predicted core region of 5T4p38 binding to HLA-DR1 highlights a sub-optimal 
peptide sequence based on the known preference for amino acids at binding peptide binding 
pockets; most notably P4 and P9 where Arg and Lys, respectively, are not favoured residues 
(Cole & Godkin 2016). 
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Table 3.4 – Prediction of 5T4-derived peptide binding core and affinity to HLA-DR1 
Underlined peptide sequence = predicted binding core region 
  
Peptide epitope Predicted binding core Predicted affinity IC50 (nM) 
5T4p2 AGDGRLRLARLALVLLGWVS 14.1 
5T4p12 FARRPPLAELAALNLSGSRL 8.0 
5T4p38 LLVLYLNRKGIKKWMHNIRD 77.5 
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3.5.2 5T4-reactive T cell clones bind poorly to cognate pMHC-II multimers 
Having shown T cell clone sensitivity to peptide and a requirement for HLA-DR1, each T cell 
clone was analysed for their ability to bind corresponding MHC-II multimers by flow cytometry.  
3.5.2.1 Production of 5T4-derived MHC-II monomers for T cell clone multimer staining 
To study the ability of TCR binding to cognate 5T4-derived pMHC-II epitopes, highly func-
tional pHLA-DR1 monomers were successfully produced from in vitro refolding of human 
HLA-DR1 molecules produced in E. coli using methods described previously (Frayser et al. 
1999). Each 5T4-derived pHLA-DR1 monomer was successfully biotinylated, in order to facil-
itate multimerisation, as shown by characteristic alteration in the electrophoretic mobility of the 
biotinylated HLA-DR1α chains in the presence of streptavidin (Figure 3.6). Moreover, each 
pHLA-DR1 monomer was shown to be functional by interaction with LAG-3+ cells as described 
in Chapter 4 (data not shown).  
3.5.2.2 Multimer staining of 5T4-reactive T cell clones with cognate pMHC-II molecules 
Given that each 5T4-reactive T cell clone successfully activated in response to cognate 5T4-
derived peptide presented on HLA-DR1, each of the three T cell clones were stained with cog-
nate 5T4-derived pMHC-II using dextramerised pHLA-DR1 molecules using an optimised 
protocol for the staining of low affinity self-antigen reactive T cells (Dolton et al. 2014; Dolton 
et al. 2015). Using this methodology, low affinity antigen specific T cells are detectable via 
multimer staining and have been used to stain viral-reactive MHC-II restricted T cell clones  
(Tungatt et al. 2015).  
Despite this protocol, however, the 5T4-reactive T cell clones stained poorly with their cognate 
5T4-derived pHLA-DR1 multimers (Figure 3.7). Only the GD.D821 clone marginally stained 
with cognate 5T4p2-HLA-DR1 multimers (Figure 3.7a) as shown by a small increase in te-
tramer positive cells (4.96 %) compared to irrelevant HLA-DR1 multimer control (0.03 %) and 
an approximate doubling (91 % increase) in geometric mean fluorescence intensity (gMFI) in 
HLA-DR1 5T4p2 multimer stained (gMFI = 222) compared to background fluorescence inten-
sity observed with HLA-DR1 multimer stained control (gMFI = 116). In contrast, GD.D104 
exhibited HLA-DR1 5T4p12 multimer staining (Figure 3.7b) only slightly above background 
(0.05 % tetramer positive) compared to irrelevant control staining (0.02 % tetramer positive), 
signified by a 34 % increase in gMFI (HLA-DR1 5T4p12 gMFI = 144, irrelevant pHLA-DR1 
= 108). Similarly, GD.C112 exhibited HLA-DR1 5T4p38 multimer effectively equal to back-
ground (HLA-DR1 5T4p38: 0.04 % tetramer positive, irrelevant pHLA-DR1: 0.02 % tetramer  
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Figure 3.6 – Generation of biotinylated 5T4-derived pHLA-DR1 monomers: 
SDS-PAGE analysis of purified biotinylated pHLA-DR1 monomers refolded with 5T4-derived 
peptides from inclusion bodies produced in E. coli in non-reducing conditions. Each monomer, 
DR1-5T4p2, DR1-5T4p12 and DR1-5T4p38, showed characteristic shift in electrophoretic 
mobility of biotinylated pHLA-DR1α chain when incubated with streptavidin (+ SA). 
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positive characterised by a less than 5 % increase in gMFI (5T4p38-HLA-DR1 gMFI = 113, 
irrelevant pHLA-DR1 = 108; Figure 3.7c).  
These data, with the exception of 5T4p2-HLA-DR1 recognition by GD.D821, suggest a prac-
tically undetectable interaction between the 5T4-reactive T cell clones and cognate pHLA using 
enhanced methodologies to detect low affinity TCR-pMHC interactions. Detectable staining of 
5T4p2-HLA-DR1 multimer binding to GD.D821 suggests the GD.D821 TCR may interact with 
the 5T4p2-HLA-DR1 antigen with the strongest affinity out of the three 5T4-reactive T cell 
clones. 
 
  
- 103 - 
 
Figure 3.7 – Minimal staining of 5T4-reactive T cell clones by cognate pMHC-II multimers: 
a) Flow cytometric analysis of pHLA-DR1 multimer staining of the 5T4p2-reactive clone 
GD.D821. 2D plots highlight difference in CD4+ multimer+ cells when stained with the cognate 
multimer (5T4p2-Dex) or irrelevant multimer (Irr-Dex) with onset numbers representing 
percentage of multimer+ cells in parent gate. Histograms represent shift in fluorescence intensity 
observed when stained with the PE-conjugated cognate multimer (black) compared to irrelevant 
multimer (grey); inset numbers = gMFI. Plots and histograms representative of two independent 
experiments. Displayed plots gated on live, CD4+ singlet lymphocytes. 
b) Flow cytometric analysis of pHLA-DR1 multimer staining of the 5T4p12-reactive clone 
GD.D104 as described in a). 
c) Flow cytometric analysis of pHLA-DR1 multimer staining of the 5T4p38-reactive clone 
GD.C112 as described in a). 
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3.5.3 Minimal binding of 5T4-reactive TCR to 5T4p38 presented on HLA-DR1 
Having observed that three 5T4-reactive T cell clones all exhibited poor or no observable 
staining via MHC-II multimers, it was hypothesised that the expressed TCRs by each T cell 
clone bound cognate 5T4-derived pHLA-DR1 molecules with a weak affinity. In order to assay 
the binding affinity of TCRs expressed by the 5T4-reactive T cell clones directly, soluble TCRs 
and 5T4-bearing HLA-DR1 molecules were produced and measurement of binding attempted 
through surface plasmon resonance (SPR). In these preliminary studies, each TCR expressed as 
inclusion bodies using methodologies to produce soluble TCR molecules from E. coli (Appendix 
3a) (Boulter et al. 2003). Despite expression of all chains in E. coli, refolding of each 5T4-
reactive TCR encountered varying success (outlined in Appendix 3b). Out of the three available 
TCRs, only the HLA-DR1 5T4p38-reactive GD.C112 TCR was able to successfully refold in 
vitro as indicated by characteristic complexing of TCRα and TCRβ chains in non-reducing SDS-
PAGE analysis (Appendix 3c). Analysis of GD.C112 TCR binding to HLA-DR1 5T4p38 via 
SPR resulted in a small but increasing signal in response to increasing TCR concentrations (Ap-
pendix 4). Such binding, therefore, suggested a weak but detectable interaction between the 
GD.C112 TCR expressed by this 5T4-reactive T cell clone and the 5T4p38 peptide restricted to 
HLA-DR1, however, further SPR experiments using higher TCR concentrations would be re-
quired to accurately measure the TCR binding affinity. 
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3.6 Structural characteristics of a 5T4 tumour epitope presented by HLA-
DR1 
The ability for CD4+ T cells to recognise tumour derived peptide antigens is determined by the 
ability to both present and recognise such peptide molecules presented on MHC-II molecules 
such as HLA-DR1. In order to therefore gain insights into (a) how the 5T4-derived peptides are 
able to be presented on their restricted MHC molecule, HLA-DR1 and (b) the molecular char-
acteristics of the peptides presented to TCR molecules bound to MHC, the 5T4-derived peptides 
bound to HLA-DR1 were studied through recombinant production of protein samples for study 
via x-ray crystallography. 
3.6.1 Production of HLA-DR1 presenting the 5T4p12 tumour antigen for structural 
analysis  
Protein crystallisation generally requires a highly pure and highly homogenous soluble protein 
sample. Due to the low refold efficiency of HLA-DR1, typically between 1 – 10 %, an affinity 
purification step, as published previous, was implemented into standard protocol for the pro-
duction of HLA-DR1 molecules (Figure 3.8a) (Stern & Wiley 1992). These methodologies 
allowed separation of non-binding wash fractions from bound HLA-DR1 bearing elution frac-
tions and allowed the highly efficient purification of desired protein in a single-step (Figure 
3.8b). For this study HLA-DR1 molecules were refolded in the presence of the three 5T4-de-
rived peptides, 5T4p2, 5T4p12 and 5T4p38 for crystallisation trials. Each 5T4-derived peptide 
successfully refolded with similar yield in order to obtain milligram quantities of highly pure 
protein sample required for screening of crystallisation conditions (Figure 3.8c). 
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Figure 3.8 – Production of HLA-DR1 5T4p12 for x-ray crystallography:  
a) Enhanced protocol for the production of HLA-DR1 molecules refolded in the presence of 
desired peptide in vitro from DR1α and DR1β inclusion bodies produced in E. coli. Addition of 
an anti-DR antibody affinity chromatography step after refold and before biotinylation and/or 
size exclusion chromatography is shown (green). Purified molecules were used for multiple 
analyses described. Biotinylation step required for SPR and multimer applications only. 
b) SDS-PAGE and spectrophotometer (A280 nm) analysis highlighting separation of anti-DR 
non-binding wash fractions and anti-DR binding 1 mL elution fractions from an example HLA-
DR1 in vitro refold. FT = flow through, M = MW marker. 
c) SDS-PAGE analysis of refolded HLA-DR1 5T4p2 -p12 and -p38 protein samples produced 
for crystallisation trials. HLA-DR1 samples exhibited shift in electrophoretic mobility in the 
non-reducing (-) compared to reducing (1 M DTT, 5 min 95 °C) conditions (+).  
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3.6.2 Optimised crystallisation of HLA-DR1 5T4p12  
HLA-DR1 molecules refolded in the presence of 5T4p2, 5T4p12 and 5T4p38 were subjected to 
crystallisation screening. Each protein sample was screened for formation of protein crystals 
using two commercially available screens (Molecular Dimensions PACT Premier & JBScreen) 
as well as the TCR-pMHC optimised protein crystallisation screen: TOPS (Bulek et al. 2012). 
Primary screens were performed at multiple concentrations (range 1 - 10 mg/mL) using sitting 
drop vapour diffusion. Later, secondary screens were performed by hanging drop in the presence 
prepared MHC-II microseeds. 
From the panel of three 5T4-derived peptides, crystals suitable for x-ray diffraction were 
obtained for the HLA-DR1 5T4p12 complex (Figure 3.9). Primary crystallisation screening 
yielded few non-diffractable crystals in both TOPS and PACT screen conditions (Figure 3.9a). 
Such crystals, whilst exhibiting macroscopic crystalline appearance, were of 1D branched nee-
dle or small 3-Dimensional crystals which were not suitable for diffraction (Figure 3.9b). In 
order to optimise crystal formation, non-diffractable crystals were harvested and combined to 
form a self-microseed stock from which numerous large 3-Dimensional crystals were formed 
through crystal microseed screening (Figure 3.9c). Such crystals were obtained through the 
screening of various microseed stock, concentration and buffer conditions. The obtained crystal 
growth conditions are outlined in Table 3.5. Obtained crystals were harvested and diffracted at 
Diamond Light Source (Harwell, UK) to a resolution extending to 1.95 Å (Table 3.6). 
3.6.3 High resolution structure of an MHC-II presented 5T4-derived peptide 
Collected diffraction data of HLA-DR1 5T4p12 at a resolution of 1.95 Å was solved using phase 
information obtained via molecular replacement by a HLA-DR1 structure (PDB: 1DLH) pub-
lished on the PDB (Stern et al. 1994) and refined until convergence of statistical parameters 
(Table 3.6). The HLA-DR1 5T4p12 structure was solved as two copies within the asymmetric 
unit formed by crystal contacts throughout the molecule. Such contacts are detailed in Appendix 
5. Some crystal contacts were made between DR1β-Q110, within a flexible loop of the DR1 β2 
domain, and the rigid central peptide core residues Glu3, Leu4 & Ala5. Likewise, Pro-2 and 
Arg-4 also made a few contacts with a flexible loop and N-terminal tail, respectively, of DR1β. 
Such contacts are detailed in Appendix 5c. These contacts are highly unlikely to significantly 
influence peptide side chain positioning due to the extensive contacts made between the peptide 
and HLA-DR1 (detailed to follow) and the lack of rigidity of contacting regions in symmetry 
mates. 
Broad analysis of the obtained structure showed the produced protein, refolded from E. coli, 
to conform to HLA-DR1 structures of similar resolution published in the PDB  
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Figure 3.9 – Optimised growth of HLA-DR1 5T4p12 protein crystals through microseeding: 
a) Schematic overview of crystal condition well locations (TOPS D1, TOPS F12 & PACT G10) 
in which primary screens yielded non-diffractable crystalline material (orange) later used as 
microseeds for crystal optimisation. 
b) Stereomicroscope images highlighting non-diffractable crystal forms from primary crystal 
screening conditions as outlined in a). 
c)  Stereomicroscope images of high-resolution diffracting 3-Dimensional HLA-DR1 5T4p12 
crystals grown at 4 mg/mL via hanging drop in PACT G10 buffer condition (0.02 M 
Sodium/potassium phosphate, 0.1 M Bis-Tris propane pH 7.5, 20 % PEG 3350) supplemented 
with microseed stocks produced from combined crystals shown in a) and b). 
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Table 3.5 – Crystallisation conditions from which HLA-DR1 5T4p12 crystals were obtained 
TOPS = TCR-pMHC Optimised Protein Screen, PACT = PACT premier™ HT-96 MD1-36 (Mo-
lecular Dimensions), % = % w/v   
  
 HLA-DR1 5T4p12 
Crystallisation conditions  
    Primary screening  
        Screen conditions  
             TOPS D1 0.1 M Hepes pH 7.0, 15 % Glycerol, 15 % PEG 4000 
             TOPS F12 0.1 M Tris pH 7.5, 0.2 M Amonium Sulphate, 25 % PEG 8000 
             PACT G10 
0.02 M Sodium/potassium phosphate, 0.1 M Bis-Tris propane pH 
7.5, 20 % PEG 3350 
        Protein concentration 4 mg/mL 
        Total drop volume 200 nL 
    Seeding  
        Parent seed protein Self (HLA-DR1 5T4p12) 
        Parent seed screen conditions TOPS D1, TOPS F12, PACT G10 
        Seed dilution volume 1 in 100 (5 mL) 
        Seed dilution buffer PACT G10 
        Reservoir buffer PACT G10 
        Protein concentration 4 mg/mL 
        Total drop volume 3 µL 
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(3PDO (Gunther et al. 2010) vs HLA-DR1 5T4p12: RMSD = 0.714 Å). All elements of the four 
globular domains (α1, α2, β1 and β2) were resolvable and described the tertiary fold of the two 
DR1α and DR1β chains non-covalently complexed to form the peptide-binding groove between 
α2 and β2 domains (Figure 3.10).  
Within the binding groove, the presented 5T4p12 peptide, of 20 amino acids in length, was 
held non-covalently atop an anti-parallel β-sheet floor constructed from the α2 and β2 chains, 
in an extended conformation. The open ended conformation characteristic of MHC-II binding 
grooves allowed the extension of 20 amino acid long peptide antigen to far extend out of the 
nonamer binding core of HLA-DR1. Presence of the 5T4p12 peptide was confirmed via peptide 
omit map analysis, whereby the peptide model was omitted during refinement and difference 
map peaks were analysed for presence/absence of density1. Through omit map analysis, obser-
vation of positive difference map peak density which accurately described the modelled 5T4p12 
peptide sequence, confirmed the presence of the desired peptide within x-ray diffraction data 
and thus not a consequence of refinement bias (Figure 3.11a) 
Of the 20 amino acids, only the N-terminal Phe residue was unable to be modelled due to a 
lack of discernible continuous electron density (Figure 3.11b). Modelling of side chain and 
backbone positioning of the peptide within the peptide binding groove was achievable at contour 
levels of 1.0 σ whilst N- and C-terminal flanks required some approximated positioning at a 
contour level of 0.5 σ2. Deterioration of electron density at the extremities of the N- and C- 
termini caused an increase in assigned isotropic displacement B-factor parameters, an indicator 
of model flexibility and thus, quantified the positional uncertainty of modelled atoms within the 
three most N-terminal residues (FARRPP-) and two most C-terminal residues (-SGSRL) (Fig-
ure 3.11c). Such increase in B-factor assignment indicates inherent flexibility at each flank 
extremity. 
  
                                                     
1 Difference map peaks highlight areas of disagreement between the modelled structure and observed 
electron density data. Positive difference map peaks represent areas of observed electron density which 
have not been filled by the modelled structure. When the modelled peptide is removed from refinement 
during omit map analysis, positive difference map peaks should resemble the omitted peptide. 
2 Sigma (σ) is a statistical parameter which describes the intensity of electron density at a given point 
in terms of standard deviation from the mean electron density of the entire map. Thus areas of electron 
density with high σ represents areas of high electron density. A σ cut-off level therefore acts as a contour 
level that determines whether a given point is visualised as containing electron density. A σ level of 1.0 
is generally used for presenting visualised electron density whilst a σ level of 0.5 can be used to model 
flexible protein residues. 
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Table 3.6 – Data reduction and refinement statistics of the HLA-DR1 5T4p12 structure 
DLS = Diamond Light Source, Dataset statistics in parentheses represent statistical value for 
data in the outermost resolution shell. RMSD = Root-mean-square deviation. 
 HLA-DR1 5T4p12 
Dataset statistics  
    Space group P 1 21 1 
    Unit cell parameters a=56.96, b=121.29, c=68.96 α=90.0°, β=107.3°, γ= 90.0° 
    Radiation source DLS I02 
    Wavelength 0.9795 Å 
    Resolution range  60.65 – 1.95 (2.00 – 1.95) Å 
    CC-half 0.995 (0.589) 
    Total reflections 239,331 (17,960)  
    Unique reflections 64,792 (4,807) 
    Completeness 99.6 (99.8) % 
    Multiplicity 3.7 
    I/σ 8.3 (1.3) 
    Rmerge 10.0 (91.3) % 
Refinement statistics  
    Phase determination Molecular replacement (PHASER) 
    No. of reflections used 64,762 
    No. of reflections in Rfree set 3,165 
    Rcryst (%) 19.31 
    Rfree (%) 24.11 
    Asymmetric unit (ASU) parameters  
        Number of copies in ASU 2 
        Number of non-H atoms 6,784 
    Deviation from ideal geometry (RMSD)  
        Bond lengths 0.0191 
        Bond angles 1.8659 
        Chiral volume 0.1086 
   Overall Wilson B factor (A
2
) 39.2   
   Ramachandran statistics (MolProbity)  
        Most favoured 756 (98.1 %) 
        Allowed 15 (1.9 %) 
        Outliers 0 (0.0 %) 
   MolProbity clash score 2.42 
   MolProbity score 1.48 
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Figure 3.10 – Refined crystal structure of HLA-DR1 presenting 5T4p12 at 1.95 Å:  
Cartoon representation of solved HLA-DR1 structure presenting the 5T4p12 peptide as stick 
representation (magenta). DR1α1 and α2 (blue) domains complex with DR1β1 and β2 domains 
(green) as depicted by front, top and side views. The 5T4p12 peptide is held within the open 
ended peptide binding groove as shown by top view. N-terminal and C-terminal peptide flanking 
residues protrude away from the peptide binding groove as shown in front and side views. 
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Figure 3.11 – Density plot analysis of peptide conformation within HLA-DR1 5T4p12: 
a) Omit map analysis of observed difference map peaks in absence of peptide during refinement. 
Presence of positive difference map peaks (green mesh; + 3.0 σ) and not negative peaks (red 
mesh; - 3.0 σ) with highly related density to modelled peptide (magenta sticks; atoms coloured: 
C = magenta, O = red, N - blue) validated the presence of 5T4p12 within electron density.  
b) Stick representation of modelled 5T4p12 peptide (magenta) within refined electron density 
map contoured at 1.0 σ and 0.5 σ (grey mesh). Peptide electron density allowed modelling of 19 
of the 20 amino acids of 5T4p12 with no observed electron density of N-terminal Phe. 
c) Stick representation of 5T4p12 peptide coloured by B-factor (blue to red; B-factor range = 
21 to 130). B-factor analysis indicated a highly stable core binding region (B-factor < 40) 
flanked by stability extending to both N-terminal and C-terminal flanking regions. Extremities 
of termini exhibited high flexibility as indicated increase in B-factors to > 80. 
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3.6.4 Definition of the 5T4p12 core epitope presented by HLA-DR1  
Previous ELISpot and ELISA experiments described the cognate 5T4-reactive GD.D104 T cell 
clone activation in response the 20 amino acid 5T4p12 (FARRPPLAELAALNLSGSRL) pre-
sented by HLA-DR1 only expressing cells. Likewise, preceding studies highlighting the 5T4p12 
as immunogenic in healthy individuals and colorectal cancer patients defined the epitope only 
to the full length 20 amino acid sequence. Definition of the nonamer peptide binding core ex-
hibited by HLA-DR1 for 5T4p12 had not previously been experimentally defined. 
The peptide binding pockets of MHC-II molecules classically define the selection of peptides 
presented by each allele. Using the solved structure of HLA-DR1 5T4p12, definition of the 
nonamer peptide binding core of 5T4p12 was achieved by assignment of the register within the 
HLA-DR1 binding groove (Figure 3.12a). In agreement with the prediction by NetMHC2.2, 
described previously, this binding core was defined to the centre of the 20 amino acid peptide 
(FARRPPLAELAALNLSGSRL; binding core bold and underlined) and as a result, the core 
immunogenic epitope was derived from 5T4117-125. Assignment of the peptide binding core, 
therefore, defined the 5T4p12 peptide to contain a six amino acid N-terminal flank (FARRPP) 
and five amino acid C-terminal flank (SGSRL).  
3.6.5 HLA-DR1 presented 5T4117-125 exhibits minimal potential TCR contact residues  
Binding of cognate TCR to peptides presented on MHC molecules and consequent triggering of 
T cell signalling is mediated by the ability of paratopic CDR loops on the TCR to interact with 
residues on the combined peptide-MHC surface volume. As a result, determinant of binding is 
governed by peptide atoms, particularly those derived from peptide side chain residues, which 
orientate in a membrane distal direction – away from the MHC binding groove. Such atoms 
allow the formation of enthalpically favourable intermolecular contacts between the peptide 
MHC and cognate TCR (Bridgeman et al. 2012). Consequently, the dimensions and chemistry 
of such orientated side chain residues are a key factor in selecting TCRs with affinity for peptide 
antigen which can form a network of electrostatic interactions between peptide and TCR.  
Analysis of the structure of 5T4p12 bound to HLA-DR1 revealed the likely residues involved 
in TCR contact within the peptide core binding region (5T4117-125; LAELAALNL) as shown by 
residues protruding away from the MHC binding groove (Figure 3.12b). Overall, the 5T4117-125 
core peptide region of 5T4p12 exhibited a mostly flat surface volume. Only Glu3 and Asn8 form 
obvious TCR contact residues. The charged carboxyl side chain of Glu3 is positioned centrally 
within the peptide and projects perpendicularly away from the peptide binding groove and, thus, 
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Figure 3.12 – Definition of the 5T4p12 core peptide region and potential TCR contact 
residues within: 
a) Sphere and surface representation of the largely flat 5T4p12 core peptide binding region 
(magenta spheres) within the HLA-DR1 molecule (DR1α = blue, DR1β = green). Peptide 
flanking residues outside of the binding core are also shown protruding away from the HLA-
DR1 molecule (light pink spheres). 
b) Stick and cartoon representation of the defined 5T4p12 core peptide binding region (coloured 
as in a)) and the potential TCR contact residues within the binding core which protrude away 
from the peptide binding groove. Orientation of such residues are denoted by upwards facing 
arrowheads and corresponding HLA-DR1 binding position. Leu7 at position P7 is orientated 
parallel to the MHC molecule and is therefore partially available for TCR contact, thus, denoted 
as a sideways arrowhead. 
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available to form hydrogen bonds or salt bridges with the TCR. Likewise, the more C-terminally 
positioned Asn8 is available for hydrogen bonding via its amide bearing side chain. Due to the 
positioning of two short aliphatic alanine residues at P2 (Ala2) and P5 (Ala5) as well the partial 
burial of Leu at P7, which provide little contact atoms for TCR interaction, no other obvious 
high enthalpy TCR contact residues are present in the 5T4117-125 peptide binding core of 5T4p12. 
NB.  
3.6.6 Intramolecular interactions mediate a hairpin turn in the C-terminal flank of 
5T4p12 
Analysis of the solved HLA-DR1 5T4p12 structure demonstrated a lack of potential TCR con-
tacts in the core peptide binding region of 5T4p12, however, observation of the flanking regions 
highlighted extended structures which protrude away from the MHC. Such residues, whilst ex-
hibiting a degree of inherent isotropic displacement, as discussed previous, formed ordered 
conformational features. 
At the N-terminal flank, the peptide remained in a relatively flat conformation by interacting 
with the MHC molecule through a network of interactions involving residues Arg-3, Pro-2 and 
Pro-1 of which these interactions, and their contribution to peptide binding to MHC are dis-
cussed in detail later. In general, these interactions extended the N-terminal flank over the top 
of the MHC-II binding groove and held the peptide backbone close to the DR1α chain (as visu-
alised in Figure 3.10; top view). This exit from the binding groove was facilitated by the flexible 
loop region connecting the 310 helix and binding groove wall α-helix. Drop-off in electron den-
sity for the peptide backbone past Arg-4, and the Arg-4 side chain itself (as shown in Figure 
3.11a) was observed as a result of the molecular dynamics of isolated polypeptide chains. Con-
sequently, the exact locale of such atoms are not fixed, however, their orientation trended away 
from the MHC where they exhibit mobility in solution. As such, these residues at the N-terminal 
flank may be free to contact the TCR through interaction with the guanidinium side chain of 
Arg-4 or the aromatic phenyl group of Phe-6. 
In comparison, at the C-terminal flank, the 5T4p12 exhibited an ordered structure that pro-
truded away from the MHC binding groove in the form of a hairpin loop (Figure 3.13). This 
hairpin loop was mediated through few intermolecular contacts with the MHC, constrained to 
Ser12 interacting with Ile72α which, via four vdW interactions, was the only residue to scaffold 
the turned peptide above itself by the MHC.  
The reverse turning of the peptide strand was instead mediated mainly through intramolecu-
lar contacts within the peptide (Figure 3.13a). The result of these interactions was the pulling 
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of the final three residues at the C-terminus into close proximity of the peptide binding core 
boundary. Such contacts within the peptide were the result of three residues, Ser10, Gly11 and 
Ser12, forming a tight reverse turn in the C-terminal flank of 5T4p12 that resembled the char-
acteristics of a type II β-turn. This turn was mediated by residues Leu9, Ser10, Gly11 and Ser12; 
assigned i, i+1, i+2 & i+3, respectively, according to convention. Specifically, as per the criteria 
of β-turns, residue Ser12 (i+3) was brought within 7 Å of Leu9 (i); as measured between Cα 
atoms (Figure 3.13b). The resulting dihedral angles about Ser10 (i+1) and Gly11 (i+2) con-
formed to typical average values observed in type II β-turns (Figure 3.13c).  
The presence of this turn was formed and constructed by interactions between the Ser12 side 
chain to Leu9 and Ser10 residues located before the turn – enabled through the locale of the 
Ser12 side chain hydroxyl group. This side chain allowed the formation of a hydrogen bond 
between the Ser12 hydroxyl and Leu9 carbonyl (Figure 3.13d). In order to accommodate this 
interaction, measured at 2.8 Å, the type II β-turn hairpin turn was opened and thus the observed 
turn was consequently more obtuse. As a result, the Ser10-Gly11-Ser12 turn did not form a fully 
recognised H-bond between the backbone carbonyl of residue i (Leu9) and backbone amide of 
i+3 (Ser12) – a criterion for classification of β-turns. In the observed hairpin, this distance (3.6 
Å) was marginally outside the general cut-off distance for H-bonds (<3.4 Å). At this distance, 
however, these atoms would still experience weak electrostatic attraction. No crystal contacts 
were made between the C-terminal hairpin loop and neighbouring symmetry mates (Appendix 
5c). 
 
  
- 118 - 
 
 
Figure 3.13 – Hairpin turn formation at the C-terminal flank of 5T4p12: 
a) Stick representation of C-terminal flanking region of 5T4p12 (coloured by B-factor; blue to 
red; range = 21 to 130) bound to HLA-DR1 highlighting a hairpin loop mediated by 
intramolecular contacts within the peptide (red dashes) before increase in B-factors. Few 
intermolecular contacts (cyan dashes) with residues Ser10-Leu14 were observed.  
b) C-terminal flanking region of 5T4p12 highlighting the hairpin loop formed by residues Leu9-
Ser12 (magenta). Cα atoms of Leu9 and Ser12 (denoted i and i+3, respectively) are separated 
by a distance typical of β-turns (<7.0 Å). 
c) C-terminal flanking region of 5T4p12 as in b) annotated with dihedral angles Φ/ ψ about 
Ser10 and Gly11. Observed dihedral angles conform to typical average values of type II β-turns: 
Φi+1 = -60°, ψ i+1 = +120°, Φi+2 = +80°, ψ i+2 = 0°. 
d) C-terminal flanking region of 5T4p12 as in b) highlighting the lack of established H-bond 
between Leu9 carbonyl and Ser12 amide due to distance (grey dashes) above H-bond cut-off 
value (3.4 Å). Hairpin turn is, instead, held by the formation of a H-bond between Leu9 carbonyl 
and Ser12 side chain hydroxyl (blue dashes) 
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3.6.7 Enhanced intermolecular binding of 5T4p12 to HLA-DR1 via contacts throughout 
the extended tumour-antigen derived peptide 
The 5T4p12-reactive T cell clone GD.D104 exhibited sensitivity to antigen presented by HLA-
DR1 only expressing cells but did not stain effectively by HLA-DR1 5T4p12 multimers. Despite 
this, 5T4p12 was immunogenic to in vitro cultured CD4+ T cells. In order to study the contribu-
tion to immunogenicity by 5T4p12 binding to MHC, the solved HLA-DR1 5T4p12 structure 
was interrogated for the intermolecular contacts that anchor and complex the peptide to MHC. 
3.6.7.1 Anchoring of the 5T4p12 peptide to HLA-DR1 incorporating leucine into the P1 
binding pocket 
Differences in HLA-DR alleles are characterised by polymorphisms in the peptide binding 
groove which alter the array of presentable peptide ligands between MHC-II molecules and 
therefore between individuals. As a result of such polymorphisms, different HLA-DR alleles 
have preference for binding different peptide motifs into the polymorphic peptide binding pock-
ets (Rammensee et al. 1995). Anchoring of 5T4p12 to the MHC was characterised by a classic 
HLA-DR1 binding motif (Figure 3.14). Binding residues at P4 (Leu4), P6 (Ala6) and P9 (Leu9) 
are within preferential and conventional residues for respective HLA-DR1 binding pockets (Fig-
ure 3.14a&b) (Cole & Godkin 2016). Such classical interactions confirm the 5T4p12 as a good 
ligand for HLA-DR1, in accordance with the predicted affinity of 5T4p12 for HLA-DR1, de-
scribed previously. 
In contrast to counterpart binding pockets, incorporation of Leu at P1 represents a sub-opti-
mal residue for the P1 pocket of HLA-DR1 which has potential for binding larger hydrophobic 
and aromatic residues (Tyr, Phe, Trp & Ile) (Figure 3.14c). As such, there are currently no pub-
lished structures in the PDB describing leucine binding at position P1 of HLA-DR1 (all 
structures assigned as using DRB1*01 beta chain; UniProtKB: P04229). Despite the smaller 
size of the leucine side chain, Ser53α, Phe54α, Phe32α, Val85β and Asn82β of the HLA-DR1 
P1 pocket were able to contact Leu1.  
The interactions between Leu1 and MHC were in the form of a network of sixteen contacts: 
fifteen van der Waals interactions and a single hydrogen bond to the peptide backbone (Figure 
3.14d), listed in Table 3.7. Such interactions are comprised of contacts with the Leu1 peptide 
backbone (7/16 contacts) but, more significantly, with aliphatic side chain atoms (9/16 contacts). 
The most contacts with Leu1 were contributed to Asn82β (6/16 contacts) which made extensive 
interactions through the Leu1 side chain and backbone. In contrast, Phe54α interacted with the 
peptide backbone only through two van der Waals interactions. The single hydrogen bond con-
tribution to binding was mediated through Ser53α interacting with the peptide bond amide group 
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Table 3.7 – Contacts enabling Leu1 mediated anchoring of 5T4p12 at position P1: 
vdW = van der Waals (=< 4.0 Å cut-off), H-bonds = hydrogen bonds (=< 3.4 Å cut-off). 
 
  
Peptide  MHC  Contact 
Residue Atom  Chain Residue Atom  Distance (Å) Type 
   Peptide backbone contacts 
Leu1 N    A Ser53 C    4 VW 
 N    A Ser53 O    2.8 HB 
 Cα   B Asn82 Oδ1  3.47 VW 
 Cα   A Ser53 O    3.82 VW 
 C    B Asn82 Oδ1  3.69 VW 
 O    A Phe54 Cε1  3.77 VW 
 O    A Phe54 Cδ1  3.32 VW 
   Peptide side chain contacts 
Leu1 Cβ   B Asn82 Oδ1  3.95 VW 
  Cβ   A Ser53 O    3.78 VW 
  Cγ   B Val85 Cγ1  3.95 VW 
  Cδ1  A Phe32 Cε1  3.79 VW 
  Cδ2  B Asn82 O    3.94 VW 
  Cδ2  B Asn82 Cγ   3.9 VW 
  Cδ2  B Asn82 Oδ1  3.51 VW 
  Cδ2  B Val85 Cβ   3.89 VW 
  Cδ2  B Val85 Cγ1  3.69 VW 
   No. of total contacts 16 
      vdW 15 
      H-bonds 1 
   No. of contacts with peptide backbone 7 
      vdW 6 
      H-bonds 1 
   No. of contacts with side chain 9 
      vdW 9 
      H-bonds 0 
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Figure 3.14 – Anchoring of 5T4p12 via partial occupancy of the P1 pocket by leucine: 
a) Stick and cartoon representation of the 5T4p12 peptide (core region = pink, flanking regions 
= pale pink sticks) and assignment of peptide residues binding to P1, P4 P6 and P9 position 
HLA-DR1 binding pockets (downward arrowheads). α2 α-helix = blue cartoon. 
b) Surface, sticks and sphere representation of top down view of 5T4p12 binding to HLA-DR1 
coloured as in a). Spheres highlight peptide residues buried into HLA-DR1 binding pockets. 
c) Surface and stick representation of the concaved P1 binding pocket constructed from HLA-
DR1α (surface, blue) and -DR1β (surface, green) chains of which the aliphatic Leu1 side chain 
(pink) of the 5T4p12 peptide (white) partially fills. 
d) Stick representation of contacts made between the Leu1 peptide residue (pink) with residues 
at the P1 binding pocket facilitating peptide binding to MHC. Leu1 made sixteen van der Waals 
contacts (black dashed lines) with the HLA-DR1α chain residues Ser53α and Phe54α (both 
green) as well as the -DR1β chain residues Phe32α, Val85β and Asn82β (all blue). 
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of Leu1 and is therefore unlikely to be impacted by side chain selection at P1. Due to the ali-
phatic nature of the Leu1 residue, no hydrogen bonding or salt bridging was observed with the 
Leu1 side chain. As a result, anchorage of Leu1 to the P1 pocket was not able to be enhanced 
by side chain linked hydrogen bonds, despite proximity of hydrogen bond capable polar residues 
such as Asn82β and Ser53α. As reference, anchoring of the influenza-derived ‘universal epitope’ 
HA306-318 peptide to the P1 pocket of HLA-DR1 is mediated by a total of 23 contacts between 
MHC and the Tyr1 residue of HA306-318 when analysed using the same contact criteria (Stern et 
al. 1994). 
3.6.7.2 Peptide flanking residues contribute to HLA-DR1 binding 
Whilst the core binding region of MHC-II restricted peptides is typically considered to define 
the ability of peptides to be selected for presentation on MHC alleles, contribution to binding 
by residues flanking the core region must also be considered. Indeed, increases in peptide flank-
ing length have suggested an influence of peptide to MHC-II affinity in vitro and 
computationally (Sant’Angelo et al. 2002; O’Brien et al. 2008). 
The 5T4p12 peptide tethered to HLA-DR1 via a network of non-covalent interactions in-
cluding 168 vdW interactions and 19 H-bonds; 187 total contacts (Figure 3.15a). Flanking the 
defined nonamer core binding region of 5T4p12 was a six amino acid N-terminal flank 
(FARRPP) and five amino acid C-terminal flank (SGSRL). In order to analyse the contribution 
of these flanking residues to 5T4p12 peptide binding to HLA-DR1, the number of contacts by 
each residue in the full length peptide was quantified (Table 3.8) and stratified for the percentage 
contribution of contacts per peptide residue to observed interactions (Figure 3.15b).  
Analysis of the distribution of contacts throughout the peptide sequence highlighted the res-
idues bound into the HLA-DR1 binding pockets as shown by increases in contacts at P1 (Leu1), 
P4 (Leu4), P6 (Ala6) and P9 (Leu9) as expected. In addition, contribution of peptide to MHC 
binding by residues within the peptide flanking residues was observed. Of the 11 flanking resi-
dues, five residues contributed to peptide binding to HLA-DR1 through the formation of 
contacts between the complexed peptide and MHC molecule; N-terminal flanking Arg-3, Pro-2 
& Pro-1 as well as the C-terminal flanking Ser10 & Ser12 (FARRPPLAELAALNLSGSRL; 
highlighted in bold, core peptide underlined).  
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Figure 3.15 – The complex interaction network between 5T4p12 and HLA-DR1: 
a) Stick representation of all contacts (=< 4.0 Å cut-off), between the 5T4p12 peptide (magenta) 
and residues of the DR1α (blue) and DR1β (green) chains. 
b) Reduction of the 5T4p12 to HLA-DR1 contact network to the number of contacts mediated 
by each single amino acid within the peptide sequence. Quantified contacts across the peptide 
sequence are presented as a histogram stratified to percentage of total contacts observed across 
the 5T4p12 peptide chain. Simplification of the contact network demonstrates contribution to 
MHC binding by residues within the peptide binding core (black) and within the peptide 
flanking residues (grey). n.d. = not determined due to lack of positional certainty. 
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Table 3.8 – Contribution of peptide residues to 5T4p12 to MHC binding  
vdW = van der Waals (=< 4.0 Å cut-off), H-bonds = hydrogen bonds (=< 3.4 Å cut-off). 
 
 
 
  
  Peptide to MHC contacts 
Residue Position vdW H-bonds Total 
   N-terminal peptide flanking residues 
Arg-3  P-3 23 3 26 
Pro-2  P-2 9 1 10 
Pro-1  P-1 8 1 9 
   Peptide binding core region 
Leu1  P1 15 1 16 
Ala2  P2 9 2 11 
Glu3  P3 11 0 11 
Leu4  P4 21 3 24 
Ala5  P5 5 2 7 
Ala6  P6 11 1 12 
Leu7  P7 13 1 14 
Asn8  P8 9 1 10 
Leu9  P9 21 1 22 
   C-terminal peptide flanking residues 
Ser10  P10 9 2 11 
Ser12  P12 4 0 4 
   No. of total contacts 187 
      vdW 168 
      H-bonds 19 
   No. of contacts with peptide flanking residues 60 
      vdW 53 
      H-bonds 7 
   No. of contacts with peptide binding core 127 
      vdW 115 
      H-bonds 12 
- 125 - 
 
3.6.7.3 Peptide to MHC contacts at the C-terminal flanking region 
Binding of peptide to MHC at the C-terminal flank was mediated via the Ser10 and Ser12 resi-
dues (P10 & P12 respectively). At Ser10, extensive contacts with five residues across both DR1α 
(Ile72α and Arg76α) and DR1β (Pro56β, Asp57β and Tyr60β) chains were made through a total 
of eleven interactions including two hydrogen bonds (Figure 3.16a). Despite the polar hydroxyl 
group side chain of Ser10, these two hydrogen bonds were made to the peptide backbone only 
and therefore the Ser10 side chain did not facilitate additional peptide anchoring through a high 
energy H-bond. Such inability to form side chain H-bonds with MHC residues was in spite of 
the relative proximity of the polar atoms of Arg76α which remained too distal to Ser10. Despite 
this, the Ser10 hydroxyl and Cβ did interact with Pro56β and Asp57β by forming weaker vdW 
interactions. 
Despite the hairpin loop observed at the C-terminal flank of 5T4p12 causing protrusion away 
from the binding groove, discussed previous, Ser12 at position P12 made some contacts with 
the MHC through interactions between the Ser12 side chain and Ile72α (Figure 3.16b). Similar 
to Ser10, contacts between MHC and Ser12 were mediated through vdW interactions and did 
not utilise the hydroxyl group of Ser12 to form contacts but instead formed four vdW interac-
tions with Ile72α; two of which were contributed by side chain atoms. Presence of fewer 
observed contacts between peptide and MHC by Ser12 at P12 is expected due to the protrusion 
of the C-terminal hairpin loop away from the MHC molecule. Nevertheless, lack of Ser12 to 
MHC contacts was a correlate of the increase flexibility of the extremities of the C-terminal 
flank of 5T4p12 as shown by B-factor analysis previous. 
Overall, analysis of the C-terminal flanking region reveals presence of interactions between 
peptide residues and the MHC, however, such interactions are far fewer than those observed in 
other regions of the peptide – specifically the peptide binding core and the HLA-DR1 binding 
pockets within. In addition, inclusion of serine residues at positions P10 and P12 have no obvi-
ous structural advantage to cause enrichment of such residues at these positions due to 
redundancy of the hydroxyl side chain in both positions in terms of contribution to peptide-
MHC binding. Nevertheless, such interactions positively benefited peptide complexing to HLA-
DR1. 
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Figure 3.16 – Intermolecular contacts between the C-terminal flank of 5T4p12 and HLA-
DR1: 
a) Stick representation of 5T4p12 peptide (white) highlighting residue Ser10 (magenta) 
interacting with DR1α residues Ile72α and Arg76α (blue) and DR1β residues Pro56β, Asp57β 
and Tyr60β (green). Van der Waals contacts (=< 4.0 Å) are shown as black dashed lines and H-
bonds (=< 3.4 Å) shown as blue dashed lines between contributing atoms. Ser10 contacted MHC 
via both side chain and peptide backbone but showed no ability to form side chain hydrogen 
bonds with neighbouring polar residues such as Arg76α. 
b) Stick representation of 5T4p12 peptide, as in a) highlighting Ser12 (magenta) interaction with 
DR1α residue Ile72α. Minimal contacts were observed including no side chain hydrogen 
bonding between the Ser12 hydroxyl group and the MHC molecule. 
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3.6.7.4 Peptide to MHC contacts at the N-terminal flanking region 
Compared to the C-terminal counterpart, the N-terminal peptide flanking region made three 
times as many total contacts with HLA-DR1 (15 compared to 45, respectively). Such contacts 
involved the three most proximal residues to the binding core: Arg-3, Pro-2 and Pro-1.  
Two consecutive proline residues proximal to the peptide binding core made a moderate 
contribution to binding, creating contacts with the MHC comparable to those exhibited by core 
peptide binding region residues outside the binding pocket positions. Contacts by Pro-1 were 
quantified as eight vdW interactions across three residues including Ser53α, which made con-
tacts at position P1, and a single H-bond to the peptide backbone (Figure 3.17a). Similar 
contacts were observed for Pro-2 where a single H-bond between the Pro-2 backbone contacted 
Ser53α, further highlighting this MHC residue proximal to the P1 pocket as key to stabilisation 
of the 5T4p12 peptide (Figure 3.17b). Due to the cyclic nature of the proline side chain, how-
ever, no obvious advantage in enrichment of prolines at P-1 and P-2, in terms of direct 
interactions to the MHC by side chain atoms, was immediately clear. 
Whilst both Pro-2 and Pro-1 made contributions to MHC binding themselves, incorporation 
of two consecutive proline residues allowed the 5T4p12 N-terminal flank to exhibit a di-proline 
kink in the peptide chain and subsequently positioned Arg-3 towards the DR1α chain proximal 
α2 domain of the peptide binding groove. This kinked conformation located Arg-3 above the 
linking region between the 310 helical and α-subunit helix of the α2 domain. Consequently, Arg-
3 was able to form a network of contacts with five residues, all localised to the DR1α chain 
(Table 3.9).  
Quantification of 26 unique contacts (23 vdW & 3 H-bonds) between Arg-3 and the MHC 
molecule showed that Arg-3 made the most inter-molecular contacts out of any single residue 
throughout the length of the peptide. Arg-3 contacted a string of five consecutive residues 
Gly49α – Ser53α by making extensive vdW interactions with both the side chain and peptide 
backbone of Arg-3 (Figure 3.17c). Most contacts however, were mediated by the large positively 
charged side chain of arginine (backbone contacts = 4, side chain contacts = 22). 
In addition to vdW interactions, contacts included three higher-energy H-bonds (2.75 - 3.0 Å 
bond length) between Arg-3 and the MHC. Firstly, the backbone carbonyl of Arg-3 contacted 
the hydroxyl of Ser53α describing how the peptide backbone of longer MHC-II restricted pep-
tides can make interactions with the MHC at position P-3 (Figure 3.17d). Furthermore, the side 
chain NH2 of Arg-3 made two H-bond interactions with Gly49α and Ala52α backbone carbonyls. 
Such interactions were enabled by the length of the Arg-3 side chain and it’s positively charged 
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guanidinium end group and thus binding of peptides to HLA-DR1 may be preferentially en-
hanced by arginine inclusion at position P-3. Such interactions here described enabled a more 
fixed N-terminal flank that, for 5T4p12, theoretically enhanced the complexing of peptide to 
HLA-DR1 and thus may impact its immunogenicity in vitro and potentially in vivo. 
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Table 3.9 – Intermolecular contacts mediating peptide binding to MHC by Arg-3  
vdW = van der Waals (=< 4.0 Å cut-off), H-bonds = hydrogen bonds (=< 3.4 Å cut-off). 
 
 
 
 
 
  
Peptide  MHC  Contact 
Residue Atom  Chain Residue Atom  Distance (Å) Type 
    Peptide backbone contacts 
Arg-3 C    A Ser53 Oγ   3.84 VW 
 O    A Ser53 N    3.78 VW 
 O    A Ser53 Cβ   3.67 VW 
 O    A Ser53 Oγ   2.82 HB 
    Peptide side chain contacts 
Arg-3 Cβ   A Ala52 Cα   3.84 VW 
 Cβ   A Phe51 C    3.83 VW 
 Cβ   A Phe51 O    3.67 VW 
 Cβ  A Ala52 N    3.8 VW 
 Cβ   A Ala52 C    3.73 VW 
 Cβ   A Ser53 N    3.93 VW 
 Cγ   A Arg50 C    3.96 VW 
 Cγ   A Arg50 O    3.43 VW 
 Cδ   A Arg50 C    3.97 VW 
 Cδ   A Arg50 O    3.71 VW 
 Cδ   A Gly49 O    3.3 VW 
 Nε   A Gly49 O    3.85 VW 
 C   A Gly49 O    3.67 VW 
 Cζ   A Ala52 O    3.93 VW 
 Cζ   A Ser53 Cβ   3.89 VW 
 NH1  A Ser53 Cβ   3.58 VW 
 NH2  A Ala52 C    3.8 VW 
 NH2  A Ser53 Cα   3.96 VW 
 NH2  A Gly49 C    3.81 VW 
 NH2  A Gly49 O    2.75 HB 
 NH2  A Ala52 O    2.99 HB 
 NH2  A Ser53 Cβ   3.91 VW 
   No. of total contacts 26 
      vdW 23 
      H-bonds 3 
   No. of contacts with peptide backbone 4 
      vdW 3 
      H-bonds 1 
   No. of contacts with side chain 22 
      vdW 20 
      H-bonds 2 
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Figure 3.17 - Inter-molecular contacts between the N-terminal flank of 5T4p12 and HLA-
DR1: 
a) Stick representation of 5T4p12 peptide (white) binding to MHC highlighting residue Pro-1 
(magenta) interacting with Ser53α (blue), His81β and Val85β (both green). Van der Waals 
contacts (=< 4.0 Å) are shown as black dashed lines and H-bonds (=< 3.4 Å) shown as blue 
dashed lines between contributing atoms. 
b) Stick representation of 5T4p12 binding as in a) highlighting Pro-2 (magenta) interacting with 
Phe51α, Ala52α & Ser53α (blue) as well asVal85β (green). 
c) Stick representation of van der Waals contacts (=< 4.0 Å) by Arg-3 at position P-3 allowing 
interaction with Gly49α to Ser53α (all blue). Contribution to MHC binding by Arg-3 was 
mediated mostly through interactions between Arg-3 side chain atoms. 
d) Stick representation of H-bond contacts between Arg-3 and HLA-DR1α chain residues 
describing backbone Arg-3 carbonyl interacting with Ser53α and side chain NH2 contacting 
backbone carbonyls of Gly49α and Ala52α. The bond distance of all three H-bonds were in the 
intermediate range 2.75 - 3.0 Å. 
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3.7 Discussion 
CD4+ T cells have been shown to recognise 5T4-derived antigens in human colorectal patients 
and loss of this recognition has been linked with  tumour progression (Scurr et al. 2013). Pro-
tection against tumour formation in models of 5T4+ tumours in mice treated with an attenuated 
5T4 bearing vaccine MVA-5T4, as well as the boosting of anti-5T4 B cell immunity, highlighted 
a role for CD4+ T cell populations in the therapeutic response to vaccination against 5T4 pre-
sented in an inflammatory context (Castro et al. 2012). As a result, analysis at the clonal level 
of T cells circulating within individuals, the desired targets for boosting by vaccination, enables 
a molecular explanation of the initial quality of the T cell response against 5T4-derived antigens. 
Moreover, analysis of the ability to present 5T4-derived peptide antigens on MHC molecules 
describes how epitopes are selected for presentation to the T cell repertoire and thus enable 
immunogenicity. 
In these studies, three generated CD4+ T cell clones were shown to be responsive to 5T4-
derived peptides presented in the context of HLA-DR1. These clones were generated from the 
peripheral blood of an HLA-DR1+ donor. The T cell clones, in response to antigen in vitro, ex-
hibited a TH1 phenotype with all clones capable of producing the type 1 inflammatory cytokines 
IFNγ and TNF-α. These clones therefore did not display a regulatory T cell phenotype despite 
the self-derived nature of the 5T4 peptide antigens. Each clone, however, exhibited individual 
sensitivities to antigen with different levels of maximal cytokine release in response to antigen. 
Despite ability to activate in response to peptide presented in the context of HLA-DR1 ex-
pressing cells only, multimer staining with HLA-DR1 complexed with cognate 5T4-derived 
peptides indicated poor antigen binding by the TCR. Such poor staining was observed despite 
using enhanced protocols for the detection of low affinity T cell clones (Tungatt et al. 2015). To 
try quantify this weak binding of 5T4-derived peptide antigens, soluble TCRs and MHC-II mol-
ecules were produced for biophysical analysis of the cognate interaction between 5T4-reactive 
TCR and 5T4-derived peptides presented on HLA-DR1. These studies, however, were ham-
pered by an inability to produce two out of the three TCRs in vitro due to poor-to-no refolding 
efficiency. Despite this, using the single TCR which was obtainable – the TCR expressed by the 
5T4p38 reactive GD.C112 – the weak engagement of cognate antigen observed in multimer 
staining analysis was replicated at the protein level by SPR. Here, GD.C112 was shown to ex-
hibit some binding to 5T4p38 presented on HLA-DR1, however, this interaction occurred at a 
low affinity that was consequently unquantifiable and thus further experiments are required. 
Together, this molecular analysis of 5T4 TCR binding shows that engagement of cognate 
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pMHC-II by the TCRs expressed by each 5T4-reactive T cell clone appears weak, yet each T 
cell clone is responsive to peptide in vitro as shown by T cell activation assays. 
pMHC structural data was sought to provide further insight into this weak TCR-pMHC in-
teraction. Acquisition of structural data regarding MHC-II presented peptide epitopes within the 
literature has been hampered by the comparative difficulties in producing high quantities of pure 
conformationally correct MHC-II protein samples. As a result, the number of MHC-II derived 
x-ray crystallographic structurers deposited to the PDB are vastly outnumbered by MHC-I coun-
terparts. Enabled by affinity purification of HLA-DR1 molecules, crystallisation of HLA-DR1 
complexed with 5T4p12 was achieved and the structure solved at 1.95 Å. This structure defined 
the peptide binding core of the epitope, the residues which anchor the peptide to the MHC and 
the residues available for TCR contact.  
The 5T4p12 peptide presented by HLA-DR1 exhibited few charged/polar residues within the 
core peptide and thus may explain the observed weak engagement by multimer stain. Glu3 and 
Asn8 exhibit the only obvious high-enthalpy contact points for TCR engagement. As a result, if 
the GD.C112 focuses binding to the peptide core, TCR engagement may be mediated by CDR 
loop binding close to the peptide backbone as well as the minimal side chains of Ala2, Ala5 and 
the partially buried Leu7 at positions P2, P5 and P7, respectively. 
Analysis of the peptide flanking residues of 5T4p12, however, highlighted a hairpin loop in 
the C-terminal flanking region that protrudes away from the peptide MHC surface volume and 
thus available for TCR binding. This hairpin loop exhibited characteristics of a type II β-turn of 
which such structural features have been described previously in a HLA-DR1 restricted HIV-
GAG peptide (Zavala-Ruiz et al. 2004). Indeed, Zavala-Ruiz et al. describe a hairpin loop 
structure that, when mutated, impacted activation of a cognate T cell clone. As a result of the 
hairpin loop observed in 5T4p12, the charged C-terminal carboxyl and Arg13 are brought back 
to the vacinity of the peptide binding core. Such residues may form high-enthalpy interactions 
with TCR and facilitate binding.  
Aside from the potential involvement in TCR binding, the observed hairpin loop describes 
an interesting MHC-II phenomena in peptide binding. In support of the observed hairpin 
described by Zavala-Ruiz et al., the structure of HLA-DR1 5T4p12 provides a further model 
example of secondary structure motifs in the C-terminal flanking region and thus provides 
evidence of structral order in the peptide flanks. Moreover, MHC-II presented peptides are gen-
erally thought to be flat and exhibit little elevation away from the MHC binding groove – in 
comparison to MHC-I presented peptides which can form large central bulges (Holland et al. 
2013). As shown by HLA-DR1 5T4p12, extension of peptides at the flanks does not necessarily 
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result in an extension of peptide width, as generally perceived. Instead, through the formation 
of the described hairpin loop in 5T4p12, peptides can elevate away from the peptide binding 
groove, increasing the peptide height and the overall peptide-MHC surface volume height.  
The observed hairpin was enabled by a Ser-Gly-Ser (SGS) sequence which is inherently very 
geometrically flexible, due to the central glycine residue, and is thus predisposed to forming 
secondary structure motifs. Analysis of the SGS structural arrangement observed at the C-ter-
minal peptide flank of HLA-DR1 5T4p12 compared to the same residues within the published 
structure of the native 5T4 protein (Zhao et al. 2014) reveals structural parallels between the 
peptide antigen in situ and in presented form (Figure 3.18). Whilst not exhibiting exact geomet-
ric conformity to the SGS sequence observed bound to the MHC, there are similarities in the 
overall structure of the sequence in the native 5T4 antigen and bound to HLA-DR1; signified 
by a root mean squared deviation (RMSD) value of 0.794 upon alignment of the SGS sequence 
in both HLA-DR1 5T4p12 and the native 5T4 protein (RMSD of 5T4126-128 (SGS) in PDB: 
4CNM vs HLA-DR1 5T4p12 = 0.794). Observation of the SGS sequence in the structure of the 
native folded 5T4 shows that the SGS sequence again forms a turn in the protein about the 
central glycine. Observation of such structural parallels may be conserved to MHC-II presented 
peptides only due to the open ended nature of the groove and its consequent loss of influence 
on extended peptide flanks; thus allowing flanking residues to form conformationally favoura-
ble motifs irrespective of the MHC molecule. 
Despite the observed poor binding shown by multimer staining of cells, the 5T4p12 peptide 
has been shown to be immunogenic. Consequently, it was reasoned that 5T4p12 bound strongly 
to HLA-DR1 and thus contributed to this immunogenicity. As such, the solved structure of 
HLA-DR1 5T4p12 was interrogated for the interactions mediating peptide binding to MHC. 
Burial of P1 (Leu1), P4 (Leu4), P6 (Ala6) and P9 (Leu9) residues of 5T4p12 enclosed into 
binding pockets and provided a large network of intermolecular contacts between peptide and 
the MHC. Assignment of this peptide binding core defined the 5T4p12 peptide as able to be 
presented by APCs using a near ideal HLA-DR1 binding motif and thus adds rationale as to why 
the 5T4p12 is immunogenic. Only Leu1 incorporation into the P1 pocket could be described as 
sub-optimal. Despite numerous contacts with Leu1, the P1 pocket remains only partially filled 
allowing for incorporation of larger side chains capable of making more extensive contact net-
works with the MHC molecule. Such contacts, were fewer compared to those observed by P1 
incorporation of tyrosine in another peptide-HLA-DR1 system (Stern et al. 1994). Nevertheless, 
the HLA-DR1 5T4p12 structure described how the P1 position of HLA-DR1 is able to accom-
modate and bind leucine residues through interaction with the leucine side chain atoms and is  
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Figure 3.18 – Structural parallels between 5T4125-128 bound to HLA-DR1 and native 5T4 
protein: 
a) Stick representation of C-terminal hairpin loop exhibited by Leu9-Ser12 of 5T4p12 
(magenta) bound to HLA-DR1 and the parameters of geometry that characterised the loop. Inset 
distances are colour coded to corresponding and Φ/ ψ about Ser10 to Gly11 are shown. 
b) Equivalent stick representation of the sequence of amino acids described in a) within the 
structure of native 5T4 (PDB: 4CNM) (Zhao et al. 2014) corresponding to residues Leu125 to 
Ser128 (cyan) of full length 5T4. Distances and angles are annotated as described in a).  
c) Aligned stick representation of 5T4125-128 bound to HLA-DR1 and as part of the native 5T4 
protein. In both structures, parallels are observed about the SGS turn sequence quantified by a 
root mean squared deviation of 0.794 Å across the three residues.  
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the first structure showing incorporation of leucine residues into the P1 binding pocket of HLA-
DR1. 
Contributions to peptide binding to the MHC-II molecules by the peptide backbone have 
been previously identified to also include residues outside the core nonamer e.g. P-2 and P10 
(Painter & Stern 2012). Such interactions were in the form of hydrogen bonds to peptide back-
bone with Ser53α and His81β at the P-2 position and Arg76α and Asp57β at the P10 position. 
Despite this, contribution of peptide flanking residues further extending out of the core peptide 
binding region is currently less understood and preference for amino acid side chains in flanks 
to enhance peptide to MHC binding has not been characterised in depth. Due to the length of 
peptide held within the MHC in the solved HLA-DR1 5T4p12 structure, these structural data 
provide an excellent model for the interrogation of peptide flanking region contribution to MHC 
binding. 
In HLA-DR1 5T4p12, the single amino acid throughout the entire peptide which contributed 
the most contacts with MHC was attributed to Arg-3 in the N-terminal flank. Such contacts 
therefore suggest that this Arg-3 residue contributed to MHC binding on a similar capacity to 
that of a peptide residue within a classical binding pocket. Moreover, the majority of these con-
tacts were mediated by the arginine side chain. Thus, incorporation of arginine residues at P-3 
may be preferential for the enhanced binding of peptides to HLA-DR1. The locale of Arg-3 may 
have been dependent, however, on the diproline kinking sequence that superseded it and allowed 
the peptide to curve towards the DR1α chain whilst sitting atop the DR1α surface.  
Together, analysis of structural data at the N- and C-terminal flanks highlight that whilst 
displaying a degree of mobility, as indicated by isotropic displacement parameters, peptide 
flanking residues can exhibit conformational structures that impact peptide binding to MHC and 
potentially the repertoire of MHC-II restricted TCRs by contributing to the conformation of the 
peptide MHC surface volume. 
3.7.1 Future directions 
The work presented in this chapter describes the efficiency of T cell recognition of 5T4-derived 
peptide antigens through the study of three epitopes and three corresponding clones. The 
efficiency of a T cell clone to respond to antigen is influenced by both the ability for TCRs to 
bind to cognate pMHC but also the ability for MHC molecules to present such peptides. As a 
result, experimental quantification of the ability for HLA-DR1 to bind and present each 5T4-
derived peptide would provide a better understanding of the comparative contribution of peptide 
affinity to HLA-DR1 in the observed efficiency and sensitivity of each described clone. This 
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could be achieved through peptide binding assays to HLA-DR1 as opposed to relying on the 
predictions described in this study. 
One limitation of this study is that whilst the three epitopes of 5T4 have been shown to be 
immunogenic in vitro through culturing and measuring responses by human T cells in the pres-
ence of synthetically produced peptide sequences, it is not guaranteed that these peptide epitopes 
are naturally processed through the MHC-II processing pathway and thus presented on profes-
sional antigen presenting cells. Nevertheless, in studies performed within our group, whole 5T4 
protein has been shown to be immunogenic in ex vivo IFNγ release ELISpot assays stimulating 
with whole protein (Clarke et al. 2006). Moreover, primary responses to these epitopes have 
been repeatedly observed in both healthy donors and CRC patients. In order to assay whether 
each epitope is naturally processed by APCs, full length 5T4 protein could be used in the T cell 
clone activation assays similar to those described with peptide.  
APCs process MHC-II peptide antigens usually by the uptake of exogenous protein via the 
endosomal or lysosomal pathway for protein digestion. To assay the abundance of the described 
5T4 epitopes as part of the presented 5T4 peptide ligandome, whole 5T4 protein could be ‘fed’ 
to APCs and the resulting ligandome studied. Using mass spectrometry of HLA-DR elution 
products, the relative abundancy of 5T4p12 presentation compared to other 5T4-derived pep-
tides, and the other peptides in the ligandome could be studied. Moreover, the nested set of 
peptides for the 5T4117-125 epitope within the 5T4p12 peptide could also be identified. 
Determination of the importance of the C-termainal hairpin loop region to TCR binding 
could be assayed through T cell clone activation assays of modified peptides using the GD.D104 
clone. Such modifications could include truncations to completely remove the N- and C-
terminal flanking regions and alanine scan mutations across the whole peptide to assay the 
contribution of each residue to TCR binding of the GD.D104 TCR including at the C-terminal 
flank. Such experiments would show whether the C-terminal carboxyl and Arg13, which are 
brought back to the facinity of the peptide binding core by the hairpin loop, contribute to binding 
through high-enthalpy interactions with a TCR. In addition, disruption of the C-terminal hairpin 
loop by mutation of the central Gly11 residue within the SGS sequence which enables flexibility 
in dihedral angles could be assayed by mutation to residues which block dihedral angle 
flexibility such as proline. 
Ultimately, the contribution of each residue to binding the GD.D104 TCR would be 
comprehensively revealed by the solving of the complexed structure between HLA-DR1 5T4-
p12 and the GD.D104 clone TCR. Such studies would require optimisation of the production of 
the GD.D104 TCR which did refold but at poor efficiency. In addition, due to the likely low 
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affinity between GD.D104 TCR and HLA-DR1-5T4p12, as indicated by multimer staining, 
acquisition of complex crystals may prove challenging. Nevertheless, complexed structures 
between TCRs and pMHC-II molecules have been solved despite an inability to detect binding 
by either SPR or multimer staining (Deng et al. 2007; Beringer et al. 2015). Such structural data 
would reveal the role in which the C-terminal flanking region plays in TCR binding. 
3.7.2 Implications of this study 
In the studies outlined in this chapter, analysis of the CD4+ T cell immune response to 5T4 
antigens has revealed the presence of 5T4-reactive T cell clones that are sensitive to antigen yet 
exhibit sub-optimal engagement of pMHC-II. In response to antigen, these T cell clones cultured 
from the peripheral blood of a healthy donor exhibit a strong TH1 functional phenotype and adds 
evidence to the surveillance of tumour antigens within the periphery through expression of 
TCRs which are able to bind self-derived antigens presented on MHC-II molecules. In efforts 
to describe this presentation of self-antigens to T cells through the solving of the HLA-DR1 
5T4p12 structure, a number of interesting observations were made regarding how HLA-DR1 is 
able to present a new peptide epitope. Firstly, this structure demonstrates that leucine can be an 
effective anchor for the P1 binding pocket of HLA-DR1. Secondly, this structure revealed that 
peptide flanking residues might contribute substantially to the binding of peptides to HLA-DR1 
and consequently suggests a preference for large charged amino acid residues at position P-3 in 
the N-terminal flanking region. Thirdly, elucidation of the HLA-DR1 5T4 structure provides a 
second model example of an MHC-II specific phenomena in peptide binding in that C-terminal 
flanking regions can form ordered hairpin loop structures that drastically alter the pMHC surface 
volume presented to the TCR repertoire. Finally, it was observed that the structure of the C-
terminal flanking hairpin loop resembled the folding of the 5T4p12 epitope in the native 5T4 
protein. This consequently challenges the dogma that peptides presented on MHC molecules are 
held in an extended conformation dictated by the MHC that are absent in secondary structural 
similarity to the native antigen.   
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4 Chapter 4: Molecular characterisation of the LAG-3-
MHC-II interaction  
4.1 Abstract 
Lymphocyte activation gene-3 (LAG-3) is expressed on a number of immune cells including 
activated CD4+ T cells and suppressive T cell subsets. On activated effector T cells, LAG-3 
functions as a co-inhibitory receptor and consequently limits T cell activation in response to 
antigen stimulus. Overexpression of LAG-3 on CD4+ T cells extracted from tumour sites has 
implicated LAG-3 in suppressing T cell immunity to tumours and consequently highlighted the 
molecule as a potential target for enhancement of anti-tumour immunity through the blockade 
or removal of LAG-3. The function of LAG-3, however, is poorly described. Here, the molecular 
role of LAG-3 is interrogated through the study of LAG-3 binding to its putative ligand, MHC-
II. Through cellular staining and flow cytometry, LAG-3 was shown to bind multimerised MHC-
II molecules. This interaction was characterised at the protein-protein level by surface plasmon 
resonance where the moderate affinity (KD = 13 µM) of MHC-II engagement by LAG-3 was 
defined. Moreover, preliminary efforts to describe LAG-3 structure via negative stain electron 
microscopy are documented with a future view to the study of LAG-3 and MHC-II using high-
resolution structural techniques. Together, these molecular studies show LAG-3 is able to bind 
MHC-II with moderate affinity providing insights into the mechanism by which LAG-3 initiates 
T cell inhibition. 
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4.2 Introduction 
Lymphocyte activation gene-3 (LAG-3) is a single pass transmembrane protein expressed on a 
number of immune cells including activated CD4+ and CD8+ αβ T cells, γδ T cells, B cells, NK 
cells and plasmacytoid dendritic cells. LAG-3 function is best described in activated CD4+ T 
cells where it has been show to inhibit T cell activation (Triebel 2003). LAG-3 expression by 
CD4+ T cells is upregulated after TCR mediated stimulation, is maximal at four days, and de-
tectable at seven days, post-activation in T cells extracted from murine spleen or lymph nodes 
challenged in vivo (Sega et al. 2014).  
Upon cell surface expression, LAG-3 is thought to localise to the immune synapse through 
an interaction with MHC-II molecules (Huard et al. 1996). Subsequently, suppression of T cell 
signalling mediated by LAG-3 has been shown to be dependent on the protein’s short cytoplas-
mic tail (Workman et al. 2002). Further suppressive function may also be enhanced through 
competition for MHC-II binding with the CD4 co-receptor (Huard et al. 1995).The signalling 
mechanisms that enable LAG-3 mediated suppression of T cell signalling have not been defined, 
however, involvement of a co-precipitated accessory protein termed LAG-3-associated protein 
may be implicated (Iouzalen et al. 2001).  
As well as a role in maintaining T cell homeostasis in the effector response against antigens, 
LAG-3 expression has also been implicated in maintaining the function of regulatory T cell 
subsets such as classical FoxP3+ regulatory T cells (Tregs) (Huang et al. 2004). In addition, tu-
mour infiltrating lymphocytes (TILs) extracted from human colorectal cancer patients exhibited 
an upregulation of LAG-3 expression compared to T cells extracted from matched PBMC and 
healthy colon and were not dependent on FoxP3 expression (Scurr et al. 2013). Moreover, LAG-
3 expression, in conjunction with CD49b, identifies a population of highly suppressive FoxP3- 
regulatory cells termed type 1 regulatory (Tr1) cells (Gagliani et al. 2013). Similarly, this Tr1 
subset of cells has also been implicated in tumour infiltration (Pedroza-Gonzalez et al. 2015). 
Together, these studies highlight LAG-3 as a marker of a sub-optimal immune response to 
tumours, either through involvement of suppression on activated effector responses or on regu-
latory populations. The basis of LAG-3 function on such cells is thought to be mediated by an 
interaction with MHC-II which consequently implicates LAG-3 with the immune synapse. 
4.2.1 Current understanding of LAG-3 binding to MHC-II 
LAG-3 was first hypothesised to bind to MHC-II molecules upon characterisation of human 
LAG3 as a gene upregulated upon activation of lymphocytes (Triebel et al. 1990). Such reason-
ing, in these early studies, was based on the similarity of LAG-3 with the already defined MHC-
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II ligand, CD4, at the gene level. Lag3 shared a neighbouring chromosomal locale with CD4 
(LAG-3: chromosome 12, p13.3; CD4 chromosome 12, pter-p12) as well as similar exon-intron 
organisation. Lag3 and CD4 genes exhibited regions of sequence homology which, importantly, 
translated to structural similarity at the gene level where both gene sequences encoded motifs 
characteristic of four Ig-like domain containing proteins. 
The first experimental evidence of a LAG-3 interaction with MHC-II was achieved through 
the characterisation of the Lag3 gene product at the protein level enabled through the generation 
of monoclonal antibodies against LAG-3 protein (Baixeras et al. 1992). Primate kidney derived 
fibroblast-like COS-7 cells expressing LAG-3 through transfection adhered to MHC-II suffi-
cient B lymphocytes. Such adhesion was observed as LAG-3+COS-7 “rosetting” with a range 
of MHC-II+ cell lines. This adhesion was abrogated through the incubation of either αHLA-DR 
(mAb clone D1.12), pan-HLA-class II (mAb clone 9.49) or an αLAG-3 (mAb clone 17B4) an-
tibody and thus indirectly indicated an interaction between LAG-3 and MHC-II proteins 
expressed on the surface of cells. Blockade of this surface interaction on cells was subsequently 
shown to have functional consequences on the activation of T cell clones (Huard et al. 1994). 
Specific cellular detection of LAG-3 binding to MHC-II was achieved through the expres-
sion of a soluble LAG-3 protein sample constructed through the fusion of a human IgG1 
fragment crystallisable (Fc) domain to the extracellular portion of LAG-3 (henceforth termed 
LAG-3:Fc). This protein molecule specifically stained HLA-DR4 transfected fibroblast cell 
lines as well as numerous HLA class II+ cell lines through secondary staining detected by flow 
cytometry (Huard et al. 1996). No such staining was observed in either non-transfected controls 
or HLA-class II- cell lines and were again abrogated by the addition of the 17B4 clone αLAG-3 
mAb whose epitope had been confirmed to the LAG-3 portion of the LAG-3:Fc protein. 
Extension of these fluorescent staining experiments, whereby titrating concentrations of 
LAG-3:Fc were used to stain HLA-class II+ cells, showed LAG-3:Fc bound to MHC-II express-
ing cells with far superior capacity to CD4:Fc equivalent molecules due to detection of binding 
down to 100-fold lower concentrations of LAG-3:Fc protein compared to CD4:Fc (Huard et al. 
1995). Using Scatchard plot analysis, the avidity of LAG-3:Fc – a dimeric form of LAG-3 – 
was deduced to a KD of 60 nM at 37 °C. Moreover, the binding of LAG-3:Fc to MHC-II blocked 
consequent interaction of CD4 with MHC-II, thus suggesting that LAG-3 and CD4 compete for 
the same binding site. Similar analyses using murine derived fusion proteins replicated the en-
hanced binding of LAG-3:Fc to MHC-II expressing cells compared to CD4:Fc (C. J. Workman 
et al. 2002). 
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Biochemical analysis of LAG-3:Fc binding enabled regional localisation of the MHC-II 
binding domain on LAG-3. Truncation of LAG-3 to the two extracellular domains (D1 & D2) 
of LAG-3 and consequent fusion to IgG1 Fc to form LAG-3D1D2:Fc localised the binding site 
of LAG-3 to the N-terminal IgSF domain (Huard et al. 1997). This binding site was resolved 
down to a 30 amino acid additional loop sequence within the membrane distal D1 domain using 
mutational analysis and consequent impact on LAG-3 mediated adhesion to MHC-II expressing 
cells. This extra loop was unique to LAG-3 compared to CD4 and as a result, it was reasoned 
that LAG-3 binding to MHC-II occurred at a higher affinity to that of CD4 binding to MHC-II 
through residues contained within the unique loop sequence. 
4.2.2 Evidence of LAG-3 multimerisation and implication on functional binding 
Evidence of oligomerisation of CD4 molecules at the cell surface drove reasoning that, due to 
similarities to the co-receptor, LAG-3 may form multimers at the cell surface which mediate an 
increased functional avidity for MHC-II as well as stabilise solvent exposed LAG-3 (Huard et 
al. 1997). Data to support such hypotheses was shown by the mutation of residues within the 
membrane distal D1 domain of LAG-3, outside the defined extra-loop binding site for MHC-II, 
which were able to remove LAG-3 functional binding to MHC-II. Here, three mutations R88A, 
D109E, and R115A in LAG-3 transfected into COS-7 cells rendered LAG-3 unable to bind 
MHC-II via adhesion assay and, when co-transfected with wild type LAG-3, was able to inhibit 
wild type binding to MHC-II. Thus, these mutations inhibited MHC-II binding with a dominant 
negative-like effect and thus suggested that dimerisation was required to facilitate MHC-II bind-
ing.  From this data, a proposed model whereby the D1 domain of LAG-3 contains a homotypic 
dimerization binding site (LAG-3 to LAG-3) as well as the ligand binding site (LAG-3 to MHC-
II) was suggested (summarised in Figure 4.1). 
Support for this described model was elucidated by the observation of LAG-3 post-transla-
tional cleavage products in murine systems. Here, a cleavage product of LAG-3 corresponding 
to the extracellular portion was shown to localise at the cell surface despite absence of the mem-
brane anchoring transmembrane and cytoplasmic domains (Li et al. 2004). This extracellular 
domain cleavage product was co-precipitated with full length LAG-3 via a homotypic interac-
tion with full length LAG-3 at the cell surface. Further evidence of oligomerisation mediated 
via the membrane distal D1 domain was achieved by the generation of D1 domain deficient 
LAG-3 constructs or LAG-3:CD4 chimeric constructs, whereby the D1 domain of LAG-3 was 
replaced with that of CD4. Such constructs once more revealed a dependency of wild type D1 
domain on observed oligomerisation. 
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Figure 4.1 – Model of LAG-3 binding to MHC-II and potential oligimerisation: 
Schematic overview of the hypothetic model of LAG-3 oligomerisation and MHC-II binding as 
proposed by Huard et al. 1997. LAG-3 was proposed to contain two binding sites: a homotypic 
(LAG-3-LAG-3) site and a heterotypic (LAG-3-MHC-II) binding site. Homotypic binding was 
proposed to be mediated by residues including R88, D109 & R115 whilst heterotypic binding 
was proposed to be mediated by residues including H56, R75 & R77 as shown by site-direct 
mutagenesis studies. Dimerisation through the D1 domain of LAG-3 was further evidenced by 
non-detection of a co-immunoprecipitating LAG-3 fusion product when the LAG-3 D1 domain 
was exchanged for the equivalent domain of CD4 (Li et al. 2004). TM = transmembrane domain 
, CT = cytoplasmic tail domain 
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Together, these indirect functional and biochemical assays provide evidence of dimeric forms 
of LAG-3 at the cell surface and therefore implicates the effect of multivalency in the function-
ality of LAG-3 binding to MHC-II molecules. 
4.2.3 Electron microscopy and surface plasmon resonance as tools to study LAG-3 struc-
ture-function 
The described avidity value of LAG-3:Fc for MHC-II (KD = 60 nM) is used in the literature to 
describe the potency of LAG-3 function on inhibition of T cell activation through a perceived 
high affinity interaction with MHC-II (Workman & Vignali 2003; Li et al. 2007; Gagliani et al. 
2013). Whilst the described analyses showed an ability of LAG-3:Fc molecules to exhibit en-
hanced binding compared to CD4:Fc molecules, these analyses do not take into account the 
potential contribution of avidity effects as a result of the dimerization of LAG-3 through the Fc 
portion of LAG-3:Fc. Moreover, differences in observed avidity between LAG-3:Fc and 
CD4:Fc molecules cannot be categorically attributed to differences in monovalent affinity be-
tween LAG-3 and CD4 for MHC-II. The ability of the dimeric fusion proteins to differentially 
bind multiple ligands may, for example, also be dependent on differences in steric hindrance or 
molecular flexibility between LAG-3:Fc and CD4:Fc molecules. Thus, in order to accurately 
describe the monovalent binding affinity of LAG-3 for MHC-II, molecular techniques which 
can account for the effects of bivalency are required. 
Despite growing interest in the function of LAG-3 on T cell homeostasis, its role within 
diseases including cancer and the therapeutic targeting of LAG-3 expressing cells, the current 
understanding of human LAG-3 structure-function and the nature of the interaction with MHC-
II has advanced little since the studies described. This stagnation is despite the evolution of 
structural and biophysical techniques for the study of protein structure and protein-protein in-
teractions. As a result, indirect fluorescence measurements of binding through analyses such as 
the Scatchard plot are considered outdated and superseded by methodologies that directly meas-
ure protein-protein interactions such as surface plasmon resonance (SPR). 
Whilst previous groups have endeavoured to prepare LAG-3 protein samples suitable for the 
study of LAG-3 structure at high resolution via x-ray crystallography, such efforts have not 
produced soluble protein able to be crystallised (F. Triebel, personal communications). As such, 
the only LAG-3 protein sample successfully produced in vitro documented in the literature is 
the dimeric LAG-3:Fc fusion protein, described previously, or variations thereof. The mamma-
lian expression system used to produce this fusion protein, which incorporates extensive post-
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translational glycosylation, has rendered the protein formulation averse to the formation of pro-
tein crystals. Nevertheless, study of the structure of LAG-3:Fc can be obtained using solution 
techniques such as single particle transmission electron microscopy (EM).  
The molecular size of LAG-3:Fc makes the protein sample amenable, but difficult, to study 
by negative stain EM. Using this technique, protein in solution is applied to a grid after which a 
high molecular weight stain, such as uranyl acetate, is applied to grids in order to create contrast 
around the low-molecular weight protein envelope (Rames et al. 2014). Prepared grids are con-
sequently analysed under a transmission electron microscope whereby single protein particles 
can by imaged. Collection of multiple EM frames is performed to achieve a dataset of particle 
“views”. These particle views are described by their orientation in Euclidian space3 and the 
parameters of which are termed the Euler angles4. Analysis of these particle views can be used 
to generate three-dimensional reconstructions of proteins through a series of image processing 
events (Tang et al. 2007). First, particle images are summated via 2D analyses to form a collec-
tion of image classes – termed class sums – whereby particle images are grouped according to 
similarity in “views” of the protein and thus increase the signal-to-noise ratio in particle images. 
Consequent 3D analysis determines the relationship between class sums and, as a result, assigns 
spatial 3D coordinates for classes. Subsequent rounds of model refinement through iterative 2D 
and 3D analyses yield reconstructions of proteins to resolutions typically capped at around 20 
Å. This resolution range is limited due to the lack of mass-contrast5 within the protein sample 
and, thus, structural information achieved through negative stain EM is mostly limited to that of 
the protein surface envelope (Boekema et al. 2009). Increasing the number of particle images, 
however, improves the accuracy and resolution of the obtained model and can reveal some sec-
ondary structure features (Zhang et al. 2008). 
As a result, negative stain electron microscopy provides a feasible technique to study the 
overall protein structure of LAG-3:Fc as a model of LAG-3 expressed at the cell surface. Whilst 
negative stain EM does not yield atomic resolution protein structure information, analysis of the 
                                                     
3 Euclidian space is the space that encompasses both the 2-dimensional plane and 3-dimensional space  
4 Euler angles are the angles that describe the orientation of an object in the 3-dimensional component 
of Euclidian space. This orientation is described by three angles: α, β, γ which represent the angle from 
the 3-dimensional planes x,y and z, respectively. 
5 Electrons passing through a sample will interact strongly with heavy atoms and weakly with light 
atoms. Proteins are generally made up of atoms of low mass, therefore interact weakly with electrons and 
are said to have low mass contrast. Proteins tend to exhibit a relatively even distribution of mass, thus, 
internal structural features – effectively differences in mass – are difficult to resolve. 
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overall shape and quaternary structure of LAG-3:Fc may aid understanding in the function of 
LAG-3 and it’s interaction with MHC-II. 
4.2.4 Aims 
At present there is currently no high- or low-resolution data that describes LAG-3 protein struc-
ture and despite evidence of LAG-3 binding to MHC-II, the structural and biophysical 
characteristics which determine such binding are poorly described. As a result, insights into the 
three-dimensional fold of LAG-3 are based on sequence based predictions from which LAG-3 
is thought to resemble the CD4 co-receptor. Whilst LAG-3 has been shown to bind specifically 
to MHC-II expressing cells in a series of studies, no direct detection of LAG-3 binding to MHC-
II has been shown at the protein-protein level. As a consequence, no direct measurement of the 
affinity of LAG-3 for MHC-II has been accurately defined using modern instrumentation and 
kinetic analysis. 
As a result, the overall aim of this chapter was to describe the nature of the LAG-3 interaction 
with MHC-II using biophysical techniques as well as structural investigations of LAG-3 with 
and without its putative ligand, MHC-II. This overall aim is divided into the following sub-aims: 
 
(i) To develop a stable LAG-3 expressing cell line as a model for LAG-3+ T cells 
(ii) To measure multimeric MHC-II binding to LAG-3+ cells using flow cytometry 
(iii) To measure LAG-3 binding to MHC-II at the protein-protein level using surface 
plasmon resonance (SPR) 
(iv) To try and establish an affinity value of monovalent LAG-3 binding to MHC-II 
(v) To gain insights into LAG-3 structure through the study of LAG-3:Fc via nega-
tive stain electron microscopy 
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4.3 Production of a stable LAG-3+ cell line 
In order to study the molecular interaction of LAG-3 and MHC-II on the surface of LAG-3 
expressing cells and facilitate the studies described in Chapter 5, a stably expressing LAG-3+ 
cell line was produced. The full length LAG-3 protein (Uniprot: P18627) was successfully 
cloned into the 3rd generation lentiviral transfer vector pELNsxv via restriction cloning (Dull et 
al. 1998). This construct, which contained LAG-3 and a P2A linked self-cleaving rat CD2 
(rCD2) marker cassette under the constitutive EF-1α promoter, allowed the tracking of trans-
duction through the rCD2 marker which is known to be detected and expressed well via 
lentiviral delivery in T cell lines. 
Wild type JRT T3.5 Jurkat cells (henceforth JRT) were successfully transduced with LAG-
3.P2A.rCD2 lentivirus, resulting in the detectable expression of both rCD2 and LAG-3 (Figure 
4.2). After transduction, 98 % of cells were rCD2 positive highlighting a high transduction effi-
ciency (data not shown). After 30 days of culture of the LAG-3.P2A.rCD2 transduced line, 79 
% and 78 % of cells were positive for rCD2 and LAG-3 expression, respectively, highlighting a 
gradual loss of construct expression (Figure 4.2a). In order to maintain a stable homogenous 
population of LAG-3 expressing cells and prevent untransduced cell outgrowth, the transduced 
line was subjected to limit dilution cloning to obtain JRT derived LAG-3+ clones (Figure 4.2b). 
This resulted in three clones: JRT LAG-3+ C8, D4 & E11. Each clone exhibited 100 % LAG-3 
expression as shown by no negative staining population whilst exhibiting similar LAG-3 ex-
pression (gMFI JRT LAG-3+ C8 = 435, D4 = 340, E11 = 372). Due to the enhanced expression 
of LAG-3, the JRT LAG-3+ C8 clone was selected for future studies. As a result, the LAG-3- 
JRT WT and JRT LAG-3+ C8 cells as well as the MOLT-3 cell line, which would later be used 
as a LAG-3- CD4+ control, were analysed for expression of TCR, LAG-3 and CD4 expression 
(Figure 4.3).  
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Figure 4.2 –Formation of the JRT LAG-3+ C8 cell line via lentiviral delivery: 
a) Flow cytometry histogram plots of rCD2 and LAG-3 expression in wild type (WT) JRT cells 
and transduced JRT line following lentiviral delivery (JRT + LAG-3 lenti). Lentiviral 
transduction resulted in fluorescence intensity shift in rCD2 expression (blue) compared to 
unstained control (grey) as well as shift in LAG-3 staining (pink) compared to unstained control 
(grey). Post-transduction, 79 % of the resultant line were positive for the rCD2 transduction 
marker and 78 % of cells LAG-3+.  
b) Flow cytometry histogram plots of LAG-3 expression in three consequent JRT LAG-3+ clones 
C8, D4 & E11 generated from the line described in a). Each clone expressed LAG-3 as shown 
by a shift in fluorescence intensity in LAG-3 stained (pink) compared to unstained control 
(grey). Inset numbers represent gMFI of LAG-3 staining. All three clones were 100 % LAG-3+ 
as shown by no negative population exhibited in the parent line. 
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Figure 4.3 – Surface characterisation of T cell derived cell lines: 
Flow cytometry histograms of TCR, LAG-3 and CD4 surface expression on LAG-3- JRT WT, 
JRT LAG-3+ C8 and MOLT-3 cells. LAG-3- JRT WT cells expressed no LAG-3 or CD4, JRT 
LAG-3+ C8 cells expressed LAG-3 but no CD4 and MOLT-3 cells expressed CD4 but no LAG-
3. Each cell line showed low expression of TCR, as expected. Stained marker = black, 
FMO/unstained control = grey. 
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4.4 MHC-II multimers bind to LAG-3+ cells 
Having generated a stably expressing LAG-3+ cell line as a model for T cells expressing LAG-
3, it was hypothesised that MHC-II multimers would bind LAG-3+ cells through a TCR inde-
pendent interaction with MHC-II. As such, LAG-3- JRT WT and JRT LAG-3+ C8 cells were 
stained using PE labelled HLA-DR1 dextramers using a protocol optimised for low affinity in-
teractions (Tungatt et al. 2015). Staining of JRT LAG-3+ C8 cells with HLA-DR1 Influenza 
HA306-318 multimers resulted in modest detection of LAG-3 replete cells compared to both FMO 
and HLA-A2 multimer controls, whilst LAG-3- JRT WT cells exhibited no staining (Figure 4.4). 
Staining of LAG-3 replete cells with HLA-DR1 multimers resulted in 19 % of cells exhibiting 
enhanced staining compared to background levels exhibited by -A2 multimers or either -DR or 
-A2 multimer staining of LAG-3 deplete cells (Figure 4.4a). Such detection resulted in a shift 
in fluorescence intensity in HLA-DR1 stained JRT LAG-3+ C8 cells only (Figure 4.4b). To en-
sure observed multimer staining did not arise due to multimer deposition on dead cells, 
experiments described were gated on live singlet cells by live/dead staining (Figure 4.4c). De-
spite the observed staining of JRT LAG-3+ C8 cells by HLA-DR1 multimers only, such staining 
was poor compared to staining of the HLA-DR1 Influenza HA306-318-specific cognate T cell 
clone (DCD10) where 98 % of cells are detected as multimer+ (Figure 4.4d). This was in spite 
of JRT LAG-3+ C8 exhibiting no LAG-3 negative population, described previously.  
In order to confirm that the observed staining of LAG-3+ cells by HLA-DR1 multimers was 
indeed mediated by LAG-3, the effect of the LAG-3 blocking antibody clone 17B4 on HLA-
DR1 multimer staining was assayed. Indeed, pre-incubation of JRT LAG-3+ C8 cells before 
multimer staining abrogated the shift in fluorescence intensity observed when staining with 
HLA-DR1 multimers (Figure 4.4e). To confirm antibody blockade had no effect on either HLA-
A2 multimers staining of LAG-3 replete cells or -DR or -A2 multimer staining of LAG-3 deplete 
cells, corresponding blockade experiments were also performed on such controls and resulted 
in no significant impact on background staining (Figure 4.4f). Moreover, an irrelevant antibody 
(αCD4) was not able to abrogate the binding of HLA-DR1 multimers to JRT LAG-3+ C8 cells 
(Figure 4.4g). 
Since CD4 also binds to MHC-II molecules, albeit via a notoriously weak interaction 
(Jönsson et al. 2016), it was reasoned that a similar staining of CD4+ cells by MHC-II multimers 
may be observed. The CD4+ LAG-3- MOLT-3 cell line, however, showed no significant detection 
of multimer+ cells using HLA-DR1 multimers compared to -A2 multimers (Figure 4.5a). As a 
result, no shift in fluorescence intensity was observed between either FMO control of HLA-A2 
multimer staining (Figure 4.5b&c). 
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Together, these data show that LAG-3 expressing cells are able to be modestly stained by 
MHC-II multimers characterised by a small shift in fluorescence intensity through an interaction 
mediated through LAG-3. Such staining was not comparable to that of a viral-derived MHC-II 
restricted cognate TCR interaction and was not observed in a LAG-3 deplete but CD4 replete 
cell line.  
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(Figure legend overleaf)  
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Figure 4.4 – Specific binding of HLA-DR1 multimers to LAG-3+ cells: 
a) 2D flow cytometry plots of MHC-multimer staining of LAG-3- JRT WT cells (left) and JRT 
LAG-3+ C8 cells (right) with HLA-A2 multimers (grey) or HLA-DR1 multimers (black). Cells 
were multimer+ above background in JRT LAG-3+ C8 cells stained with HLA-DR1 multimers 
only. Inset numbers = percentage multimer+, colour coded as described. 
b) Flow cytometry histograms of MHC-multimer staining as in a) highlighting no increase in 
fluorescence intensity staining above FMO in LAG-3- JRT WT cells stained with HLA-A2 or -
DR1 multimers. Increase in fluorescence intensity above FMO was observed in JRT LAG-3+ C8 
cells stained with HLA-DR1 but not -A2 multimers. Colours as described previously. 
c) Example gating strategy of lymphocyte gate and live PB-A- cells used in a) and b). Example 
shown is JRT LAG-3+ C8 cells stained with HLA-DR1 multimers. 
d) 2D flow cytometry plot of cognate CD4+ T cell clone (DCD10) staining with HLA-DR1 
multimers used in experiments described. Peptide specific staining of T cell clone exhibited 
significantly enhanced staining compared to peptide non-specific staining of LAG-3+ cells. 
e) Flow cytometry histograms of MHC-multimer staining of LAG-3- JRT WT cells (left) and 
JRT LAG-3+ C8 cells (right) stained with HLA-DR1 multimers pre-blocked with unconjugated 
anti-LAG-3 mAb clone 17B4 (orange; dashed) or media control (black). HLA-DR1 specific 
shift in fluorescence intensity is removed to background -A2 levels (grey) by 17B4 blockade. 
f) FMO subtracted quantification of gMFI in experiments described in e). 17B4 blockade 
influenced HLA-DR1 multimer staining of JRT LAG-3+ C8 cells only as shown by decrease in 
gMFI compared to media only control. Blockade with 17B4 had no influence on the negative 
staining of LAG-3- JRT WT cells or JRT LAG-3+ C8 cells with -A2 multimers.  
g) Quantification of HLA-DR1 binding to JRT LAG-3+ C8 cells pre-incubated with control 
(media), irrelevant mAb (irrel) or anti-LAG-3 mAb (17B4). Percentage binding normalised to 
background subtracted gMFI observed for control blockade of -DR1 binding. 
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Figure 4.5 – No observed binding of HLA-DR1 multimers to LAG-3-  CD4+ cells: 
a) 2D flow cytometry plots of MHC-multimer staining of LAG-3- CD4+  MOLT-3 cells with 
HLA-A2 multimers (grey) or HLA-DR1 multimers (black). Multimer+ cells were equivalent 
with both HLA-DR1 and -A2 multimers. Inset numbers = percentage multimer+, colour coded 
as described. 
b) Flow cytometry histograms of MHC-multimer staining as in a) highlighting no increase in 
fluorescence intensity staining above FMO in cells stained with HLA-A2 or -DR1 multimers. 
Colours as described previously. 
c) FMO subtracted quantification of gMFI in experiments described in b). Staining of LAG-3- 
CD4+  MOLT-3 cells with either HLA-A2 or -DR1 multimers exhibited no increase in gMFI 
compared to FMO. 
 
 
 
  
- 154 - 
 
4.5 LAG-3 binds HLA-DR1 via a moderate affinity interaction 
4.5.1 LAG-3:Fc as a model protein of LAG-3 function 
Study of the molecular function of LAG-3 has been hampered by the difficulties in producing 
LAG-3 protein samples to facilitate the study of LAG-3 at the biophysical level. Initially, efforts 
were concentrated on producing recombinant LAG-3 protein via production of the extracellular 
domain of LAG-3 in monomeric form by both E. coli and sf9 insect cells. Production of such 
protein was detectable in sf9 cells, however, production yield was not efficient enough to gen-
erate sufficient protein mass for biophysical and structural studies in the given time frame (data 
not shown).  
Through a collaboration with Professor Frédéric Triebel (Prima BioMed, Sydney, Australia), 
LAG-3 protein was instead obtained in the form of a LAG-3:Fc fusion protein (Huard et al. 
1995). This construct of LAG-3 utilised the fusion of the extracellular domain of LAG-3 to a 
human IgG1 Fc domain in order to form a functionally viable and stable protein dimer. This 
dimer of LAG-3 has been used extensively to describe LAG-3 function, as previously described, 
and as a therapeutic agent (Brignone et al. 2007). The LAG-3 protein was obtained was GMP-
grade protein expressed in glycosylation-sufficient Chinese hamster ovary (CHO) cells. 
4.5.2 LAG-3 binds HLA-DR1 independent of peptide and expression system 
In order to directly determine at the protein level whether LAG-3 binds to MHC-II molecules, 
LAG-3 binding to HLA-DR1 was assayed by surface plasmon resonance (SPR). Such experi-
ments were designed to analyse LAG-3:Fc as analyte and MHC molecules as ligands 
immobilised to SPR sensor chips (Figure 4.6a). 
To first confirm that LAG-3:Fc did not bind to an MHC-I molecule, LAG-3:Fc was assayed 
as analyte for binding to HLA-A2 complexed with the hTERT540-548 peptide. Indeed, LAG-3:Fc 
exhibited no interaction with HLA-A2 as shown by no observed binding in blank flow cell ref-
erence subtracted sensograms (Figure 4.6b). No binding was observed to HLA-A2 using 
concentrations of LAG-3 analyte up to 57 µM. As a result, all future experiments were per-
formed using reference subtraction from HLA-A2 immobilised flow cells.  
In contrast, LAG-3:Fc bound specifically to HLA-DR1 complexed with the HA309-318 peptide 
as shown by HLA-A2 reference subtracted sensograms (Figure 4.6c). Such binding was con-
centration dependent where binding was detectable down to the lowest tested concentration of 
analyte (0.11 µM). Binding to HLA-DR1 molecules was not altered by the peptide presented  
 
- 155 - 
 
Figure 4.6 –Binding of LAG-3:Fc to HLA-DR1 observed via SPR: 
a) Cartoon schematic describing formulation of SPR experiments performed using LAG-3:Fc 
as analyte injected over MHC immobilised sensor chips. Biotinylated MHC molecules were 
immobilised via coupling of streptavidin to sensor chips. FC = Flow cell. 
b) SPR analysis of LAG-3:Fc injection over immobilised HLA-A2 complexed with the 
hTERT540-548 peptide. Sensograms reference subtracted from a blank no-ligand control flow cell 
(FC3-FC1 as shown in a)) exhibited no binding across a titrating range of LAG-3:Fc 
concentrations (57 µM to 0.11 µM). 
c) SPR analysis showing concentration-dependent binding of LAG-3:Fc to HLA-DR1 produced 
from E. coli by in vitro refolding in the presence of the HA306-318 peptide. Binding was observed 
in HLA-A2 reference subtracted sensograms (FC2-FC3 as shown in a)) and was detectable at 
all concentrations throughout a dilution series of 57 µM to 0.11 µM. 
d) SPR analysis as described in c) showing concentration-dependent binding of LAG-3:Fc to 
HLA-DR1 produced in S.frugiperda (sf9) insect cells expressed with covalently linked CLIP. 
Binding was observed at all concentrations in HLA-A2 reference subtracted sensograms. 
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within the HLA-DR1 binding pocket as well as independent of HLA-DR1 expression system, 
as shown by equal binding to HLA-DR1 produced via a covalently-linked CLIP construct in sf9 
insect cells (Figure 4.6d). Broad observation of the kinetics of LAG-3:Fc binding to HLA-DR1 
were fast in nature – characterised by fast on-rate and fast off-rate. 
4.5.3 LAG-3:Fc binds immobilised HLA-DR1 with weak bivalency 
To determine the monovalent affinity between LAG-3 and MHC-II, the mode of valency exhib-
ited by the dimeric LAG-3:Fc fusion protein was first required to be determined. To this end, 
various simultaneous kon/koff modelling curves were applied to observed binding sensograms at 
concentrations of 0.1 – 7 µM of LAG-3:Fc and compared for visual goodness-of-fit as well as 
analysis of χ2 and residual plot parameters (Figure 4.7). An overview of the candidate binding 
models tested is described in Table 4.1. 
No model demonstrated perfect matching to observed data across multiple concentrations, 
however, kinetic data was best described by the bivalent analyte model of binding by satisfying 
multiple analysed analyte concentration sensograms (Figure 4.7a). Bivalent analytes, however, 
can exhibit altered kinetics at different analyte concentrations making fitting global parameters 
that satisfy multiple LAG-3:Fc injection concentrations difficult. Analysis of kinetic fitting to a 
single intermediate concentration of analyte (local fitting) resulted in a similar good fit and com-
parable kinetic parameters to those observed in global fitting (Figure 4.7b). Thus, LAG-3:Fc 
binding was best described by bivalent binding to immobilised HLA-DR1.  
This model can be rationally applied to the bivalent system being studied whereby two mol-
ecules (A & B) bind to form a complex (AB) which undergoes a second binding event with a 
second molecule of B forming a heterotrimeric complex (ABB):  
 
𝐴        +       2 𝐵        
𝑘𝑜𝑛1
𝑘𝑜𝑓𝑓1
         𝐴𝐵 + 𝐵       
𝑘𝑜𝑛2
𝑘𝑜𝑓𝑓2
         𝐴𝐵𝐵 
(Eq. 4.1) 
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Table 4.1 – Candidate binding models to describe LAG-3:Fc binding to HLA-DR1 
 
  
 Binding Model 
Kinetic  
Parameters 
Rate equations 
1:1 
Langmuir 
A + B          AB 
kon 
koff 
 
𝑑𝐴𝐵
𝑑𝑡
= 𝑘𝑜𝑛[𝐴][𝐵] − 𝑘𝑜𝑓𝑓[𝐴𝐵] 
 
Bivalent 
analyte 
A + B        AB + B        ABB 
kon1 
koff1 
kon2 
koff2 
 
𝑑𝐴𝐵
𝑑𝑡
= ((2 ∙ 𝑘𝑜𝑛1)[𝐴][𝐵] − 𝑘𝑜𝑓𝑓1[𝐴𝐵]) − 
          (𝑘𝑜𝑛2[𝐴𝐵][𝐵] − (2 ∙ 𝑜𝑓𝑓2)[𝐴𝐵𝐵]) 
 
𝑑𝐴𝐵𝐵
𝑑𝑡
= (𝑘𝑜𝑛2[𝐴𝐵][𝐵] − (2 ∙ 𝑘𝑜𝑓𝑓2)[𝐴𝐵𝐵]) 
Two-state 
reaction 
A + B           AB           ABx 
kon1 
koff1 
kon2 
koff2 
 
𝑑𝐴𝐵
𝑑𝑡
= (𝑘𝑜𝑛1[𝐴][𝐵] − 𝑘𝑜𝑓𝑓1[𝐴𝐵]) − 
          (𝑘𝑜𝑛2[𝐴𝐵] − 𝑘𝑜𝑓𝑓2[𝐴𝐵𝑥]) 
 
𝑑𝐴𝐵𝑥
𝑑𝑡
= 𝑘𝑜𝑛2[𝐴𝐵] − 𝑘𝑜𝑓𝑓2[𝐴𝐵𝑥] 
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Figure 4.7 – LAG-3:Fc binding to HLA-DR1 exhibits bivalent analyte kinetics: 
a) Global fit analysis of reference subtracted sensograms of LAG-3:Fc (0.1 – 7 µM) binding to 
immobilised (525 RU) HLA-DR1 fitted with three candidate models: 1:1 Langmuir binding, 
bivalent analyte and two-state reaction. Global fitting analysis highlight a good overall fit with 
the bivalent analyte model. Observed sensograms are shown as grey solid lines, fitted curves as 
black dashed lines with inset χ2 value and kinetic derived dissociation affinity constant KD1 
calculated as in Eq 4.6 according to bivalent analyte binding. Corresponding curve fit residual 
plots are shown below each fit. 
b) Local fit analysis of the reference subtracted sensogram describing LAG-3:Fc binding at 7 
µM to immobilised HLA-DR1 as described in a). Local fitting analysis highlighted a good 
overall fit with the bivalent analyte model and similar KD1 value to global analysis. 
χ2 = ∑
(𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑−𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑)2
𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑
; lower χ2 values indicate better model fitting. 
- 159 - 
 
In the bivalent analyte model, there are four kinetic parameters (kon1, koff1, kon2 and koff2) which 
describe the rates at which the two complex states (AB and ABB) of the reaction model form. 
These rate constants are described by the following rate equations: 
𝑑𝐴𝐵
𝑑𝑡
= ((2 ∙ 𝑘𝑜𝑛1)[𝐴][𝐵] − 𝑘𝑜𝑓𝑓1[𝐴𝐵]) − (𝑘𝑜𝑛2[𝐴𝐵][𝐵] − (2 ∙ 𝑘𝑜𝑓𝑓2)[𝐴𝐵𝐵]) 
(Eq. 4.2) 
𝑑𝐴𝐵𝐵
𝑑𝑡
= (𝑘𝑜𝑛2[𝐴𝐵][𝐵] − (2 ∙ 𝑘𝑜𝑓𝑓2)[𝐴𝐵𝐵]) 
(Eq. 4.3) 
Application of this bivalent analyte model to the system being studied is visualised by the 
following schematic whereby Eq 4.1 has been modified to include terms of the LAG:Fc to HLA-
DR1 system being studied:  
 
 
(Eq. 4.4) 
NB. Schematic drawings of binding are for illustrative purposes only and no inference of binding 
sites on LAG-3:Fc or HLA-DR1 should be made. 
 
Whilst LAG-3:Fc binding was best described by the bivalent analyte model, it was observed 
that dissociation of LAG-3:Fc unexpectedly occurred with fast kinetics; within the timescale of 
seconds. Such fast kinetics are atypical of dimeric molecules binding with bivalency – as 
demonstrated by contrasting binding of antibody-antigen interactions in Chapter 5. To therefore 
determine the contribution of the rates of 𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1 (AB) formation and 
𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1: 𝐷𝑅1 (ABB) formation to overall observed kinetics, the kinetic parameters of 
bivalent binding (kon1, koff1, kon2 and koff2) were calculated from kinetic fits as shown in Figure 
4.6 and are reported in Table 4.2.  
 
 
𝐿𝐴𝐺3𝐹𝑐 + 2 𝐷𝑅1   
𝑘𝑜𝑛1
⇄
𝑘𝑜𝑓𝑓1
   𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1 + 𝐷𝑅1   
𝑘𝑜𝑛2
⇄
𝑘𝑜𝑓𝑓2
   𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1: 𝐷𝑅1 
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Table 4.2 – Bivalent analyte model parameters of LAG-3:Fc binding to HLA-DR1 
[Analyte] = Concentration of injected LAG-3:Fc analyte, RU = Response units,  
Rmax = Maximum analyte binding capacity in RU, RI = Bulk refractive index effect in RU,  
χ2 = ∑
(𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑−𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑)2
𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑
; lower χ2 values indicate better model fitting. 
KD1= the affinity equilibrium association constant calculated as described by Eq. 4.6 
KD2 = the affinity equilibrium dissociation constant calculated as described by Eq. 4.8 
   
Fit [Analyte] (µM) Rmax (RU) RI (RU) χ2  kon1 (1/Ms) koff1 (1/RU) kon2 (1/s) koff2 (1/s)  KD1 (M) KD2 (M)  KD1 (µM) 
Local 7.1 1190 6.6 39.6  7.24 x104 0.439 9.70 x10-6 4.30 x10-3  6.06 x10-6 4.43 x102  6.06 
Global 0.1 – 7.1 962 4.6 – 16.9 27.6  5.22 x104 0.380 6.00 x10-6 4.10 x10-3  7.28 x10-6 6.83 x102  7.28 
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These kinetic parameters can consequently be used to deconvolute kinetic derived dissocia-
tion affinity constant measurements which determine both stages of LAG-3:Fc binding. 
Specifically, the affinity constant KD1, which defines the monovalent component of the interac-
tion, and the affinity constant KD2, which defines the bivalent component, can be calculated.  
Firstly, the monovalent affinity constant KD1 describes the formation of 𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1 as 
follows: 
 
(Eq. 4.5) 
As a result, the affinity constant (KD1) can be calculated from defined kinetic rate constants 
described in Table 4.2 as follows: 
𝐾𝐷1 = 
𝑘𝑜𝑓𝑓1
𝑘𝑜𝑛1
 
(Eq. 4.6) 
Similarly, the equilibrium dissociation constant KD2, which defines the bivalent component 
of observed kinetics due to the formation of the heterotrimeric 𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1: 𝐷𝑅1 is as follows:  
 
 
 
 
 
(Eq. 4.7) 
As a result, the affinity constant (KD2) can be calculated from defined kinetic rate constants 
described in Table 4.2 as follows: 
𝐾𝐷2 = 
𝑘𝑜𝑓𝑓2
𝑘𝑜𝑛2
 
(Eq. 4.8) 
𝐿𝐴𝐺3𝐹𝑐 + 2 𝐷𝑅1   
𝐾𝐷1
↔    𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1 + 𝐷𝑅1   
𝐾𝐷2
↔    𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1: 𝐷𝑅1 
𝐿𝐴𝐺3𝐹𝑐 + 2 𝐷𝑅1   
𝐾𝐷1
↔    𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1 + 𝐷𝑅1   
𝐾𝐷2
↔    𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1: 𝐷𝑅1 
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Analysis of the kinetic derived equilibrium dissociation constants suggested that the contri-
bution of bivalent effects to observed LAG-3:Fc binding in these experiments was minimal as 
signified by a calculated KD2 in excess of molar concentration (Table 4.2). Thus, in order to 
achieve occupancy of the heterotrimeric complex 𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1: 𝐷𝑅1 high concentrations of 
the preceding 𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1 complex was required. As a result, the observed kinetics are dom-
inated by 1:1 binding with minimal contribution of bivalency. These data suggest that, in these 
SPR experiments, LAG-3:Fc bound poorly to multiple MHC-II molecules. 
Similarly, deconvolution of the kinetic derived equilibrium dissociation constant KD1 which 
describes the monovalent interaction between 𝐿𝐴𝐺3𝐹𝑐 and 𝐷𝑅1 and therefore represents an 
estimated affinity of LAG-3 for HLA-DR1 at 6.1 or 7.3 µM using local and global fitting, re-
spectively (Table 4.2 & Figure 4.7). Kinetic fitting of binding systems exhibiting fast kinetics, 
however, can lead to inaccuracies in calculated affinity and therefore further analysis is required. 
Moreover, affinity values calculated from kinetic analysis can be skewed by mass transfer ef-
fects – particularly at high ligand concentrations6. 
4.5.4 LAG-3 binds HLA-DR1 with micromolar KD affinity 
Having shown that LAG-3:Fc bound MHC-II via a bivalent interaction estimated in the mi-
cromolar range, further SPR experiments were performed to elucidate an accurate affinity for 
monovalent LAG-3 binding to HLA-DR1. This was achieved using steady state analysis where 
kinetic affinity is calculated from the response observed during the steady state phase of associ-
ation which is manifested in sensograms as a plateau during injections. This type of analysis is 
preferable over kinetic analysis when fast kinetics allow binding to establish steady state within 
short injection times. This was the case for LAG-3:Fc binding to HLA-DR1 system studied here, 
whereby steady state at multiple injection concentrations was reached by 20 seconds of analyte 
injection as can be seen in Figure 4.7. Calculation of a more accurate affinity by steady state 
analysis comes at a trade-off as through this analysis, no kinetic parameters (on- and off-rates) 
are obtained.   
In order to deduce a monovalent affinity for LAG-3 binding to HLA-DR1, steady state ex-
periments must be formulated such that the observed binding is either monovalent or dominated 
by monovalent binding. This is achievable for dimeric molecules such as LAG-3:Fc which, as 
                                                     
6 Mass transfer effects can manifest as artefacts in SPR experiments whereby at high ligand densities 
observed affinity increases as dissociating analytes do not diffuse away from the ligand surface back to 
the bulk flow path of the flow cell. This causes faster rebinding of analyte. Such experiments are said to 
be mass transport limited as opposed to kinetic limited. 
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evidenced by kinetic analysis described previously, is able to bind with a weak capacity for 
bivalency. In order to observe binding dominated by a monovalent interaction, removal of biva-
lent binding can be achieved by lowering the density of ligand on the chip surface. This lower 
ligand density increases the spatial distance between ligand molecules on the chip surface and, 
as a result, reduces the availability of a second ligand species to engage with bivalently. The 
presence of bivalency can therefore also be confirmed by the increase in ligand density, thus, 
increasing bivalent binding character and consequent increase in observed affinity/avidity. A 
schematic overview of the effect of ligand density on observed affinity/avidity is presented in 
Figure 4.8. 
To this end, different concentrations of HLA-DR1 was immobilised to flow cells of the same 
sensor chip such that the effect of LAG-3:Fc analyte binding to low, intermediate and high lig-
and densities could be studied (Figure 4.9). Here, increase in ligand density prolonged binding 
kinetics by lengthening the observed off-rate of LAG-3:Fc (Figure 4.9a). In agreement with 
described kinetic modelling of LAG-3:Fc binding, this lengthening of off-rate was likely con-
tributable to bivalent binding of LAG-3:Fc at higher ligand densities. Similarly to previous 
kinetic analysis, at the highest ligand density tested, LAG-3:Fc did not exhibit antibody-like off-
rate once more suggesting that LAG-3:Fc does not efficiently engage with multiple HLA-DR1 
molecules. 
In contrast to higher ligand densities, sensograms at low ligand concentration displayed fast 
kinetics and no extension of dissociation. As a result, LAG-3:Fc binding at low ligand density 
exhibited sensograms characteristic of kinetics predominated by one-to-one monovalent binding 
behaviour. Indeed, low ligand density sensograms did not adhere to bivalent kinetic model fit-
ting (data not shown). As SPR data at low ligand density exhibited monovalent characteristic 
binding, in order to determine an accurate monovalent LAG-3 to HLA-DR1 monovalent affinity, 
sensograms were analysed under the assumption of the Langmuir 1:1 binding model for bimo-
lecular interactions:  
𝐴        +        𝐵        
𝑘𝑜𝑛
↔
𝑘𝑜𝑓𝑓
         𝐴𝐵    
(Eq. 4.9) 
 
- 164 - 
 
 
 
Figure 4.8 – Effects of ligand density on observed LAG-3:Fc bivalency: 
Schematic overview of the effects of increasing concentration of ligand on the observed binding 
of LAG-3:Fc in SPR experiments. At low ligand density (top) spatial distance between HLA-
DR1 ligand molecules (green/blue) is increased and thus LAG-3:Fc (red:grey) is unable to 
sterically bind multiple HLA-DR1 ligand molecules. The observed binding is therefore 
dominated by monovalent kinetics and thus affinity measurements are made. At high ligand 
density (bottom) spatial distance between HLA-DR1 ligand molecules is decreased and thus 
LAG-3:Fc is able to bind multiple HLA-DR1 ligand molecules. The observed binding is 
therefore dominated by bivalent kinetics and thus avidity measurements are made. Increase in 
bivalent binding character causes a decrease in observed KD i.e. increase in affinity/avidity. 
Arrow direction represent increase from low→high. 
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In the Langmuir 1:1 binding model, there is a single complex species (AB) whose formation 
is described by the following single rate equation: 
𝑑𝐴𝐵
𝑑𝑡
= 𝑘𝑜𝑛[𝐴][𝐵] − 𝑘𝑜𝑓𝑓[𝐴𝐵] 
(Eq. 4.10) 
Application of this monovalent analyte model to the system being studied, whereby at low 
ligand density engagement of a second ligand molecule by LAG-3:Fc is not achievable due to 
spatial separation of ligand, is visualised by the following schematic. Here, Eq 4.9 has been 
modified to include terms of the LAG:Fc to HLA-DR1 system being studied: 
𝐿𝐴𝐺3𝐹𝑐 + 𝐷𝑅1     
𝑘𝑜𝑛
↔
𝑘𝑜𝑓𝑓
    𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1  
 
(Eq. 4.11) 
As a result, a steady state derived affinity can be calculated from sensograms collected at 
low ligand density. At steady state, the equilibrium binding constant (KD) can be calculated from 
the molecular ratio of unbound to bound components of the system. This is possible because at 
steady state the rate of formation of the complex (𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1 ) is equal to zero: 
𝑑𝐿𝐴𝐺3𝐹𝑐:𝐷𝑅1
𝑑𝑡
= 𝑘𝑜𝑛[𝐿𝐴𝐺3𝐹𝑐][𝐷𝑅1] − 𝑘𝑜𝑓𝑓[𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1] = 0 
(Eq. 4.12) 
𝑘𝑜𝑛[𝐿𝐴𝐺3𝐹𝑐][𝐷𝑅1] = 𝑘𝑜𝑓𝑓[𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1] 
 (Eq. 4.13) 
 
𝑘𝑜𝑓𝑓
𝑘𝑜𝑛
=
[𝐿𝐴𝐺3𝐹𝑐][𝐷𝑅1]
[𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1]
  
(Eq. 4.14) 
As the affinity constant (KD) is equivalent to  
𝑘𝑜𝑓𝑓
𝑘𝑜𝑛
: 
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𝐾𝐷 =
[𝐿𝐴𝐺3𝐹𝑐][𝐷𝑅1]
[𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1]
  
(Eq. 4.15) 
As such, KD can be calculated from plotted steady state response unit values (RU) at a series 
of concentrations. The relationship between which is fitted with a non-linear regression least 
squares ordinary fit in accordance with the Michaelis-Menten model formulated for protein-
protein interactions: 
𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1 =  
[𝐿𝐴𝐺3𝐹𝑐] ∙  𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1𝑚𝑎𝑥
𝐾𝐷 + [𝐿𝐴𝐺3𝐹𝑐]
 
(Eq. 4.16) 
In SPR experiments, observed response unit values, 𝑅𝑈, are an observed measure of 
L𝐴𝐺3𝐹𝑐: 𝐷𝑅1 complex formation, thus: 
𝑅𝑈 =  
[𝐿𝐴𝐺3𝐹𝑐] ∙  𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1𝑚𝑎𝑥
𝐾𝐷 + [𝐿𝐴𝐺3𝐹𝑐]
 
(Eq. 4.17) 
As 𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1𝑚𝑎𝑥 is the maximal complex formation when the system is saturated and 
𝑅𝑈 is an observed measure of 𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1 complex formation, 𝐿𝐴𝐺3𝐹𝑐: 𝐷𝑅1𝑚𝑎𝑥 is calcu-
lated as the maximal observed 𝑅𝑈 during saturated binding, termed 𝑅𝑚𝑎𝑥. This is achievable 
experimentally providing high concentrations of analyte are used in order to either saturate 
available ligand molecules or such that the saturation point can be accurately calculated during 
model fitting. As a result: 
𝑅𝑈 =  
[𝐿𝐴𝐺3𝐹𝑐] ∙  𝑅𝑚𝑎𝑥
𝐾𝐷 + [𝐿𝐴𝐺3𝐹𝑐]
 
(Eq. 4.18) 
In order to determine 𝐾𝐷 in terms of [𝐿𝐴𝐺3𝐹𝑐] the equation is reduced to the following, 
when 𝐾𝐷 =  [𝐿𝐴𝐺3𝐹𝑐]: 
𝑅𝑈 =  
[𝐿𝐴𝐺3𝐹𝑐] ∙  𝑅𝑚𝑎𝑥
[𝐿𝐴𝐺3𝐹𝑐] + [𝐿𝐴𝐺3𝐹𝑐]
 
(Eq. 4.19) 
𝑅𝑈 =  
[𝐿𝐴𝐺3𝐹𝑐] ∙  𝑅𝑚𝑎𝑥
2[𝐿𝐴𝐺3𝐹𝑐]
 
(Eq. 4.20) 
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𝑅𝑈 =  
𝑅𝑚𝑎𝑥
2
 
(Eq. 4.21) 
Therefore, the 𝐾𝐷 of the interaction between LAG-3:Fc and HLA-DR1 was calculated as the 
concentration of LAG-3:Fc at which 𝑅𝑈 is equal to half of 𝑅𝑚𝑎𝑥 i.e. (
𝑅𝑚𝑎𝑥
2
).  
Using this described steady-state analysis, the monovalent affinity of LAG-3 binding to 
HLA-DR1 is calculated at 13.1 µM (Figure 4.9b). Moreover, application of one-to-one equilib-
rium analysis to intermediate and high ligand densities resulted in a modest decrease in  
𝑅𝑚𝑎𝑥
2
, 
thus, further evidencing LAG-3:Fc binding via weak bivalency in experiments designed to allow 
bivalent binding.  
Since the lowest ligand density tested may still contain mixed kinetics with contribution of 
bivalent binding, the calculated monovalent KD value under the assumption of one-to-one bind-
ing may over-calculate the monovalent affinity. In order to therefore further validate the 
assumption of one-to-one binding, SPR data at intermediate density was analysed by kinetic 
analysis. Global and local fitting of the bivalent analyte model analysed as described in Eq. 4.1 
– 4.7 revealed an equilibrium dissociation constant (KD1) for the monovalent affinity for LAG-
3 to HLA-DR1 within a similar range as shown by equilibrium binding analysis (Figure 4.9c). 
This similar kinetic rate derived affinity constant validates the assumption that low ligand den-
sity steady-state analysis was predominated by monovalent binding character and thus, 1:1 
Langmuir binding kinetics can be applied. Together, these data therefore define the affinity of 
LAG-3 for HLA-DR1 to be 13 µM at 25 °C and consequently in the range of high affinity MHC-
II restricted TCR binding to MHC-II. 
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(Figure legend overleaf)  
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Figure 4.9 – LAG-3 binds HLA-DR1 with micromolar affinity: 
a) SPR analysis of LAG-3:Fc binding to HLA-DR1 immobilised at low (244 RU), intermediate 
(792 RU) and high (3659 RU) ligand concentrations. Titrating concentrations of LAG-3:Fc (57 
– 0.1 µM) bound HLA-DR1 with prolonged kinetics to higher ligand concentrations as shown 
by reference subtracted sensograms. Binding of LAG-3:Fc to low ligand density HLA-DR1 
exhibited kinetics characteristic of one-to-one binding kinetics. 
b) Steady-state analysis of LAG-3:Fc binding to HLA-DR1 at varying ligand concentrations 
analysed from sensograms as described in a) by plotting RU increase from baseline during 
steady-state (25 seconds into injections) against concentration of LAG-3:Fc. Under the 
assumption of one-to-one binding, LAG-3 monovalent affinity (KD) was defined (inset on low 
ligand density only) for low ligand density only (top) at 13 µM. Saturation of HLA-DR1 binding 
was observed at lower concentrations of LAG-3:Fc when ligand density was increased. This 
difference in saturation concentration is attributable to the increase in bivalent binding character 
as spatial distance between ligands is decreased. The effect of this bivalency can be quantified 
by observation of [𝐿𝐴𝐺3𝐹𝑐]
𝑅𝑚𝑎𝑥
2
 (inset at intermediate and high ligand density).  
c) Kinetic analysis of LAG-3:Fc binding to HLA-DR1 at intermediate ligand density (792 RU) 
exhibited some bivalent binding as shown by kinetic modelling. Global fitting (left) of LAG-
3:Fc binding at 0.9 – 14.3 µM as well as local fitting (right) at the concentration closest to 
perceived KD1 (7.2 µM) described a similar monovalent affinity as calculated by steady-state 
analysis described in b). KD1 was calculated through the first step complex formation affinity 
constant KD1 in accordance with the bivalent binding model as shown by Eq. 4.6 and is thus 
equivalent to a monovalent affinity. 
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4.6 Preliminary studies of LAG-3 structure by negative stain electron mi-
croscopy 
There is currently no structural data describing LAG-3, and as a result, knowledge of the protein 
domain organisation of LAG-3 is based on interference at the gene level, and comparison to 
homologous proteins whose structure may have been elucidated. As a result, little is known 
about how LAG-3 functionally impinges on the immune synapse resulting in T cell inhibition 
(C. C. J. Workman et al. 2002). 
This lack of structural data has stemmed from the lack of soluble LAG-3 protein samples 
suitable for high-resolution studies by x-ray crystallography. The soluble LAG-3:Fc fusion pro-
tein used to describe HLA-DR1 binding is produced in Chinese hamster ovary (CHO) cells and 
is post-translationally modified to include approximately 18 kDa of N-linked glycosylation (F. 
Triebel, personal communications). In this formulation, protein crystal formulation is highly 
unlikely due to carbohydrate flexibility and heterogeneity. However, recent advances in electron 
microscopy techniques for protein samples have enabled the study of protein structure to reso-
lutions nearing that of x-ray crystallography (Egelman 2016). Such techniques are not dependent 
on crystal formation and, thus, can be performed on glycosylated protein samples. Furthermore, 
enhanced techniques are enabling the study of smaller proteins, near to the 161 kDa LAG-3:Fc, 
which have previously been too small to study via EM (Ciuffa et al. 2015). 
Despite advances in cryo-EM based methodologies, access to microscope time on such in-
struments is limited at present and requires a pre-requisite knowledge of sample at low 
resolution before preceding to high resolution studies. To this end, these studies outline the pre-
liminary results in efforts to define LAG-3 structure through the study of LAG-3:Fc at near 
atomic-resolution using negative stain electron microscopy with a view to future study at 
atomic-resolution using cryo-electron microscopy. 
4.6.1 Collection of LAG-3:Fc and LAG-3:Fc + HLA-DR1 negative stain EM datasets 
In order to gain knowledge of the overall size and shape of the LAG-3:Fc protein envelope, as 
well as validate the quality of the protein preparation, LAG-3:Fc was studied by negative stain 
EM (Figure 4.10). Obtainment of EM datasets first required the generation of LAG-3:Fc and 
LAG-3:Fc in complex with HLA-DR1 protein grids optimally stained with the contrasting agent 
uranyl acetate, outlined in Figure 4.10a, modified from methodologies previously described 
(Rames et al. 2014). Using grids prepared under the described conditions, LAG-3:Fc and LAG-
3:Fc combined with HLA-DR1 were imaged at 50,000 times magnification using a 200 kV 
transmission electron microscope (TEM). Micrographs of LAG-3:Fc showed that the protein 
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Figure 4.10 – Preparation of samples and collection of negative stain EM datasets: 
a) Schematic overview of the optimised conditions for preparation of negative stained LAG-
3:Fc and LAG-3:Fc + HLA-DR1 complexed sample grids for imaging via transmission electron 
microscopy (TEM). Protein samples were applied to grids at an angle of 45 ° over ice, washed 
three times with deionised water before undergoing three consecutive incubations in 2 % uranyl 
acetate (UA) for time periods indicated. Grids were air dried before imaging. 
b) Overview of current datasets for LAG-3:Fc and LAG-3:Fc + HLA-DR1 samples. Example 
micrographs at 50k X magnification at 200 kV acceleration voltage and detected using a charged 
coupled device (CCD) camera (top). Example particles from each dataset using manual particle 
picking in the EMAN 2.1 software package (bottom). LAG-3:Fc particles exhibited good stain 
contrast and homogenous particles across micrographs. LAG-3:Fc + HLA-DR1 datasets 
exhibited less contrast and heterogeneity in particle size across micrographs. Current dataset 
sizes indicated below.  
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 sample was homogenous and devoid of large aggregation and exhibited no visible oligomeri-
sation or polymerisation (Figure 4.10b). Distinct LAG-3:Fc single particles were visible and 
suitable for single particle reconstruction. As a result, 130 micrographs of LAG-3:Fc were col-
lected from which a limited dataset of 2,062 particles were picked for single particle 
reconstruction analysis. 
Imaged LAG-3:Fc grids complexed with HLA-DR1, however, exhibited sample heterogene-
ity and some aggregation (Figure 4.10c). Nevertheless, micrographs were dominated with 
particles of a similar to slightly enlarged size suggesting inclusion of complexed particles. A 
total of 195 micrographs were consequently collected from which a dataset of 3,219 picked 
particles has been obtained. Due to the heterogeneity of the particle dataset, however, and its 
limited size, the current dataset, at present, was not suitable for single particle reconstruction 
analysis. 
4.6.2 A single particle reconstruction of the LAG-3:Fc surface envelope 
The 2,062 particle dataset of LAG-3:Fc was subjected to single particle reconstruction analysis 
using the EMAN2.1 project workflow7 (Tang et al. 2007). Multiple symmetry restrained initial 
models were built from 2D class averages8 generated from particles exhibiting the best signal-
to-noise ratio. From these initial models, refined reconstructions of LAG-3:Fc were achieved by 
iterative refinement through gradual inclusion of particle images and increasing resolution tar-
gets. Refinements of LAG-3:Fc models restraining for different symmetry groups revealed that 
the protein exhibited c1 point group symmetry i.e. no symmetry. At low-resolution, therefore, 
LAG-3:Fc exhibits asymmetry and does not possess a symmetry axis about the plane of the 
dimerisation interface. 
The refined reconstruction shows LAG-3:Fc as a non-spherical protein with three distinct 
globular domains (Figure 4.11). Each globular domain combines to form a Y-shaped molecule 
with approximate maximal dimensions of 150 x 140 x 130 Å (width, height, depth; as viewed 
from front). One globular domain exhibits smaller dimensions (65 x 65 Å) and is therefore likely 
the Fc portion of the molecule. The second two domains were matched in overall size (65 x 75 
Å) and appearance and thus likely represent the two LAG-3 components of the fusion protein.  
                                                     
7 EMAN2.1 is a software suite comprised of software packages that allow analysis of raw micrograph 
data to particle reconstructions (protein models). 
8 2D class averages are the resulting particle image generated from the summation of particles assigned 
to similar views (class sums). 
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Figure 4.11 – Single particle reconstruction of LAG-3:Fc by negative stain EM: 
a) 3D single particle reconstruction of LAG-3:Fc shown by surface volume contoured at 0.41   
σ contour level. LAG-3:Fc exhibits an antibody-like Y-shape surface envelope as shown by front 
view. Top and side views show the globular nature of two LAG-3 domains and third Fc domain. 
The approximate overall dimensions of the LAG-3:Fc are defined as 150 x 140 x 130 Å (width, 
height, depth; as viewed from front). 
b) Measurements of the globular domains of LAG-3:Fc single particle reconstruction front view. 
The reconstruction suggested two globular domains of similar size (top of model) and a third 
smaller domain (bottom of model) which likely represents the LAG-3 and Fc domains, 
respectively. 
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Due to the quality of the model, however, domain matching with known structures of the Fc 
domain were unable to confirm such assignments (data not shown). 
The refined LAG-3:Fc model was reconstructed from inclusion of the full particle dataset 
(2,062 particles). Class averages and corresponding model projections showed good overall 
agreement9. However, better matching was observed in class averages of front views of LAG-
3:Fc suggesting better model accuracy of front view projections (Figure 4.12a). Analysis of the 
Euler map of class averages – a plotted representation of the assigned Euler angles to each class 
average – showed that angular assignment of class averages exhibited good coverage across 
particle views10 (Figure 4.12b). Class averages which were comprised of larger image stacks 
(typically 8 to 16 particles per class average) were clustered to front views, once more high-
lighting increased image data skewed towards front views. Top and side view class averages 
were formed typically from only 3 to 8 particle images per class. As a result, to improve model 
accuracy and resolution, further particle images from a larger dataset of LAG-3:Fc micrographs 
are required; particular containing LAG-3:Fc top and side views. For assessment of resolution, 
LAG-3:Fc model of Fourier shell correlation (FSC) curves11 were subjected to the gold-standard 
resolution criteria (Figure 4.12c) (Scheres & Chen 2012). The resolution of the model using 
these criteria is estimated to between 23.2 – 24.0 Å depending on applied masking criteria. A 
conservative resolution of the LAG-3:Fc model is therefore estimated at 24.0 Å. 
The solution of this reconstruction of LAG-3:Fc, therefore, described LAG-3:Fc as a non-
polymerising asymmetric protein consisting of three distinguishable globular domains that com-
bined to overall dimensions similar to that of an antibody. Moreover, imaging of the LAG-3:Fc 
                                                     
9 Model projections are computed views through the reconstructed model. In effect, model projections 
represent a computed representation of a particle view from a given angle. Thus, model projections can 
be used to validate that observed particle views are equivalent to modelled particle views. 
10 To generate an accurate 3D reconstruction of a protein molecule, the particle dataset must contain 
particle views that encompass all possible views. A perfect Euler map would describe an even distribution 
of 2D class averages (views) with a similar number of images per class average (image stacks).   
11 FSC curves allow the assessment of resolution of structural information. Fourier shell correlation 
(FSC) is the cross-correlation coefficient between two 3-dimensional volumes. This correlation is calcu-
lated by reconstructing two models from half the available dataset each. In an FSC curve, FSC is plotted 
as a function of spatial frequency. At low resolutions (low spatial frequencies) each of the two compared 
models have high FSC i.e. a high degree of correlation and are in agreement between models. At higher 
resolutions (high spatial frequencies) the two models exhibit low FSC i.e. no correlation, as they trend 
towards random noise. If high resolution structural information is contained within the model, high FCS 
extends out into higher spatial frequencies and the FSC curve reaches baseline at higher spatial frequen-
cies.  
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protein by negative stain EM showed that the current protein formulation was largely homoge-
nous, devoid of aggregation and thus a viable sample for the study of LAG-3 using higher-
resolution EM techniques. 
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Figure 4.12 – Validation of the current LAG-3:Fc single particle reconstruction: 
a) Sixteen example class averages (CA) and corresponding projections (PR) from the refined 
model of LAG-3:Fc based on current particle dataset. CA and PR matched at certain Euler 
angles, particularly front views. CA and PR at other angles, particular side views, exhibited 
poorer matching due to the limited dataset. 
b) Distribution of Euler angles assigned to class averages of LAG-3:Fc represented by cylinders 
scaled to particle stack size. Cylinders represent a single class average which is derived from a 
number of particles images of similar ‘views’. Class averages were relatively evenly spread 
across all possible ‘views’ meaning few ‘views’ of LAG-3:Fc were missing from the dataset. 
Each class average had a relatively even number of constituent particle images, however, some 
skewing towards LAG-3:Fc front views was observed as shown by increased stack height of 
cylinders about the map circumference.  
c) Fourier shell correlation (FSC) curves and gold-standard resolution criteria of the refined 
LAG-3:Fc reconstruction which can be used to give an indication of model resolution. FSC 
curves are shown of unmasked (green) loose (blue) and tight (black) masks applied to the refined 
model which show extension of FSC out to moderate spatial frequencies only and no data out 
to high spatial frequencies. Resolution is estimated at 23.7 Å using the most conservative tight 
masking in accordance with the gold-standard resolution criteria (Scheres & Chen 2012).  
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4.7 Discussion 
LAG-3 has been shown to bind MHC-II expressed at the cell surface (Huard et al. 1995). This 
interaction has not been characterised at the protein level, nor has an affinity value been at-
tributed to LAG-3 binding MHC-II through direct protein measurements. 
Studies into the functional binding of LAG-3 were enabled by the development of a LAG-3 
expressing cell line. The resulting transduced Jurkat cells clone expressed high levels of LAG-
3 and remained as a homogenous LAG-3+ population throughout prolonged culture periods of 
~90 days. This JRT LAG-3+ C8 cell line developed was also essential for the studies described 
to follow in Chapter 5. 
LAG-3 was first shown to interact with the MHC-II molecule HLA-DR1 by the staining of 
LAG-3+ cells with HLA-DR1 multimers. Such multimers were shown to stain LAG-3 replete 
and not LAG-3 deplete cells. Moreover, the binding of multimers to LAG-3 replete cells was 
observed only with HLA-DR1 multimers and not MHC-I multimers of HLA-A2. Such staining 
could not be attributed to TCR binding due to the lack of TCRβ chain expression in the JRT3 
T3.5 Jurkat cell line as confirmed by minimal staining of JRT LAG-3+ C8 cells with a pan-αβ 
TCR antibody. The observed staining was instead shown to be LAG-3 dependent by the block-
ade of multimer staining by the 17B4 clone αLAG-3 antibody. 
Despite 100 % LAG-3 expression by JRT LAG-3+ C8 cells, only a fraction of cells were 
detected as HLA-DR1 multimer+. Staining of cells was characterised by only a moderate shift 
in fluorescence intensity. Indeed, the HLA-DR1 multimers used (batch matched) had the capac-
ity to achieve near complete recovery of cells when staining a cognate T cell clone. These data 
initially suggested that the LAG-3 interaction with HLA-DR1, at least as a multimeric molecule, 
stained LAG-3 cells with a weaker avidity compared to the cognate interaction between HLA-
DR1 and TCR. Poorer staining could, however, be attributed to a number of factors that are 
difficult to deduce from cell surface expressed LAG-3 staining. 
To this end, LAG-3 binding to the MHC-II molecule HLA-DR1 was interrogated at the pro-
tein level using surface plasmon resonance (SPR) experiments. Such experiments required the 
acquisition of LAG-3 and HLA-DR1 protein samples. Production of a monomeric LAG-3 pro-
tein has proved difficult in-house and thus hampered the ability to measure the affinity of the 
LAG-3-MHC-II interaction through monovalent SPR experiments. As a result LAG-3 binding 
to HLA-DR1 was measured using the bivalent LAG-3:Fc fusion protein.  
SPR experiments directly confirmed, as previously observed at the cell surface, that LAG-3 
binds to the MHC-II molecule HLA-DR1 at the protein level and shows no specific interaction 
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with the MHC-I molecule HLA-A2. This interaction with HLA-DR1 was shown to be inde-
pendent of complexed peptide and thus supports a model of LAG-3 binding uninfluenced by 
presented peptide. Moreover, LAG-3 similarly bound to HLA-DR1 molecules produced in ei-
ther E. coli or sf9 insect cells and is therefore appears uninfluenced by MHC glycosylation 
differences. 
This interaction between LAG-3 and HLA-DR1 was described in terms of its affinity through 
a combination of kinetic and steady-state SPR analyses. These analyses quantified the affinity 
of binding between LAG-3 and HLA-DR1 as 13 µM (KD) using steady-state analysis. This af-
finity is comparable to that of TCR engagement of pathogen-derived pMHC-II and is slightly 
higher than average TCR-pMHC-II binding (D. Cole et al. 2007). This micromolar affinity is 
considerably weaker than the calculated avidity of dimeric LAG-3 binding in indirect cell sur-
face experiments (KD = 60 nM at 37 °C) (Huard et al. 1995). 
Despite a weaker affinity than previously described, these studies show LAG-3 binds HLA-
DR1 at a significantly higher affinity that CD4; for which a soluble affinity of binding has not 
been determined by SPR due to its weak nature. Indeed, CD4 binding to MHC-II was unable to 
be detected at concentrations as high as 2.5 mM (Jönsson et al. 2016). As LAG-3 binding to 
MHC-II molecules has been shown to block consequent CD4 binding, at the cell surface (Huard 
et al. 1995), competition between LAG-3 and CD4 for MHC-II binding would favour engage-
ment by LAG-3. Thus, this enhanced engagement by LAG-3 may contribute to the potency of 
LAG-3 mediated T cell inhibition.  
Although LAG-3 binds MHC-II via a higher affinity interaction compared to CD4, LAG-3 
dissociation was shown to have very fast kinetics. These data suggest that LAG-3 engagement 
of MHC-II at the cell surface is likely a transient process maintained by fast rebinding to MHC-
II as opposed to prolonged attachment at the cell surface. Such kinetics are observed for co-
receptor binding to MHC, whereby co-receptor binding affinity is tuned with TCR affinity such 
that T cell signalling remains highly sensitive yet maintains specificity to cognate TCR-pMHC 
stimulation (Hoerter et al. 2013). As a result, T cell signalling by agonist interaction between 
TCR and cognate pMHC can be initiated by very few binding events (Irvine et al. 2002). For 
CD4, despite a weak affinity, MHC-II binding maintains TCR phosphorylation at an active basal 
level by recruitment of Lck and thus poises T cells for cognate TCR-pMHC engagement 
(Jönsson et al. 2016). Since LAG-3 also exhibits fast kinetic binding to MHC-II, parallels be-
tween LAG-3 and co-receptor maintenance of antigen specificity may exist. Indeed, surface 
bound LAG-3 mediated inhibition of dendritic cell maturation has been shown to be antigen 
specific and require TCR-pMHC-II engagement by LAG-3 expressing regulatory T cells (Liang 
et al. 2008). Thus, the affinity of LAG-3 engagement of MHC-II expressing APCs must be tuned 
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such that ligand discrimination is maintained. The effect of LAG-3 expression on antigen spe-
cific stimulation on human T cells, however, is poorly understood. Consequently, further 
knowledge of LAG-3 signalling is required to understand how this observed affinity for MHC-
II affects LAG-3 mediated T cell homeostasis. 
Definition of LAG-3 affinity for MHC-II at 13 µM describes a similar affinity to that of the 
MHC-I co-inhibitory molecule Immunoglobulin-like transcript 2 (ILT2) which impairs T cell 
signalling in MHC-I restricted T cells (Liang et al. 2006). Exhibiting parallels to LAG-3, ILT2 
inhibits T cell activation through an interaction through CD8 co-receptor competitive binding 
with MHC-I; measured at 7 µM using similar SPR analyses (Moysey et al. 2010). Unlike CD4 
binding, CD8 co-receptor binds to HLA-A2 with a measurable affinity defined at 137 µM (Cole 
et al. 2007). As a result, ILT2 binding to MHC-I is approximately 20-fold higher affinity than 
that of CD8 binding. In contrast, the relative affinity of LAG-3 for MHC-II is >200-fold com-
pared to CD4 binding (assuming a CD4-MHC-II KD of >2.5mM). Thus, despite a slightly 
weaker affinity compared to ILT-MHC-I binding, the enhanced ability of LAG-3 to out-compete 
CD4 binding may make LAG-3 a more potent inhibition of MHC-II restricted T cell activation 
compared to ILT2 mediated inhibition in MHC-I restricted T cells. 
Whilst the dimeric LAG-3:Fc molecule exhibited some bivalent effects, the contribution of 
bivalency to LAG-3:Fc binding was minimal. At high ligand concentrations, where spatial den-
sity of MHC-II molecules should enable multivalent interactions, LAG-3:Fc off-rate was only 
minimally extended  through bivalency. As a result, functional binding of the LAG-3:Fc fusion 
protein exhibited poor ability to engage multiple MHC-II molecules. Since there is evidence 
that LAG-3 forms dimeric molecules at the cell surface, dimerisation of LAG-3 molecules may 
contribute to an increase in functional potency (Li et al. 2004). These data, however, suggest 
that dimerisation of LAG-3 does not drastically influence the strength of MHC-II engagement. 
Such observations should be made with caution, however, as it is not known how representative 
the LAG-3:Fc protein is of dimeric LAG-3 forms found at the cell surface. 
Having shown that LAG-3 bound MHC-II with a micromolar (KD) affinity, structural data to 
describe this interaction was sought. Initially, efforts were made to produce samples for study 
by x-ray crystallography. Despite detectable expression of LAG-3 products, which comprised 
of the four extracellular domains of LAG-3 expressed in insect cells, sufficient yield required 
for structural studies was not achieved. As a result, the dimeric LAG-3:Fc fusion protein re-
mained the best available reagent for the study of LAG-3 structure function. 
- 180 - 
 
Insights into LAG-3 structure by study of LAG-3:Fc by electron microscopy were instead 
initiated. Using negative stain electron microscopy, a low-resolution model of LAG-3:Fc, esti-
mated at 24 Å resolution, was produced which described the fusion protein’s overall surface 
envelope. This reconstruction showed that the LAG-3:Fc molecule did not form any unexpected 
oligomerisation events. In addition, the LAG-3:Fc protein formed a Y-shaped globular structure 
reminiscent of immunoglobulins. At this resolution, however, little inference about LAG-3 
structure-function can be made. Instead, these data represent preliminary experiments required 
in order to progress towards the study of LAG-3:Fc at higher resolution by cryo-electron mi-
croscopy. Importantly, these data show that the quality of the LAG-3:Fc preparation is sufficient 
to proceed to more complex structural analyses. 
4.7.1 Future directions 
In these studies, LAG-3:Fc binding was described to a single MHC-II molecule: HLA-DR1. To 
this end, it is unknown whether LAG-3 binds to other MHC-II alleles with similar affinity. Hav-
ing established methodologies to quantify LAG-3 affinity to HLA-DR1, similar experiments 
could be performed using different HLA-DR, HLA-DQ and HLA-DP molecules. Indeed, CD8 
co-receptor affinity for different MHC-I molecules ranges from (KD) affinity of 100 µM for 
HLA-A11 to >1000 µM for HLA-A68 binding (Gao et al. 2000). Analysis of binding of these 
alleles could also be studied by HLA allele multimer staining of LAG-3+ cells. 
 In addition, some evidence has emerged of a second potential ligand for LAG-3 in the cell-
adhesion molecule LSECtin/CLEC4G (Xu et al. 2014). Such binding has been proposed as a 
potential mechanism of LAG-3 mediated inhibition of CD8+ T cell activation. Dependent on 
availability of LSECtin samples, SPR experiments using LAG-3:Fc could be performed to ro-
bustly determine the presence of such an interaction and again describe its affinity. 
At present, there is still a vast gap in understanding in how LAG-3 mediates inhibition of T 
cell activation, particularly at the structural level. As described, the next steps in efforts to gain 
high-resolution insights into LAG-3 structure would be the study of LAG-3:Fc via cryo-electron 
microscopy which, through the development of advanced microscopes, automated imaging, ad-
vanced reconstruction software and expanding computation power has begun to yield protein 
structures at near-atomic resolution (Egelman 2016). Moreover, recent implementation of Volta 
phase plate (VPP) technology into TEM set-ups, which increase contrast at the focal plane, will 
allow the study of smaller proteins, such as LAG-3:Fc, via high-resolution cryo-EM imaging 
(Danev & Baumeister 2016). In order to access such microscopes, LAG-3:Fc cryo-protected 
grids must first be produced and shown to be of sufficient quality for high-resolution TEM. Such 
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methodologies could also be applied to the study LAG-3:Fc complexed with HLA-DR1 which, 
at higher-resolution, would be easier to filter out sample heterogeneity.  
Despite unsuccessful attempts to produce suitable protein sample, study of LAG-3 structure 
may still be achievable by x-ray crystallography. In order to try generate soluble LAG-3 sam-
ples, a high-throughput construct screening process may prove to be a viable approach. Here, 
multiple LAG-3 derived constructs could be designed in silico to include (a) sequential trunca-
tion of Ig-like domains (b) mutation of glycosylation signal sequences and/or (c) fusion protein 
screening. Indeed, production of a monomeric form of LAG-3:Fc, by mutation of the disulphide 
mediating residues, resulted in inefficient expression indicating that monomeric forms of LAG-
3 in vitro may not be achievable (Huard et al. 1996). These high-throughput screens could there-
fore focus on constructs which enable LAG-3 stability through dimerisation. These constructs 
could consequently be screened for production in different expression systems which are either 
glycosylation deficient or impaired (Chang et al. 2007).  
4.7.2 Implications of this study 
Firstly, initial experiments describing binding of MHC-II multimers to LAG-3+ pose an indirect 
implication in CD4+ T cell biology experimental design. MHC-II multimers are used to specif-
ically stain and sort antigen-specific T cells based on a desired interaction with the pMHC-II 
epitope. These experiments highlight a requirement for the use of irrelevant multimer controls 
in such experiments in order to prevent misdetection of LAG-3+ cells as perceived antigen-spe-
cific multimer+ cells. Such controls become increasingly important in self-derived MHC-II 
multimer experiments where low affinity clones do not exhibit a considerable increase in fluo-
rescence intensity as a result of multimer binding. To this end, these data show that flow 
cytometric gating of multimer+ cells should be performed using matched HLA multimers and 
that use of MHC-I irrelevant controls in staining MHC-II restricted T cells may result in the 
aberrant antigen non-specific detection of LAG-3+ cells and are thus not suitable. 
In terms of LAG-3 function, these studies provide the most comprehensive evidence of LAG-
3 binding to MHC-II at the protein level. Moreover, definition of the affinity of the interaction 
alters the perception that LAG-3 binds MHC-II via a high affinity interaction as the data pre-
sented in this Chapter describes a more moderate interaction strength. Nevertheless, this binding 
affinity is significantly higher than the immeasurably low CD4-MHC-II soluble affinity. As a 
result, these data add evidence to a model where LAG-3 is able to out compete CD4 for MHC-
II binding as one potential mechanism of LAG-3 mediated T cell suppression.  
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5 Chapter 5: Molecular tools for the characterisation and 
molecular targeting of LAG-3+ T cells 
5.1 Abstract 
Immune responses to tumours are sub-optimal leading to immune evasion and consequent pro-
gression of malignancies. Efforts to improve T cell responses to tumours by tuning the activation 
of T cells in human cancers has shown promising clinical benefit and have been licensed for use 
in some cancers. As a result, therapeutic agents which target T cells expressing surface markers 
involved in immune suppression are of clinical interest. Lymphocyte activation gene-3 (LAG-
3), a protein expressed on activated T cells and regulatory T cells, is associated with a highly 
suppressive T cell phenotype. LAG-3+ cells are enriched in lymphocytes extracted from colo-
rectal cancer tumours and as a result, LAG-3 has been highlighted as a potential therapeutic 
target for enhancement of anti-tumour T cell responses. To this end, a panel of mouse monoclo-
nal anti-LAG-3 antibodies were generated using the whole protein immunisation of mice. 
Consequent antibody responses were quantified by direct ELISA and flow cytometry allowing 
for the cloning of six monoclonal antibodies reactive to LAG-3 expressing cells. Antibodies 
were subsequently characterised by sequence, function and antibody-antigen binding strength. 
Generated antibodies were able to bind LAG-3 specifically by flow cytometry and Western blot 
via a sub-nanomolar (KD) avidity with antigen, as shown by surface plasmon resonance meas-
urements. The development of such antibodies will aid in the detection of LAG-3 expressing 
cells, the generation of LAG-3 protein samples and represent the starting pipeline in the gener-
ation of antibody therapeutics to target LAG-3 expressing cells in human cancers. 
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5.2 Introduction 
Tumour-specific T cells are detected within tumours as tumour infiltrating lymphocytes (TILs) 
and play an important role in the regulation of malignancies. Despite a correlation between the 
presence of TILs and 5 year survival in colorectal cancer patients, T cells cannot prevent tumour 
occurrence (Galon et al. 2006). Current immunotherapy research is focusing on the modulation 
of checkpoint inhibitor proteins, such as CTLA-4 and PD-1, which can downregulate anti-tu-
mour T cell responses (Sharma & Allison 2015). For example, in a phase III study, treatment of 
unresectable stage III or stage IV metastatic melanoma patients with ipilimumab and nivolumab, 
which target CTLA-4 and PD-1 respectively, showed a significant increase in progression free 
survival (11.5 months) compared to monotherapy (ipilimumab alone: 2.9 months, nivolumab 
alone: 6.9 months) (Larkin et al. 2015). Despite success of such agents in the clinic, increased 
progression free survival is not observed in all patients, highlighting a need to identify further 
immune checkpoint targets for tailored treatment or combination treatment across different in-
dividuals. One such potential target is LAG-3, which, as discussed previously, plays a complex 
role in suppressing adaptive immunity.  
Interest in depleting LAG-3 expressing T cells in tumours, or blocking the action of LAG-3 
by such T cells, stems from the glycoprotein’s expression on inhibitory T cell populations. LAG-
3 in CD4+ CD25+ Tregs is upregulated and its function is required for maximal suppressive 
activity (Huang et al. 2004). As a result of LAG-3 expression, such cells are inherently anergic 
to proliferation upon exposure to antigen. In addition, CD4+ TILs extracted from human colo-
rectal cancer tumours have shown a significant upregulation of LAG-3 expression compared to 
CD4+ T cells from matched healthy colon and PBMCs (Scurr et al. 2013). These T cells, taken 
from tumour, were 50-fold more suppressive than classical CD25hi FoxP3+ CD4+ Tregs as shown 
by in vitro suppression assays. LAG-3 expression is also a characteristic marker on Tr1 cells, a 
highly suppressive T cell subset found in the periphery as well as infiltrating in human hepato-
cellular carcinomas (Pedroza-Gonzalez et al. 2015).  
Whilst LAG-3 is expressed on T cells with regulatory function, expression of LAG-3 on 
effector activated T cells must also be considered (Wojciech et al. 2014). Depletion of LAG-3 
expressing T cells, either possessing anti-tumour effector function, or the capacity to regain 
functionality as memory T cells, might impact on T cell immunity as a whole.  Depletion of 
LAG-3 expressing activated effector T cells, in a primate model of type IV hypersensitivity, 
reduced T cell mediated symptoms and reversed T cell driven pathology (Poirier et al. 2011). 
These data would suggest that removal of such cells in a cancer setting might in theory be a 
detrimental intervention. Studies involving ipilimumab, which specifically targets CTLA-4 to 
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block and induce depletion, have shown that antigen-target depletion of T cells is compartment 
specific and it is hypothesised that whilst therapeutic depletion of CTLA-4 expressing activated 
effector T cells may occur, providing the depletion of CTLA-4 expressing cells shifts the effector 
to regulatory T cell ratio in favour of increased anti-tumour effector cells, an enhanced immune 
response is observed (Simpson et al. 2013). 
Whilst LAG-3 is expressed on activated effector T cells, the role of LAG-3 on such cells is 
to inhibit their further T cell activation signalling (Workman et al. 2002). It can therefore be 
hypothesised that depletion of such cells would have less impact on potential anti-tumour im-
munity due to their impaired function. LAG-3 has also been shown as a marker of T cell 
exhaustion and, thus, mediate the proliferative and functional impairment of tumour-reactive T 
cells within tumours (Woo et al. 2012). Moreover, blockade of LAG-3, in combination with PD-
1 blockade, is able to reverse T cell exhaustion and promote enhanced clearance of parasite load 
in chronic infections, a model of chronic antigen exposure (Butler et al. 2012). 
Together, these data highlight LAG-3 as a potential target for combination or monotherapeu-
tic modulation of T cell immunity in colorectal and other cancers. To study the effect of blockade 
and depletion of LAG-3 expressing cells in vitro and later in human studies, accessible mono-
clonal antibodies designed with the correct formulation to promote such blockade or depletion 
are required. 
5.2.1 Antibodies as biotherapeutic agents 
Antibodies provide an essential molecular tool in immunology, diagnostic medicine and biology 
as a whole. In the last ~20 years, these protein molecules have come to importance in clinical 
medicine as biotherapeutic agents. These proteins, like T cell receptors, exhibit exquisite speci-
ficity to target molecules through the somatic recombination of immunoglobulin genes. The 
resulting antibody proteins therefore provide an effective solution to target specific molecules 
in vivo to disrupt or block native biological systems, or reverse pathophysiological transfor-
mations of biological systems. In addition, due to being derived from the immune system 
themselves, these biotherapeutic antibodies are able to modulate the host recipient’s immune 
system into targeting an immune response against the antigenic target. This function, therefore, 
allows the therapeutic targeting of cells expressing cellular markers, such as LAG-3, through 
the recruitment of the host’s immune networks. 
Antibodies are multivalent protein molecules. IgG class antibodies, the focus of this chapter 
and most of the on-the-market antibody therapeutics, contain two antigen binding sites. As a 
result of bivalency, IgG molecules have exceptionally long off-rates in the order of hours and 
thus, immunoglobulins such as IgG class antibodies are effective at coating antigen expressing 
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cells (Weiner 2015). This high avidity property along with their long half-lives, 15 days for 
ipilimumab and 12 to 20 days for nivolumab (depending on dose), make IgG proteins an ideal 
molecular solution for targeting certain cell populations based on their antigenic expression 
(Fellner 2012; Glassman & Balthasar 2014). Moreover, the large protein volume of antibodies 
enables the inhibition of interactions to be mediated via the steric blockade of protein-protein 
interactions at the surface of cells (Shih et al. 2014). 
5.2.2 Antibody isotypes and recruitment of immune effectors 
As well as enabling blockade of molecular function, antibody molecules are also able initiate 
depletion of antigen-bearing cells through the recruitment of immune cells or proteins. Such 
processes are dependent on the antibody isotype of a developed antibody agent. A cellular based 
response against surface expressed antigen is dependent on the Fc receptor (FcR) family of pro-
teins which bind antibodies at varying affinities dependent on subclass of both receptor and 
antibody (Guilliams et al. 2014). 
Natural killer (NK) cell mediated depletion, through the process of antibody dependent cel-
lular cytotoxicity (ADCC) occurs through the activating FcγRIIIa (CD16a) receptor expressed 
by NK cells and, as a result, IgG1 and IgG3 subclass antibodies are the choice isotype for ADCC 
induction (Seidel et al. 2013). Similarly, antibody dependent cellular phagocytosis (ADCP) by 
macrophages, which express a wide range of FcγR proteins, can be mediated through IgG mol-
ecules (Nimmerjahn & Ravetch 2008). Preference for the IgG1 subclass to initiate functional 
depletion by macrophages is based on its preferential binding to activating FcγRs such as 
FcγRIIa and FcγRIIIa compared to the inhibitory FcγRIIa – the latter of which can limit the 
efficacy of cellular depletion by macrophages (Beers et al. 2016). 
In concurrence with a cellular based response, complement activation has also been shown 
as a mechanism of depletion of antigen-bearing target cells in vivo (Weiner 2010). Complement 
dependent cytotoxicity (CDC), against antibody opsonised targets, is facilitated by IgM, IgG1 
and IgG3 molecules and enabled through an ability to interact with the C1q component of the 
classical complement activation pathway (Poons et al. 1985; Bindon et al. 1988).  
Due to the ability to activate ADCC, ADCP and CDC immune networks, the IgG1 isotype is 
regarded as the most effective antibody isotype for the therapeutic targeting of antigen-bearing 
cells (Beers et al. 2016). 
5.2.3 Anti-LAG-3 antibodies currently described in the literature and beyond 
The generation of antibodies targeting human LAG-3 has been achieved previously by a number 
of academic laboratories, pharmaceutical companies and commercial biotechnology companies. 
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There are currently twelve available monoclonal antibodies targeting human LAG-3 protein 
(Table 5.1). As well as those available to purchase commercially, a number of additional anti-
body formulations are documented in the literature and are either in the possession of 
laboratories that are not distributed commercially or their use has been halted (Huard et al. 1994; 
Baixeras et al. 1992). In addition, a number of antibodies against LAG-3 are being developed 
as part of therapeutics by pharmaceutical companies of which, at the time of writing, little is 
known about their formulation, function and therapeutic potential.  
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Clone or 
Identifier 
Species Isotype Availability Immunogen Function Origin 
Commercially available antibodies 
17B4 Mouse IgG1 Enzo Lifescience The unique 30 aa loop of the first N-terminal D1 domain of human LAG-3 Blocking (Triebel group)1 
28C5 Mouse IgG1 Creative Diagnostics Synthetic peptide covering the 30 aa extra loop of human LAG-3 (aa70-99)   
22F4 Mouse IgG1 Creative Diagnostics N-terminal D1 domain of human LAG-3   
FQS5403(3) Rabbit IgG Creative Diagnostics Synthetic peptide within C-terminus of human LAG-3 sequence   
DOB.53 Mouse IgM Creative Diagnostics n.s.   
3DS223H Mouse IgG1 eBioscience Human LAG-3 (no further specification)    
3C39 Mouse IgG2 GeneTex Human recombinant LAG-3 (no further specification)   
11E3 Mouse IgG1 LifeSpan Biosciences Bacculoviralsf9 expressed human LAG-3. Recognizes the D1 domain  (Triebel group)2 
8G6 Mouse IgG2b OriGene Human recombinant aa66-332 of human LAG3 produced in E.coli   
10E7 Mouse IgG2a OriGene Human recombinant aa66-332 of human LAG3 produced in E.coli   
5C3 Mouse IgG2b OriGene Human recombinant aa66-332 of human LAG3 produced in E.coli   
874501 Mouse IgG1 R&D Systems Whole  nS0-derived, recombinant human LAG3   
       
Unavailable antibodies 
15A9 Mouse IgG1 None Bacculoviral sf9 expressed human LAG-3.  (Triebel group)2 
4F4 Mouse IgM None 30 aa extra-loop of the first N-terminal D1 domain of human LAG-3  (Triebel group)1 
13E2 Mouse IgG1 None n.s. Non-blocking (Triebel group) 
Documented pharmaceutical agents 
BMS-986016 Human n.s. None (BMS) n.s. n.s.  
LAG525 Humanised n.s None (Novartis) n.s. Blocking IMP701 (Triebel group) 
GSK2831781 Humanised n.s. None (GSK) n.s. Depleting IMP731 (Triebel group) 
 
Table 5.1 – Summary of available anti-LAG-3 antibodies  
Anti-LAG3 antibodies that are commercial available, currently unavailable or are known to be developed as pharmaceutical agents are listed. BMS = Bristol-
Myers Squibb, GSK = GlaxoSmithKline. Antibodies of ‘Triebel group’ origin represent antibodies commercialised or derived from the laboratory of F. Triebel. 
1Generation referenced in (Baixeras et al. 1992), 2Generation referenced in (Huard et al. 1994). 
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5.2.4 Aims 
Despite a number of anti-LAG-3 antibodies having already been generated, such antibodies are 
currently unavailable for academic laboratories to analyse the efficacy of LAG-3+ cell depletion 
either as a monotherapy or in combination therapy with agents aimed at enhancing immune 
responses to tumour antigens in cancer patients. Furthermore, none of these antibodies have yet 
shown clinical efficacy for the treatment of cancer, demonstrating the need for more investiga-
tion. In addition, dissection of the mechanisms involved in LAG-3 mediated T cell suppression 
have been hampered by a lack of suitable soluble LAG-3 protein. The development of an in-
house supply of LAG-3 binding antibody would assist in the generation of recombinant LAG-3 
protein for future cellular, biochemical, biophysical and structural studies. 
As a result, the overall aim of this chapter was to develop an in-house monoclonal antibody 
which could be used as (i) an experimental tool for identifying LAG-3 expressing cells (ii) a 
molecular tool for the study of LAG-3 structure-function and (iii) a potential therapeutic agent 
for clinical cancer therapy. The overall aim of this chapter is divided into the following sub-
aims: 
(i) To develop a panel of monoclonal antibodies with specificity for human LAG-3  
(ii) To produce the large (milligram) quantities of antibody required for in vitro assays 
and LAG-3 protein chemistry. 
(iii) To characterise each mAb in terms of their clonotype and isotype. 
(iv) To assess the functional binding characteristics of generated monoclonal antibodies 
for LAG-3. 
(v) To assess the binding strength of the interaction between generated antibodies for 
LAG-3 protein in vitro. 
(vi) To assess the ability to block the LAG-3-MHC-II interaction 
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5.2.5 Strategy of monoclonal antibody generation 
The generation of antigen specific antibodies against human molecules is typically performed 
through the immunisation of small mammals (mice, rats or rabbits etc.) and consequent gener-
ation of clonal immortalised B hybridoma cell lines such that the cost and ethical expense of 
animals is minimised. More recent methodologies in generating human antibodies, driven by 
the generation of antibodies for therapeutics, utilise either immunoglobulin gene humanised 
mice or the complete bypassing of experimental mammals by generating human monoclonal 
antibodies through phage or yeast display libraries techniques  (Lonberg 2005; Jespers et al. 
1994). 
Due to the expertise within the Division of Infection and Immunity, Cardiff University, the 
immunisation of mice with human derived LAG-3 immunogen approach was taken. This pro-
cess was performed in collaboration with Professor Paul Morgan. 
5.2.5.1 Choice of immunogen 
When developing monoclonal antibodies against a specific target, the immunogen used must be 
selected based on the desired application of the developed antibodies. Generally, mouse anti-
body responses are raised against recombinately expressed whole protein or short peptides 
derived from the whole protein.  
Generating monoclonal antibodies against short peptide epitopes (typically 6 – 25 amino 
acids in length) is the most commonly used tactic for generating highly specific antibodies to a 
desired target. As small, low molecular weight compounds are not immunogenic when injected 
into the host species, short peptide epitopes are typically conjugated to a carrier protein such as 
keyhole limpet hemocyanin (KLH) which increases the mass of the immunogen and conse-
quently the immunogenicity. This method is preferable as a certain locale of the antigen can be 
targeted as the raised epitope. For example, if the rationale for antibody development is to block 
a protein function, such as interaction with a ligand or multimerisation, peptide-KLH immuno-
gens can be used to narrow the generated B cell repertoire to have this desired functionality.  
Narrowing the immunogen, however, limits the diversity of the B cell response which, in 
turn, can have a negative impact on the ability to generate high affinity antibodies against the 
protein target. This can occur if the narrow peptide epitope does not contain favourable chemical 
properties for the formation of a high affinity antibody-antigen interaction. This can be over-
come by in vitro affinity maturation techniques such as phage or yeast display, however, this 
process can be lengthy and resource heavy. In addition, use of peptide-KLH immunogens re-
quires some knowledge of the antigen’s protein structure to ensure that the target epitope 
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sequence is surface exposed and sterically accessible in the antigen’s native conformation. For 
this reason, the peptide-KLH approach is less suited in the generation of antibodies against pro-
teins such as LAG-3 where the high resolution protein structure is not known. Antibody epitope 
prediction programs can, however, be used to assess whether the peptide-KLH antigen contains 
a favourable amino acid sequence for epitope generation, however, these programs result in a 
prediction only. 
An alternative approach involves the immunisation of the host animal with whole antigenic 
protein. This method generates a diverse B cell response against the immunogen, within which 
the polyclonal response will be spread across epitopes of the whole heterologous protein. This 
is advantageous as the B cell repertoire is not limited to a narrow portion of the protein. Instead, 
antibodies are generated against the whole available protein surface, allowing the host B cell 
repertoire to sample molecular surfaces for all available potential epitopes. In the same respect, 
the disadvantage of this approach is that the epitope repertoire generated is far less focused, 
thus, if an antibody with a specific function is required, as discussed previously, this function 
must be screened for from the generated polyclonal B cell response via a functional assay – as 
opposed to selected for at the point of generation as in the case for peptide-KLH antibody gen-
eration. 
For whole protein antigens larger than approximately 20 kDa in size, whole protein immu-
nogens do not require carrier protein conjugation. As a result, carrier protein specific antibodies 
do not need to be affinity purified out (at the protein level) or cloned out (at the cellular level). 
Most importantly, the probability of generated antibodies having the capacity to bind natively 
folded antigen is significantly higher than if peptide-KLH conjugates are used as the immunogen 
is presented to the B cell repertoire in a similar (or the same) conformational state to that of the 
endogenously expressed target protein.  
In this study, the whole protein approach was taken to generate anti-LAG-3 antibodies using 
the LAG-3:Fc fusion protein. The decision to opt for the whole protein approach was due to (i) 
the lack of LAG-3 structural data (ii) the increased probability of obtaining antibodies with 
binding capacity for in vivo cellularly expressed LAG-3 and (iii) the increased probability of 
achieving high affinity antibodies without requiring in vitro affinity maturation. Furthermore, 
the LAG-3:Fc fusion protein was chosen as the whole protein immunogen due to (i) the availa-
bility of the reagent through commercial sources (ii) the functionality of the molecule as 
demonstrated in the literature and (iii) the comparative stability of LAG-3:Fc compared to other 
LAG-3 reagents. 
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5.2.5.2 Anti-LAG-3 specific antibody screening strategy 
In order to select for host sera or B cell hybridoma clone supernatants which contained antibod-
ies specific for LAG-3, a two-fold screening approach was used which incorporated both direct 
ELISA and fluorescent antibody staining of LAG-3 expressing cells. This two-fold strategy was 
essential due to the nature of the LAG-3:Fc immunogen used. 
Firstly, antibody containing samples were screened for specificity to the LAG-3:Fc immu-
nogen by direct ELISA. In this assay, antibodies which are able to bind the LAG-3:Fc 
immunogen were first captured by their interaction with LAG-3:Fc and secondly detected by a 
HRP-conjugated anti-mouse Ig specific antibody. Thus, assay wells which produced a colori-
metric output could be attributed to the presence of a substance with affinity to LAG-3:Fc, as 
test sample is subjected to extensive washing after incubation with the immunogen. Secondly, 
use of a mouse Ig specific secondary antibody confirms that such substance is indeed mouse 
immunoglobulin. This secondary antibody used was a Fab specific anti-mouse Ig to avoid po-
tential cross-reactivity to the human Fc portion of the LAG-3:Fc fusion protein. This screening 
step has the advantage of being high-throughput. 
Due to the LAG-3:Fc fusion protein containing a human Fc domain, one must consider the 
impact this portion will have on the generated mouse B cell response, as human and mouse Fc 
portions of immunoglobulins are also heterologous. As a result, a second screening procedure, 
which selected for antibodies generated against the LAG-3 portion of LAG-3:Fc was required. 
As production of unfused LAG-3 protein has proven to be challenging, an alternative non-pro-
tein based method of selection was required. Here, anti-sera or culture supernatant were 
screened for their ability to stain LAG-3 expressing cells via flow cytometry using the lentivi-
rally transduced LAG-3+ C8 Jurkat cell line developed as described in Chapter 4. This assay is 
much lower-throughput; hence this step was not used as the primary screening step. 
As a result, this two stage screening process validated mouse antibody responses which could 
bind LAG-3 as both soluble protein and as a cell surface bound antigen. Additionally, antibodies 
raised against LAG-3:Fc may be dependent on post-translational carbohydrates added by the 
non-human cell line in which the LAG-3:Fc was produced – Chinese hamster ovary (CHO) 
cells. As a result, screening of binding to LAG-3 surface expressed on the human derived Jurkat 
cell line provides a better selection model of specificity for in vivo human LAG-3 glycoprotein. 
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5.3 Generation of monoclonal anti-human LAG-3 antibodies 
Through the subcutaneous injection of mice, in the presence of adjuvant, immunised mice gen-
erated a robust peripheral antibody response to heterologous LAG-3. Such responses were 
experimentally quantified in the sera of immunised mice through reactivity to LAG-3:Fc, as 
shown by direct ELISA and, secondly, through specific binding by flow cytometry to LAG-3+ 
cells. Immunised mouse B cells were extracted by splenectomy and fused with a myeloma de-
rived cell line to form a library of polyclonal immortalised B cells. Anti-LAG-3 specific 
hybridomas were present within the repertoire of B cell fusion products and were subsequently 
cloned to form a panel of monoclonal anti-LAG-3 expressing hybridomas. Subsequent hybrid-
oma clones were high-density cultured and produced antibodies harvested and purified for 
consequent characterisation. The immunisation of mice and production of initial hybridomas 
was performed by and in collaboration with Professor Paul Morgan (Cardiff University). 
5.3.1 Anti-LAG-3 antibody responses in immunised mouse serum 
During the immunisation schedule, at day 14 post initial treatment, all mice were screened 
for the presence of secreted anti-LAG-3 specific immunoglobulins in the serum of circulating 
peripheral blood via direct ELISA. The mouse sera with highest ELISA reactivity was screened 
for the ability to stain cellular expressed human LAG-3 protein through flow cytometric staining 
of JRT LAG-3+ C8 cells, developed as described in Chapter 4, when secondary-stained with a 
FITC conjugated anti-mouse Ig antibody (Figure 5.1). Background staining by both control sera 
and immunised sera was observed when staining LAG-3- JRT WT cells compared to secondary 
only control and clarifying a background sera fluorescence intensity shift (Figure 5.1a). Fur-
thermore, immunised sera showed no significant fluorescence intensity increase compared to 
control sera. 
In JRT LAG-3+ C8 cells, immunised mouse serum was able to stain the LAG-3 expressing 
cells as indicated by a fluorescence intensity shift compared to control sera (Figure 5.1b). This 
staining capacity was compared to the FITC-conjugated anti-LAG-3 clone 17B4 which binds 
JRT LAG-3+ C8 but not JRT WT cells. 
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Figure 5.1 – LAG-3 dependent staining capacity of immunised mouse anti-sera:  
a) Fluorescence histograms from flow cytometry analysis of anti-sera from LAG-3:Fc 
immunised mice (red) and control mouse (black) exhibiting no significant binding to LAG-3- 
JRT WT cells detected using FITC-conjugated anti-mouse secondary staining. Both control and 
immunised anti-sera show significant background staining compared to FMO plus secondary 
only control (dark grey) and commercial anti-LAG-3 clone 17B4 (orange). 
b) Flow cytometric analysis of LAG-3:Fc immunised mouse anti-sera (red) binding to JRT 
LAG-3+ C8 cells detected using FITC-conjugated anti-mouse secondary staining as 
demonstrated by a shift in fluorescence intensity compared to control mouse anti-sera (black) 
and FMO plus secondary only control (dark grey).  LAG-3:Fc immunised mouse anti-sera 
exhibited enhanced staining compared to the commercial anti-LAG-3 clone 17B4 (orange). 
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5.3.2 Cloning of α-LAG-3 specific B cell hybridomas clones 
Having established anti-LAG-3 specific antibody responses within the serum of an immunised 
mouse, the mouse was sacrificed, spleen removed, splenocytes harvested and fused to an im-
mortalised B cell line to form a polyclonal library of B cell hybridomas. This polyclonal library 
was cloned by serial dilution and individual culture wells were screened for LAG-3 reactivity 
by ELISA and flow cytometry as described previously. In the first round of cloning, 960 culture 
well supernatants were screened by direct ELISA using LAG-3:Fc as the adsorbed antigen. 
ELISA positive wells were observed and defined as a significant increase in colorimetric output 
compared to an irrelevant adsorbed antigen. 
Of the ELISA positive wells, ten culture supernatants were selected for screening for reac-
tivity to LAG-3 via flow cytometry. These wells were selected from an array of ELISA positive 
wells due to (i) the highest colorimetric output (ii) the degree of dilution factor, with preferences 
for wells subject to more dilution and (iii) wells which derived from distinct starting populations 
i.e. wells from different cloning plates. These criteria were used in order to increase the proba-
bility of selecting high affinity antibodies, of monoclonality or low polyclonality and of distinct 
clonotypes. Of the ten ELISA positive cultures screened, seven cultures were LAG-3 positive, 
as defined by a significant increase in gMFI in JRT LAG-3+ C8 but not JRT WT cells. The seven 
candidate clones were subjected to three further rounds of limiting dilution cloning to ensure 
single cell clonality. During this process, one clone, 6D3, lost expression of anti-LAG-3 specific 
antibodies. This left a final candidate antibody panel consisting of six monoclonal hybridomas 
termed 1B5, 6F7, 6D6, 4C10, 10C8 and 4B1 which all expressed LAG-3 specific antibodies 
within their culture supernatants (Figure 5.2). 
5.3.3 Production of anti-human LAG-3 specific antibodies 
Having successfully cloned six anti-LAG-3 antibody expressing hybridomas and confirmed 
their clonality (described in section 5.5), all six hybridoma clones were taken forward for large 
scale antibody production and purification for downstream experiments. These experiments, 
such as biophysical, cellular and in vitro characterisation assays require purified antibody of 
known concentration, as opposed to the crude culture supernatants used in screening selection. 
Through high-density culture in bovine Ig depleted serum, milligram quantities of antibody were 
purified using affinity chromatography of varying yields ranging from 5.5 – 75.4 mg (Appendix 
6). The resulting purified mAb preparation was of high purity, demonstrated by SDS-PAGE 
analysis, and showed molecular mass separation indicative of immunoglobulin (Ig): a single 
~150 kDa band in non-reduced conditions and two bands, ~50 kDa and ~25 kDa, in reduced 
conditions representing Ig heavy and light chains, respectively (Figure 5.3). 
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Figure 5.2 –LAG-3 specific antibody responses in screened hybridoma supernatants:  
 a) Fluorescence histograms from flow cytometry analysis showing LAG-3 specific binding of 
generated mouse hybridoma supernatants to JRT LAG-3+ C8 cells (right) and not JRT LAG-3-  
WT cells (left), detected using FITC-conjugated anti-mouse secondary antibody staining. Each 
monoclonal hybridoma culture supernatant is coloured as in b), background FMO plus 
secondary antibody (grey). 
b) Raw geometric mean fluorescence intensity (gMFI) values generated from flow cytometry 
data shown in a) demonstrating specific binding of all hybridoma culture supernatants to JRT 
LAG-3+ C8 cells (right) with significant staining above background FMO plus secondary 
control (FMO+2). Staining in JRT LAG-3- WT cells (left) is equivalent to background. 
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Figure 5.3 – Generation of high purity anti-LAG-3 monoclonal antibody samples: 
a) Example affinity chromatography purification of mouse mAbs from monoclonal hybridoma 
culture supernatants. Absorbance at 280nm (A280) FPLC trace of binding, wash and elute 
phases of purification (left) shows separation of non-specific proteins during binding and wash 
phase and elution of mAb during elute phase. Enlargement of the elute phase trace (right) high-
lights single-peak protein species within affinity column bound eluents. 
b) SDS-PAGE analysis showing protein purity after affinity and size exclusion chromatography 
purification of the six candidate mAbs highlighting in-tact whole Ig in non-reducing conditions 
(left) and individual heavy (IgH) and light (IgL) chains in reducing conditions (right).  
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5.4 Sequence characterisation of generated anti-LAG-3 monoclonal anti-
bodies 
Having established and produced a panel of six candidate anti-LAG-3 antibodies, each mAb 
clone was characterised in terms of their genetic and protein sequence. This process was fol-
lowed for a number of reasons. Firstly, knowledge of antibody protein sequences allows the 
production of the antibodies recombinately in alternative cell lines or expression systems should 
(i) a hybridoma stop expressing and secreting antibody or (ii) the antibodies are required to be 
reformatted i.e. chimerisation or humanisation. Secondly, knowledge of the protein sequence, 
particularly that of the complementarity determining regions (CDRs) is required for patent ap-
plication to demonstrate the novelty of the intellectual property. Thirdly, analysis of each 
sequence with respect to each other gives an indication of the diversity of the candidate antibody 
panel with respect to the epitopes of LAG-3 each antibody binds to. 
As cloning of each mAb was performed at the cellular stage, each mAb can be defined at the 
protein level by inference to the corresponding B cell hybridoma cells mRNA sequences of the 
translated clonal antibodies. As a result, each candidate antibody was sequenced from RNA in 
order to obtain the variable domain sequence of each antibody and isotyped to determine the 
constant domain sequence usage of each antibody. From this information, one can determine the 
full protein sequence of each generated anti-LAG-3 antibody. 
5.4.1 Candidate LAG-3 antibodies have narrow isotypes 
Antibodies in vivo are able to mediate a diverse range of functions through the usage of different 
antibody classes. As a result, the isotype of a raised anti-LAG-3 antibody would influence its 
functional ability in future studies, when used in their current form i.e. without isotype switch-
ing. Experimentally, antibody isotype influences the affinity of antibody for Fc binding agents 
such as Protein A and Protein G which are often used in purification or in the immobilisation of 
antibodies in a favourable orientation for antigen binding. Moreover, knowledge of the antibody 
isotype is a pre-requisite in the determination of variable chain usage and clonotype in the pro-
cess of antibody sequence determination. To this end, the isotype of each antibody was 
determined. 
Antibody isotype was firstly assayed at the protein level through the use of isotype immuno-
assay shift sticks by testing soluble antibody within culture supernatants (Appendix 7). This 
isotype was then used in the selection of sequencing primers for the determination of each heavy 
and light variable chain VH and VL, respectively. The success of this experimental procedure, 
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therefore, confirmed and consolidated the isotyping initially shown through immunoassay shift 
sticks (Table 5.2).  
The six candidate antibodies consisted of two different isotypes as defined by their constant 
heavy (CH) gene usage: five antibodies (1B5, 6D6, 6F7, 10C8 & 4C10) were all IgG2b isotype 
and one antibody (4B1) of IgG2a isotype. All candidate antibodies had kappa constant light 
chain usage (CL). This moderate diversity in isotype suggested either a diversity in generated 
clonotypes against the LAG-3:Fc immunogen, or alternatively, a single isotype shifting event as 
a result of the maturing B cell response by the immunised mouse across the boosted immunisa-
tion schedule. 
Both forms of IgG2 used by the generated antibodies have favourable affinities for the acti-
vating Fc receptor (FcR) found on mouse macrophages and natural killer cell (NK) cells, 
FcγRIII (CD16) (Bruhns et al. 2012). Binding of antibodies by NK cells via their Fc domain 
signals the lysis of antibody coated target cells through the antibody-dependent cellular cyto-
toxicity (ADCC) capabilities of NK cells. These antibodies, in the current protein formulation, 
therefore provide a useful reagent in studying the capacity of each antibody to perform mouse 
NK cell ADCC in vitro. Likewise, IgG2a and IgG2b isotypes have favourable affinities for the 
antibody binding protein C1q and could therefore be theoretically capable of triggering classical 
complement pathway activation. C1q complex formation can consequently promote comple-
ment dependent cytotoxicity (CDC), making these antibodies in their current formulation of 
favourable isotype for the capacity of CDC using mouse serum proteins in vitro (Neuberger & 
Rajewsky 1981). 
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5.4.2 LAG-3 antibodies are highly related clones 
Having determined the isotype of each mAb, each hybridoma clone had their antibody variable 
chains (VH and VL) sequenced. Due to the highly variable nature of a VH and VL RNA sequence, 
performing PCR amplification of Ig sequences, sufficient for sequencing from a cDNA library, 
is not trivial and requires a library of degenerate primers. As a result, each hybridoma was se-
quenced commercially from frozen cell samples (Absolute Antibody, UK).  
The resulting data yielded the full length VH and VL DNA sequences for each of the six can-
didate hybridoma clones as well as the heavy and light chain signal sequences for five (6F7, 
4B1, 10C8, 6D6, 1B5) of the six hybridoma clones. The sixth clone, 4C10, proved to be difficult 
to sequence likely due to low levels of VH and VL mRNA transcript obtained during RNA ex-
traction. This observation correlated with the low protein yield obtained during large scale 
expression and purification of each mAb described previously (section 5.3.3). A full length se-
quence for the VH and VL of 4C10, however, was still obtained. The ability to determine a reliable 
Sanger sequencing chromatogram for each of the six candidate mAbs confirmed their clonality 
and therefore confirmed purified antibody samples contain a single mouse anti-LAG-3 antibody 
sequence. In addition, each antibody was confirmed to contain functional Ig recombination 
events based on its sequence, which is expected since antibodies were screened and selected for 
based on functionality. 
Sequence analysis of six candidate VH and VL sequences identify each mAb as being unique 
but highly related clones. This low sequence variability, particularly across the Ig framework 
region, is caused by the usage of the same IGH and IGL gene segments during antibody rear-
rangement. Each VH sequence had the same V, D & J-segment usage, V1-19*01, D2-3*01 and 
J2*01 respectively, according to sequence alignment to the IMGT/V-QUEST reference directory 
sequences for mouse immunoglobulins (Table 5.2). Likewise VL sequences were assigned to use 
identical V & J-genes, V19-93*01 and J2*01 (Lefranc 2008).  
For both VH and VL sequences, the query antibody sequences did not contain complete iden-
tity to the reference directory sequences, ranging from 89.36 % to 100 % sequence identity. This 
indicates mutations incorporated into the VH and VL sequences outside of the hypermutated 
CDRs. This is commonly found in hybridoma cultures where mutations occur due to genomic 
instability within the first 1-2 weeks after fusion and stabilise over culture time and rounds of 
single cell cloning (Maynard & Georgiou 2000). These mutations, although outside of the anti-
gen binding site, can also influence antigen binding affinity and can result during the process of 
affinity maturation (Wedemayer et al. 1997). 
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These mutational differences can be visualised through analysis of the Shannon positional 
entropy across the length of the six VH and VL sequences (Figure 5.4a). Despite these mutations 
occurring throughout the sequence, all six antibodies show no variability, H(x) = 0, across the 
conserved residues Cys23, Trp41, Met89, Cys104 & Trp118. Mutations in these residues, away 
from those that are allowed, would result in a non-functional Ig sequence and would, therefore, 
be selected against during screening.  
5.4.3 LAG-3 antibodies contain highly related but unique paratopes 
Like the framework regions, all six generated candidate clones exhibit different, but related, 
CDR loop sequences as assigned by the IMGT/V-QUEST reference sequence alignment tool 
(Table 5.2). As the CDR loops, in combination, make up the sequence specificity of the antigen 
binding site, the fact that all sequences have highly related CDR loops suggests that each anti-
body binds to a similar, or the same, epitope.  
Despite similarities of CDR usage between each mAb, subtle differences between each anti-
body are present across the CDR loop regions (Figure 5.4a). This diversity is not consistent 
throughout the different CDR loops i.e. each loop does not contain an equal range of diversity. 
Similarly, certain CDR loop positions exhibit a greater degree of diversity, such as VL CDR3 
residue 5 which has three possible amino acids across the mAb panel and is the single contrib-
utor to diversity across this CDR loop compared to VL CDR2 which exhibits no diversity across 
the dataset (Figure 5.4b).  
By analysing each CDR loop as a fixed string of amino acids, one can assign usage similarity 
of each individual CDR string by each mAb clone (Figure 5.4c). For example, 1B5, 6F7, 6D6 
& 4C10 all used a common VL CDR3 sequence string, whereas 10C8 and 6F7 used a unique 
sequence string each resulting in three possible VL CDR3 sequence strings. In contrast, as pre-
viously stated, all VL CDR2 sequences were identical across all mAb clones, thus, resulting in 
one single possible sequence string. The greatest whole CDR sequence string diversity within 
the mAb candidate clones was exhibited by VH CDR3 which incorporated four different possible 
sequence strings. This variation aligns with knowledge of VH CDR3 diversity which, due to D-
segment incorporation during immunoglobulin rearrangement, is the most variable CDR loop 
in immunoglobulins (Jung et al. 2006). 
Despite similarities in CDR usage, no two candidate mAbs had identical amino acid se-
quences across the length of the variable domain (VH & VL) or, more relevantly, the full paratope 
(VH CDR1, 2 & 3, VL CDR1, 2 & 3) as shown by no common identical sequence string usage 
(Figure 5.4d). Moreover, analysis of the phylogeny of each protein sequence, either entire VH 
VL or the full paratope, (VHVL CDRs) revealed the common ancestry of each antibody sequence 
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(Figure 5.4e). Here, each antibody can be compared, either at the full length or paratope level, 
to one another in terms of their overall sequence similarity. 
Together, these data summarise the similarities between each of the generated anti-LAG-3 
mAb clones in terms of their protein sequence and the antigen binding sites encoded within 
them. As each mAb clone had a unique but highly related antigen binding site sequence, one 
can hypothesise that each mAb will bind to the same or similar epitope. Due to subtle differences 
being present, however, one can also hypothesise that each mAb may bind to the epitope with 
varying binding affinity and thus potentially varying functionality. By correlating sequence us-
age with later functional characterisation, it may be possible to attribute sequence specific 
explanation for observed functional capacity.  
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Table 5.2 – Sequence characterisation of α-LAG-3 antibodies aligned to IMGT reference database 
 
  
mAb Chain Type V-Gene % Identity J-Gene % Identity D-Gene CDR1 CDR2 CDR3 
1B5 H IgG2b V1-19*01 93.06 J2*01 89.36 D2-3*01 GYRITDFY INPYNGDT CARDDGNYVRFDYW 
 L κ V19-93*01 95.34 J2*01 97.30  QDIKRF YTST CLQYDNLYTF 
4B1 H IgG2a V1-19*01 95.49 J2*01 87.50 D2-3*01 GFRITDYY INPYNGDT CTRDDGNYVRFDYW 
 L κ V19-93*01 97.49 J2*01 97.30  QDINKF YTST CLQYVNLYTF 
6D6 H IgG2b V1-19*01 96.18 J2*01 89.36 D2-3*01 GYTITDYY INPYNGVT CARDDGNYVRFDYW 
 L κ V19-93*01 98.93 J2*01 100  QDINKF YTST CLQYDNLYTF 
6F7 H IgG2b V1-19*01 96.18 J2*01 89.36 D2-3*01 GYRITDFY INPYNGDT CARDDGNYIRFDYW 
 L κ V19-93*01 98.92 J2*01 94.59  QDIKKF YTST CLQYDNLYTF 
10C8 H IgG2b V1-19*01 97.92 J2*01 89.36 D2-3*01 GYTITDYY INPYNGVT CARDDGNYVRFDYW 
 L κ V19-93*01 97.85 J2*01 100  QDINKF YTST CLQYFNLYTF 
4C10 H IgG2b V1-19*01 97.57 J2*01 89.36 D2-3*01 GYTITDYY INPYNGDT CARDDGNYVRFDYW 
 L κ V19-93*01 97.85 J2*01 100  QDINKF YTST CLQYDNLYTF 
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(Figure legend overleaf) 
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Figure 5.4 –Bioinformatic analysis of aligned anti-LAG-3 mAb amino acid sequences: 
a) Shannon positional entropy plots highlighting entropy (variation) in VH and VL sequences by 
the six candidate mAb clones. Sequence differences, quantified by higher entropy, are found 
within (black bars) and outside (grey bars) the CDR loop regions (red). 
b) Sequence logo plots of amino acid usage and variation within the CDR loops of the six 
candidate mAb clones coloured by amino acid properties: polar (green) basic (blue) acidic (red) 
hydrophobic (black). 
c) Circular relationship graphs highlighting identical sequence string usage at each CDR loop 
by the six candidate mAb clones. Connected nodes represent clones with identical sequence 
usage for the given CDR loop. Inset numbers show the number of unique sequence strings within 
the dataset for the given CDR loop. 
d) Circular relationship graphs, as in c), highlighting the uniqueness (no connected nodes) of 
each candidate mAb clone at both the full length variable region (VH VL) and the full paratope 
(VH VL CDRs). 
e) Unrooted neighbour joining phylogenetic tree for both the full length variable region (VH VL) 
and the full paratope (VH VL CDRs) highlighting sequence relationships between mAb clones. 
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5.5 Functional binding characterisation of anti-LAG-3 antibodies 
Having determined that the panel of anti-LAG-3 monoclonal antibodies have unique antigen 
binding sites, each antibody was characterised for its ability to bind to LAG-3 in a cellular and 
in vitro protein context. As the primary aim of generating these anti-LAG-3 antibodies is to bind 
human LAG-3 expressed in vivo on LAG-3+ T cells in order to induce the functional depletion 
of those cells, generated antibodies must be able to (i) bind to LAG-3 protein on the surface of 
cells (ii) discriminate LAG-3 from other human proteins i.e. maintain specificity. Thus, the can-
didate antibody panel was screened to establish which antibody, or antibodies, best satisfied 
these criteria. This characterisation would lead to rational preference for an antibody, or anti-
bodies, to be used in downstream effector functional characterisation experiments. 
As a result, purified antibody samples were firstly assayed for their capacity to stain LAG-
3+ cells and not cross-react with CD4+ cells by flow cytometry. Secondly, antibodies were tested 
for the ability to detect LAG-3 protein by Western blot. 
5.5.1 Mouse monoclonal antibodies specifically bind LAG-3+ cells 
In order to confirm that purified antibody samples bound LAG-3 expressing cells, and to assay 
the staining capacity of each generated anti-LAG-3 antibody within the candidate panel, each 
antibody was characterised by their ability to bind a LAG-3 expressing cell line by flow cytom-
etry at varying concentrations. The JRT LAG-3+ C8 lentivirally transduced cells, described 
previously, were once again used as a LAG-3 expressing cell model. Purified antibody samples 
were used as primary antibody stains at a concentration series from 2 µg/mL to 3.2 ng/mL by 
serial dilution. Staining capacity was detected through a fixed concentration of secondary anti-
body (2 µg/mL) and performed on fixed cell numbers (0.1 x106 cells).  
As shown using hybridoma culture supernatants, all generated mAb bound LAG-3+ cells 
where each mAb exhibited concentration-dependent binding to LAG-3+ cells as indicated by 
increasing fluorescence intensity shifts at increasing mAb concentration (Appendix 8a). Each 
mAb showed similar binding capacity, with no obvious differences in fluorescent staining. Each 
antibody exhibited sigmoidal log(dose) response when background subtracted geometric mean 
intensity (gMFI) values were taken as response values (Appendix 8b). Identical experiments 
were also performed using the commercially available 17B4 anti-LAG-3 antibody (Appendix 
8c&d).  
Alignment of the log(dose) response of each antibody show that each of the generated clones 
exhibit similar dose responses (Figure 5.5a). Despite similarities, subtle differences in staining 
capacity were observed. Three antibodies, 6F7, 10C8 and 1B5 exhibited enhanced staining at 
0.4 µg/mL which is in the range of a typical starting point concentration used for flow cytometric 
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analysis. All generated antibodies, however, performed very similarly at low concentrations 
(0.016 µg/mL) and, thus, no single antibody had significant performance advantage at low con-
centration. 
By stratifying each mAb by the gMFI observed at the highest concentration, it was demon-
strated that one clone, 6F7, exhibited enhanced staining compared to the mAb panel as well as 
the commercial clone 17B4 (Figure 5.5b&c). In addition, all antibodies exhibited an enhanced 
staining capacity compared to 17B4 at this concentration. These data suggest that the antibody 
panel presents comparable experimental functionality compared to the 17B4 commercial anti-
body, which is typically used throughout the literature to quantify the expression of human 
LAG-3 expressing cells by flow cytometry (Baixeras et al. 1992; Tian et al. 2015).  
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Figure 5.5 – Comparative analysis of anti-LAG-3 antibody binding to LAG-3+ cells: 
a) Combined background subtracted geometric mean fluorescence intensity (gMFI) response 
values as a function of log10 antibody concentration for each of the six candidate and commercial 
(17B4) anti-LAG-3 mAbs. Log(dose) response curves show similar binding capacity of 
generated candidate mAbs and enhanced staining capacity compared to 17B4 at higher, 
experimentally relevant, concentrations. 
b) Fluorescence histograms from flow cytometry analysis of each anti-LAG-3 mAb clone 
(coloured as in a) and c))at 2 µg/mL binding JRT LAG-3+ C8 cells detected by secondary 
staining with FITC-conjugated anti-mouse secondary antibody staining. 
c) Background subtracted geometric mean fluorescence intensity (gMFI) values at 2 µg/mL 
(calculated from data shown in b)) stratified by decreasing response. All generated mAb clones 
exhibit enhanced staining capacity compared to the 17B4 commercial anti-LAG-3 antibody with 
6F7 generating the largest response.  
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5.5.2 Mouse monoclonal antibodies demonstrate no cross reactivity to CD4 expressing 
cells 
As the immunogen used to generate the anti-LAG-3 specific responses in mice was a whole 
protein, the probability of generating antibodies with off target affects is greater than that of a 
short peptide-KLH conjugated immunogen approach (Hancock & OReilly 2005). Whilst gener-
ated antibodies demonstrated no significant background binding to LAG-3- JRT WT cells, this 
cell line does not express CD4 protein at the cell surface (as described in Chapter 4). CD4 is 
predicted to have a highly related protein structure to LAG-3, despite its low sequence homology 
(Baixeras et al. 1992). As a result, the epitope(s) of the generated anti-LAG-3 mAbs may have 
commonality in CD4 and could, thus, exhibit cross-reactivity.  
In order to assess any potential cross-reactive binding, the MOLT-3 T lymphoblast cell line 
was stained with the candidate mAb panel and analysed by flow cytometry. MOLT-3 cells have 
been shown to be LAG-3- by flow cytometry using the 17B4 anti-LAG-3 mAb clone (Chapter 
4), as this clone was raised against the unique D1 loop region not found in CD4 (Baixeras et al. 
1992). Likewise, MOLT-3 cells have also been shown to express CD4 (Chapter 4). Conse-
quently, the six candidate anti-LAG-3 antibodies were used to stain MOLT-3 cells to which no 
binding was observed (Figure 5.6a). LAG-3 staining by the candidate antibodies resulted in no 
significant shift in fluorescence intensity or gMFI compared to controls or MOLT-3 staining by 
the 17B4 clone. In addition, pre-incubation of MOLT-3 cells with the 1B5 mAb clone made no 
impact on consequent CD4 staining which is also replicated by 17B4 (Figure 5.6b). Together, 
these data show that the generated anti-LAG-3 antibodies show no ability to bind cell surface 
expressed CD4+ by flow cytometry and that the generated antibodies do not compete with a CD4 
specific antibody staining of CD4+ cells. 
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Figure 5.6 – Anti-LAG-3 mAbs show no cross-reactive binding to LAG-3- CD4+ cells: 
a) Fluorescence histograms from flow cytometry analysis of each anti-LAG-3 mAb clone 
(coloured as indicated) on LAG-3- CD4+ MOLT-3 cells detected by secondary staining with 
FITC-conjugated anti-mouse antibody. All mAb clones show no significant binding to LAG-3- 
CD4+ MOLT-3 compared to FMO + secondary control (grey). 
b) Fluorescence histograms from flow cytometry analysis of CD4 staining on LAG-3- CD4+ 
MOLT-3 cells pre-stained with buffer control (black; solid) or anti-LAG-3 antibody clone 1B5 
(cyan; dashed) or 17B4 (orange; dashed). Pre-staining with LAG-3 antibodies showed no 
abrogation of CD4 staining observed compared to FMO control (grey). 
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5.5.3 Mouse monoclonal antibodies specifically bind LAG-3 by Western blot 
Having established that the LAG-3 antibodies bind LAG-3 expressing cells, each antibody was 
tested for the ability to bind full length LAG-3 protein from cell lysates. Analysis of binding by 
Western blotting reveals the molecular weight of the antigen and can thus be used to confirm 
binding antigen is of a molecular mass known for that antigen. In addition, detection of antigen 
via Western blot is a strong indicator that the antigen epitope is a linear epitope as tertiary protein 
fold is not maintained during SDS-PAGE separation. Moreover, Western blotting provides a 
sensitive method for detecting low levels of protein analyte or, alternatively, lower affinity and 
less specific interactions. Whilst these low specificity interactions typically manifest themselves 
as unwanted background, Western blots can also give an indication of cross-reactivity and con-
sequently an antibodies ability to discriminate towards the desired antigen. 
Given this, each of the six mAbs were assayed for binding to JRT LAG-3+ C8, LAG-3- JRT 
WT and LAG-3- CD4+ MOLT3 cell lysates (Figure 5.7). Each antibody bound a single band, 
with varying intensity, at approximately 72 kDa in size in LAG-3 expressing JRT LAG-3+ C8 
cells only. Despite a theoretical molecular mass of 54 kDa as defined by the protein component 
of LAG-3, Western blot analysis using anti-human and anti-mouse LAG-3 antibodies have iden-
tified full length LAG-3 at ~72 kDa attributed to the extensive carbohydrate post-translational 
modifications (Baixeras et al. 1992; Li et al. 2004). This size band was also observed using the 
17B4 and 13E2 mAb clones as a primary probe. By normalising protein mass loaded, secondary 
antibody conditions and blot exposure between mAb probe antibodies, each antibody can be 
compared for ability to bind LAG-3 in a Western blot assay. 4B1 and 1B5 clone antibodies 
produced the largest signal, however, some background detection due to potential LAG-3 deg-
radation or cleavage products was observed. The 6D6 clone demonstrated the most desirable 
detection qualities by distinguishing an intense single protein band. 
Since previous flow cytometry experiments did not give an indication of molecular weight 
of their binding antigen, these previous experiments did not rule out the, albeit highly unlikely, 
chance that antibodies bound to rat CD2 protein inserted as a marker alongside LAG-3 as a 
marker of lentiviral transduction. Rat CD2, which was also present in JRT LAG-3+ C8 but not 
JRT WT cells, is detected at a molecular weight of approximately 45 kDa and is thus distin-
guishable from LAG-3 via Western blot. These results clarify that the anti-LAG-3 antibodies 
detect a protein present in the LAG-3 expressing cell lysates of a molecular mass similar to that 
of previously documented full length LAG-3 glycoprotein and identical to that of commercial 
and independently generated anti-LAG-3 antibodies. 
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Figure 5.7 – Western blot characterisation of generated anti-LAG-3 antibodies: 
Detection of a single band protein at approximately 72 kDa in size present in JRT LAG-3+ C8 
cells (C8) and not LAG-3- JRT WT cells (WT) or LAG-3- CD4+ MOLT3 cells (M3) by primary 
probing with the six indicated candidate mAb clones. Dashed white lines represent cuts made 
to incubate membrane with differing primary antibodies. 
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5.6 Generated antibodies bind LAG-3 antigen at high avidity 
In order to further characterise each antibody and quantify an accurate measure of antibody 
to antigen binding, the six mAb candidate clones were assayed in terms of their binding avidity 
for their antigen. Whilst previous experiments have indicated varying capacities for binding 
LAG-3 in experimental systems, these assays do no accurately quantify binding strength for 
LAG-3 protein.  
To fulfil the primary aim of generating anti-LAG-3 mAbs which bind human LAG-3 expressed 
in vivo on LAG-3+ T cells in order to induce the functional depletion of those cells, the binding 
of generated antibodies must (i) occur with sufficient on rate such that dosage relevant concen-
trations effectively bind LAG-3 and (ii) bind LAG-3 long enough to facilitate functional 
depletion of those cells. Since one of the most important criteria for a good therapeutic agent is 
the strength or potency at which the agent can bind to its target, an accurate measurement of this 
potency could define the rationale for selection of that agent for further development. 
5.6.1 LAG-3 mAbs bind LAG-3:Fc immunogen via a monogamous bivalent two-state 
binding reaction 
Binding avidity/affinity measurements between the anti-LAG-3 mAb panel and LAG-3:Fc were 
determined via surface plasmon resonance (SPR) analysis of immobilised LAG-3:Fc. Binding 
of antibodies was measured by the individual single-injection of mAbs as analyte. Due to the 
bivalent nature of both LAG-3:Fc ligand and mAb analyte, SPR experiments were performed at 
low ligand densities in order to reduce mixed reaction kinetics. 
All generated antibodies specifically bound LAG-3:Fc demonstrated by response unit bind-
ing curves observed in control surface subtracted sensograms (Figure 5.8a). The sensograms 
revealed binding kinetics typical of an antibody binding with bivalency, characterised by a slow 
association rate and orders of magnitude slower dissociation rate. The anti-LAG-3 mAbs 
demonstrated matching broad kinetics to that of the commercial 17B4 clone antibody (Figure 
5.8b). This analysis suggests all antibodies tested exhibit binding strength within a similar range 
in agreement with observed cellular binding capacity shown by flow cytometry. 
To quantify this binding strength and explain the valency of binding being observed, a num-
ber of single injection kinetic binding models were applied and fitted to the observed 
experimental data as shown in Chapter 4 (Table 4.1). Applied models were compared for quality 
of fit by visual observation of the curve fit quality, analysis of χ2 values and residual plots. 
Simultaneous curve fit analysis determined that anti-LAG-3 antibody binding to LAG-3:Fc was 
best described by the two-state reaction model. As a result, the binding strength observed in 
these SPR experiments was the result of avidity effects.  
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Application of the two-state reaction model generated a good fit across all the generated 
mAbs (Figure 5.8a) as well as the commercial 17B4 clone (Figure 5.8b). This model, which 
can rationally be applied to the system being studied, is described by the following reaction 
equation, where two ligands (A & B) bind to form a complex (AB) which undergoes a second 
binding event to form a second state complex (ABx): 
𝐴        +        𝐵        
𝑘𝑜𝑛1
↔
𝑘𝑜𝑓𝑓1
         𝐴𝐵        
𝑘𝑜𝑛2
↔
𝑘𝑜𝑓𝑓2
         𝐴𝐵𝑥 
(Eq. 5.1) 
In the two-state reaction model, there are four kinetic constants (kon1, koff1, kon2 and koff2), 
which describe the rates at which the two complex states (AB and ABx) of the reaction model 
form. These rate constants are described by the following rate equations: 
𝑑𝐴𝐵
𝑑𝑡
= (𝑘𝑜𝑛1[𝐴][𝐵] − 𝑘𝑜𝑓𝑓1[𝐴𝐵]) − (𝑘𝑜𝑛2[𝐴𝐵] − 𝑘𝑜𝑓𝑓2[𝐴𝐵𝑥]) 
(Eq. 5.2) 
𝑑𝐴𝐵𝑥
𝑑𝑡
= 𝑘𝑜𝑛2[𝐴𝐵] − 𝑘𝑜𝑓𝑓2[𝐴𝐵𝑥] 
(Eq. 5.3) 
Relation of this model to the system being studied, whereby bivalent mAbs are binding LAG-
3:Fc, with independent but identical binding sites, allowed the formation of a monogamous bi-
valent mode of binding, visualised by the following schematic and equation. Here, Eq.5.1 has 
been modified to include terms of the antibody-antigen system being studied: 
       
(Eq 5.4) 
Having applied the two-state reaction model to the observed data, the four kinetic parameters 
which describe the rate of binding (kon1, koff1, kon2 and koff2) were determined from the model 
𝐿𝐴𝐺3: 𝐹𝑐       +          𝑚𝐴𝑏           
𝑘𝑜𝑛1
↔
𝑘𝑜𝑓𝑓1
       𝐿𝐴𝐺3𝐹𝑐: 𝑚𝐴𝑏     
𝑘𝑜𝑛2
↔
𝑘𝑜𝑓𝑓2
     𝐿𝐴𝐺3𝐹𝑐: 𝑚𝐴𝑏𝑥 
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(Table 5.3). Whilst these kinetic parameters can, themselves, yield comparative information 
about the strength of each antibody-antigen interaction, the observed avidity or affinity is an 
accumulation of all of the four kinetic parameters. These kinetic parameters are, therefore, best 
used to form the basis for the mathematical determination of consequent anti-LAG-3 mAb equi-
librium constant avidity measurements for LAG-3:Fc. The application of the two-state binding 
model with acceptable fit, however, strongly suggests a mode of binding measured as a result 
of monogamous bivalent binding as opposed to observed polygamous binding, which would 
favour a bivalent interaction kinetic model. 
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Figure 5.8 – Anti-LAG-3 mAbs bind LAG-3:Fc with monogamous bivalent two-state kinetics: 
a) Surface plasmon resonance (SPR) analysis of each indicated candidate mAb binding to LAG-
3:Fc. Analyte contact time is shown by arrowhead lines where injection length (solid) and 
dissociation time (dashed) are indicated. Experimental sensograms (grey) and two-state kinetic 
model fits (black; dashed) from which kinetic parameters of binding are calculated are shown. 
Residual plots and χ2 values show the quality of fit of the two-state kinetic model to the observed 
data. 
b) Surface plasmon resonance (SPR) analysis the commercial 17B4 mAb binding to LAG-3:Fc 
as described in a). 
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Table 5.3 – Two state reaction model fit parameters of mAb to LAG-3:Fc binding 
[Analyte] = Concentration of injected mAb analyte, RU = Response units, Rmax = Maximum 
analyte binding capacity in RU, RI = Bulk refractive index effect in RU,  
χ2 = ∑
(𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑−𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑)2
𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑
; lower χ2 values indicate better model fitting. 
 
  
mAb kon1 (1/Ms) koff1 (1/s) kon2 (1/s) koff2 (1/s)  [Analyte] (µM) Rmax (RU) RI (RU)  χ
2
 
1B5 5.94 x10
4
 0.0409 0.0274 3.56 x10
-5
  1.29 817 -6.78  1.77 
4B1 9.28 x10
4
 0.0453 0.0298 6.00 x10
-5
  1.29 275 2.83  0.371 
10C8 8.28 x10
4
 0.0268 0.0109 6.76 x10
-5
  1.29 283 -5.95  6.43 
4C10 3.30 x10
4
 0.0265 0.0208 8.28 x10
-5
  1.29 793 -12.6  6.22 
6F7 4.64 x10
4
 0.0155 0.0155 1.28 x10
-4
  1.29 930 -12  18.0 
6D6 6.30 x10
4
 0.0207 0.0100 1.56 x10
-4
  1.29 317 -2.31  5.63 
17B4 5.72 x10
4
 0.0334 0.0212 6.87 x10
-5
  1.37 869 -8.96  10.6 
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5.6.2 LAG-3 mAbs bind LAG-3:Fc with subnanomolar-to-nanomolar avidity 
Once a suitable kinetic model which explained the observed kinetics of mAb binding to LAG-
3:Fc had been applied, these kinetic fits were used to calculate the avidity observed for each 
mAb binding to the LAG-3:Fc protein. As a result, this obtained avidity could be used to com-
pare (i) each antibody to each other within the mAb panel, (ii) the generated antibodies with the 
commercial 17B4 clone and (iii) the generated antibodies with other published therapeutically 
relevant antibody-antigen avidity data. 
Due to the formulation of the SPR experiment, the applied model and its observed relevance 
to the experimental data, the detected binding strength is a result of monogamous bivalency and 
are therefore avidity measurements. From the kinetic parameters determined and shown previ-
ously (Table 5.3), association equilibrium constants (KA) and dissociation equilibrium constants 
(KD) can be calculated as was discussed for one-to-one as discussed in Chapter 4. Due to the 
valency of the binding model, however, these constants are defined by altered equilibrium equa-
tions. To distinguish these equilibrium constants as avidity values, the terms KAv and KDv will 
be used to represent association and dissociation constants, respectively.  
The formation of the final LAG-3:Fc-mAb complex (ABx) is dependent on the rate of for-
mation of the intermediate AB complex. As a result, the cumulative association constant, KAv, is 
a function of the formation of AB and ABx which themselves can be represented by their own 
equilibrium constants KA1 and KA2 respectively. The associated equilibrium affinity constant rep-
resenting the formation of AB, described as KA1 is as follows: 
𝐾𝐴1 = 
𝑘𝑜𝑛1
𝑘𝑜𝑓𝑓1
 
(Eq 5.5) 
Likewise, the associated equilibrium affinity constant representing the formation of ABx, 
described as KA2 is as follows: 
𝐾𝐴2 = 
𝑘𝑜𝑛2
𝑘𝑜𝑓𝑓2
 
(Eq 5.6) 
As KAv is an avidity constant as a consequence of the cumulative equilibrium from A and B 
as unbound ligands, through AB to ABx (as shown in Eq 5.1), KAv is calculated by the following: 
 𝐾𝐴𝑣 =  𝐾𝐴1 + ( 𝐾𝐴1 ∙  𝐾𝐴2 ) 
(Eq. 5.7) 
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Which, by substitution of  𝐾𝐴1 with Eq. 5.5 and 𝐾𝐴2 with Eq. 5.6, results in the following: 
𝐾𝐴𝑣 =  
𝑘𝑜𝑛1
𝑘𝑜𝑓𝑓1
 +  
𝑘𝑜𝑛1 ∙ 𝑘𝑜𝑛2
𝑘𝑜𝑓𝑓1 ∙ 𝑘𝑜𝑓𝑓2
 
(Eq 5.8) 
  Finally, by the reduction of Eq. 5.8, KAv can now be calculated from the kinetic parameters 
kon1, koff1, kon2 and koff2 shown previously (Table 5.3) by the following: 
 𝐾𝐴𝑣 = 
𝑘𝑜𝑛1
𝑘𝑜𝑓𝑓1
 ∙ (1 +
𝑘𝑜𝑛2
𝑘𝑜𝑓𝑓2
) 
(Eq 5.9) 
However, as the units of  𝐾𝐴𝑣 are M
-1, dissociation equilibrium constant (𝐾𝐷𝑣) values, whose 
units are in molar (M), represent a more digestible explanation of the avidity between mAb and 
LAG-3:Fc. As a result,  𝐾𝐷𝑣 is calculated by taking the reciprocal of 𝐾𝐴𝑣: 
  𝐾𝐷𝑣 =  
1
𝑘𝑜𝑛1
𝑘𝑜𝑓𝑓1  ∙ (1 +
𝑘𝑜𝑛2
𝑘𝑜𝑓𝑓2)
 
(Eq. 5.10) 
Which reduces to the following, from which 𝐾𝐷𝑣 values have been calculated: 
  𝐾𝐷𝑣 = 
1
𝑘𝑜𝑛1
∙ (
𝑘𝑜𝑓𝑓1 ∙ 𝑘𝑜𝑓𝑓2
𝑘𝑜𝑓𝑓2 + 𝑘𝑜𝑛2
) 
(Eq 5.11) 
As a result, KDv values for each of the six mAb candidate clones and the commercial 17B4 
mAb, calculated from the experimental SPR measurements described, are presented in Table 
5.4. The resulting avidities for each of the generated anti-LAG-3 antibodies show binding to 
LAG-3:Fc with nanomolar range dissociation constant avidity KDv (0.89 – 5.05 nM). In addition, 
two generated anti-LAG-3 antibodies bound with higher avidity than that of the commercial 
17B4 clone antibody (KDv =1.89 nM). These two antibodies, 1B5 and 4B1 bound LAG-3:Fc 
with subnanomolar avidity (KDv = 0.89 and 0.98 nM, respectively). These results therefore allow 
the ranking of each antibody, based on their avidity for the LAG-3:Fc immunogen. 
This range of avidity is typical of antibody binding to antigen with bivalent effects and is 
comparable to measurements of free antibody binding to high density ligands by other antibod-
ies against different antigens either by SPR or ELISA based methods. 
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Table 5.4 – Avidity equilibrium constant analysis of anti-LAG-3 antibodies for LAG-3:Fc 
KAv = the avidity equilibrium association constant calculated as described by Eq. 5.9 
KDv = the avidity equilibrium dissociation constant calculated as described by Eq. 5.11 
  
mAb kon1 (1/Ms) koff1 (1/s) kon2 (1/s) koff2 (1/s)  KAv (1/M) KDv (M)  KDv (nM) 
1B5 5.94 x104 0.0409 0.0274 3.56 x10-5  1.12 x109 8.93 x10-10  0.89 
4B1 9.28 x104 0.0453 0.0298 6.00 x10-5  1.02 x109 9.80 x10-10  0.98 
10C8 8.28 x104 0.0268 0.0109 6.76 x10-5  5.00 x108 2.00 x10-9  2.00 
4C10 3.30 x104 0.0265 0.0208 8.28 x10-5  3.14 x108 3.18 x10-9  3.18 
6F7 4.64 x104 0.0155 0.0155 1.28 x10-4  2.98 x108 3.36 x10-9  3.36 
6D6 6.30 x104 0.0207 0.0100 1.56 x10-4  1.98 x108 5.05 x10-9  5.05 
17B4 5.72 x104 0.0334 0.0212 6.87 x10-5  5.3 x108 1.89 x10-9  1.89 
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5.6.3 Antibody-antigen single site binding affinity occurs at micromolar affinity 
Analysis of SPR data obtained for mAb binding to the LAG-3:Fc protein can be used to infer 
an affinity measurement for one mAb antigen binding site binding to one LAG-3 epitope anti-
gen. This is possible using the two-state reaction model and kinetic parameters applied 
previously and using an equilibrium constant term described previously, KA1 (Eq. 5.5).  
Since KA1 is the equilibrium association constant associated with the formation of the inter-
mediate AB complex, from unbound A and B, this constant describes the formation of a complex 
by which one single mAb arm binds to one LAG-3 arm: 
 
 
(Eq. 5.12) 
Considering the kinetic parameters kon1 and koff1 which, as illustrated in Eq. 5.5 describes the 
equilibrium association constant of LAG-3:Fc and mAb to form LAG-3Fc:mAb (KA1), a single 
binding event affinity can be inferred. It is worth clarifying that whilst the formation of ABx 
and its contribution to the observed binding measurements are, in this analysis, ignored, these 
kinetics are still present in the model. Instead, the contribution of the first step binding event, 
described by KA1, are deconvoluted from the overall observed two-state reaction model kinetics. 
The same analysis can be performed on the second step interaction i.e. KA2, however, this inter-
action step has less biological relevance in describing the antibody-antigen interaction at the 
single site level. Like with avidity measurements, KA1 has units of M-1 and as a result, KD1, with 
units in M, is preferred and therefore used in the analysis: 
𝐾𝐷1 = 
𝑘𝑜𝑓𝑓1
𝑘𝑜𝑛1
 
(Eq 5.13) 
Observation of calculated KD1 affinity values suggests an alternative hierarchy of binding 
strength amongst the tested anti-LAG-3 antibodies (Table 5.5). All antibodies exhibit affinity 
𝐿𝐴𝐺3: 𝐹𝑐       +          𝑚𝐴𝑏           
𝑘𝑜𝑛1
↔
𝑘𝑜𝑓𝑓1
       𝐿𝐴𝐺3𝐹𝑐: 𝑚𝐴𝑏     
𝑘𝑜𝑛2
↔
𝑘𝑜𝑓𝑓2
     𝐿𝐴𝐺3𝐹𝑐: 𝑚𝐴𝑏𝑥 
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dissociation constants in the submicromolar range (KD1 = 0.32 – 0.80 µM). Four of the generated 
mAbs (10C8, 6D6, 6F7 and 4B1) demonstrated higher affinity KD1 values than the commercial 
17B4 antibody (KD1 = 0.80 µM). Using this analysis, the highest affinity binding antibody was 
10C8 which bound at KD1 = 0.32 µM.  
To this end, the results presented in this section show that the generated anti-LAG-3 antibod-
ies specifically bind LAG-3 glycoprotein at a subnanomolar to nanomolar avidity typical of a 
high affinity immunoglobulin (Figure 5.9). Fine differences in binding kinetics were apparent 
in each of the mAb-antigen interactions and these measurements can thus be used to distinguish 
a hierarchy of binding in which some of the generated antibodies bind with higher affinity and 
avidity than the 17B4 commercial antibody which is most commonly used in the literature. In 
addition, these data show that the generated antibodies and the commercial 17B4 clone are able 
to bind two independent binding sites of LAG-3:Fc through kinetic model fitting of measured 
analyte-ligand binding interactions at low ligand density. 
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Table 5.5 – Affinity equilibrium constant analysis of anti-LAG-3 antibodies for LAG-3:Fc 
KA1= the affinity equilibrium association constant calculated as described by Eq. 5.5 
KD1 = the affinity equilibrium dissociation constant calculated as described by Eq. 5.13 
  
mAb kon1 (1/Ms) koff1 (1/s)  KA1 (1/M) KD1 (M)  KD1 (µM) 
10C8 8.28 x10
4
 0.0268  3.09 x10
6
 3.24 x10
-7
  0.32 
6D6 6.30 x10
4
 0.0207  3.04 x10
6
 3.29 x10
-7
  0.33 
6F7 7.48 x10
4
 0.0335  2.99 x10
6
 3.34 x10
-7
  0.33 
4B1 9.28 x10
4
 0.0453  2.05 x10
6
 4.88 x10
-7
  0.49 
1B5 5.94 x10
4
 0.0409  1.45 x10
6
 6.89 x10
-7
  0.69 
4C10 3.30 x10
4
 0.0265  1.25 x10
6
 8.03 x10
-7
  0.80 
17B4 5.72 x10
4
 0.0334  1.71 x10
6
 5.84 x10
-7
  0.58 
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Figure 5.9 – Kinetic summary of anti-LAG-3 antibodies binding to LAG-3:Fc: 
a) Observed binding curves of each of the indicated anti-LAG-3 antibodies binding to 
immobilised LAG-3:Fc. Inset numbers indicate the avidity (KDv) and affinity (KD1) equilibrium 
dissociation constants determined by simultaneous kinetic model fitting. 
b) Schematic of mAb (black) binding to LAG-3:Fc (red:grey) via a monogamous bivalent 
interaction and the definition of avidity and affinity values used in a). 
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5.7 The LAG-3 mAb panel bind a similar or the same LAG-3 epitope  
Given the similarity in sequence, functional and biophysical characteristics of each antibody, 
the capacity of each antibody to block one-another was investigated using a ‘pulse-chase’ com-
petitive binding approach. Binding of mAb was once again measured against immobilised LAG-
3:Fc using SPR. Determination of binding site competition (epitope competition) was achieved 
by first saturating the available binding sites on the immobilised LAG-3:Fc chip surface with a 
first ‘pulse’ antibody before injecting a second ‘chase’ antibody immediately after. Due to the 
slow mAb dissociation kinetics discussed previously, the second ‘chase’ antibody injection was 
made whilst the epitope of the first ‘pulse’ antibody remained near saturation. Should the ‘chase’ 
antibody be sterically hindered by the ‘pulse’ antibody, due to binding to the same or similar 
epitope on the surface volume of LAG-3:Fc, the resulting association measurement of the 
‘chase’ antibody would be considerably diminished. Thus, by comparison of the binding profile 
of the ‘chase’ antibody with or without pre-bound ‘pulse’ antibody, such steric blocking can be 
deduced. 
Using this described methodology, each of the six candidate mAb clones were shown to 
block the binding of one-another suggesting each antibody binds to the same or similar epitope 
(Figure 5.10a). In order to minimise the protein required to deduce cross-blocking between the 
mAb panel, ‘pulse-chase’ experiments were performed in a cyclic chain; applying the assump-
tion that capacity to block was transferred throughout the chain. For example, if mAb A blocks 
mAb B, and mAb B blocks mAb C, it is assumed that mAb A would also block mAb C. Using 
this assumption, it was possible to deduce that each antibody within the panel blocked one an-
other’s binding. In addition, the 17B4 clone, of which the generated epitope is known, was able 
to be blocked by one of the generated mAb clones (10C8) as well as block one of the generated 
mAb clones (6F7). These data therefore suggest that 17B4 and the generated mAbs also bind to 
a similar or the same epitope.  
In order to ensure that antibody blocking was in fact dependent on the antigenic epitope, a sec-
ond anti-LAG-3 antibody from outside of the generated six mAbs (13E2) was tested for its 
capacity to block binding of candidate or 17B4 antibodies. This antibody is known to bind to a 
unique epitope from 17B4 (F. Triebel, personal communications). As such, saturation of LAG-
3:Fc with 13E2 as the ‘pulse’ antibody was not able to impact on the association of the generated 
6D6 mAb clone (Figure 5.10b). These data suggest that 13E2 binds to a distinct epitope from a 
shared or similar epitope of the candidate mAb panel and 17B4, based on the assumption de-
scribed previously. These results were replicated in a pair-wise sandwich ELISA assay in which 
the generated mAbs and 17B4 used as binding pairs, were unable to detect LAG-3:Fc in the 
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ELISA assay (data not shown). On the other hand, 13E2 was able to pair with any of the gener-
ated mAbs or 17B4 and successfully detect LAG-3:Fc as antigen (data not shown). 
In corroboration with the sequencing data described in this section, these competitive binding 
assays strongly suggest that each of the six generated mAbs bind to the same epitope which is 
in a similar proximity to the epitope for the 17B4 antibody but distinct from the 13E2 antibody. 
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Figure 5.10 – Competitive blocking of anti-LAG-3 antibodies: 
a) Overlay kinetic binding curves of anti-LAG-3 antibody binding to immobilised LAG-3:Fc 
with (black sensograms) and without (colour coded sensograms according to text) saturation of 
the LAG-3:Fc surface with a competitor anti-LAG-3 antibody. Competitor (pulse) antibody in 
each experiment is shown by flat-ended arrow indicating inhibition of query (chase) antibody. 
Classification of inhibition was made by the reduction of association kinetics compared to 
unblocked injections. Chain of inhibition proceeds in a clockwise orientation. Colour coded 
double headed arrows indicate analyte contact time as described in Figure 5.8. 
b) Overlay kinetic binding curves as described in a) highlighting no capacity of mAb 13E2 clone 
antibody to block mAb 6D6 clone binding to LAG-3:Fc thus binding to a distinct epitope of 
LAG-3:Fc. 
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5.8 Molecular blockade of LAG-3-MHC-II binding 
Given that the generated mAbs bind to a similar or the same epitope as the commercial 17B4 
antibody clone, which is known to block the LAG-3-MHC-II interaction (Baixeras et al. 1992), 
it seemed likely that the generated new mAbs would also block the LAG-3-MHC-II interaction. 
As a result, this blocking ability was assayed using SPR binding analysis of the LAG-3:Fc-
HLA-DR1 interaction as established in Chapter 4. In addition, the ability of antibodies to block 
the staining of cellularly expressed full length LAG-3 by HLA-DR1 multimers was assayed 
using the JRT LAG-3 C8 cell line as described in Chapter 4. 
5.8.1 Direct blockade of LAG-3:Fc binding to HLA-DR1 
To directly study the ability of generated antibodies to block the protein-protein interaction be-
tween LAG-3 and MHC-II, LAG-3:Fc protein was incubated with anti-LAG-3 antibodies 
(17B4, 13E2 and 6F7) and analysed for binding of analyte to a HLA-DR1 immobilised sensor 
chip via SPR. Incubation and co-injection of an excess of each anti-LAG-3 antibody (17B4, 
13E2 and 6F7) with LAG-3:Fc did indeed result in the abrogation of LAG-3:Fc binding to HLA-
DR1 compared to unblocked and an irrelevant antibody control (Figure 5.11a&b). This abroga-
tion was observed as a complete reversal of binding in reference subtracted sensograms (Figure 
5.11a). Quantification of the observed response units at 20 seconds into LAG-3:Fc injection 
highlighted the complete blockade of LAG-3:Fc binding to HLA-DR1 when co-injected with 
17B4, 13E2 or one of the generated anti-LAG-3 antibodies, 6F7 (Figure 5.11b).  
To confirm LAG-3:Fc-HLA-DR1 blockade by 6F7, LAG-3:Fc, at a fixed concentration (0.3 
mg/mL, 2.0 µM), was incubated and co-injected with titrating concentrations (0.6 µM  – 13.2 
µM) of 6F7. Observed reference subtracted sensograms exhibited clear titratable reversal of 
LAG-3:Fc binding to HLA-DR1 at increasing concentrations of 6F7 antibody (Figure 5.11c). 
Moreover, quantified response units at 20 seconds into LAG-3:Fc injection highlighted titratable 
inhibition of binding (Figure 5.11d). This blockade was observed at limiting (0.1 mg/mL, 0.6 
µM), comparable (0.5 mg/mL, 3.2 µM) and excess (2.0 mg/mL, 13.2 µM) concentrations of 
antibody compared to LAG-3:Fc (0.3 mg/mL, 2.0 µM). These data, therefore, show a direct 
ability of the generated 6F7 antibody to block the protein-protein interaction between LAG-3-
MHC-II in the context of LAG-3:Fc-HLA-DR1 binding, similarly to two other anti-LAG-3 an-
tibodies. 
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Figure 5.11 – Direct blockade of the LAG-3:Fc-HLA-DR1 protein-protein interaction: 
a)  Surface plasmon resonance (SPR) analysis of LAG-3:Fc binding to immobilised HLA-DR1 
in the presence and absence of anti-LAG-3 antibodies. Co-injection of 2 µM LAG-3:Fc with 
13.2 µM 17B4, 13E2 and 6F7 antibodies (colours as shown in b)) abrogated observed binding 
in reference subtracted sensograms compared to in the absence of antibody (unblocked, black) 
or a control antibody (irrelevant, grey).  
b) Normalised quantification of binding at 20 sec into co-injection of 13.2 µM irrelevant, 17B4, 
13E2 and 6F7 antibodies with 2 µM LAG-3:Fc or 2 µM LAG-3:Fc alone (unblocked). 
Percentage binding values are normalised to unblocked binding response from sensograms 
shown in a). 
c) SPR analysis of LAG-3:Fc binding to immobilised HLA-DR1, as described in a), performed 
at titrated concentrations of 6F7 anti-LAG-3 antibody. Increasing concentrations of 6F7 during 
co-injection correlated with inhibition of observed binding in reference subtracted sensograms 
compared to in the absence of antibody (black). Inset numbers mark co-injection concentration 
in µM of 6F7 antibody. 
d) Normalised quantification of binding at 20 sec into co-injection of 6F7 antibodies at given 
concentrations with LAG-3:Fc or LAG-3:Fc alone (0 µM). Percentage binding values are 
normalised to unblocked (0 µM) binding response from sensograms shown in c). 
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5.8.2 Blockade of HLA-DR1 multimer binding to cellularly expressed LAG-3 
Having established direct blockade of LAG-3:Fc binding to HLA-DR1 using SPR, the ability 
of a generated LAG-3 mAb to block MHC-II binding to cellularly expressed LAG-3 was con-
firmed using flow cytometric analysis of multimerised HLA-DR1 staining of JRT LAG-3+ C8 
cells. The capacity to inhibit multimerised HLA-DR1 staining of JRT LAG-3+ C8 cells, as shown 
in Chapter 4, was assayed by pre-staining cells with three anti-LAG-3 antibodies (17B4, 13E2 
and 1B5) prior to HLA-DR1 multimer staining. 
In agreement with SPR data shown previously, 17B4 and 13E2 antibodies both blocked mul-
timerised HLA-DR1 binding to cellularly expressed LAG-3 where 19 % of cells exhibited 
increased fluorescence staining above background in unblocked conditions compared to 0.1 and 
0.3 % of cells in the presence of 17B4 and 13E2 anti-LAG-3 antibodies, respectively. The gen-
erated mAb tested, 1B5, blocked binding to MHC-II as shown by a reduction in multimer 
positive cells to 0.1 % (Figure 5.12a). Such reduction in staining was highlighted by a complete 
reversal of HLA-DR1 staining; to fluorescence intensities observed for control multimer (HLA-
A2) binding to JRT LAG-3+ C8 cells (Figure 5.12b). Reversal of HLA-DR1 multimer binding 
to JRT LAG-3+ cells was not observed using an irrelevant antibody control as shown by equiv-
alent binding to unblocked multimers (Figure 5.12c). 
These data, therefore, show a direct ability of a generated anti-LAG-3 antibody, 1B5, to block 
binding between MHC-II and LAG-3 expressed in a cellular context. In combination with the 
ability to block LAG-3:Fc binding to HLA-DR1 at the protein level, these results show an ability 
of anti-LAG-3 antibodies of the generated panel, which bind the same or similar epitope, to 
modulate the interaction between LAG-3 and MHC-II. 
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Figure 5.12 – Antibody mediated inhibition of HLA-DR1 multimer staining of LAG-3+ cells: 
a) Flow cytometric analysis of HLA-DR1 multimer staining of JRT LAG-3+ C8 cells following 
pre-staining with unconjugated anti-LAG-3 antibodies. Pre-staining of cells with 17B4, 13E2 
and 1B5 anti-LAG-3 antibodies (coloured, + mAb + DR1) reversed staining by PE conjugated 
multimers compared to PBS control (black, + DR1). Multimer positive gate set by HLA-A2 
negative control multimer staining. 
b) Fluorescence histograms of multimer staining of JRT LAG-3+ C8 cells as described in a). 
Observed binding of unblocked HLA-DR1 binding to cells (black, + DR1) was reversed to 
levels observed by control HLA-A2 multimers (grey, + A2) by pre-staining with 17B4, 13E2 
and 1B5 anti-LAG-3 antibodies (coloured, + mAb + DR1). 
c) Normalised quantification of HLA-DR1 multimer binding in the presence of an irrelevant, 
17B4, 13E2 and 1B5 antibodies compared to unblocked (PBS) multimer staining. Percentage 
binding calculated by background subtraction of HLA-A2 multimer gMFI from observed HLA-
DR1 multimer gMFI, from experiments as shown in b) normalised to unblocked control. 
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5.9 Discussion 
The blocking of LAG-3 function or depletion of LAG-3 expressing cells has gathered great 
therapeutic interest due to the role of LAG-3 in suppressing T cell responses (Sega et al. 2014; 
Turnis et al. 2015). Moreover, the upregulation of LAG-3 on highly suppressive T cells extracted 
from within human colorectal tumours suggest a role for LAG-3 in the sub-optimal immune 
response to tumours (M Scurr et al. 2013). Indeed, pre-clinical studies have shown that blocking 
of LAG-3 function, in combination with PD-1 blockade unleashed an effective anti-tumour re-
sponse in multiple mouse models of cancer (Woo et al. 2012). The blockade and/or depletion of 
such suppressive cells in tumours, through the expression of LAG-3, is therefore a desirable 
therapeutic goal in the field of cancer immunotherapy. 
To this end, in these studies, a panel of anti-LAG-3 antibodies were successfully generated 
by the whole protein immunisation of mice. The resulting monoclonal antibody panel high-
lighted a robust and focused B cell response against the immunogen. Of the six mAb generated, 
each antibody exhibited high similarity, at the DNA, protein, functional and biophysical level. 
This occurred despite a wide immunisation and selection approach. The generated antibodies, 
therefore, likely arose from a single dominant parent clonotype generated from a single recom-
bination event in vivo as a response to exposure to heterologous LAG-3 protein. Despite overall 
similarity, subtle differences at the protein sequence level were observed which likely arose 
from either affinity maturation of the parent clone or through random mutations inserted 
throughout the antibody sequence as a consequence of hybridoma culture. Nevertheless, subtle 
difference in protein sequence between antibodies translated into subtle differences in binding 
characteristics; both in terms of functional binding and binding kinetics. 
The analysis of each antibody by SPR allowed the accurate characterisation of such binding 
strength. Dissection of these kinetic parameters will aid in the narrowing of the antibody panel 
for further functional characterisation. In depth analysis of the kinetic properties of antibody-
antigen binding allowed the determination of avidity and affinity measurements for each anti-
body. As such, this comprehensive view of antibody-antigen binding will allow the selection of 
antibodies based on subtle differences in kinetics depending on application. Experiments or 
therapeutic scenarios where LAG-3 ligand density is lower would favour an antibody with 
higher affinity as opposed to avidity. Indeed, affinity measurements of each antibody show better 
correlation with maximum fluorescence cytometry staining compared to avidity measurements, 
albeit both not reaching significance (two-tailed Spearman’s rank correlation; KD1 to max gMFI 
(p= 0.1389, r= -0.6487) KDv to max gMFI (p= 0.2357, r= 0.5357)). Thus, it is suggested that 
selection of an antibody with strongest affinity (lowest KD1) may be preferential for ligand den-
sities such as those found at the cell surface. In turn, strongest avidity (lowest KDv) may be more 
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favourable for high ligand density experiments such as ELISAs and Western blots. Considera-
tion of binding strength on therapeutically relevant target cells would enable the design of an 
antibody with optimal therapeutic potency. 
Initial experiments identifying the binding region of each of the generated mAbs revealed 
that each of the candidate antibodies competed for binding with one another. Alongside the de-
scribed sequencing data, it is concluded that each antibody binds to the same epitope. Moreover, 
competitive binding was also exhibited with a commercial anti-LAG-3 mAb which was raised 
via peptide-KLH immunisation against a 30 amino acid extra loop unique to LAG-3 within the 
D1 domain (LAG-370-99) with the purpose of generating an antibody able to block the LAG-3-
MHC-II interaction (Baixeras et al. 1992). Indeed, a representative antibody was able to block 
the binding of LAG-3 and MHC-II in competitive SPR binding analysis and MHC-II multimer 
staining. Future characterisation of the generated mAbs would benefit from defining the epitope 
recognition sequence at higher resolution and thus compound the capacity to block the LAG-3-
MHC-II interaction, based on these initial competitive binding assays. The benefit of blocking 
LAG-3 and/or depleting such human cells could consequently be investigated in vitro. Indeed, 
both blocking and depletion of CTLA-4 cells has been shown to contribute to the clinical effi-
cacy of ipilimumab (Peggs et al. 2009; Simpson et al. 2013).  
5.9.1 Future directions 
The work presented in this chapter represent the initial stages of a translational project to syn-
thesise antibodies targeting the suppressive T cell molecule LAG-3 with them aim of future 
development of therapeutic agents targeting LAG-3 expressing cells. The use of such agents 
clinically requires the human-mouse chimerisation or full humanisation of generated mouse an-
tibodies in order to minimise the effects of an anti-mouse Ig immune response against the protein 
agent, which results in low efficacy due to poor pharmacokinetic outcome (Weiner 2015). More-
over, in order to most effectively recruit human immune effector networks, mAb humanisation 
or chimerisation is required to optimally initiate LAG-3+ cell depletion in vivo through favour-
able affinities with human antibody binding receptors or soluble proteins such as Fcγ receptors 
or C1q complement factors. 
Humanisation of antibodies, through the grafting of CDR regions to human framework Ig 
sequences can be used to increase pharmacokinetic half-life by minimising, but not eliminating, 
anti-mouse recipient immunogenicity (Harding et al. 2010). The process of humanisation, how-
ever, can be time and resource heavy due to loss of antigen specificity requiring consequent 
back-mutation screening. Chimerisation of antibodies, whilst exhibiting increased immunogenic 
risk and comparatively shorter half-lives, can still be clinical beneficial. Rituximab, a chimeric 
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mouse/human anti-CD20 antibody, is an effective depleting antibody in a range of human dis-
eases where pathophysiology is driven by aberrant B cells such as B cell lymphoma 
(McLaughlin et al. 1998). 
As a result, to assay ability of the mAbs to initiate in vitro antibody dependent cellular phag-
ocytosis (ADCP) by macrophages, complement dependent cytotoxicity (CDC) and antibody 
dependent cellular cytotoxicity (ADCC) by NK cells, the candidate antibody/antibodies would 
first be chimerised through the exchange of mouse constant region domains with human con-
stant domain gene sequences. Ability of chimeric anti-LAG-3 mAbs to deplete LAG-3 human 
cells in vitro could initially be performed using JRT LAG-3+ C8 cells, and later ex vivo human 
LAG-3 expressing T cells. Selection of human Fc domain sequences, determining the antibody 
isotype, would require careful consideration to ensure maximum recruitment of the three de-
scribed effector networks (ADCP, ADCC & CDC) to allow consequent depletion of LAG-3 
opsonised cells (Isaacs et al. 1998). For example, the therapeutic antibody rituximab, which uses 
human IgG1 isotype, has been shown to be the most effective Fc domain due to its preference 
for binding activating Fcγ receptors such as FcγRIIIA (Beers et al. 2016). Likewise, through an 
IgG1 Fc domain, B cell depletion by rituximab is enhanced by C1q binding and consequent  
complement activation (Idusogie et al. 2000). Ability to generate an effective depletion in vivo, 
however, would be dependent on effector cells expression of suitable activating FcγRs as well 
as complement availability within the desired target depletion site or organ. Thus, chimerisation 
of anti-LAG-3 mAbs could be performed using multiple Fc isotypes to find an optimal isotype 
for the given therapeutic setting. Indeed, engineering of generated mAbs to incorporate a deple-
tion inert isotype would enable the dissection of phenotype as a result of LAG-3+ cell depletion 
and LAG-3 blockade in in vitro assays. 
5.9.2 Implications of this study 
In the studies outlined in this chapter, a panel of high avidity and highly specific anti-LAG-3 
antibodies have been generated that will be used for a number of different applications. Firstly, 
high quantities of mouse anti-LAG-3 antibodies will be used in the ongoing effort to produce 
soluble LAG-3 proteins for structural, biophysical and molecular characterisation of this high 
interest, yet difficult to characterise, immune regulator protein. Secondly, these antibodies will 
be used to help characterise LAG-3 expression on T cells found infiltrating in human colorectal 
cancer tumours whom have the potential to suppress an anti-tumour immune response. Finally, 
these antibodies will be developed and engineered with the ultimate goal of being tested for 
safety and efficacy in the clinic. Such efforts will require, and has already involved, collabora-
tion of laboratory groups throughout Cardiff and beyond. 
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6 Chapter 6: Discussion 
6.1 Implications of this thesis 
The studies outlined in this thesis described the recognition and presentation of a colorectal 
tumour-derived antigen, 5T4, by CD4+ T cells through the TCR-pMHC-II interaction. Moreo-
ver, LAG-3 was shown to bind MHC-II which, given its involvement in T cell regulation and 
high expression on CD4+ T cells in colorectal cancer, may suppress T cell immunity to 5T4 
antigen through this interaction. Thirdly, specific monoclonal antibodies were developed which 
efficiently bound, targeted and blocked this interaction and provide a platform for development 
of therapeutics aimed at depleting suppressive LAG-3+ cells with the aim of enhancing immun-
ity against 5T4 and other tumour antigens.  
6.1.1 5T4-reactive CD4+ T cell clones are present in the periphery  
In Chapter 3, three CD4+ T cell clones derived from the peripheral blood of a healthy donor were 
described in terms of their MHC restriction, ability to activate in response to tumour-derived 
peptides, functional cytokine release and ability to engage with cognate pMHC. These studies 
showed that within peripheral blood were CD4+ T cell clones that were able to activate in re-
sponse to presented 5T4-derived peptides on the MHC-II molecule HLA-DR1. These clones 
were sensitive to peptide in response to in vitro stimulation resulting in the release of TH1 cyto-
kines IFNγ and TNFα. Such activation occurred despite little to no detectable binding by cognate 
pMHC multimers. The ability of these clones to be sensitive in response to peptide yet exhibit 
weak engagement with cognate peptide MHC raises interesting questions about the origin of 
these clones from within the T cell repertoire such as (i) the nature of the optimal peptide agonist 
for these 5T4-reactive TCRs and (ii) whether the described clones were derived from naïve or 
memory T cell pools. 
6.1.2 Structural definition of the 5T4117-125 tumour-derived CD4+ T cell epitope 
In Chapter 3, the presentation of a 5T4-derived peptide by the MHC-II molecule HLA-DR1 was 
studied at high resolution by x-ray crystallography. These studies revealed structural insights 
into the presentation of a 5T4-derived peptide at 1.95 Å resolution. This structure of HLA-DR1 
presenting the 5T4p12 peptide defined the core epitope to 5T4117-125. It was revealed that the 
core epitope 5T4117-125 bound with a near optimal HLA-DR1 binding motif with the exception 
of the partial filling of the P1 peptide binding pocket. The 5T4117-125 core epitope was able to 
incorporate leucine into the P1 peptide binding pocket of HLA-DR1 and, despite its shorter side 
chain, made a number of contacts with the MHC molecule to anchor the peptide into the peptide 
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binding groove. This near optimal binding motif may have contributed to the in vitro immuno-
genicity of the 5T4117-125 bearing 5T4p12. Nevertheless, the potential for further enhancement of 
the presentation of 5T4117-125 by HLA-DR1 could be assayed by the generation of an altered 
peptide ligand of 5T4117-125 by substitution of the Leu1 residue for a more favoured residue such 
as tyrosine, tryptophan or phenylalanine (Cole & Godkin 2016).  
Altered peptide ligands which enhance peptide-MHC binding have been studied extensively 
in MHC-I systems. Modifications of melanoma antigen gp100 epitopes, for example, have been 
shown to enhance CD8+ T cell responses in in vitro cultures of PBMCs from melanoma patients 
(Parkhurst et al. 1996). In MHC-II systems, however, similar tactics have resulted in the gener-
ation of heterogeneity in the consequent CD4+ T cell response as incorporation of peptide-MHC-
II enhancing peptide modifications had subtle structural implications on TCR contact residues 
(Chen et al. 2013). Consequently, an understanding of the impact on recognition by the T cell 
repertoire as a result of 5T4117-125 Leu1 candidate modifications would also be required. 
6.1.3 Peptide flanking residues can contribute to MHC-II anchoring 
The HLA-DR1 5T4p12 structure described the presentation of a peptide longer than any current 
published pMHC-II structure. HLA-DR1 presented 5T4p12 with six and five amino acid PFRs 
at the N- and C-terminus, respectively. This structure therefore provided a model for the study 
of PFR interactions with the MHC-II. 
In addition to the near ideal HLA-DR1 motif, contribution to binding between the MHC-II 
and the peptide flanking residues – particularly at the N-terminus – was observed. Indeed, 
through the large guanidinium side chain of Arg-4, binding by the P-4 residue to the HLA-DR1α 
chain contributed the most intermolecular contacts between peptide and MHC-II by any residue 
out of the entire peptide. This observation suggests that preference for lysine residues at P-4 
may allow enhanced binding of peptide epitopes to HLA-DR1. Indeed, this enhanced binding 
contribution by the PFRs, in combination with the near ideal epitope of 5T4117-125, may have 
contributed to the observed immunogenicity of the 5T4p12 peptide in vitro. 
6.1.4 Formation of secondary structure elements reminiscent of native antigen in MHC-
II peptide flanking residues 
Further analysis of the peptide flanking residues of the HLA-DR1 5T4p12 structure revealed a 
novel structural feature of MHC-II presentation. Loss of influence imposed on the peptide by 
HLA-DR1 due to extension of the C-terminus of the peptide outside the peptide binding groove 
allowed the formation of a hairpin turn in the peptide with type II β-turn characteristics. This 
turn was mediated primarily by intramolecular (peptide to peptide) contacts and with smaller 
contributions by intermolecular (MHC to peptide) contacts.  
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Formation of this turn was enabled by a Ser10-Gly11-Ser12 series of amino acids which 
allowed flexibility in the peptide chain and formation of a high-energy hydrogen bond between 
the Ser12 side chain hydroxyl and the backbone carbonyl that preceded the Ser10-Gly11-Ser12 
motif. A similar structural motif has been documented previously in a HLA-DR1 presented HIV-
gag derived peptide, however, this hairpin loop was mediated primarily by a peptide backbone-
to-backbone contact (Zavala-Ruiz et al. 2004). The studies described in this thesis, together with 
those reported by Zavala-Ruiz et al., suggest that secondary structure elements such as hairpin 
turns may be a common feature of MHC-II peptide presentation.  
Due to the open-ended nature of the peptide binding groove and the minimal contacts ob-
served between the 5T4p12 hairpin turn and the MHC molecule, it is hypothesised that this 
structural motif likely arose due to the loss-of-influence on the peptide at the N-terminal flank. 
Indeed, comparison of the 5T4p12 sequence within the published structure of the 5T4 native 
antigen (Zhao et al. 2014) and the HLA-DR1 presented 5T4p12 revealed structural similarity; 
where in the native protein, the Ser-Gly-Ser sequence also forms a hairpin with type II β turn 
characteristics. This observation poses interesting questions about MHC-II peptide presentation 
such as (i) whether this structural motif would form in solution before MHC-II loading or after 
and (ii) how the low pH exhibited during peptide loading in the MHC-II compartment would 
affect secondary structure formation within the 5T4p12 C-terminal peptide flanking region.  
6.1.5 LAG-3 function is mediated by a moderate affinity interaction with MHC-II 
Using SPR analysis of a LAG-3:Fc fusion protein, supported by cellular flow cytometry staining 
of LAG-3+ cells, a direct interaction between LAG-3 and MHC-II was confirmed and described 
kinetically in Chapter 4. Through kinetic and equilibrium analysis, the affinity of the LAG-3-
MHC-II interaction was defined as 13 µM. This moderate affinity is higher than the immeasur-
ably low affinity between MHC-II and the competing CD4 co-receptor. This affinity is at least 
200-fold higher than CD4 binding to MHC-II based on the current upper limit of solution affin-
ity between CD4 and MHC-II (Jönsson et al. 2016). 
LAG-3 binding was characterised by fast kinetics typical of MHC co-receptors and suggests 
that out-competition of CD4 for MHC-II may be mediated by rapid rebinding of MHC-II by 
LAG-3. Indeed, it is known that cytoplasmic signalling through LAG-3 is required for inhibitory 
function, therefore, CD4 out-competition is not the only potential mechanism of LAG-3 medi-
ated suppression of T cells. This moderate affinity is weaker than the antibody-like avidity 
reported in the literature as a result of indirect fluorescence measurements of LAG-3:Fc at the 
surface of MHC-II expressing cells (Huard et al. 1995) and therefore alters the perception of 
how LAG-3 is able to inhibit T cell activation with such potency.  As a result of the observed 
weaker affinity, it is likely that the potency of LAG-3 mediated T cell suppression is mediated 
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through the effectiveness of LAG-3 negative signalling; as opposed to simply the competitive 
blockade of CD4 binding to MHC-II and consequent removal of activating T cell signalling. 
6.1.6 Implications in LAG-3:Fc adjuvant therapy 
These data defining the affinity of LAG-3 for MHC-II, as well as the effects of bivalency by 
dimeric LAG-3:Fc, described in Chapter 4, pose interesting questions about the functionality of 
LAG-3:Fc as a cancer therapeutic. LAG-3:Fc (termed IMP321 in the clinical setting) has been 
shown to enhance immunity through agonizing MHC-II mediated dendritic cell activation 
(Brignone et al. 2007). Indeed, in a phase II trial incorporating LAG-3:Fc in combination with 
chemotherapy, treatment resulted in increased activation of monocytes and dendritic cells and 
subsequent increase in NK and cytotoxic effector-memory CD8+ T cells (Brignone et al. 2010). 
Subcutaneous injection of LAG-3:Fc up to 2 mg/injection in combined therapy with chemother-
apy resulted in no severe adverse events in a cohort of pancreatic adenocarcinoma patients 
(Wang-Gillam et al. 2013). Subcutaneous injection of up to 30 mg/injection as a monotherapy 
or at lower doses with chemotherapy has been well tolerated (Brignone et al. 2009; Wang-Gillam 
et al. 2013). Despite this, induction of an enhanced T cell immunity required doses higher than 
6 mg of LAG-3:Fc and, as a consequence, tumour growth was reduced in patients with advanced 
renal cell carcinoma only at these higher doses (Brignone et al. 2009). 
 In light of the data described in this thesis, the effectiveness of LAG-3:Fc to induce dendritic 
cell maturation may be open to enhancement by improving the engagement of MHC-II mole-
cules by LAG-3 – given the described micromolar KD affinity. As LAG-3:Fc is derived from an 
antibody format, it may have been assumed that LAG-3:Fc binding to MHC-II with multivalent 
avidity may exhibit antibody-like kinetics i.e. greatly enhanced off-rates, as shown by antibody 
binding in Chapter 5. Kinetic analysis of LAG-3:Fc binding with bivalency in SPR experiments, 
however, did not support an antibody-like avidity.  
Improvement of the LAG-3:Fc avidity may be possible via the enhancement of the monova-
lent LAG-3 to MHC-II affinity. Indeed, mutations which enhance LAG-3 binding to MHC-II as 
shown by indirect cell adhesion assays have been previously described (Huard et al. 1997). 
Analysis of the impact of such mutations on MHC-II engagement could be assayed as described 
in this thesis as a methodology for the screening of mutations which would enhance MHC-II 
binding and may facilitate enhanced LAG-3:Fc pharmacokinetics. 
6.1.7 Working towards a high-resolution structure of LAG-3 
Despite interest in modulating the function of LAG-3 for therapy, the high-resolution structure 
of LAG-3 remains undescribed. In Chapter 4, preliminary efforts were made to describe LAG-
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3 function through the study of LAG-3:Fc at low resolution by negative stain electron micros-
copy. These studies showed that the available sample of LAG-3:Fc is homogenous, devoid of 
higher oligomeric species and suitable for study at higher resolution via cryo-electron micros-
copy. These preliminary studies provide required pre-requisite knowledge before proceeding to 
imaging cyro-preserved samples. 
High-resolution understanding of LAG-3 binding to MHC-II would not only elicit detailed 
insights into LAG-3 function but would also be beneficial in the development of therapeutics to 
block LAG-3 function and thus modulate immunity – whether by monoclonal antibody block-
ade, as described in Chapter 5, or by protein-protein interface disruption using small molecule 
agents. Structural understanding of this molecular interface could be used to design a candidate 
small molecule library for the development of a protein-protein interaction inhibitor. Such in-
hibitors have been designed to disrupt the LFA-1-ICAM-1 interaction at the immune synapse 
and have consequently shown inhibition of T cell adhesion and activity (Semba & Gadek 2016). 
This therapeutic tactic may provide an alternate route of LAG-3 functional blockade by the 
implementation of small-molecule kinetics (and cost benefits) associated with small molecule 
drugs.  
6.1.8 Monoclonal antibodies for the study and targeting of LAG-3 
In Chapter 5, a panel of anti-LAG-3 monoclonal antibodies were produced and characterised. 
These antibodies were shown to be specific for LAG-3 and could discriminate LAG-3 from 
CD4. They were characterised as binding with comparable or higher affinity and avidity com-
pared to a commercially available anti-LAG-3 antibody and bound to a similar or the same 
epitope as shown by cross-blockade and were able to block LAG-3 interacting with MHC-II at 
the cell surface, by flow cytometry, and at the protein level, by surface plasmon resonance. 
These antibodies may provide valuable tools in the efforts to describe LAG-3 function by 
serving as a molecular probe for purifying LAG-3 protein formulations generated in vitro for 
structural studies. Such studies would not be feasible with commercially purchased antibodies 
due to the large quantities of reagents required. Moreover, the ability of these antibodies to mod-
ulate T cell function in vitro can be studied either by blockade of LAG-3 or by depletion of 
LAG-3 expressing cells. This study represented the first steps of a translation project towards 
an overall goal of developing antibody molecules for checkpoint inhibitor therapy. 
6.2 Concluding remarks 
The studies in this thesis focused on two aspects of cancer immunology which represent future 
avenues for immunotherapy: (i) the presentation and recognition of a tumour antigen, 5T4, by 
CD4+ T cells whose presence have the potential for boosting through cancer vaccines and (ii) 
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the suppression of immune responses by the inhibitory molecule LAG-3, which has the potential 
for enhancing immunity by removal of this inhibitory signal. Many developing immunothera-
peutic interventions are combined therapies such as those combining multiple checkpoint 
inhibitors (Larkin et al. 2015). Indeed, an ongoing phase I/IIa clinical trial for solid tumours is 
aimed at assessing the safety of anti-LAG-3 and anti-PD-1 therapeutics as a combined treatment 
(ClinicalTrials.gov Identifier: NCT01968109). Combination therapies, however, need not be 
limited to multiple checkpoint inhibitors. In one study, treatment of cancer patients with the 
MVA-5T4 (Trovax®) vaccine enhanced IFNγ mediated immunity (Harrop et al. 2007) whilst in 
a second study depletion of CD25+ Treg cells revealed an enhanced CD4+ T cell response (Elkord 
et al. 2008). Together, these studies provide rationale for the initial depletion of T cells with 
regulatory function, such as LAG-3 expressing cells, followed by the boosting of immunity 
through vaccination against cancer antigens, such as 5T4. Such tactics may enable the priming 
of T cell responses to 5T4 vaccine in a less suppressive environment and thus promote better 
anti-tumour immunity. The studies described in this thesis add basic understanding of these two 
aspects of anti-tumour immunology and have developed molecules for its potential modulation. 
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APPENDIX 
Appendix 1  
 
Lymphoprep™ – Axis-Shield 
CD4 MicroBeads, human – Miltenyi Biotec 
Human T-Activator CD3/CD28 Dynabeads® – Life Technologies 
IFNγ Secretion Assay Cell Enrichment and Detection Kit (PE), human – Miltenyi Biotec 
Human IFNγ ELISpotBASIC (ALP) – Mabtech 
AP Conjugate Substrate Kit #1706432 – Bio-Rad 
Human IFN-gamma DuoSet ELISA kit – R&D Systems 
Human TNF-alpha DuoSet ELISA kit – R&D Systems 
Human CCL4/MIP-1 beta DuoSet ELISA kit – R&D Systems 
HRP Substrate Reagent Pack – R&D Systems 
Stop Solution 2N Sulfuric Acid – R&D Systems 
Roswell Park Memorial Institute (RPMI) 1640 media – Gibco, Life Technologies 
Foetal calf serum (FCS) – Gibco, Life Technologies 
L-Glutamine – Gibco, Life Technologies 
Penicillin-Streptomycin – Gibco, Life Technologies 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) – Fisher Scientific 
Non-essential amino acids – Gibco, Life Technologies 
Sodium pyruvate – Gibco, Life Technologies 
Human recombinant IL-2 (Proleukin®) – provided by University Hospital of Wales Pharmacy 
LIVE/DEAD® Fixable Violet Dead Cell Stain – Invitrogen 
Dimethyl sulfoxide (DMSO) – Sigma-Aldrich 
Phytohaemagglutinin (PHA) – Alere Medical Inc. 
Rosetta™(DE3) Competent Cells – Novagen 
Carbenicillin – Carbenicillin Direct 
Tryptone – Fisher Scientific 
Yeast Extract – Fisher Scientific 
Potassium Phosphate Dibasic (K2HPO4) – Acros Organics 
Sodium Chloride (NaCl) – Fisher Scientific 
Agar Bacteriological – Thermo Scientific 
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) – Fisher Scientific 
Ethylenediaminetetraacetic acid (EDTA) – Sigma Aldrich 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) – Generon 
5 mL Hi-Trap Q Sepharose HP anion exchange columns – GE Healthcare Life Science 
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One Shot® TOP10 Chemically Competent E. coli – Life Technologies 
FastDigest BamHI - ThermoFisher 
FastDigest EcoRI - ThermoFisher 
Tris base – Sigma-Aldrich 
NaCl – Sigma-Aldrich 
Urea – Sigma-Aldrich 
Triton X-100 – Sigma-Aldrich 
Dithiothreitol (DTT) – Sigma-Aldrich 
TOPS crystallization Screen– Custom Formulation by Molecular Dimensions 
PACT premier™ MD1-29 crystallization screen – Molecular Dimensions 
JBScreen PEG/Salt HTS CS-205L crystallization screen – Jena Bioscience GmbH 
ARI INTELLI-PLATE 96-2 Low Volume Reservoir plates – Art Robbins Instruments, LLC. 
ClearVue™ Sealing Sheets – Molecular Dimensions 
MicroSeed Beads™ kit – Hampton Research 
EasyXtal X-Seal crystal supports – Qaigen 
EasyXtal 15-well DG plates – Qaigen 
20 µm Mounted Round LithoLoops – Molecular Dimensions 
40 µm Mounted Round LithoLoops – Molecular Dimensions 
Roswell Park Memorial Institute (RPMI) 1640 media – Gibco, Life Technologies 
Foetal calf serum (FCS) – Gibco, Life Technologies 
Dimethyl sulfoxide (DMSO) – Sigma-Aldrich 
L-Glutamine – Gibco, Life Technologies 
Penicillin-Streptomycin – Gibco, Life Technologies 
XbaI FastDigest restriction endonuclease – Thermo Scientific 
XhoI FastDigest restriction endonuclease – Thermo Scientific 
FastDigest restriction endonuclease 10x Green buffer - Thermo Scientific 
UltraPure™ Agarose – Life Technologies 
HyperLadder™ 1kb DNA molecular weight marker – Bioline 
QIAquick Gel Extraction Kit – Qiagen   
XL10 Gold Ultracompetent cells – Agilent Technologies 
T4 DNA ligase – Life Technologies 
DNA ligase buffer – Life Technologies 
Carbenicillin – Carbenicillin Direct 
Tryptone – Fisher Scientific 
Yeast Extract – Fisher Scientific 
Potassium Phosphate Dibasic (K2HPO4) – Acros Organics 
Sodium Chloride (NaCl) – Fisher Scientific 
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Agar Bacteriological – Thermo Scientific 
Zippy Plasmid DNA mini-prep kit – Zymo Research 
PureLink® HiPure Plasmid Filter Maxiprep Kit – Life Technologies 
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) – Fisher Scientific 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) – Fisher Scientific 
Ethylenediaminetetraacetic acid (EDTA) – Sigma Aldrich 
Hydrogen Chloride (HCl) – Fisher Scientific 
Sodium Hydroxide (NaOH) – Fisher Scientific 
Calcium chloride dihydrate (CaCl2 · 2H2O) – Sigma Aldrich 
Sodium phosphate dibasic anhydrous (Na2HPO4) – Sigma Aldrich 
Series S CM5 Sensor Chip – GE Healthcare Life Sciences   
N-(3-dimethylaminopropyl)-N3-ethylcarbodiimide (EDC) – GE Healthcare Life Sciences   
N-hydroxysuccinimide (NHS) – GE Healthcare Life Sciences   
Streptavidin solution in 10 mM acetate pH 4.5 – Sigma-Aldrich 
1 M ethanolamine – GE Healthcare Life Sciences 
Sodium citrate dihydrate – Sigma-Aldrich   
L-Arginine – Sigma-Aldrich 
Tween-20 – Sigma-Aldrich 
Citric acid – Sigma-Aldrich  
2 % Uranyl acetate – Agar Scientific 
Carbon Films on 400 Mesh Grids Copper – Agar Scientific 
Filter paper (Whatman No.1 filter papers) – GE Heathcare Life Sciences    
LAG-3:Fc fusion protein – Adipogen 
Freund’s Complete Adjuvant (CFA) – Sigma-Aldrich 
Freund’s incomplete adjuvant (IFA) – Sigma-Aldrich 
HRP Substrate Reagent Pack – R&D Systems 
Stop Solution 2N Sulfuric Acid – R&D Systems 
Bovine Serum Albumin (BSA) – Sigma Aldrich 
Roswell Park Memorial Institute (RPMI) 1640 media – Gibco, Life Technologies 
Foetal calf serum (FCS) – Gibco, Life Technologies 
L-Glutamine – Gibco, Life Technologies 
Penicillin-Streptomycin – Gibco, Life Technologies 
Ultra-Low IgG Fetal Bovine Serum (Ig- FCS) – ThermoFisher Scientific 
INTEGRA CELLine flasks – INTEGRA Biosciences AG 
Tween® 20 – Sigma Aldrich 
Sodium Chloride (NaCl) – Fisher Scientific 
Tris – Sigma Aldrich 
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Triton X-100 – Sigma Aldrich 
Invitrolon™ 0.45 µm Pore PVDF/Filter Paper Sandwich – ThermoFisher Scientific 
100 % isopropanol – Fisher Chemicals 
Bolt® Transfer Buffer – ThermoFisher Scientific 
Marvel Whole Skimmed Milk Powder – Premier Foods Group Ltd 
Pierce™ ECL Plus Western Blotting Substrate – ThermoFisher Scientific 
Series S CM5 Sensor Chip – GE Healthcare Life Sciences   
CM5 Sensor Chip – GE Healthcare Life Sciences   
N-(3-dimethylaminopropyl)-N3-ethylcarbodiimide (EDC) – GE Healthcare Life Sciences   
N-hydroxysuccinimide (NHS) – GE Healthcare Life Sciences   
1 M ethanolamine – GE Healthcare Life Sciences 
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Appendix 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 – HLA-type of the HD216 healthy donor from which T cell clones were derived 
  
Gene Allele Allele 
HLA-A *24 *11 
HLA-B *07 *51 
HLA-DRB1 *01 *12 
HLA-DQB1 *05 *03(7) 
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Appendix 3  
Appendix 3 – Production of 5T4-reactive TCRs for SPR analysis 
a) SDS-PAGE analysis of 5T4-TCRα and -TCRβ chain inclusion body preparations produced 
from transformed E. coli cultures. TCR chains from each clone, GD.D821, GD.D104 and 
GD.C112, was produced as shown by additional protein band indicative of TCRα and TCRβ 
chains in IPTG induced (+) compared to uninduced (-) bacterial cultures. 
b) Summary of the success of the TCRαβ refolding and purification pathway of each of the 5T4-
reactive TCRs. GD.D821 and GD.D104 TCRs failed to successfully pass TCRαβ refolding, 
whilst the GD.C112 TCR was successfully refolded and purified for functional analysis. 
c) SDS-PAGE analysis of refolded GD.C112 TCRαβ after processing shown in b) highlighting 
characteristic dimerization of TCRα and TCRβ chains in non-reducing conditions (-), to form 
TCRαβ, and subsequent dissociation to single chains in the presence of reducing conditions (+) 
by incubation of sample in 1 M DTT at 95 °C for 5 min. 
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Appendix 4 
 
 
 
Appendix 4 –Preliminary binding of the GD.C112 TCR to HLA-DR1 5T4p38: 
a) SPR analysis of minimal but detectable binding of the GD.C112 TCR interacting with HLA-
DR1 5T4p38 as shown by reference subtracted sensograms performed at 0.3 µM to 161 µM 
concentrations of analyte TCR. Increase in response units during TCR contact time (black 
arrow), particularly at highest TCR concentrations (labelled by inset numbers) indicated binding 
of GD.C112 TCR to 5T4p38 followed by fast dissociation kinetics upon removal of analyte 
(black dashed arrow) 
b) Response unit differences from baseline observed during equilibrium phase of binding (10 
seconds) at individual TCR ligand concentration calculated from reference subtracted 
sensograms shown in a). TCR concentration correlated with observed signal, however, due to 
inability to reach saturation at high concentrations of TCR and weak signal, TCR binding 
affinity KD could not be calculated by a reliable non-linear curve fit. 
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Appendix 5 
Appendix 5 – Crystal packing and symmetry interactions of the HLA-DR1 5T4p12 structure: 
a) Cartoon and stick representation of HLA-DR1 5T4p12 within the unit cell (black box) of the 
analysed crystal structure. The asymmetric unit consisted of two HLA-DR1 5T4p12 copies: 
chain A, B & C (green, cyan & pink respectively) from which analyses are calculated, and a 
second copy D, E & F (dark grey). Symmetry mate within the unit cell is also shown (light grey). 
b) Cartoon representation of HLA-DR1 5T4p12 within the observed crystal lattice showing 
symmetry mates within a single two-dimensional lattice (light grey). Asymmetric unit coloured 
as in a). 
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Appendix 5 cont.  
c) Cartoon and stick representation of crystal packing interactions.  All theoretical crystal con-
tacts (distance ≤ 4.0 Å) between the HLA-DR1 5T4p12 (chain A, B & C of asymmetric unit) 
to the second copy of HLA-DR1 5T4p12 within the asymmetric unit and contacting symmetry 
mates. Contacts are shown as red dashed lines. Contact hotspots (red circles) included the β1 
helix centre (A), the α1 helix C-terminal edge (B), β2 domain back (C) and α2 domain side 
(D). Some contacts by Pro-2 and Arg-4, to flexible loop regions of symmetry mates, was ob-
served within the peptide N-terminus (grey circle 1). In addition, DR1β-Q110, within a 
flexible loop of the DR1 β2 domain was stabilised by the rigid central peptide core residues 
Glu3, Leu4 & Ala5 (grey circle 2). No crystal contacts were made by the C-terminal hairpin 
loop (grey circle 3). HLA-DR1 represented as cartoon (green & cyan; symmetry mates grey) 
with contacting side chains represented as sticks. Peptide is represented as sticks coloured by 
B-factor (blue to red; B-factor range = 21 to 130).  
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Appendix 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 6  – Yields of affinity purified anti-LAG-3 monoclonal antibodies stratified by yield 
 
  
mAb Protein yield (mg) 
6F7 75.4 
4B1 52.0 
6D6 37.7 
10C8 33.3 
1B5 25.8 
4C10 5.5 
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Appendix 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7  – Isotype characterisation of generated anti-LAG-3 antibodies: 
Isotype immunoassay shift stick tests defining the isotype characterised by CH and Ig light chain 
usage of the six candidate mAbs.  
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Appendix 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Figure continued overleaf) 
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Appendix 8 – Titratable binding of anti-LAG-3 antibodies to LAG-3+ cells: 
a) Fluorescence histograms from flow cytometry analysis showing titratable staining profile of 
each anti-LAG-3 mAb clone at (2, 0.4, 0.08, 0.016, 0.0032 µg/mL) on JRT LAG-3+ C8 cells 
detected by secondary staining with FITC-conjugated anti-mouse antibody. 
b) Background subtracted (IgG2a or IgG2b isotype control) geometric mean fluorescence 
intensity values at varying concentrations (as in a)) as a function of log10 antibody concentration. 
Log(dose) response curves are shown for each mAb clone.   
c) Fluorescence histograms showing titratable staining profile of commercial 17B4 as described 
in a). 
d) Background subtracted (secondary only) log(dose) response curve of 17B4 binding as 
described in b). 
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